{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::969c68a43132", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "1", "section_title": "Services", "clause_type": "Services", "path": "1 ➞ 1. Services", "text": "Exhibit 10.7\n\nCONSULTING AGREEMENT\n\nAduro Biotech, Inc., with a place of business at 740 Heinz Avenue, Berkeley, CA 94710 (\"Aduro\") and IREYA B.V having an address at\nStaalwijkstraat 16, 2313 XR Leiden, the Netherlands, represented by Andrea van Elsas, (\"Consultant\") agree to all terms and conditions of this Consulting\nAgreement (\"Agreement\") dated June 1, 2020, effective as of July 1, 2020 (\"Effective Date\").\n\n1. Services. At the request and direction of Aduro and the agreement of Consultant, Consultant will provide advice and consultation to Aduro with\nrespect to its research, clinical development programs and other business matters as requested by Aduro from time to time.", "numbers_present": null, "definition_terms": ["Aduro", "Consultant", "Agreement", "Effective Date"], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": null, "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::2b04b2e66412"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::2b04b2e66412", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "2", "section_title": "Compensation and Expenses", "clause_type": "Compensation / Payment and Expenses", "path": "2", "text": "consultation to Aduro with\nrespect to its research, clinical development programs and other business matters as requested by Aduro from time to time.\n\n2. Compensation and Expenses. Aduro shall pay Consultant for the Services at the rate of €500 per hour. On a monthly basis, Consultant shall submit to\nAduro an invoice for the hours worked along with itemized documentation and receipts and other information for pre-approved travel and/or out-ofpocket expenses as Aduro reasonably requests at the time reimbursement is requested. Consultant will not incur any travel and/or other out-of-pocket\nexpenses of more than €5,000 individually or €20,000 in the aggregate without the prior written consent of Aduro. Aduro shall pay Consultant any\namounts due that are not reasonably disputed by Aduro, by check or direct bank deposit, within thirty days after receiving the invoice. Consultant's sole\ncompensation for the Services shall be the amounts set forth above in this Section 2. Invoices shall be sent to the attention of:\n\nap@aduro.com\nAttn: Accounts Payable", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::969c68a43132", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::42553ae9d5c2"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::42553ae9d5c2", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "3", "section_title": "Term of Agreement", "clause_type": "Term/Termination", "path": "3", "text": "the Services shall be the amounts set forth above in this Section 2. Invoices shall be sent to the attention of:\n\nap@aduro.com\nAttn: Accounts Payable\n\n3. Term of Agreement. This Agreement shall begin on the Effective Date and shall continue until December 31, 2020, unless extended or earlier\nterminated. Either party may terminate this Agreement at any time on prior written notice to the other. This Agreement may be extended upon mutual\nwritten agreement of the parties.\n\n4. Confidential Information.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::2b04b2e66412", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::3184cc863ba9"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::3184cc863ba9", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "4.(a)", "section_title": "Confidential Information", "clause_type": "Confidentiality / Definition", "path": "4 ➞ 4.(a)", "text": "time on prior written notice to the other. This Agreement may be extended upon mutual\nwritten agreement of the parties.\n\n4. Confidential Information.\n\n(a) \"Confidential Information\" means any information, materials or methods in whatever form or embodiment that has not been made available by\nAduro to the general public and any information, materials or methods in the possession or control of Consultant on the Effective Date or developed in\nthe performance of the Services, except that Confidential Information shall not include any information, material or method that (i) at the time of disclosure\nis in, or after disclosure becomes part of the public domain, through no improper act on the part of Consultant or any of its employees; (ii) was in\nConsultant's possession at the time of disclosure, as shown by written evidence, and was not acquired, directly or indirectly, from work with Aduro; or\n(iii) Consultant receives from a third party, provided that such Confidential Information was not obtained by such third party, directly or indirectly, from\nAduro.", "numbers_present": null, "definition_terms": ["Confidential Information"], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::42553ae9d5c2", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::34e0c04370a8"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::34e0c04370a8", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "4.(a)-(b)", "section_title": "Confidential Information", "clause_type": "Confidentiality (Definition and Obligations)", "path": "4 ➞ 4.(a)-(b)", "text": "ant receives from a third party, provided that such Confidential Information was not obtained by such third party, directly or indirectly, from\nAduro.\n\nSpecific information disclosed as part of the Confidential Information shall not be deemed to be in the public domain or in the prior possession of\nConsultant merely because it is encompassed or contemplated by more general information in the public domain or in the prior possession of the\nConsultant. Failure to mark any of the Confidential Information as confidential or proprietary shall not affect its status as Confidential Information under\nthe terms of this Agreement.\n\n(b) Consultant shall keep all Confidential Information confidential, and Consultant shall not disclose, disseminate, publish, reproduce or use\nConfidential Information except to perform the Services. If Consultant is required by judicial or administrative process to disclose Confidential\nInformation, Consultant shall promptly notify Aduro to allow Aduro a reasonable time to oppose such process and Consultant shall reasonably\ncooperate in Aduro's efforts.", "numbers_present": null, "definition_terms": ["Confidential Information"], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::3184cc863ba9", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::325e8e687162"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::325e8e687162", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "4(b)-(d)", "section_title": "Confidential Information", "clause_type": "Confidentiality (return, destruction, cooperation)", "path": "4 ➞ 4(b) ➞ 4(c) ➞ 4(d)", "text": "tant shall promptly notify Aduro to allow Aduro a reasonable time to oppose such process and Consultant shall reasonably\ncooperate in Aduro's efforts.\n\n(c) On Aduro's request, or upon the termination or expiration of this Agreement, Consultant shall immediately: (i) stop using Confidential\nInformation; (ii) return all materials provided by Aduro to Consultant that contain Confidential Information, except for one copy that may be retained by\nConsultant's legal counsel to confirm compliance with the obligations under this Agreement; (iii) destroy all copies of Confidential Information in any\nform including Confidential Information contained in computer memory or data storage apparatus or materials prepared by or for Consultant; and (iv)\nprovide a written warranty to Aduro that Consultant has taken all the actions described in the foregoing Subparagraphs 4(c)(i-iii).\n\n(d) Any breach of this Paragraph 4 by an employee or agent of Consultant shall be deemed to be a breach by Consultant.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::34e0c04370a8", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::f41dabff560e"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::f41dabff560e", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "4(d)-(e)", "section_title": "Confidential Information", "clause_type": "Confidentiality; Defend Trade Secrets Act / whistleblower notice", "path": "4 ➞ 4(d)-(e)", "text": "ing Subparagraphs 4(c)(i-iii).\n\n(d) Any breach of this Paragraph 4 by an employee or agent of Consultant shall be deemed to be a breach by Consultant.\n\n(e) Defend Trade Secrets Act Notice: Nothing herein shall prevent Consultant from reporting possible violations of federal or state law or regulation\nto any governmental agency or entity, or making other disclosures that are protected under the whistleblower provisions of federal or state law or\nregulation. Consultant does not need the prior authorization of Aduro to make any such reports or disclosures and is not required to notify Aduro that it\nhas made such reports or disclosures. In addition, as set forth in 18 U.S.C. §1833(b), Consultant shall not be held criminally or civilly liable under any\nfederal or state trade secret law for the disclosure of a trade secret that is made in confidence to a federal, state or local government official, either directly\nor indirectly, or to an attorney, and that is made solely for the purpose of reporting or investigating a suspected violation of law, or that is made in a\ncomplaint or other document filed in a lawsuit or other proceeding if such filing is made under seal.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::325e8e687162", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::511d085d0d94"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::511d085d0d94", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "5", "section_title": "Independent Contractor", "clause_type": "Independent contractor relationship", "path": "5", "text": "suspected violation of law, or that is made in a\ncomplaint or other document filed in a lawsuit or other proceeding if such filing is made under seal.\n\n5. Independent Contractor. Consultant's relationship to Aduro shall be that of an independent contractor. Consultant shall be responsible for the timely\npayment of his or her own self-employment and income taxes. Neither party shall have any authority to bind the other.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::f41dabff560e", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::9947d3e9e52e"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::9947d3e9e52e", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "6", "section_title": "Intellectual Property", "clause_type": "Intellectual Property assignment", "path": "6", "text": "ll be responsible for the timely\npayment of his or her own self-employment and income taxes. Neither party shall have any authority to bind the other.\n\n6. Intellectual Property. Aduro shall be the sole and exclusive owner of, and Consultant hereby assigns to Aduro, any and all writings, documents, work\nproduct, inventions, developments, improvements, discoveries, know-how, processes, chemical entities, compounds, plans, memoranda, tests, research,\ndesigns, specifications, models and data that Consultant makes, conceives, discovers or develops, either solely or jointly with any other person in\nperformance of the Services (collectively, \"Work Product\"). Consultant shall promptly disclose to Aduro all information relating to Work Product as\nappropriate as part of the Services and at the request of Aduro. To the extent, if any, that Consultant has rights in or to any Work Product or any data or\ninventions developed in connection with work under this Agreement (\"Aduro IP\"), Consultant hereby irrevocably assigns and transfers to Aduro, and to\nthe extent that an executory assignment is not enforceable, Consultant hereby agrees to assign and transfer to Aduro, in writing, from time to time, upon\nrequest, any and all right, title, or interest that Consultant has or may obtain in any Work Product and/or Aduro IP without the necessity of further\nconsideration. Aduro shall be entitled to obtain and hold in its own name all copyrights, patents, trade secrets and trademarks with respect thereto. At\nAduro's request and expense, Consultant shall assist Aduro in acquiring and maintaining its right in and title to, any Work Product. Such assistance may\ninclude, but will not be limited to, signing applications and other documents, cooperating in legal proceedings, and taking any other steps considered\nnecessary or desirable by Aduro.", "numbers_present": null, "definition_terms": ["Work Product", "Aduro IP"], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::511d085d0d94", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::2bda49b9a37d"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::2bda49b9a37d", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "7; 8(a)", "section_title": "Nonsolicitation; Representations (partial)", "clause_type": "Nonsolicitation (restrictive covenant) and Representations (warranties)", "path": "7 ➞ 8 ➞ 8.(a)", "text": "to, signing applications and other documents, cooperating in legal proceedings, and taking any other steps considered\nnecessary or desirable by Aduro.\n\n7. Nonsolicitation. From the Effective Date and for twelve (12) months after the termination of this Agreement (the \"Restricted Period\"), Consultant shall\nnot, without Aduro's prior written consent, directly or indirectly, solicit or encourage any employee or contractor of Aduro or its affiliates to terminate\nemployment with, or cease providing Services to, Aduro or its affiliates. In the event of a breach of this Paragraph 7 by Consultant, Aduro shall be\nentitled to entry of injunctive relief. Such injunctive remedy shall be nonexclusive and shall be in addition to any and all other remedies which may be\navailable to it at law or in equity, including without limitation, the recovery of direct, indirect, incidental, consequential and/or punitive damages.\n\n8. Representations. Consultant represents as follows:\n\n(a) Consultant is not subject to any other agreement that Consultant will violate by signing this Agreement;", "numbers_present": null, "definition_terms": ["Restricted Period"], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::9947d3e9e52e", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::fc84eedd6012"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::fc84eedd6012", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "8.(a)-(c)", "section_title": "Representations", "clause_type": "Representations", "path": "8 ➞ 8.(a) ➞ 8.(b) ➞ 8.(c)", "text": "tions. Consultant represents as follows:\n\n(a) Consultant is not subject to any other agreement that Consultant will violate by signing this Agreement;\n\n(b) Consultant has and shall continue to have the knowledge, experience, qualifications and required skill to perform, and shall perform, the\nServices in a professional manner;\n\n(c) Consultant to perform the Services in accordance with all Applicable Law; and", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::2bda49b9a37d", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::fb9a597b233b"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::fb9a597b233b", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "8.(b)-(d)", "section_title": "Representations", "clause_type": "Representations (including conflict of interest covenant)", "path": "8 ➞ 8.(b) ➞ 8.(c) ➞ 8.(d)", "text": "perform, and shall perform, the\nServices in a professional manner;\n\n(c) Consultant to perform the Services in accordance with all Applicable Law; and\n\n(d) During the term of this Agreement, Consultant will not, directly or indirectly (whether for compensation or without compensation) engage in or\nprovide consulting services, or enter into any agreement either written or oral, that would present a material conflict with any of the provisions of this\nAgreement, or would preclude Consultant from complying with the terms and conditions hereof. If during the term of this Agreement any situation or\ncircumstance arises that might reasonably be expected to present a conflict of interest, or if Consultant might be unable to render Services or otherwise\nparticipate in such work without risk of breaching an obligation of confidentiality to another party, Consultant will promptly advise the Company's\nGeneral Counsel of the situation and Company and Consultant shall, in good faith, attempt to resolve any such conflicts(s). If requested by the\nCompany's General Counsel, Consultant will recuse herself from providing Services for the duration of the conflict.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::fc84eedd6012", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::87a7bd824955"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::87a7bd824955", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "9", "section_title": "Material Non-Public Information", "clause_type": "Insider trading / trading restrictions", "path": "9", "text": "conflicts(s). If requested by the\nCompany's General Counsel, Consultant will recuse herself from providing Services for the duration of the conflict.\n\n9. Material Non-Public Information. Consultant may have access to, or learn, \"material non-public information\" about Aduro or companies working with\nAduro during the course of performing Services under this Agreement. Consultant acknowledges that it is illegal to buy or sell Aduro's stock or the stock\nof companies working with Aduro, on the basis of \"material non-public information.\" It is also illegal to pass such information on to others who use it to\nbuy or sell Aduro stock. Consultant is subject to and will comply with Aduro's Insider Trading and Trading Window Policy.", "numbers_present": null, "definition_terms": ["material non-public information"], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::fb9a597b233b", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::c2364a5646a0"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::c2364a5646a0", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "10", "section_title": "Miscellaneous", "clause_type": "Boilerplate/Miscellaneous", "path": "9 ➞ 10", "text": "n on to others who use it to\nbuy or sell Aduro stock. Consultant is subject to and will comply with Aduro's Insider Trading and Trading Window Policy.\n\n10. Miscellaneous. This Agreement shall be construed and enforced in accordance with the laws of the State of California, without regard to the conflict\nof law principles of California or any other jurisdiction. This Agreement contains the entire agreement and understanding of the parties relating to the\nsubject matter hereof and merges and supersedes all prior discussions, agreements and understandings of every nature between them with respect to the\nsubject matter hereof. For the avoidance of doubt, this Agreement does not supersede or in modify in anyway any other written agreement between the\nparties. This Agreement may not be changed or modified, except by an agreement in writing signed by both of the parties hereto. The obligations of\nConsultant as set forth herein, other than Consultant's obligations to perform the Project, shall survive the termination of Consultant's engagement with\nAduro. If any provision of this Agreement is found to be illegal or unenforceable, the other provisions of this Agreement shall remain effective and\nenforceable to the greatest extent permitted by law. This Agreement shall not be assignable by Consultant. This Agreement may be executed in any\nnumber of counterparts, and each such counterpart shall be deemed to be an original instrument, but all such counterparts together shall constitute but\none agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::87a7bd824955", "next_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::2e08b1598b45"}
{"id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::2e08b1598b45", "doc_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee", "section_number": "10", "section_title": "Miscellaneous", "clause_type": "Execution/Signature (Counterparts)", "path": "10", "text": "rparts, and each such counterpart shall be deemed to be an original instrument, but all such counterparts together shall constitute but\none agreement.\n\nADURO BIOTECH, INC.\nCONSULTANT\n\nBy:\n/s/ Stephen T. Isaacs\nBy:\n/s/ Andrea van Elsas\nName:\nStephen T. Isaacs\nName:\nAndrea van Elsas\nTitle:\nPresident and Chief Executive Officer\nTitle:\nChief Scientific Officer", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Consulting Agreement", "party_role": "client, consultant", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biotechnology"}, "prev_id": "d1c37a97-22f1-46d8-a106-ad706fbc0aee::c2364a5646a0", "next_id": null}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::15d05d2c7f02", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": null, "section_title": "AGENCY AGREEMENT", "clause_type": "Preamble/Introductory recital", "path": null, "text": "Exhibit 1.1\n\n1,265,000 Shares\n                   (subject to increase up to 1,454,750 shares\n                      in the event of an oversubscription)\n\nAFSALA BANCORP, INC.\n                            (a Delaware corporation)\n\nCOMMON STOCK\n                           ($0.10 Par Value Per Share)\n\nSubscription Price: $10.00 Per Share\n\nAGENCY AGREEMENT\n\n____________, 1996\n\nCapital Resources, Inc.\n1701 K Street, N.W.\nSuite 700\nWashington, D.C. 20006\n\nLadies and Gentlemen:\n\nAFSALA  Bancorp,  Inc. (the  \"Company\") and Amsterdam  Federal\nSavings and Loan  Association,  a federally  chartered  mutual  savings and loan\nassociation  (\"Association\"),  with its deposit  accounts insured by the Savings\nAssociation   Insurance  Fund  (\"SAIF\")  administered  by  the  Federal  Deposit\nInsurance  Corporation  (\"FDIC\"),  hereby  confirm their  agreement with Capital\nResources, Inc. (\"Capital Resources\") as follows:", "numbers_present": null, "definition_terms": ["Company", "Association", "SAIF", "FDIC", "Capital Resources"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": null, "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5d14d85be631"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5d14d85be631", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "1", "section_title": "The Offering", "clause_type": "Offering / Subscription Terms", "path": "1", "text": "e  Federal  Deposit\nInsurance  Corporation  (\"FDIC\"),  hereby  confirm their  agreement with Capital\nResources, Inc. (\"Capital Resources\") as follows:\n\nSECTION 1. The Offering.  The Association,  in accordance with\nand pursuant to its plan of conversion  adopted by the Board of Directors of the\nAssociation  (the \"Plan\"),  intends to be converted  from a  federally-chartered\nmutual savings and loan association to a federally-chartered  stock savings bank\nand will  sell all of its  issued  and  outstanding  stock to the  Company.  The\nCompany  will  offer  and  sell its  common  stock  (the  \"Common  Stock\")  in a\nsubscription  offering  (\"Subscription  Offering\") to (1) tax qualified employee\nbenefit plans of the Association,  (2) depositors of the Association as of March\n31, 1995 (\"Eligible Account  Holders\"),  (3) depositors of the Association as of\nJune 30, 1996  (\"Supplemental  Eligible  Account  Holders\"),  (4) certain  other\ndeposit  account  holders  and  borrower  members  of  the  Association  (\"Other\nMembers\") and (5) to its employees,  officers and directors,  pursuant to rights\nto  subscribe  for shares of Common Stock (the  \"Shares\").  Subject to the prior\nsubscription rights of the above-listed  parties, the Company may offer for sale\nin a public offering (the \"Public  Offering,\" and when referred to together with\nthe Subscription  Offering,  the \"Subscription and Public Offerings\")  conducted\nafter the Subscription  Offering, the Shares not so subscribed for or ordered in\nthe  Subscription  Offering  to the  general  public  (all such  offerees  being\nreferred to in the aggregate as \"Eligible Offerees\"). Shares may also be sold in\nthe Public Offering by a selling group of  broker-dealers  organized and managed\nby Capital  Resources.  It is  acknowledged  that the  purchase of Shares in the\nSubscription  and Public  Offerings  is subject to maximum and minimum  purchase\nlimitations as described in the Plan and that the Company may reject in whole or\nin part any subscriptions received from subscribers in the Public Offering.", "numbers_present": null, "definition_terms": ["FDIC", "Capital Resources", "Plan", "Common Stock", "Subscription Offering", "Eligible Account Holders", "Supplemental Eligible Account Holders", "Other Members", "Shares", "Public Offering", "Subscription and Public Offerings", "Eligible Offerees"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::15d05d2c7f02", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::75b065d96922"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::75b065d96922", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "1", "section_title": "The Offering", "clause_type": "Engagement/Retention", "path": "1", "text": "tions as described in the Plan and that the Company may reject in whole or\nin part any subscriptions received from subscribers in the Public Offering.\n\nThe  Company  and the  Association  desire to  retain  Capital\nResources to assist the Company with its sale of the Shares in the  Subscription\nand Public  Offerings.  By and  through  this  Agreement,  the  Company  and the\nAssociation confirm the retention of Capital Resources to assist the Company and\nthe Association during the Subscription and Public Offerings.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5d14d85be631", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4d29623ca6cf"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4d29623ca6cf", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "SECTION 1", "section_title": "The Offering", "clause_type": "Definitions and regulatory filings", "path": "1", "text": "and the\nAssociation confirm the retention of Capital Resources to assist the Company and\nthe Association during the Subscription and Public Offerings.\n\nThe  Company  has  filed  with  the  Securities  and  Exchange\nCommission  (the  \"Commission\")  a registration  statement on Form S-l (File No.\n333-6399)  containing an offering  prospectus  relating to the  Subscription and\nPublic  Offerings for the registration of the Shares under the Securities Act of\n1933, as amended (the \"1933 Act\"),  and has filed such  amendments  thereto,  if\nany, and such amended  prospectuses as may have been required to the date hereof\n(the  \"Registration  Statement\").  The prospectus,  as amended,  included in the\nRegistration   Statement  at  the  time  it  initially  becomes  effective,   is\nhereinafter called the \"Offering  Prospectus\",  except that if any prospectus is\nfiled by the Company pursuant to Rule 424(b) or (c) of the rules and regulations\nof the Commission under the 1933 Act (the \"1933 Act Regulations\") differing from\nthe offering  prospectus  included in the Registration  Statement at the time it\ninitially becomes effective,  the term \"Offering  Prospectus\" shall refer to the\noffering prospectus filed pursuant to Rule 424(b) or (c) from and after the time\nsaid offering prospectus is filed with or mailed to the Commission for filing.", "numbers_present": null, "definition_terms": ["Commission", "Registration Statement", "Offering Prospectus", "1933 Act", "1933 Act Regulations"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::75b065d96922", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::99d3b48316ab"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::99d3b48316ab", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "2", "section_title": "Retention of Capital Resources; Compensation; Sale and Delivery of the Shares", "clause_type": "Retention/Agency and Compensation; Sale and Delivery", "path": "2", "text": "prospectus filed pursuant to Rule 424(b) or (c) from and after the time\nsaid offering prospectus is filed with or mailed to the Commission for filing.\n\nIn accordance  with Title 12, Part 563b of the Code of Federal\nRegulations (the \"Conversion  Regulations\"),  the Association has filed with the\nOffice  of Thrift  Supervision  (the  \"OTS\")  an  Application  for  Approval  of\nConversion  on Form AC (the  \"Conversion  Application\")  including  the Offering\n\nProspectus  and has filed  such  amendments  thereto,  if any,  as may have been\nrequired by the OTS. The  Conversion  Application  has been approved by the OTS.\nThe Company has filed with the OTS its application on Form H-(e)lS (the \"Holding\nCompany  Application\")  to acquire the  Association  under the Home Owners' Loan\nAct, as amended (12 U.S.C. ss. 1467a) (\"HOLA\").\n\nSECTION 2. Retention of Capital Resources;  Compensation; Sale\nand  Delivery  of the  Shares.  Subject to the terms and  conditions  herein set\nforth, the Company and the Association hereby appoint Capital Resources as their\nagent to advise and assist the Company and the  Association  with the  Company's\nsale of the Shares in the Subscription and Public Offerings.", "numbers_present": null, "definition_terms": ["Conversion Regulations", "OTS", "Conversion Application", "Holding Company Application", "HOLA"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4d29623ca6cf", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::85f67eac1907"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::85f67eac1907", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "SECTION 2", "section_title": "Retention of Capital Resources; Compensation; Sale and Delivery of the Shares", "clause_type": "Retention/Agency appointment and termination (engagement of Capital Resources; scope; termination/End Date; payment timing)", "path": "2", "text": "as their\nagent to advise and assist the Company and the  Association  with the  Company's\nsale of the Shares in the Subscription and Public Offerings.\n\nOn  the  basis  of  the   representations,   warranties,   and\nagreements herein contained,  but subject to the terms and conditions herein set\nforth, Capital Resources accepts such appointment and agrees to consult with and\nadvise the Company and the Association as to matters  relating to the Conversion\nand the Subscription and Public Offerings. It is acknowledged by the Company and\nthe  Association  that Capital  Resources  shall not be required to purchase any\nShares and shall not be obligated to take any action which is inconsistent  with\nany  applicable  laws,  regulations,  decisions  or orders.  If requested by the\nCompany or the  Association,  Capital  Resources  also may assemble and manage a\nselling group of broker dealers which are members of the National Association of\nSecurities  Dealers,  Inc. (the \"NASD\") to  participate in the  solicitation  of\npurchase  orders  for  Shares  under a selected  dealers'  agreement  (\"Selected\nDealers'  Agreement\").  The  obligations of Capital  Resources  pursuant to this\nAgreement  shall  terminate upon the completion or termination or abandonment of\nthe  Plan  by  the  Company  or  the  Association  or  upon  termination  of the\nSubscription  and  Public  Offerings,  or if the  terms  of the  Conversion  are\nsubstantially  amended  so as to  materially  and  adversely  change the role of\nCapital  Resources,  but in no event later than 45 days after the  completion of\nthe Subscription and Public Offerings (the \"End Date\").  All fees due to Capital\nResources  but unpaid will be payable to Capital  Resources in next day funds at\nthe earlier of the Closing Date (as hereinafter defined) or the End Date. In the\nevent the  Subscription  and Public  Offerings are extended beyond the End Date,\nthe Company, the", "numbers_present": null, "definition_terms": ["NASD", "Selected Dealers' Agreement", "End Date"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::99d3b48316ab", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fe024558aa8d"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fe024558aa8d", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "2", "section_title": "Retention of Capital Resources; Compensation; Sale and Delivery of the Shares", "clause_type": "Termination/Refund", "path": "2", "text": "ate (as hereinafter defined) or the End Date. In the\nevent the  Subscription  and Public  Offerings are extended beyond the End Date,\nthe Company, the\n\n-2-\n\nAssociation  and Capital  Resources may mutually  agree to renew this  Agreement\nunder mutually acceptable terms.\n\nIn the event  the  Company  is  unable  to sell a  minimum  of\n935,000  Shares  within  the  period  herein  provided,   this  Agreement  shall\nterminate,  and the Company shall refund to any persons who have  subscribed for\nany of the Shares,  the full amount  which it may have  received  from them plus\naccrued  interest  as set  forth  in the  Offering  Prospectus;  and none of the\nparties  to this  Agreement  shall  have any  obligation  to the  other  parties\nhereunder,  except as set forth in this  Section 2 and in  Sections  7, 9 and 10\nhereof.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::85f67eac1907", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6ae13663d963"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6ae13663d963", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "2", "section_title": "Retention of Capital Resources; Compensation; Sale and Delivery of the Shares", "clause_type": "Termination; Reimbursement of expenses", "path": "2", "text": "greement  shall  have any  obligation  to the  other  parties\nhereunder,  except as set forth in this  Section 2 and in  Sections  7, 9 and 10\nhereof.\n\nIn the event the closing  does not occur,  the  Conversion  is\nterminated  or  otherwise  abandoned,   or  the  terms  of  the  Conversion  are\nsubstantially  amended  so as to  materially  and  adversely  change the role of\nCapital  Resources,  Capital  Resources  shall be reimbursed  for all reasonable\nlegal fees and  out-of-pocket  expenses for  rendering  financial  advice to the\nAssociation  concerning the structure of the Conversion,  preparing a market and\nfinancial analysis, performing due diligence and assisting in the preparation of\nthe Application for Conversion and the  Registration  Statement,  which shall be\npaid upon such termination, abandonment or amendment or within five days of such\nevent.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fe024558aa8d", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0e2ed7f40e5b"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0e2ed7f40e5b", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "2", "section_title": "Retention of Capital Resources; Compensation; Sale and Delivery of the Shares", "clause_type": "Closing and Delivery", "path": "2", "text": "r Conversion and the  Registration  Statement,  which shall be\npaid upon such termination, abandonment or amendment or within five days of such\nevent.\n\nIf  all  conditions  precedent  to  the  consummation  of  the\nConversion,  including,  without limitation,  the sale of all Shares required by\nthe Plan to be sold, are  satisfied,  the Company agrees to issue or have issued\nthe Shares  sold in the  Subscription  and Public  Offerings  and to release for\ndelivery  certificates  for such  Shares  on the  Closing  Date (as  hereinafter\ndefined)  against  payment to the Company by any means  authorized  by the Plan,\nprovided,  however, that no certificates shall be released for such shares until\nthe  conditions  specified in Section 7 hereof shall have been  complied with to\nthe reasonable satisfaction of Capital Resources and its counsel. The release of\nShares against payment  therefor shall be made on a date and at a time and place\nacceptable to the Company, the Association and Capital Resources.  The date upon\nwhich the Company shall  release or deliver the Shares sold in the  Subscription\nand Public Offerings,  in accordance with the terms hereof, is herein called the\n\"Closing Date.\"", "numbers_present": null, "definition_terms": ["Closing Date"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6ae13663d963", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d705fce1e33a"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d705fce1e33a", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "2.(a)(i)-(ii)", "section_title": "Retention of Capital Resources; Compensation; Sale and Delivery of the Shares", "clause_type": "Compensation", "path": "2 ➞ 2.(a) ➞ 2.(a)(i)-(ii)", "text": "lease or deliver the Shares sold in the  Subscription\nand Public Offerings,  in accordance with the terms hereof, is herein called the\n\"Closing Date.\"\n\nCapital Resources shall receive the following compensation for\nits services hereunder:\n\n(a) (i) a  marketing  fee in the  amount  of (x)  two  percent\n(2.0%) of the aggregate dollar amount of all Shares sold in the Subscription and\nPublic Offerings,  excluding sales made through broker assisted  purchases or by\nother NASD member firms  participating  in the Subscription and Public Offerings\npursuant  to  the  Selected  Dealers'  Agreement,  if  any  (for  which  Capital\nResources'  compensation shall be pursuant to sub-paragraph  (ii)) and excluding\nshares sold to the  Association's  Employee  Stock  Ownership  Plan,  directors,\nofficers or employees and any member of such person's  immediate family (defined\nto include children, spouse, parents, grandparents and grandchildren);\n\n(ii)    a management fee in the amount of one percent\nand one-half (1.5%) of the aggregate dollar amount of Shares sold through broker\nassisted  purchases or through selected dealers, if any.", "numbers_present": null, "definition_terms": ["Closing Date"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0e2ed7f40e5b", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::713e4086a34f"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::713e4086a34f", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "2.(a)(ii)-(b)", "section_title": "Retention of Capital Resources; Compensation; Sale and Delivery of the Shares (Compensation)", "clause_type": "Compensation and Expense Reimbursement", "path": "2 ➞ 2.(a) ➞ 2.(a)(ii) and 2 ➞ 2.(b)", "text": "one percent\nand one-half (1.5%) of the aggregate dollar amount of Shares sold through broker\nassisted  purchases or through selected dealers, if any.\n\n(b) Capital  Resources  shall be reimbursed for all reasonable\nout-of-pocket  expenses,  including,  but not  limited to,  legal fees,  travel,\ncommunications  and  postage,  incurred by it whether or not the  Conversion  is\nsuccessfully completed as set forth in Section 7 hereof. Capital Resources shall\nbe  reimbursed  promptly  for all  out-of-pocket  expenses  upon  receipt by the\nCompany or the Association of a monthly  itemized bill summarizing such expenses\nsince the date of the last bill, if any, to the date\n\n-3-\n\nof the current bill.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d705fce1e33a", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::c262bb36d504"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::c262bb36d504", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "SECTION 2", "section_title": "Retention of Capital Resources; Compensation; Sale and Delivery of the Shares", "clause_type": "Compensation and reimbursement (fees and commissions)", "path": "2 ➞ 2.(b)", "text": "the Association of a monthly  itemized bill summarizing such expenses\nsince the date of the last bill, if any, to the date\n\n-3-\n\nof the current bill.\n\nIn the event other broker-dealers are assembled and managed by\nCapital  Resources  under a  selling  syndicate  to  participate  in the  Public\nOffering  pursuant to the  Selected  Dealers'  Agreement or  participate  in the\nPublic Offering as assisting  brokers,  the Company and the Association  will be\ndirectly  responsible for the payment of selected  dealers'  commissions to such\nparticipating  firms or assisting  brokers'  commissions up to a maximum of four\npercent (4%) and four percent (4%), respectively, of the amount of stock sold by\nsuch firms.  Capital Resources' fees are limited to those stated in subparagraph\n(a) above and all other  brokers  will be paid fees based upon the  capacity  in\nwhich they are acting in the particular stock sale.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::713e4086a34f", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fd369d2cea46"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fd369d2cea46", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "3-4", "section_title": "Offering Prospectus; Subscription and Public Offerings / Representations and Warranties", "clause_type": "Offering/Subscription clause; Representations and Warranties", "path": "3 ➞ 4", "text": "d in subparagraph\n(a) above and all other  brokers  will be paid fees based upon the  capacity  in\nwhich they are acting in the particular stock sale.\n\nAll subscription  funds received by Capital  Resources (and if\nby check  shall be made  payable to the  Company)  or by other  NASD  registered\nbroker-dealers soliciting subscriptions (if any) shall be transmitted (either by\nU.S.  Mail  or  similar  type  of  transmittal)  to the  Company  by noon of the\nfollowing business day.\n\nSECTION  3.  Offering  Prospectus;   Subscription  and  Public\nOfferings. The Shares are to be initially offered in the Subscription and Public\nOfferings at the  Purchase  Price as set forth on the cover page of the Offering\nProspectus.\n\nSECTION 4.  Representations and Warranties.  The Company and \nthe Association jointly and severally represent and warrant to Capital Resources\nas follows:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::c262bb36d504", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3ce40bd5aeba"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3ce40bd5aeba", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(a)", "section_title": "Representations and Warranties", "clause_type": "Representation and warranty", "path": "4 ➞ 4(a)", "text": "ION 4.  Representations and Warranties.  The Company and \nthe Association jointly and severally represent and warrant to Capital Resources\nas follows:\n\n(a) The Registration  Statement was declared  effective by the\nCommission  on  __________,  1996.  At  the  time  the  Registration  Statement,\nincluding the Offering Prospectus  contained therein (including any amendment or\nsupplement thereto),  became effective,  the Registration  Statement complied in\nall material  respects  with the  requirements  of the 1933 Act and the 1933 Act\nRegulations and the Registration  Statement,  including the Offering  Prospectus\ncontained therein (including any amendment or supplement thereto),  any Blue Sky\nApplication  or any Sales  Information  (as such  terms are  defined  previously\nherein or in Section 8 hereof)  authorized by the Company or the Association for\nuse in connection with the  Subscription and Public Offerings did not contain an\nuntrue statement of a material fact or omit to state a material fact required to\nbe stated therein or necessary to make the statements  therein,  in light of the\ncircumstances  under which they were made, not  misleading,  and at the time any\nRule  424(b)  or (c)  Offering  Prospectus  was  filed  with  or  mailed  to the\nCommission  for filing and at the  Closing  Date  referred  to in Section 2, the\nRegistration  Statement  including  the Offering  Prospectus  contained  therein\n(including any amendment or supplement thereto), any Blue Sky Application or any\nSales  Information (as such terms are defined  previously herein or in Section 8\nhereof)  authorized by the Company or the Association for use in connection with\nthe  Subscription and Public Offerings will not contain an untrue statement of a\nmaterial  fact or omit to state a material  fact  necessary in order to make the\nstatements  therein,  in the light of the  circumstances  under  which they were\nmade, not misleading; provided, however, that the representations and warranties\nin this Section  4(a) shall not apply to  statements  in or omissions  from such\nRegistration  Statement  or Offering  Prospectus  made in  reliance  upon and in\nconformity with written information  furnished to the Company or the Association\nby Capital  Resources  expressly  regarding  Capital Resources for use under the\ncaption \"The Conversion-Marketing Arrangements.\"", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fd369d2cea46", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::539b019348c6"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::539b019348c6", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(b)", "section_title": "Representations and Warranties", "clause_type": "Representation and Warranty", "path": "4 ➞ 4.(b)", "text": "y or the Association\nby Capital  Resources  expressly  regarding  Capital Resources for use under the\ncaption \"The Conversion-Marketing Arrangements.\"\n\n(b)      The Conversion Application, including the Offering\nProspectus, was approved by the OTS on __________, 1996.  At the time of the\napproval of the Conversion Application, including\n\n-4-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3ce40bd5aeba", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6f7fc74d7922"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6f7fc74d7922", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(b)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4(b)", "text": "uding the Offering\nProspectus, was approved by the OTS on __________, 1996.  At the time of the\napproval of the Conversion Application, including\n\n-4-\n\nthe Offering  Prospectus,  by the OTS  (including  any  amendment or  supplement\nthereto)  and at all times  subsequent  thereto  until  the  Closing  Date,  the\nConversion  Application,  including the Offering Prospectus,  will comply in all\nmaterial  respects  with the  Conversion  Regulations  and any  other  rules and\nregulations  of the OTS.  The  Conversion  Application,  including  the Offering\nProspectus (including any amendment or supplement thereto), does not include any\nuntrue  statement of a material fact or omit to state any material fact required\nto be stated  therein or necessary to make the statements  therein,  in light of\nthe circumstances under which they were made, not misleading; provided, however,\nthat  representations  or  warranties  in this  Section  4(b) shall not apply to\nstatements or omissions  made in reliance  upon and in  conformity  with written\ninformation   furnished  to  the  Association  by  Capital  Resources  expressly\nregarding Capital Resources for use in the Offering Prospectus  contained in the\nConversion   Application   under  the   caption   \"The   Conversion-   Marketing\nArrangements.\"", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::539b019348c6", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::03047b921e25"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::03047b921e25", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(c)-(d)", "section_title": "Representations and Warranties", "clause_type": "Representations and warranties", "path": "4 ➞ 4.(c) and 4.(d)", "text": "s for use in the Offering Prospectus  contained in the\nConversion   Application   under  the   caption   \"The   Conversion-   Marketing\nArrangements.\"\n\n(c) The  Company  has filed with the OTS the  Holding  Company\nApplication  and will have  received,  as of the Closing  Date,  approval of its\nacquisition of the Association from the OTS.\n\n(d) No order has been issued by the OTS, the  Commission,  the\nFDIC (and  hereinafter  reference to the FDIC shall include the SAIF), or to the\nbest knowledge of the Company or the  Association  any State  regulatory or Blue\nSky authority,  preventing or suspending the use of the Offering  Prospectus and\nno action by or  before  any such  government  entity  to revoke  any  approval,\nauthorization  or order of  effectiveness  related to the  Conversion is, to the\nbest knowledge of the Association or the Company, pending or threatened.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6f7fc74d7922", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ad013adf526d"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ad013adf526d", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(e)", "section_title": "Representations and Warranties", "clause_type": "Representations and warranties", "path": "4 ➞ 4.(e)", "text": "horization  or order of  effectiveness  related to the  Conversion is, to the\nbest knowledge of the Association or the Company, pending or threatened.\n\n(e) At the  Closing  Date  referred  to in Section 2, the Plan\nwill have been  adopted by the Board of  Directors  of both the  Company and the\nAssociation,  the Company and the Association will have completed all conditions\nprecedent to the  Conversion and the offer and sale of the Shares will have been\nconducted in accordance with the Plan, the Conversion  Regulations and all other\napplicable  laws,  regulations,  decisions  and  orders,  including  all  terms,\nconditions, requirements and provisions precedent to the Conversion imposed upon\nthe  Company  or the  Association  by  the  OTS,  the  Commission  or any  other\nregulatory authority and in the manner described in the Offering Prospectus.  At\nthe  Closing  Date,  no person  will have  sought to obtain  review of the final\naction of the OTS,  to the  knowledge  of the  Company  or the  Association,  in\napproving the Plan or in approving the  Conversion or the Company's  application\nto acquire all of the capital stock and control of the  Association  pursuant to\nthe HOLA or any other statute or regulation.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::03047b921e25", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::11989fca2686"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::11989fca2686", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(f)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4(f)", "text": "e Company's  application\nto acquire all of the capital stock and control of the  Association  pursuant to\nthe HOLA or any other statute or regulation.\n\n(f)  The  Association  is now a  duly  organized  and  validly\nexisting  federally-chartered  savings  and loan  association  in mutual form of\norganization  and upon the  Conversion  will become a duly organized and validly\nexisting federally-chartered savings bank in capital stock form of organization,\nin both instances  duly  authorized to conduct its business and own its property\nas described in the  Registration  Statement  and the Offering  Prospectus;  the\nCompany and the  Association  have obtained all material  licenses,  permits and\nother  governmental  authorizations  currently required for the conduct of their\nrespective   businesses;   all   such   licenses,   permits   and   governmental\nauthorizations are in full force and effect, and the Company and the Association\nare in all material  respects  complying with all laws,  rules,  regulations and\norders applicable to the operation of their  businesses;  and the Association is\nin good standing  under the laws of the United States and is duly qualified as a\nforeign  corporation  to  transact  business  and is in  good  standing  in each\njurisdiction  in which its ownership of property or leasing of properties or the\nconduct of its business requires such qualification, unless the failure to be so\nqualified in one or more of such jurisdictions would not have a material adverse\neffect on the condition,  financial or otherwise, or the business, operations or\nincome of the Association. The Association does not own", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ad013adf526d", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8252ec4961e5"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8252ec4961e5", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(f)", "section_title": "Representations and Warranties", "clause_type": "Representation and Warranty", "path": "4 ➞ 4(f)", "text": "erial adverse\neffect on the condition,  financial or otherwise, or the business, operations or\nincome of the Association. The Association does not own\n\n-5-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::11989fca2686", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5e60c5bba0f4"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5e60c5bba0f4", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(f)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4(f)", "text": "adverse\neffect on the condition,  financial or otherwise, or the business, operations or\nincome of the Association. The Association does not own\n\n-5-\n\nequity securities or any equity interest in any other business enterprise except\nas described in the Offering  Prospectus.  Upon the completion of the Conversion\nof the Association pursuant to the Plan to a  federally-chartered  stock savings\nbank, (i) all of the authorized and outstanding capital stock of the Association\nwill be  owned  by the  Company,  and  (ii)  the  Company  will  have no  direct\nsubsidiaries other than the Association.  The Conversion will have been effected\nin  all  material   respects  in  accordance   with  all  applicable   statutes,\nregulations,  decisions  and orders;  and except  with  respect to the filing of\ncertain post-sale,  post-conversion reports and documents in compliance with the\n1933 Act Regulations or the OTS's resolutions or letters of approval. All terms,\nconditions,  requirements and provisions with respect to the Conversion  imposed\nby the Commission, the OTS and the FDIC, if any, will have been complied with by\nthe Company and the Association in all material respects or appropriate  waivers\nwill have been  obtained and all material  notice and waiting  periods will have\nbeen satisfied, waived or elapsed.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8252ec4961e5", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::2db6ca59de60"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::2db6ca59de60", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(g)", "section_title": "Representations and Warranties", "clause_type": "Representation and warranty (corporate existence and authority)", "path": "4 ➞ 4.(g)", "text": "l respects or appropriate  waivers\nwill have been  obtained and all material  notice and waiting  periods will have\nbeen satisfied, waived or elapsed.\n\n(g) The  Company  has been duly  incorporated  and is  validly\nexisting  as a  corporation  in good  standing  under  the laws of the  State of\nDelaware  with  corporate  power and  authority  to own,  lease and  operate its\nproperties  and to  conduct  its  business  as  described  in  the  Registration\nStatement  and the  Offering  Prospectus,  and the  Company is  qualified  to do\nbusiness as a foreign  corporation in any  jurisdiction  in which the conduct of\nits business requires such qualification, except where the failure to so qualify\nwould not have a material adverse effect on the business of the Company.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5e60c5bba0f4", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::153fd38886bd"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::153fd38886bd", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(h)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4(h)", "text": "business requires such qualification, except where the failure to so qualify\nwould not have a material adverse effect on the business of the Company.\n\n(h) The  Association is a member of the Federal Home Loan Bank\nof New York (\"FHLBNY\");  and the deposit accounts of the Association are insured\nby the FDIC up to the applicable  limits.  Upon  consummation of the Conversion,\nthe  liquidation  account  for the  benefit  of  Eligible  Account  Holders  and\nSupplemental  Eligible  Account  Holders will be duly  established in accordance\nwith the requirements of the Conversion Regulations.", "numbers_present": null, "definition_terms": ["FHLBNY"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::2db6ca59de60", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::de06e13033f2"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::de06e13033f2", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(i)", "section_title": "Representations and Warranties", "clause_type": "Representation and Warranty (Title)", "path": "4 ➞ 4.(i)", "text": "nt  Holders  and\nSupplemental  Eligible  Account  Holders will be duly  established in accordance\nwith the requirements of the Conversion Regulations.\n\n(i) The Company and the  Association  have good and marketable\ntitle to all assets  owned by them which are  material  to the  business  of the\nCompany and the  Association and to those assets  described in the  Registration\nStatement and Offering Prospectus as owned by them, free and clear of all liens,\ncharges,  encumbrances  or  restrictions,  except such as are  described  in the\nRegistration Statement and Offering Prospectus or are not materially significant\nor important in relation to the business of the Company and the Association; and\nall of the leases and subleases  material to the business of the Company and the\nAssociation  under  which  the  Company  or the  Association  holds  properties,\nincluding those described in the Registration Statement and Offering Prospectus,\n\nare in full force and effect.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::153fd38886bd", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ba4efb14e2c2"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ba4efb14e2c2", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(j)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4.(j)", "text": "r the  Association  holds  properties,\nincluding those described in the Registration Statement and Offering Prospectus,\n\nare in full force and effect.\n\n(j) The  Association  has  received an opinion of its counsel,\nMalizia,  Spidi,  Sloane & Fisch,  P.C.,  with respect to the federal income tax\nconsequences of the Conversion of the Association from mutual to stock form, the\nacquisition of the capital stock of the Association by the Company,  the sale of\nthe Shares,  and the  reorganization  of the  Association  as  described  in the\nRegistration Statement and the Offering Prospectus and an opinion from KPMG Peat\nMarwick,  LLP (\"KPMG\") with respect to the State income tax  consequences of the\nproposed transaction;  all material aspects of the opinions of Silver Freedman &\nTaff, L.L.P. and KPMG are accurately summarized in the Offering Prospectus;  and\nthe facts and  representations  upon which such opinions are based are truthful,\naccurate and complete, and neither the Association nor the Company will take any\naction inconsistent therewith.", "numbers_present": null, "definition_terms": ["KPMG"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::de06e13033f2", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::051df928ca02"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::051df928ca02", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(k)", "section_title": "Representations and Warranties", "clause_type": "Representation and Warranty", "path": "4 ➞ 4(k)", "text": "such opinions are based are truthful,\naccurate and complete, and neither the Association nor the Company will take any\naction inconsistent therewith.\n\n(k)      The Company and the Association have all such power,\nauthority, authorizations, approvals and orders as may be required to enter into\nthis Agreement, to carry out the provisions and conditions hereof and to issue \nand sell the Capital Stock of the Association to the Company and Shares to be\nsold by the Company as provided herein and as described in the Offering\nProspectus.  The\n\n-6-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ba4efb14e2c2", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7c6d33d2b8af"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7c6d33d2b8af", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(k)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty (corporate authorization and enforceability)", "path": "4 ➞ 4(k)", "text": "Stock of the Association to the Company and Shares to be\nsold by the Company as provided herein and as described in the Offering\nProspectus.  The\n\n-6-\n\nconsummation of the Conversion, the execution,  delivery and performance of this\nAgreement and the consummation of the transactions herein contemplated have been\nduly and validly authorized by all necessary corporate action on the part of the\nCompany and the  Association  and this  Agreement has been validly  executed and\ndelivered by the Company and the Association and is the valid, legal and binding\nagreement of the Company and the Association  enforceable in accordance with its\nterms  (except as the  enforceability  thereof  may be  limited  by  bankruptcy,\ninsolvency, moratorium,  reorganization or similar laws relating to or affecting\nthe  enforcement  of creditors'  rights  generally or the rights of creditors of\nsavings and loan  holding  companies,  the  accounts of whose  subsidiaries  are\ninsured by the FDIC or by general equity  principles  regardless of whether such\nenforceability  is considered in a proceeding in equity or at law, and except to\nthe  extent,  if any,  that the  provisions  of  Sections 9 and 10 hereof may be\nunenforceable as against public policy).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::051df928ca02", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::85537c259908"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::85537c259908", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(l)", "section_title": "Representations and Warranties", "clause_type": "Representation and Warranty", "path": "4 ➞ 4(l)", "text": "ity or at law, and except to\nthe  extent,  if any,  that the  provisions  of  Sections 9 and 10 hereof may be\nunenforceable as against public policy).\n\n(l) The Company and the  Association  are not in  violation of\nany directive  which has been delivered to the Company or the  Association or of\nwhich management of the Company or the Association has actual knowledge from the\nOTS, the Commission, the FDIC or any other agency to make any material change in\nthe  method of  conducting  their  businesses  so as to  comply in all  material\nrespects  with all  applicable  statutes  and  regulations  (including,  without\nlimitation,  regulations,  decisions,  directives  and  orders  of the OTS,  the\nCommission and the FDIC) and except as set forth in the  Registration  Statement\nand the Offering  Prospectus there is no suit or proceeding or, to the knowledge\nof the Company or the Association,  charge, investigation or action before or by\nany court,  regulatory  authority or governmental agency or body, pending or, to\nthe  knowledge  of the  Company  or the  Association,  threatened,  which  might\nmaterially  and  adversely  affect  the  Conversion,  the  performance  of  this\nAgreement or the consummation of the  transactions  contemplated in the Plan and\nas described in the Registration Statement or which might result in any material\nadverse  change in the condition  (financial or otherwise),  earnings,  capital,\nproperties,  business  affairs  or  business  prospects  of the  Company  or the\nAssociation or which would materially affect their properties and assets.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7c6d33d2b8af", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8980384c8f20"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8980384c8f20", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(m)", "section_title": "Representations and Warranties", "clause_type": "Representation and Warranty (financial statements/accounting)", "path": "4 ➞ 4.(m)", "text": "erties,  business  affairs  or  business  prospects  of the  Company  or the\nAssociation or which would materially affect their properties and assets.\n\n(m)  The  financial  statements  which  are  included  in  the\nRegistration  Statement  and which are part of the  Offering  Prospectus  fairly\npresent the financial  condition,  results of operations,  retained earnings and\ncash  flows of the  Association  at the  respective  dates  thereof  and for the\nrespective  periods  covered  thereby,  and  comply  as to form in all  material\nrespects with the applicable accounting  requirements of Title 12 of the Code of\nFederal  Regulations  and  generally  accepted  accounting  principles  (\"GAAP\")\n(including  those  requiring  the  recording of certain  assets at their current\nmarket value).  Such financial  statements have been prepared in accordance with\ngenerally  accepted  accounting  principles  consistently  applied  through  the\nperiods  involved,  present  fairly in all  material  respects  the  information\nrequired to be stated therein and are consistent with the most recent  financial\nstatements and other reports filed by the Association with the OTS and the FDIC,\nexcept  that  accounting   principles   employed  in  such  filings  conform  to\nrequirements  of such  authorities  and not  necessarily  to generally  accepted\naccounting   principles.   The  other  financial,   statistical  and  pro  forma\ninformation and related notes included in the Offering Prospectus present fairly\nthe  information  shown  therein  on a basis  consistent  with the  audited  and\nunaudited  financial  statements,  if any,  of the  Association  included in the\nOffering Prospectus,  and as to the pro forma adjustments,  the adjustments made\ntherein have been properly applied on the basis described therein.", "numbers_present": null, "definition_terms": ["GAAP"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::85537c259908", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8b85f9fc2bbe"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8b85f9fc2bbe", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(n)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4.(n)", "text": "he\nOffering Prospectus,  and as to the pro forma adjustments,  the adjustments made\ntherein have been properly applied on the basis described therein.\n\n(n)  Since the  respective  dates as of which  information  is\ngiven in the Registration  Statement and the Offering Prospectus,  except as may\notherwise be stated therein: (i) there has not been any material adverse change,\nfinancial or otherwise,  in the condition of the Company or the Association,  or\nof the Company  and the  Association  considered  as one  enterprise,  or in the\nearnings, capital,\n\n-7-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8980384c8f20", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::efd0f5d06f6c"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::efd0f5d06f6c", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(n)", "section_title": "Representations and Warranties", "clause_type": "Representation and warranty", "path": "4 ➞ 4.(n)", "text": "dition of the Company or the Association,  or\nof the Company  and the  Association  considered  as one  enterprise,  or in the\nearnings, capital,\n\n-7-\n\nproperties,  business  affairs  or  business  prospects  of the  Company  or the\nAssociation,  whether or not arising in the ordinary  course of  business,  (ii)\nthere has not been (A) an  increase  of greater  than  $500,000 in the long term\ndebt of the Association or (B) an increase of $100,000 or more in loans past due\n90 days or more or (C) an increase  of $100,000 or more in real estate  acquired\nby  foreclosure  or (D) a decrease of $50,000 or more in the  allowance for loan\nlosses or (E) any decrease in total  retained  earnings or (F) a decrease in net\nincome from January 1, 1996 to date when  compared to the like period in 1995 or\n(G) any change in total  assets of the  Association  in an amount  greater  than\n$2,000,000 or (H) any other material  change which would require an amendment to\nthe Offering Prospectus;  (iii) the Association has not issued any securities or\nincurred any  liability or obligation  for borrowing  other than in the ordinary\ncourse of business;  (iv) there have not been any material  transactions entered\ninto  by  the  Company  or  the  Association,   except  with  respect  to  those\ntransactions  entered  into in the  ordinary  course  of  business;  and (v) the\ncapitalization,  liabilities, assets, properties and business of the Company and\nthe Association  conform in all material  respects to the  descriptions  thereof\ncontained  in  the  Offering  Prospectus,   and  neither  the  Company  nor  the\nAssociation have any material liabilities of any kind,  contingent or otherwise,\nexcept as set forth in the Offering Prospectus.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8b85f9fc2bbe", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::96a1ee78d5fa"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::96a1ee78d5fa", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(o)", "section_title": "Representations and Warranties", "clause_type": "Representation and Warranty", "path": "4 ➞ 4.(o)", "text": "he  Company  nor  the\nAssociation have any material liabilities of any kind,  contingent or otherwise,\nexcept as set forth in the Offering Prospectus.\n\n(o) As of the date hereof and as of the Closing Date,  neither\nthe  Company  nor  the  Association  is  in  violation  of  its  certificate  of\nincorporation or charter,  respectively, or its bylaws (and the Association will\nnot be in  violation  of its  charter or bylaws in capital  stock form as of the\nClosing  Date) or in default in the  performance  or  observance of any material\nobligation,  agreement, covenant, or condition contained in any contract, lease,\nloan agreement, indenture or other instrument to which it is a party or by which\nit, or any of its property may be bound which would result in a material adverse\nchange in the condition (financial or otherwise), earnings, capital, properties,\nbusiness  affairs or business  prospects of the Company or  Association or which\nwould  materially  affect their  properties or assets.  The  consummation of the\ntransactions  herein  contemplated  will not (i) conflict  with or  constitute a\nbreach of, or default under, the certificate of incorporation  and bylaws of the\nCompany,  the charter and bylaws of the Association (in either mutual or capital\nstock form), or any material  contract,  lease or other  instrument to which the\nCompany or the  Association  has a beneficial  interest,  or any applicable law,\nrule, regulation or order; (ii) violate any authorization,  approval,  judgment,\ndecree,  order,  statute,  rule or  regulation  applicable to the Company or the\nAssociation;  or (iii) with the exception of the Liquidation Account established\nin the  Conversion,  result in the  creation  of any  material  lien,  charge or\nencumbrance upon any property of the Company or the Association.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::efd0f5d06f6c", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0fb4a4af85d6"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0fb4a4af85d6", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(p)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4.(p)", "text": "shed\nin the  Conversion,  result in the  creation  of any  material  lien,  charge or\nencumbrance upon any property of the Company or the Association.\n\n(p) No default  exists,  and no event has occurred  which with\nnotice or lapse of time, or both,  would constitute a default on the part of the\nCompany or the  Association,  in the due performance and observance of any term,\ncovenant or condition of any indenture, mortgage, deed of trust, note, bank loan\nor credit agreement or any other instrument or agreement to which the Company or\nthe  Association  is a party or by which any of them or any of their property is\nbound or affected in any respect  which,  in any such cases,  is material to the\nCompany or the Association; such agreements are in full force and effect; and no\nother party to any such  agreements  has instituted or, to the best knowledge of\nthe Company or the Association,  threatened any action or proceeding wherein the\nCompany  or  the  Association  would  or  might  be  alleged  to be  in  default\nthereunder.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::96a1ee78d5fa", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::c816cb4677fd"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::c816cb4677fd", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(q)", "section_title": "Representations and Warranties", "clause_type": "Representation/Warranty (capitalization and issuance of shares)", "path": "4 ➞ 4.(q)", "text": "ciation,  threatened any action or proceeding wherein the\nCompany  or  the  Association  would  or  might  be  alleged  to be  in  default\nthereunder.\n\n(q)  Upon  consummation  of the  Conversion,  the  authorized,\nissued and  outstanding  equity  capital of the Company will be within the range\nset forth in the Registration Statement under the caption  \"Capitalization,\" and\nno shares of Common Stock have been or will be issued and  outstanding  prior to\nthe  Closing  Date  referred to in Section 2; the Shares will have been duly and\nvalidly  authorized  for issuance  and, when issued and delivered by the Company\npursuant to the Plan against payment of the\n\n-8-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0fb4a4af85d6", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::172c3bd9342a"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::172c3bd9342a", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(q)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4.(q)", "text": "l have been duly and\nvalidly  authorized  for issuance  and, when issued and delivered by the Company\npursuant to the Plan against payment of the\n\n-8-\n\nconsideration  calculated  as  set  forth  in  the  Plan  and  in  the  Offering\nProspectus,  will be duly and validly issued and fully paid and  non-assessable;\nthe issuance of the Shares will not violate any preemptive rights; and the terms\nand  provisions  of the Shares  will  conform in all  material  respects  to the\ndescription  thereof  contained in the  Registration  Statement and the Offering\nProspectus.  Upon the  issuance of the Shares,  good title to the Shares will be\ntransferred from the Company to the purchasers thereof against payment therefor,\nsubject to such claims as may be  asserted  against  the  purchasers  thereof by\nthird party claimants.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::c816cb4677fd", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4475ac9cab19"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4475ac9cab19", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(r)-(s)", "section_title": "Representations and Warranties", "clause_type": "Representations and warranties (regulatory approvals; auditor independence)", "path": "4 ➞ 4.(r)-(s)", "text": "e purchasers thereof against payment therefor,\nsubject to such claims as may be  asserted  against  the  purchasers  thereof by\nthird party claimants.\n\n(r) No  approval of any  regulatory  or  supervisory  or other\npublic  authority is required in  connection  with the execution and delivery of\nthis  Agreement  or the  issuance of the Shares,  except for the approval of the\nOTS, the Commission and any necessary  qualification  or registration  under the\nsecurities or blue sky laws of the various  states in which the Shares are to be\noffered and as may be required under the regulations-of the National Association\nof Securities Dealers,  Inc. (\"NASD\") and the National Association of Securities\nDealers Automated Quotation (\"NASDAQ\") National Market.\n\n(s) KPMG, which has certified the financial  statements of the\nAssociation  included in the  Registration  Statement,  are with  respect to the\nCompany and the Association independent public accountants within the meaning of\nthe Code of Professional  Ethics of the American  Institute of Certified  Public\nAccountants and Title 12 of the Code of Federal Regulations, Section 571.2(c)(3)\nand the 1933 Act and the 1933 Act Regulations.", "numbers_present": null, "definition_terms": ["NASD", "NASDAQ"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::172c3bd9342a", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::75f44da9aa36"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::75f44da9aa36", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4.(t)-(u)", "section_title": "Representations and Warranties", "clause_type": "Representations and warranties", "path": "4 ➞ 4.(t) and 4.(u)", "text": "e of Certified  Public\nAccountants and Title 12 of the Code of Federal Regulations, Section 571.2(c)(3)\nand the 1933 Act and the 1933 Act Regulations.\n\n(t) The  Company  and the  Association  have  (subject  to all\nproperly  obtained  extensions)  timely filed all required federal and state tax\nreturns, have paid all taxes that have become due and payable in respect of such\nreturns,  have made adequate  reserves for similar future tax liabilities and no\ndeficiency has been asserted with respect thereto by any taxing authority.\n\n(u)  Appropriate  arrangements  have been made for placing the\nfunds  received  from  subscriptions  for  Shares  in  special  interest-bearing\naccounts  with the  Association  until all  Shares  are sold and paid for,  with\nprovision for refund to the  purchasers in the event that the  Conversion is not\ncompleted  for whatever  reason or for delivery to the Company if all Shares are\nsold.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4475ac9cab19", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4610ad7c05f2"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4610ad7c05f2", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(v)-(w)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant(s)", "path": "6 ➞ 6.(v)-(w)", "text": "und to the  purchasers in the event that the  Conversion is not\ncompleted  for whatever  reason or for delivery to the Company if all Shares are\nsold.\n\n(v) The Company and the  Association  are in compliance in all\nmaterial  respects with the  applicable  financial  record keeping and reporting\nrequirements of the Currency and Foreign Transactions  Reporting Act of 1970, as\namended, and the regulations and rules thereunder.\n\n(w) To the knowledge of the Company and the Association,  none\nof the Company,  the Association nor employees of the Company or the Association\nhave made any  payment of funds of the Company or the  Association  as a loan to\nany person for the purchase of the Shares.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::75f44da9aa36", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bc136b74e776"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bc136b74e776", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(x)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4(x)", "text": "Company or the Association\nhave made any  payment of funds of the Company or the  Association  as a loan to\nany person for the purchase of the Shares.\n\n(x)  Prior  to  the   Conversion,   the  Association  was  not\nauthorized  to issue  shares of capital  stock and  neither  the Company nor the\nAssociation has: (i) issued any securities within the last 18 months (except for\nnotes to evidence  other bank loans and reverse  repurchase  agreements or other\nliabilities);  (ii) had any material  dealings within the twelve months prior to\nthe date  hereof  with any  member  of the NASD,  or any  person  related  to or\nassociated with such member, other than discussions and meetings relating to the\nproposed  Subscription and Public  Offerings and routine  purchases and sales of\nU.S.  government and agency  securities and other investment  securities;  (iii)\nentered  into  a  financial  or  management   consulting   agreement  except  as\ncontemplated  hereunder;  and (iv)  engaged  any  intermediary  between  Capital\nResources and the Company and the Association in connection with the offering of\nCommon Stock, and no person is being compensated in any manner for such service.\n\n-9-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4610ad7c05f2", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::05427d894714"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::05427d894714", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "5", "section_title": "Capital Resources represents and warrants to the Company and the Association that", "clause_type": "Representations and Warranties", "path": "5 ➞ 5.(a)", "text": "e Company and the Association in connection with the offering of\nCommon Stock, and no person is being compensated in any manner for such service.\n\n-9-\n\n(y)      The Association has no subsidiaries.\n\nAny  certificates  signed by an officer of the  Company or the\nAssociation and delivered to Capital Resources or its counsel that refer to this\nAgreement shall be deemed to be a representation  and warranty by the Company or\nthe Association to Capital  Resources as to the matters covered thereby with the\nsame effect as if such representation and warranty were set forth herein.\n\nSECTION 5. Capital  Resources  represents  and warrants to the\nCompany and the Association that:\n\n(a) Capital Resources is a corporation and is validly existing\nin good standing  under the laws of the District of Columbia with full power and\nauthority  to provide  the  services  to be  furnished  to the  Company  and the\nAssociation hereunder.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bc136b74e776", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::46b633818740"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::46b633818740", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "5.(b)-(c)", "section_title": "Capital Resources represents and warrants to the Company and the Association", "clause_type": "Representations and Warranties", "path": "5 ➞ 5.(b)-(c)", "text": "f the District of Columbia with full power and\nauthority  to provide  the  services  to be  furnished  to the  Company  and the\nAssociation hereunder.\n\n(b) The  execution  and  delivery  of this  Agreement  and the\nconsummation of the transactions  contemplated hereby have been duly and validly\nauthorized by all necessary  action on the part of Capital  Resources,  and this\nAgreement has been duly and validly executed and delivered by Capital  Resources\nand is the legal, valid and binding agreement of Capital Resources,  enforceable\nin accordance with its terms.\n\n(c) Each of Capital  Resources and its  employees,  agents and\nrepresentatives  who shall perform any of the services  hereunder  shall be duly\nauthorized  and  empowered,  and shall have all licenses,  approvals and permits\nnecessary,  to perform  such  services  and Capital  Resources  is a  registered\nselling  agent in the  jurisdictions  listed in Exhibit A hereto and will remain\nregistered  in such  jurisdictions  in which  the  Company  is  relying  on such\nregistration for the sale of the Shares,  until the Conversion is consummated or\nterminated.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::05427d894714", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d4334eb89d3c"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d4334eb89d3c", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "5.(d)-(e); 6", "section_title": "Covenants of the Company and Association", "clause_type": "Covenants; Representations and Warranties", "path": "5 ➞ 5.(d) & 5.(e) ➞ 6", "text": "risdictions  in which  the  Company  is  relying  on such\nregistration for the sale of the Shares,  until the Conversion is consummated or\nterminated.\n\n(d) The  execution  and delivery of this  Agreement by Capital\nResources,  the  consummation  of  the  transactions   contemplated  hereby  and\ncompliance  with the terms and  provisions  hereof will not  conflict  with,  or\nresult  in a breach  of,  any of the  terms,  provisions  or  conditions  of, or\nconstitute  a default (or event which with notice or lapse of time or both would\nconstitute  a  default)  under,  the  certificate  of  incorporation  of Capital\nResources or any  agreement,  indenture  or other  instrument  to which  Capital\nResources is a party or by which its property is bound,  or law or regulation by\nwhich Capital Resources is bound.\n\n(e) Funds  received by Capital  Resources  to purchase  Common\nStock  will be handled  in  accordance  with Rule  15c2-4  under the  Securities\nExchange Act of 1934, as amended.\n\nSECTION 6.  Covenants  of the  Company  and  Association.  The\nCompany and the Association  hereby jointly and severally  covenant with Capital\nResources as follows:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::46b633818740", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::aa8976db96ab"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::aa8976db96ab", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(a)-(b)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenants", "path": "6 ➞ 6.(a)-(b)", "text": "enants  of the  Company  and  Association.  The\nCompany and the Association  hereby jointly and severally  covenant with Capital\nResources as follows:\n\n(a) The Company has filed the Registration  Statement with the\nCommission.  The Company  will not, at any time after the date the  Registration\n\nStatement  is  declared  effective,  file any  amendment  or  supplement  to the\nRegistration  Statement  without  providing Capital Resources and its counsel an\nopportunity  to review such  amendment or file any  amendment or  supplement  to\nwhich amendment Capital Resources or its counsel shall reasonably object.\n\n(b)      The Association has filed the Conversion Application \nwith the OTS. The\n\n-10-\n\nAssociation  will not, at any time after the date the Conversion  Application is\napproved, file any amendment or supplement to the Conversion Application without\nproviding  Capital  Resources  and its  counsel an  opportunity  to review  such\namendment or supplement  or file any amendment or supplement to which  amendment\nor supplement Capital Resources or its counsel shall reasonably object.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d4334eb89d3c", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8c4eaeef38d7"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8c4eaeef38d7", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(c)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant", "path": "6 ➞ 6.(c)", "text": "endment or supplement  or file any amendment or supplement to which  amendment\nor supplement Capital Resources or its counsel shall reasonably object.\n\n(c) The  Company  and the  Association  will  use  their  best\nefforts to cause any post-effective  amendment to the Registration  Statement to\nbe declared effective by the Commission and any post-effective  amendment to the\nConversion  Application  to be  approved  by the OTS and will  immediately  upon\nreceipt of any  information  concerning  the events listed below notify  Capital\nResources and promptly confirm the notice in writing:  (i) when the Registration\nStatement,   as  amended,  has  become  effective;   (ii)  when  the  Conversion\nApplication,  as amended,  has been approved by the OTS; (iii) of the receipt of\nany comments from the Commission,  the OTS or the FDIC or any other governmental\nentity with respect to the Conversion or the  transactions  contemplated by this\nAgreement;  (iv) of the  request by the  Commission,  the OTS or the FDIC or any\nother  governmental  entity for any amendment or supplement to the  Registration\nStatement or for additional information;  (v) of the issuance by the Commission,\nthe OTS, the FDIC or any other governmental  entity of any order or other action\nsuspending the  Subscription or Public  Offerings or the use of the Registration\nStatement or the Offering  Prospectus or any other filing of the Company and the\nAssociation  under the Conversion  Regulations or other  applicable  law, or the\nthreat of any such action;  (vi) the issuance by the Commission,  the OTS or the\nFDIC,  or  any  other  state  authority,   of  any  stop  order  suspending  the\neffectiveness  of the  Registration  Statement or of the initiation or threat of\ninitiation  or  threat  of any  proceedings  for that  purpose;  or (vii) of the\noccurrence of any event  mentioned in paragraph  (h) below.  The Company and the\nAssociation  will make every  reasonable  effort to prevent the  issuance by the\nCommission,  the OTS or the FDIC, or any other state authority of any such order\nand,  if any such  order  shall at any time be  issued,  to obtain  the  lifting\nthereof at the earliest possible time.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::aa8976db96ab", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::87047ba195cf"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::87047ba195cf", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6(d)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant", "path": "6 ➞ 6(d)", "text": "te authority of any such order\nand,  if any such  order  shall at any time be  issued,  to obtain  the  lifting\nthereof at the earliest possible time.\n\n(d) The  Company  and the  Association  will  provide  Capital\nResources and its counsel notice of its intention to file,  and reasonable  time\nto  review  prior to  filing  any  amendment  or  supplement  to the  Conversion\nApplication  or the  Holding  Company  Application  and  will  not file any such\namendment or supplement to which Capital  Resources shall  reasonably  object or\nwhich shall be reasonably disapproved by its counsel.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8c4eaeef38d7", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e8b5c3d8f637"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e8b5c3d8f637", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(e)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant (delivery of documents)", "path": "6 ➞ 6.(e)", "text": "t file any such\namendment or supplement to which Capital  Resources shall  reasonably  object or\nwhich shall be reasonably disapproved by its counsel.\n\n(e) The Company and the  Association  will  deliver to Capital\nResources  and to its  counsel  two  conformed  copies of each of the  following\ndocuments, with all exhibits: the Conversion Application and the Holding Company\nApplication,  as originally  filed and of each amendment or supplement  thereto,\nand the Registration  Statement, as originally filed and each amendment thereto.\nFurther,  the Company and the Association will deliver such additional copies of\nthe foregoing  documents to counsel for Capital Resources as may be required for\nany NASD and blue sky filings. In addition, the Company and the Association will\nalso  deliver  to  Capital  Resources  such  number of  copies  of the  Offering\nProspectus,  as amended or  supplemented,  as Capital  Resources may  reasonably\nrequest.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::87047ba195cf", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3a307b01cb94"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3a307b01cb94", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(f)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant", "path": "6 ➞ 6.(f)", "text": "apital  Resources  such  number of  copies  of the  Offering\nProspectus,  as amended or  supplemented,  as Capital  Resources may  reasonably\nrequest.\n\n(f) The Company will furnish to Capital  Resources,  from time\nto time during the period when the Offering  Prospectus (or any later prospectus\nrelated to this Offering) is required to be delivered  under the 1933 Act or the\nSecurities  Exchange Act of 1934 (the \"1934 Act\"), such number of copies of such\nprospectus  (as amended or  supplemented)  as Capital  Resources may  reasonably\nrequest  for the  purposes  contemplated  by the 1933 Act or the 1934 Act or the\nrespective  applicable rules and regulations of the Commission  thereunder.  The\nCompany authorizes Capital Resources to use the Offering  Prospectus (as amended\nor supplemented, if amended or supplemented) for any lawful manner in\n\n-11-\n\nconnection with the sale of the Shares by Capital Resources.", "numbers_present": null, "definition_terms": ["1934 Act"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e8b5c3d8f637", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::25896caced76"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::25896caced76", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6(g)", "section_title": "Covenants of the Company and the Association", "clause_type": "Covenant", "path": "6 ➞ 6(g)", "text": "(as amended\nor supplemented, if amended or supplemented) for any lawful manner in\n\n-11-\n\nconnection with the sale of the Shares by Capital Resources.\n\n(g)  The  Company  and  the  Association  will  comply  in all\nmaterial  respects  with  any  and  all  terms,  conditions,   requirements  and\nprovisions  with respect to the  Conversion  and the  transactions  contemplated\nthereby imposed by the Commission, by applicable state law and regulations,  and\nby the 1933 Act, the 1934 Act and the rules and  regulations  of the  Commission\npromulgated  under such statutes,  to be complied with prior to or subsequent to\nthe Closing Date and when the Offering  Prospectus  is required to be delivered,\nthe Company and the Association will comply in all material  respects,  at their\nown expense,  with all requirements imposed upon them by the OTS, the Conversion\nRegulations,  the FDIC, the Commission,  by applicable state law and regulations\nand by the  1933  Act,  the  1934  Act  and the  rules  and  regulations  of the\nCommission promulgated under such statutes,  including, without limitation, Rule", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3a307b01cb94", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a17374d0e4cf"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a17374d0e4cf", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6(g)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant (Regulatory compliance)", "path": "6 ➞ 6(g)", "text": "1933  Act,  the  1934  Act  and the  rules  and  regulations  of the\nCommission promulgated under such statutes,  including, without limitation, Rule\n\n10b-6 under the 1934 Act, in each case as from time to time in force,  so far as\nnecessary  to permit  the  continuance  of sales or  dealing in shares of Common\nStock  during  such  period in  accordance  with the  provisions  hereof and the\nOffering Prospectus.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::25896caced76", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::b4ba00141a6c"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::b4ba00141a6c", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6(h)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant (prospectus amendment/supplement obligation)", "path": "6 ➞ 6(h)", "text": "nuance  of sales or  dealing in shares of Common\nStock  during  such  period in  accordance  with the  provisions  hereof and the\nOffering Prospectus.\n\n(h) If,  at any time  during  the  period  when  the  Offering\nProspectus  relating  to the  Shares  is  required  to be  delivered,  any event\nrelating to or affecting the Company or the Association shall occur, as a result\nof which it is necessary or  appropriate,  in the reasonable  opinion of counsel\nfor the  Company and the  Association  or in the  reasonable  opinion of Capital\nResources'  counsel,  to amend  or  supplement  the  Registration  Statement  or\nOffering  Prospectus  in order to make the  Registration  Statement  or Offering\nProspectus not misleading in light of the circumstances  existing at the time it\nis delivered  to a purchaser,  the Company and the  Association  will,  at their\nexpense,  forthwith prepare, file with the Commission and the OTS and furnish to\nCapital  Resources a reasonable  number of copies of any amendment or amendments\nof, or a supplement or supplements  to, the  Registration  Statement or Offering\nProspectus (in form and substance  reasonably  satisfactory to Capital Resources\nand its  counsel  after a  reasonable  time  for  review)  which  will  amend or\nsupplement the Registration  Statement or Offering Prospectus so that as amended\nor  supplemented  it will not contain an untrue  statement of a material fact or\nomit to state a material fact necessary in order to make the statements therein,\nin light of the  circumstances  existing  at the  time the  Offering  Prospectus\nreasonably is delivered to a purchaser, not misleading.  For the purpose of this\nAgreement,  the Company and the Association  each will timely furnish to Capital\nResources such information with respect to itself as Capital  Resources may from\ntime to time request.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a17374d0e4cf", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::29c2d63dce91"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::29c2d63dce91", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(i)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant (Blue Sky qualification/registration obligation)", "path": "6 ➞ 6.(i)", "text": "ssociation  each will timely furnish to Capital\nResources such information with respect to itself as Capital  Resources may from\ntime to time request.\n\n(i) The Company and the  Association  will take all  necessary\nactions, in cooperation with Capital Resources,  and furnish to whomever Capital\nResources may direct, such information as may be required to qualify or register\nthe Shares for offering and sale by the Company under the applicable  securities\nor blue sky laws of such  jurisdictions  in which the shares are required  under\nthe  Conversion  Regulations  to be sold or as Capital  Resources may reasonably\ndesignate and as reasonably  agreed to by the  Association;  provided,  however,\nthat the Company  shall not be obligated to file any general  consent to service\nof process or to qualify to do business in any  jurisdiction  in which it is not\nso  qualified.  In each  jurisdiction  where any of the  Shares  shall have been\nqualified or registered as above  provided,  the Company will make and file such\nstatements  and reports in each  fiscal  period as are or may be required by the\nlaws of such jurisdiction.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::b4ba00141a6c", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8c65cae6562f"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8c65cae6562f", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(j)-(k)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant", "path": "6 ➞ 6.(j)-(k)", "text": "ided,  the Company will make and file such\nstatements  and reports in each  fiscal  period as are or may be required by the\nlaws of such jurisdiction.\n\n(j) The liquidation account for the benefit of account holders\nwith account  balances of $50 or more as of the applicable  record dates will be\nduly  established and maintained in accordance with the requirements of the OTS,\nand such Eligible Account Holders and Supplemental  Eligible Account Holders who\ncontinue to maintain  their  savings  accounts in the  Association  will have an\ninchoate interest\n\n-12-\n\nin their pro rata portion of the liquidation account which shall have a priority\nsuperior  to that of the  holders  of shares  of Common  Stock in the event of a\ncomplete liquidation of the Association.\n\n(k) The  Company and the  Association  will not sell or issue,\ncontract  to sell or  otherwise  dispose  of, for a period of 180 days after the\ndate hereof,  without Capital  Resources' prior written  consent,  any shares of\nCommon Stock other than in connection with any plan or arrangement  described in\nthe Offering Prospectus.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::29c2d63dce91", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::2f763049614c"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::2f763049614c", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(l)-(m)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant (registration and reporting obligations)", "path": "6 ➞ 6.(l); 6 ➞ 6.(m)", "text": "rces' prior written  consent,  any shares of\nCommon Stock other than in connection with any plan or arrangement  described in\nthe Offering Prospectus.\n\n(l) The Company shall  register its Common Stock under Section\n12(g) of the 1934 Act concurrent  with the stock  offering  pursuant to the Plan\nand shall request that such  registration  be effective  upon  completion of the\nConversion.  The Company shall maintain the  effectiveness of such  registration\nfor not less than three years or such shorter period as permitted by the OTS.\n\n(m) During the period during which the Company's  common stock\nis  registered  under  the 1934 Act or for  three  years  from the date  hereof,\nwhichever  period is greater,  the Company will furnish to its  stockholders  as\nsoon as  practicable  after  the  end of  each  fiscal  year  an  annual  report\n(including a balance sheet and  statements of income,  stockholders'  equity and\nchanges in  financial  position or cash flow  statement of the Company as at the\nend of and for such  year,  certified  by  independent  public  accountants  and\nprepared in accordance with Regulation S-X under the 1934 Act).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8c65cae6562f", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f538efc6f9d7"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f538efc6f9d7", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(n)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant", "path": "6 ➞ 6.(n)", "text": "t the\nend of and for such  year,  certified  by  independent  public  accountants  and\nprepared in accordance with Regulation S-X under the 1934 Act).\n\n(n) During the period of three years from the date hereof, the\nCompany  will  furnish to Capital  Resources:  (i) a copy of each  report of the\nCompany  furnished  to or filed  with the  Commission  under the 1934 Act or any\nnational  securities  exchange or system on which any class of securities of the\nCompany is listed or quoted (including but not limited to, reports on Form 10-K,\n10-Q and 8-K and all proxy  statements  and annual reports to  stockholders),  a\ncopy of each report of the Company mailed to its  stockholders or filed with the\nCommission or the OTS or any other  supervisory  or regulatory  authority or any\nnational  securities  exchange or system on which any class of securities of the\nCompany is listed or quoted,  each press  release  and  material  news items and\nadditional  public  documents and information with respect to the Company or the\nAssociation as Capital Resources may reasonably  request,  and (ii) from time to\ntime, such other publicly available  information  concerning the Company and the\nAssociation as Capital Resources may reasonably request.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::2f763049614c", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a5ba79a80573"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a5ba79a80573", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6(o)-(q)", "section_title": "Covenants of the Company and the Association", "clause_type": "Covenant", "path": "6 ➞ 6.(o) ➞ 6.(p) ➞ 6.(q)", "text": "from time to\ntime, such other publicly available  information  concerning the Company and the\nAssociation as Capital Resources may reasonably request.\n\n(o)      The Company and the Association will use the net\n\nproceeds from the sale of the Shares in the manner set forth in the Offering\nProspectus under the caption \"Use of Proceeds.\"\n\n(p) Other than as permitted by the Conversion Regulations, the\n1933 Act, the 1933 Act Regulations and the laws of any state in which the Shares\nare qualified for sale,  neither the Company nor the Association will distribute\nany prospectus,  offering circular or other offering material in connection with\nthe offer and sale of the Shares.\n\n(q) The Company will make generally  available to its security\nholders  as soon as  practicable,  but not later than 90 days after the close of\nthe period an earnings  statement (in form complying with the provisions of Rule\n158 under the 1933 Act) covering a twelve-month  period beginning not later than\nthe first day of the Company's  fiscal quarter next following the effective date\n(as defined in said Rule 158) of the Registration Statement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f538efc6f9d7", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::07b09d1fd6b5"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::07b09d1fd6b5", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(r)-(s)", "section_title": "Covenants of the Company and the Association", "clause_type": "Covenant", "path": "6 ➞ 6.(r)-(s)", "text": "ter than\nthe first day of the Company's  fiscal quarter next following the effective date\n(as defined in said Rule 158) of the Registration Statement.\n\n(r) The Company will file with the Commission  such reports on\nForm SR as may be required pursuant to Rule 463 under the 1933 Act.\n\n-13-\n\n(s)  The  Company  will  obtain   approval  for  and  maintain\nquotation of the shares on the NASDAQ National  Market  effective on or prior to\nthe Closing Date.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a5ba79a80573", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e80b88ceeeb7"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e80b88ceeeb7", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(s)-(t)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant", "path": "6 ➞ 6.(s) ➞ 6.(t)", "text": "ompany  will  obtain   approval  for  and  maintain\nquotation of the shares on the NASDAQ National  Market  effective on or prior to\nthe Closing Date.\n\n(t) The Association will maintain appropriate arrangements for\ndepositing all funds received from persons mailing  subscriptions  for or orders\nto  purchase   Shares  in  the   Subscription   and  Public   Offerings   on  an\ninterest-bearing  basis at the rate described in the Offering  Prospectus  until\nthe Closing Date and satisfaction of all conditions  precedent to the release of\nthe   Association's   obligation  to  refund  payments   received  from  persons\nsubscribing for or ordering Shares in the  Subscription  and Public Offerings in\naccordance  with the  Plan as  described  in the  Offering  Prospectus  or until\nrefunds  of such  funds  have  been  made to the  persons  entitled  thereto  or\nwithdrawal  authorizations canceled in accordance with the Plan and as described\nin the Offering  Prospectus.  The Association  will maintain such records of all\nfunds received to permit the funds of each  subscriber to be separately  insured\nby the FDIC (to the maximum extent  allowable) and to enable the  Association to\nmake the  appropriate  refunds of such funds in the event that such  refunds are\nrequired to be made in accordance with the Plan and as described in the Offering\nProspectus.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::07b09d1fd6b5", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::120e59da3954"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::120e59da3954", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(u)-(x)", "section_title": "Covenants of the Company and Association", "clause_type": "Covenant", "path": "6 ➞ 6.(u) ➞ 6.(v) ➞ 6.(w) ➞ 6.(x)", "text": "refunds of such funds in the event that such  refunds are\nrequired to be made in accordance with the Plan and as described in the Offering\nProspectus.\n\n(u)      The Company will promptly register as a savings and \nloan holding company under the HOLA.\n\n(v) The Company and the Association will take such actions and\nfurnish such  information  as are reasonably  requested by Capital  Resources in\norder for Capital Resources to ensure compliance with the \"Interpretation of the\nBoard of Governors of the NASD on Free Riding and Withholding.\"\n\n(w) The Company will conduct its  businesses  in compliance in\nall  material  respects  with all  applicable  federal  and state  laws,  rules,\nregulations,   decisions,   directives  and  orders,  including  all  decisions,\ndirectives and orders of the Commission, the OTS and the FDIC.\n\n(x) The  Association  will not  amend  the Plan of  Conversion\nwithout  Capital  Resources'  prior  written  consent in any manner that, in the\nreasonable opinion of Capital  Resources,  would materially and adversely affect\nthe sale of the Shares or the terms of this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e80b88ceeeb7", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bf0525d4eb17"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bf0525d4eb17", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "6.(x)-(y)", "section_title": "Covenants of the Company and Association", "clause_type": "covenant", "path": "6 ➞ 6.(x) / 6 ➞ 6.(y)", "text": "r that, in the\nreasonable opinion of Capital  Resources,  would materially and adversely affect\nthe sale of the Shares or the terms of this Agreement.\n\n(y) The Company shall advise Capital Resources,  if necessary,\nas to the allocation of the Shares in the event of an oversubscription and shall\nprovide  Capital  Resources  with any  information  necessary to assist  Capital\nResources in allocating the Shares in such event and such  information  shall be\naccurate and reliable.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::120e59da3954", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d4d3b3ddbcbb"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d4d3b3ddbcbb", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "7", "section_title": "Payment of Expenses", "clause_type": "Expenses / Reimbursement clause", "path": "7", "text": "any  information  necessary to assist  Capital\nResources in allocating the Shares in such event and such  information  shall be\naccurate and reliable.\n\nSECTION 7. Payment of Expenses.  Whether or not this Agreement\nbecomes effective,  the Conversion is completed or the sale of the Shares by the\nCompany is consummated,  the Company and Association jointly and severally agree\nto pay directly for or to reimburse  Capital  Resources  for (to the extent that\nsuch expenses have been reasonably incurred by Capital Resources) (a) all filing\nfees and expenses  incurred in connection with the qualification or registration\nof the Shares for offer and sale by the Company under the securities or blue sky\nlaws of any  jurisdictions  Capital  Resources  and the  Company  may agree upon\npursuant to subsection  (i) of Section 6 above,  including  counsel fees paid or\nincurred by the Company, the Association or Capital Resources in connection with\nsuch   qualification   or  registration  or  exemption  from   qualification  or\nregistration;  (b) all filing fees in connection with all filings with the NASD;\n(c) any stock issue or transfer  taxes which may be payable  with respect to the\nsale of the Shares to purchasers in the Conversion; (d) reasonable and necessary\nexpenses of the Conversion,", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bf0525d4eb17", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::27c426e8d458"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::27c426e8d458", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "7(d)-(e)", "section_title": "Payment of Expenses", "clause_type": "Expense allocation / Reimbursement", "path": "7 ➞ 7(d)-(e)", "text": "which may be payable  with respect to the\nsale of the Shares to purchasers in the Conversion; (d) reasonable and necessary\nexpenses of the Conversion,\n\n-14-\n\nincluding but not limited to,  attorneys'  fees,  transfer agent,  registrar and\nother agent charges,  fees relating to auditing and accounting or other advisors\nand costs of printing all documents necessary in connection with the Conversion;\n\nand (e) out-of-pocket  expenses incurred by Capital Resources in connection with\nthe  Conversion  or any  of the  transactions  contemplated  hereby,  including,\nwithout limitation,  the fees of its attorneys, and reasonable communication and\ntravel expenses.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d4d3b3ddbcbb", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::dbf7ac958fea"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::dbf7ac958fea", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Conditions precedent", "path": "8", "text": "the  transactions  contemplated  hereby,  including,\nwithout limitation,  the fees of its attorneys, and reasonable communication and\ntravel expenses.\n\nSECTION  8.  Conditions  to  Capital  Resources'  Obligations.\nCapital Resources'  obligations  hereunder,  as to the Shares to be delivered at\nthe Closing Date,  are subject to the  condition  that all  representations  and\nwarranties and other  statements of the Company and the Association  herein are,\nat and as of the  commencement of the  Subscription  and Public Offerings and at\nand as of the Closing  Date,  true and  correct in all  material  respects,  the\ncondition  that the  Company and the  Association  shall have  performed  in all\nmaterial  respects  all of their  obligations  hereunder  to be  performed on or\nbefore such dates, and to the following further conditions:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::27c426e8d458", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::67983bf1da67"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::67983bf1da67", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(a)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Conditions precedent", "path": "8 ➞ 8.(a)", "text": "d  in all\nmaterial  respects  all of their  obligations  hereunder  to be  performed on or\nbefore such dates, and to the following further conditions:\n\n(a) At the Closing Date, the Company and the Association  will\nhave  completed  the  conditions  precedent  to,  and shall have  conducted  the\nConversion in all material respects in accordance with, the Plan, the Conversion\nRegulations and all other  applicable laws,  regulations,  decisions and orders,\nincluding all terms,  conditions,  requirements and provisions  precedent to the\nConversion imposed upon them by the OTS.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::dbf7ac958fea", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::533c3b3018a0"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::533c3b3018a0", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8(b)-(c)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Conditions precedent / Closing conditions", "path": "8 ➞ 8(b) ➞ 8(c)", "text": "ions,  decisions and orders,\nincluding all terms,  conditions,  requirements and provisions  precedent to the\nConversion imposed upon them by the OTS.\n\n(b)  The  Registration  Statement  shall  have  been  declared\neffective by the Commission and the Conversion  Application  approved by the OTS\nnot later than 5:30 p.m.  (eastern time) on the date of this Agreement,  or with\nCapital  Resources' consent at a later time and date; and at the Closing Date no\nstop order suspending the effectiveness of the Registration Statement shall have\nbeen issued under the 1933 Act or proceedings  therefore initiated or threatened\nby  the  Commission  or any  state  authority,  and no  order  or  other  action\nsuspending the  authorization of the Offering  Prospectus or the consummation of\nthe Conversion shall have been issued or proceedings  therefore initiated or, to\nthe Company's or Association's knowledge, threatened by the Commission, the OTS,\nthe FDIC or any state authority.\n\n(c)      At the Closing Date, Capital Resources shall have\nreceived:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::67983bf1da67", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::11e7d1490582"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::11e7d1490582", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(c)(1)(i)-(ii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Conditions precedent (required legal opinions)", "path": "8 ➞ 8.(c) ➞ 8.(c)(1) ➞ 8.(c)(1)(i)-(ii)", "text": "owledge, threatened by the Commission, the OTS,\nthe FDIC or any state authority.\n\n(c)      At the Closing Date, Capital Resources shall have\nreceived:\n\n(1)  The  favorable  opinion,  dated  as of the  Closing  Date\naddressed to Capital Resources and for its benefit, of Malizia,  Spidi, Sloane &\nFisch, P.C., counsel for the Company and the Association dated the Closing Date,\naddressed to Capital Resources and in form and substance to the effect that:\n\n(i) The  Company  has been duly  incorporated  and is  validly\nexisting  as a  corporation  in good  standing  under  the laws of the  State of\nDelaware.\n\n(ii) The Company has  corporate  power and  authority  to own,\nlease and operate its properties and to conduct its business as described in the\nRegistration Statement and the Offering Prospectus; and the Company is qualified\nto do  business  as a  foreign  corporation  in New  York,  to the  best of such\ncounsel's  knowledge based on the  conferences and document review  specified in\nitem (xiii) below, the only state in which it is doing business.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::533c3b3018a0", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::83cfb9a95a26"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::83cfb9a95a26", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(iii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent (counsel opinion requirement)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(iii)", "text": "such\ncounsel's  knowledge based on the  conferences and document review  specified in\nitem (xiii) below, the only state in which it is doing business.\n\n(iii) The  Association  was a duly  organized and is a validly\nexisting  federally-chartered  savings  and loan  association  in mutual form of\norganization  and upon the  Conversion  will become a duly organized and validly\nexisting federally-chartered savings bank in capital stock form of organization,\nin\n\n-15-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::11e7d1490582", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f76341366bcd"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f76341366bcd", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "4(f)", "section_title": "Representations and Warranties", "clause_type": "representation and warranty", "path": "4 ➞ 4(f)", "text": "on the  Conversion  will become a duly organized and validly\nexisting federally-chartered savings bank in capital stock form of organization,\nin\n\n-15-\n\nboth instances  duly  authorized to conduct its business and own its property as\ndescribed in the Registration Statement; and the Association is in good standing\nunder  the  laws  of the  United  States  and is  duly  qualified  as a  foreign\ncorporation to transact business and is in good standing in each jurisdiction in\nwhich its  ownership of property or leasing of  properties or the conduct of its\nbusiness  requires such  qualification  unless the failure to be so qualified in\none or more such  jurisdictions  would not have a material adverse effect on the\ncondition,  financial or  otherwise,  or the  business,  operations or income or\nbusiness  prospects of the  Association.  The  activities of the  Association as\ndescribed  in the  Offering  Prospectus,  insofar  as they are  material  to the\noperations  and  financial  condition of the  Association,  are permitted by the\nrules,  regulations and resolutions and practices of the OTS or the FDIC and any\nother federal or state authorities.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::83cfb9a95a26", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d566009e9323"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d566009e9323", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(iv)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "closing condition / counsel opinion", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(iv)", "text": "ssociation,  are permitted by the\nrules,  regulations and resolutions and practices of the OTS or the FDIC and any\nother federal or state authorities.\n\n(iv)  The  Association  is a  member  of the  FHLBNY,  and the\ndeposit  accounts of the  Association  are insured by the FDIC up to the maximum\namount  allowed  under  law  and to the  best  of such  counsel's  knowledge  no\nproceedings  for the  termination or revocation of such insurance are pending or\nthreatened;  and the description of the liquidation  account as set forth in the\nRegistration  Statement  and the  Offering  Prospectus  under the  caption  \"The\nConversion - Effects of Conversion to Stock Form on Depositors  and Borrowers of\nthe  Bank -  Liquidation  Account\"  has been  reviewed  by such  counsel  and is\naccurate in all material respects.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f76341366bcd", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::dd6b8554efeb"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::dd6b8554efeb", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(v)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent (counsel opinion / closing condition)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(v)", "text": "rm on Depositors  and Borrowers of\nthe  Bank -  Liquidation  Account\"  has been  reviewed  by such  counsel  and is\naccurate in all material respects.\n\n(v)  Upon  consummation  of the  Conversion,  the  authorized,\nissued and outstanding  capital stock of the Company will be as set forth in the\nRegistration   Statement   and  the  Offering   Prospectus   under  the  caption\n\"Capitalization,\"  and no shares of Common  Stock have been issued  prior to the\nClosing Date; at the time of the Conversion,  the Shares subscribed for pursuant\nto the Offerings will have been duly and validly  authorized  for issuance,  and\nwhen issued and delivered by the Company pursuant to the Plan against payment of\n\nthe consideration  calculated as set forth in the Plan, will be duly and validly\nissued and fully paid and non-assessable;  and the issuance of the Shares is not\nsubject to preemptive rights.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d566009e9323", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::df80fbcca694"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::df80fbcca694", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(vi)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "condition precedent (opinion of counsel regarding issuance and ownership of stock)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(vi)", "text": "h in the Plan, will be duly and validly\nissued and fully paid and non-assessable;  and the issuance of the Shares is not\nsubject to preemptive rights.\n\n(vi)  The  issuance  and  sale  of  the  common  stock  of the\nAssociation  to the  Company  have  been  duly  and  validly  authorized  by all\nnecessary  corporate  action on the part of the Company and the Association and,\nupon payment  therefor in accordance  with the terms of the Plan of  Conversion,\nwill be duly and validly issued, fully paid and non-assessable and will be owned\nof  record  by the  Company,  free and  clear  of any  mortgage,  pledge,  lien,\nencumbrance or claim (legal or equitable).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::dd6b8554efeb", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e083fd1dbe2e"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e083fd1dbe2e", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(c)(1)(vii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Opinion of counsel / closing condition", "path": "8 ➞ 8.(c) ➞ 8.(c)(1) ➞ 8.(c)(1)(vii)", "text": "sessable and will be owned\nof  record  by the  Company,  free and  clear  of any  mortgage,  pledge,  lien,\nencumbrance or claim (legal or equitable).\n\n(vii) The  execution  and delivery of this  Agreement  and the\nconsummation of the transactions  contemplated hereby have been duly and validly\nauthorized  by  all  necessary  action  on  the  part  of the  Company  and  the\nAssociation; and this Agreement is a valid and binding obligation of the Company\nand the  Association,  enforceable  in accordance  with its terms (except as the\nenforceability  thereof may be limited by  bankruptcy,  insolvency,  moratorium,\nreorganization  or similar laws  relating to or  affecting  the  enforcement  of\ncreditors'  rights generally or the rights of creditors of savings  associations\nor savings and loan holding  companies,  the accounts of whose  subsidiaries are\ninsured by the FDIC or by general equity principles,  regardless of whether such\nenforceability  is considered in a proceeding in equity or at law, and except to\nthe  extent,  if any,  that the  provisions  of  Sections 9 and 10 hereof may be\nunenforceable as against public policy).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::df80fbcca694", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f1d7a472f068"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f1d7a472f068", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(viii)-(ix)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent (counsel opinion / legal opinion requirement)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(viii)-(ix)", "text": "ity or at law, and except to\nthe  extent,  if any,  that the  provisions  of  Sections 9 and 10 hereof may be\nunenforceable as against public policy).\n\n(viii) The Plan has been duly adopted by the required  vote of\nthe Directors of the Company and the Association and members of the Association.\n\n-16-\n\n(ix)  Subject to the  satisfaction  of the  conditions  to the\nOTS's approval of the  Conversion  and the Company's  application to acquire the\nAssociation, no further approval, registration,  authorization, consent or other\norder of any regulatory  agency,  public board or body is required in connection\nwith the  execution and delivery of this  Agreement,  the issuance of the Shares\nand the  consummation  of the  Conversion,  except as may be required  under the\nregulations of the NASD and the NASDAQ National Market.  The Conversion has been\nconsummated  in  all  material   respects  in  accordance  with  all  applicable\nprovisions of the HOLA,  the Conversion  Regulations,  Federal and State law and\nall applicable rules and regulations promulgated thereunder.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::e083fd1dbe2e", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4103333c0389"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4103333c0389", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(x)-(xi)", "section_title": "At the Closing Date, Capital Resources shall have received", "clause_type": "condition precedent", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(x)-(xi)", "text": "plicable\nprovisions of the HOLA,  the Conversion  Regulations,  Federal and State law and\nall applicable rules and regulations promulgated thereunder.\n\n(x)  The   Conversion   Application   including  the  Offering\nProspectus  as filed with the OTS was complete in all material  respects and has\nbeen  approved by the OTS.  The OTS has issued its order of  approval  under the\nsavings and loan holding company provisions of the HOLA, and the purchase by the\nCompany of all of the issued and  outstanding  capital stock of the  Association\nhas been  authorized  by the OTS and no action has been taken,  or to  counsel's\nknowledge  is  pending  or  threatened,  to  revoke  any such  authorization  or\napproval.\n\n(xi) The  Registration  Statement is effective  under the 1933\nAct and no stop order  suspending  the  effectiveness  has been issued under the\n1933  Act  or  proceedings   therefor  initiated  or,  to  counsel's  knowledge,\nthreatened by the Commission.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f1d7a472f068", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f06cd0f85d31"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f06cd0f85d31", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(xii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent (counsel opinion requirement)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xii)", "text": "ffectiveness  has been issued under the\n1933  Act  or  proceedings   therefor  initiated  or,  to  counsel's  knowledge,\nthreatened by the Commission.\n\n(xii) At the time the  Conversion  Application,  including the\nOffering Prospectus contained therein, was approved,  the Conversion Application\nincluding the Offering Prospectus contained therein (as amended or supplemented,\nif so amended or supplemented) complied as to form in all material respects with\nthe  requirements  of all  applicable  federal laws and the rules,  regulations,\ndecisions  and orders of the OTS (except as to the financial  statements,  other\nfinancial data and stock valuation information included therein as to which such\ncounsel need express no opinion); to the best of such counsel's knowledge, based\non  conferences  with  management  of and the  independent  accountants  for the\nCompany and the Association,  and on such investigation of the corporate records\nof the Company and the Association as such counsel  conducted in connection with\nthe preparation of the  Registration  Statement and the Conversion  Application,\nall material  documents  and exhibits  required to be filed with the  Conversion\nApplication (as amended or  supplemented,  if so amended or  supplemented)  have\nbeen so filed.  The  description in the Conversion  Application and the Offering\nProspectus  contained  therein of such documents and exhibits is accurate in all\nmaterial respects and fairly presents the information required to be shown.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::4103333c0389", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a690e8da143c"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a690e8da143c", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(c)(1)(xiii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "condition (counsel opinion requirement)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xiii)", "text": "ctus  contained  therein of such documents and exhibits is accurate in all\nmaterial respects and fairly presents the information required to be shown.\n\n(xiii)  At the time  that the  Registration  Statement  became\neffective,  (i) the  Registration  Statement (as amended or  supplemented  if so\namended  or  supplemented)  (other  than  the  financial  statements  and  other\nfinancial and statistical data and stock valuation information included therein,\nas to which no opinion  need be  rendered),  complied as to form in all material\nrespects with the  requirements of the 1933 Act and the 1933 Act Regulations and\n(ii) the Offering  Prospectus  (other than the  financial  statements  and other\nfinancial and  statistical  data and the stock  valuation  information  included\ntherein,  as to which no opinion  need be  rendered)  complied as to form in all\nmaterial  respects  with  the  requirements  of  the  1933  Act,  the  1933  Act\nRegulations,  Conversion Regulations and Federal and State law (other than state\nblue sky law as to which we express no opinion).  To the best of such  counsel's\nknowledge based on the conferences and document review  specified in item (xiii)\nabove,  all  material  documents  and  exhibits  required  to be filed  with the\nRegistration   Statement  (as  amended  or   supplemented,   if  so  amended  or\nsupplemented) have been so filed. The description in the Registration  Statement\nand the Offering  Prospectus  of such  documents and exhibits is accurate in all", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f06cd0f85d31", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::39da5f37545d"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::39da5f37545d", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(xiii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Closing condition / Counsel opinion", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xiii)", "text": "d) have been so filed. The description in the Registration  Statement\nand the Offering  Prospectus  of such  documents and exhibits is accurate in all\n\nmaterial respects and fairly\n\n-17-\n\npresents the  information  required to be shown.  To the best of such  counsel's\nknowledge,  no person has sought to obtain  regulatory or judicial review of the\nfinal action of the OTS approving the Conversion Application or in approving the\nHolding Company Application.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::a690e8da143c", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5aac77236b94"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5aac77236b94", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(xiv)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "counsel opinion / representation (condition to Capital Resources' obligations)", "path": "8 ➞ 8.C ➞ 8.C.(xiv)", "text": "in  regulatory or judicial review of the\nfinal action of the OTS approving the Conversion Application or in approving the\nHolding Company Application.\n\n(xiv) During the course of such  counsel's  representation  of\nthe Company and the  Association,  nothing has come to such counsel's  attention\nthat  caused it to believe  that (i) the Company  and the  Association  have not\nconducted the  Conversion,  in all material  respects,  in  accordance  with all\napplicable  requirements  of the Plan and applicable law, and (ii) the Plan, the\nConversion  Application,  the Registration Statement and the Offering Prospectus\n(other than the financial  statements and other financial and  statistical  data\nand the stock valuation information included therein as to which no opinion need\nbe rendered) do not comply in all material  respects with all  applicable  laws,\nrules,  regulations,  decisions  and orders  including,  but not limited to, the\nConversion Regulations,  the HOLA, the 1933 Act and 1933 Act Regulations and all\nother  applicable  laws,  regulations,   decisions  and  orders,  including  all\napplicable  terms,  conditions,  requirements  and  provisions  precedent to the\nConversion imposed upon it by the OTS, the Commission and the FDIC, if any.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::39da5f37545d", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3de005e1aa23"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3de005e1aa23", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(xv)", "section_title": null, "clause_type": "opinion of counsel (condition to closing)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xv)", "text": "able  terms,  conditions,  requirements  and  provisions  precedent to the\nConversion imposed upon it by the OTS, the Commission and the FDIC, if any.\n\n(xv) The  terms  and  provisions  of the  Common  Stock of the\nCompany  conform  to the  description  thereof  contained  in  the  Registration\nStatement  and the Offering  Prospectus,  and the form of  certificates  used to\nevidence the Shares are in due and proper form.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5aac77236b94", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ae93db5fe21c"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ae93db5fe21c", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(xvi)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "condition precedent (counsel opinion)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xvi)", "text": "in  the  Registration\nStatement  and the Offering  Prospectus,  and the form of  certificates  used to\nevidence the Shares are in due and proper form.\n\n(xvi) To the best  knowledge  of such  counsel,  there  are no\nlegal or governmental proceedings pending or threatened which are required to be\ndisclosed in the Registration Statement and the Offering Prospectus,  other than\nthose disclosed therein,  and all pending legal and governmental  proceedings to\nwhich  the  Company  or the  Association  is a party  or of  which  any of their\nproperty is the subject  which are not described in the  Registration  Statement\nand the Offering Prospectus, including ordinary routine litigation incidental to\nthe business, are, considered in the aggregate, not material;  provided that for\nthis purpose, any litigation or governmental  proceeding is not considered to be\n\"threatened\"  unless  the  potential  litigant  or  governmental  authority  has\nmanifested  to the  management  of the  Company or the  Association,  or to such\ncounsel, a present intention to initiate such litigation or proceeding.", "numbers_present": null, "definition_terms": ["threatened"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3de005e1aa23", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::62ab6d17e350"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::62ab6d17e350", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8(c)(1)(xvii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "counsel opinion", "path": "8 ➞ 8(c) ➞ 8(c)(1) ➞ 8(c)(1)(xvii)", "text": "nifested  to the  management  of the  Company or the  Association,  or to such\ncounsel, a present intention to initiate such litigation or proceeding.\n\n(xvii) To the best knowledge of such counsel,  the Company and\nthe  Association  have  obtained all  licenses,  permits and other  governmental\nauthorizations  required for the conduct of their respective businesses,  except\nwhere the failure to have such  licenses,  permits or  authorizations  would not\nhave a material adverse effect on the business, operations or income or business\nprospects of the Company and the Association, and all such licenses, permits and\nother governmental  authorizations are in full force and effect, and the Company\nand the Association are in all material respects complying therewith.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ae93db5fe21c", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ea2fa3568d34"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ea2fa3568d34", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(xviii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition to closing / Counsel opinion (legal opinion regarding corporate authority and compliance)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xviii)", "text": "other governmental  authorizations are in full force and effect, and the Company\nand the Association are in all material respects complying therewith.\n\n(xviii)   Neither  the  Company  nor  the  Association  is  in\ncontravention of its certificate of incorporation or its charter,  respectively,\nor its bylaws (and the Association  will not be in  contravention of its charter\nor bylaws in stock form upon  consummation  of the  Conversion)  or, to the best\nknowledge  of such  counsel,  in  contravention  of any  obligation,  agreement,\ncovenant or condition contained in any material contract,  indenture,  mortgage,\nloan  agreement,  note,  lease or other  instrument to which it is a party or by\nwhich it or its property may be bound which  contravention  would be material to\nthe business of the Company and the  Association  considered as one  enterprise;\nthe execution and delivery of this Agreement by the Company and the Association,\nthe incurring of the  obligations  herein set forth and the  consummation of the\ntransactions contemplated herein have been duly authorized by all necessary\n\n-18-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::62ab6d17e350", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d8c0a6116142"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d8c0a6116142", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(xviii)", "section_title": "At the Closing Date, Capital Resources shall have received:", "clause_type": "condition (counsel opinion)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xviii)", "text": "g of the  obligations  herein set forth and the  consummation of the\ntransactions contemplated herein have been duly authorized by all necessary\n\n-18-\n\ncorporate action of the Company and the Association,  and, to the best knowledge\nof such counsel,  will not constitute a material breach of, or default under, or\nresult in the creation or imposition of any material lien, charge or encumbrance\nupon any property or assets of the Company or the Association which are material\nto their  business  considered  as one  enterprise,  pursuant  to any  contract,\nindenture,  mortgage,  loan agreement,  note, lease or other instrument to which\nthe Company or the  Association is a party or by which any of them may be bound,\nor to which any of the property or assets of the Company or the  Association  is\nsubject.  In addition,  such action will not result in any  contravention of the\nprovisions of the certificate of  incorporation  or bylaws of the Company or the\nAssociation  or any  applicable  law,  act,  regulation or order or court order,\nwrit,  injunction or decree.  The charter of the  Association  in stock form has\nbeen approved by the OTS.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ea2fa3568d34", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5c22344e7446"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5c22344e7446", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(c)(1)(xix)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "condition (counsel opinion regarding title and leases)", "path": "8 ➞ 8.(c) ➞ 8.(c)(1) ➞ 8.(c)(1)(xix)", "text": "act,  regulation or order or court order,\nwrit,  injunction or decree.  The charter of the  Association  in stock form has\nbeen approved by the OTS.\n\n(xix) To the best  knowledge of such counsel,  the Company and\nthe  Association  have good and  marketable  title to all  properties and assets\ndescribed in the Registration  Statement as owned by them, free and clear of all\nliens,  charges,  encumbrances or restrictions,  except such as are described in\nthe  Registration  Statement  or are not material in relation to the business of\nthe Company and the Association considered as one enterprise; and to the best of\nsuch  counsel's  knowledge,  all of the leases  and  subleases  material  to the\nbusiness  of the  Company  and the  Association  under which the Company and the\n\nAssociation hold properties,  as described in the Registration Statement, are in\nfull force and effect.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d8c0a6116142", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::778d2e49494e"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::778d2e49494e", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(xx)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "closing condition (counsel opinion)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xx)", "text": "Association  under which the Company and the\n\nAssociation hold properties,  as described in the Registration Statement, are in\nfull force and effect.\n\n(xx) The Company and the  Association  are not in violation of\nany directive from the OTS or the FDIC to make any material change in the method\nof conducting  their business and the Company and the Association have conducted\nand are conducting their business so as to comply in all material  respects with\nall  applicable  statutes  and  regulations   (including,   without  limitation,\nregulations, decisions, directives and orders of the OTS and the FDIC).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5c22344e7446", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6fa5ac08ef7e"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6fa5ac08ef7e", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(xxi)", "section_title": "Favorable opinion of Company's/Association's counsel (Malizia, Spidi, Sloane & Fisch, P.C.)", "clause_type": "counsel opinion / condition to closing", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(xxi)", "text": "l  applicable  statutes  and  regulations   (including,   without  limitation,\nregulations, decisions, directives and orders of the OTS and the FDIC).\n\n(xxi)  The  information  in  the  Registration  Statement  and\nOffering Prospectus under the captions  \"Regulation,\"  \"Certain  Restrictions on\nAcquisitions of the Company,\" \"The  Conversion,\"  \"Description of Capital Stock\"\nand the  information  in response to Items 7(d)(l),  7(f),  7(g) and 7(i) of the\nForm PS of the Conversion Regulations, to the extent that it constitutes matters\nof  law,  summaries  of  legal  matters,  documents  or  proceedings,  or  legal\nconclusions,  has been  reviewed by such  counsel and is correct in all material\nrespects  (except  as to the  financial  statements  and  other  financial  data\nincluded therein as to which such counsel need express no opinion).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::778d2e49494e", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7012c3841ec0"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7012c3841ec0", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "condition (reliance on counsel opinion)", "path": "8 ➞ 8.C ➞ 8.C.(1)", "text": "l\nrespects  (except  as to the  financial  statements  and  other  financial  data\nincluded therein as to which such counsel need express no opinion).\n\nIn  rendering  such  opinion,  such counsel may rely (A) as to\nmatters  involving the  application of laws of any  jurisdiction  other than the\nUnited  States,  to the extent such counsel  deems proper and  specified in such\nopinion satisfactory to Capital Resources,  upon the opinion of other counsel of\ngood  standing  (providing  that such counsel  states that Capital  Resources is\njustified in relying upon such  specified  opinion or  opinions),  and (B) as to\nmatters of fact,  to the extent such counsel deems proper,  on  certificates  of\nresponsible  officers of the Company and the  Association  and public  officials\n(but not on  conclusions  of law which  may be set forth in said  certificates);\nprovided copies of any such opinion(s) or  certificates  are delivered  pursuant\nhereto  or to  Capital  Resources  together  with  the  opinion  to be  rendered\nhereunder by special  counsel to the Company and the  Association.  Such counsel\nmay assume that any agreement is the valid and binding obligation of any parties\nto such agreement other than the Company or the Association.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::6fa5ac08ef7e", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9249f5c5b2cf"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9249f5c5b2cf", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(2)", "section_title": "At the Closing Date, Capital Resources shall have received:", "clause_type": "condition; counsel opinion/letter", "path": "8 ➞ 8.C ➞ 8.C.(2)", "text": "counsel\nmay assume that any agreement is the valid and binding obligation of any parties\nto such agreement other than the Company or the Association.\n\n(2) The  letter  of  Malizia,  Spidi,  Sloane &  Fisch,  P.C.,\ncounsel for the  Company and the  Association  addressed  to Capital  Resources,\ndated the Closing Date, in form and substance to the effect that:\n\n-19-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7012c3841ec0", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f27cc2a419e6"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f27cc2a419e6", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8(c)(2)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent (counsel opinion)", "path": "8 ➞ 8.C ➞ 8.C.(2)", "text": "unsel for the  Company and the  Association  addressed  to Capital  Resources,\ndated the Closing Date, in form and substance to the effect that:\n\n-19-\n\nDuring the  preparation  of the  Conversion  Application,  the\nRegistration Statement and the Offering Prospectus, such counsel participated in\nconferences with management of, and the independent  public  accountants for the\nCompany  and the  Association.  Based  upon  such  conferences  and a review  of\ncorporate  records of the Company and the Association as such counsel  conducted\nin connection with the preparation of the Registration  Statement and Conversion\nApplication, nothing has come to their attention that would lead them to believe\nthat the  Conversion  Application,  the  Registration  Statement,  the  Offering\nProspectus,  or any  amendment or supplement  thereto  (other than the financial\nstatements  and  other  financial  and  statistical  data  and  stock  valuation\ninformation  included  therein,  as to which such counsel need express no view),\ncontained an untrue  statement of a material fact or omitted to state a material\nfact required to be stated therein or necessary to make the statements  therein,\nin light of the circumstances under which they were made, not misleading.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9249f5c5b2cf", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::93266b0c2e0b"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::93266b0c2e0b", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(c)(3)-(d)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Conditions precedent (counsel opinions and document delivery)", "path": "8 ➞ 8.(c) ➞ 8.(c)(3); 8 ➞ 8.(d)", "text": "required to be stated therein or necessary to make the statements  therein,\nin light of the circumstances under which they were made, not misleading.\n\n(3) The  favorable  opinion,  dated as of the Closing Date, of\nSerchuk &  Zelermyer,  LLP,  Capital  Resources'  counsel,  with respect to such\nmatters as Capital Resources may reasonably require.  Such opinion may rely upon\nthe opinions of counsel to the Company and the Association, and as to matters of\nfact,  upon  certificates  of  officers  and  directors  of the  Company and the\nAssociation  delivered  pursuant  hereto  or as such  counsel  shall  reasonably\nrequest.\n\n(d) At the Closing Date,  counsel to Capital  Resources  shall\nhave been  furnished  with such  documents  and opinions as they may  reasonably\nrequire  for the  purpose  of  enabling  them to render  the  opinion  as herein\ncontemplated  and related  proceedings or in order to evidence the occurrence or\ncompleteness of any of the representations or warranties,  or the fulfillment of\nany of the conditions, herein contained.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f27cc2a419e6", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::1eef73e4da46"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::1eef73e4da46", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(e)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition / Closing deliverable (certificate requirement)", "path": "8 ➞ 8.(e)", "text": "o evidence the occurrence or\ncompleteness of any of the representations or warranties,  or the fulfillment of\nany of the conditions, herein contained.\n\n(e) At the Closing  Date,  Capital  Resources  shall receive a\ncertificate of the Chief Executive  Officer and the Chief  Financial  Officer of\nthe Company and of the Chief Executive  Officer and Chief  Financial  Officer of\nthe  Association,  dated as of such Closing Date,  to the effect that:  (i) they\nhave carefully  examined the Offering  Prospectus and, in their opinion,  at the\ntime the  Offering  Prospectus  became  authorized  for final use,  the Offering\nProspectus  did not contain an untrue  statement  of a material  fact or omit to\nstate a material  fact  necessary in order to make the  statements  therein,  in\nlight of the  circumstances  under which they were made,  not  misleading;  (ii)\nsince the date the Offering Prospectus became authorized for final use, in their\nopinion no event has  occurred  which should have been set forth in an amendment\nor  supplement  to the  Offering  Prospectus  which  has not been so set  forth,\nincluding specifically,  but without limitation,  any material adverse change in\nthe condition,  financial or otherwise, or in the earnings, capital, properties,\nbusiness  prospects or business affairs of the Company or the  Association,  and\nthe conditions set forth in this Section 8 have been satisfied;  (iii) since the\nrespective dates as of which information is given in the Registration  Statement\nand the Offering  Prospectus,  there has been no material  adverse change in the\ncondition,  financial or  otherwise,  or in the earnings,  capital,  properties,\nbusiness  affairs or  business  prospects  of the  Company  or the  Association,", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::93266b0c2e0b", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::eb4956c8b1d0"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::eb4956c8b1d0", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8(e)(iv)-(vii)", "section_title": "Certificate of the Chief Executive Officer and the Chief Financial Officer (officer certifications)", "clause_type": "Condition precedent; officer certifications (representations and warranties)", "path": "8 ➞ 8(e) ➞ 8(e)(iv)-(vii)", "text": "financial or  otherwise,  or in the earnings,  capital,  properties,\nbusiness  affairs or  business  prospects  of the  Company  or the  Association,\n\nindependently,  or  of  the  Company  and  the  Association  considered  as  one\nenterprise,  whether or not arising in the ordinary course of business;  (iv) to\nthe best  knowledge  of such  officers the  representations  and  warranties  in\nSection  4 are true  and  correct  with the same  force  and  effect  as  though\nexpressly  made  at and  as of  the  Closing  Date;  (v)  the  Company  and  the\nAssociation  have complied with all material  agreements and  satisfied,  in all\nmaterial  respects at or prior to the Closing Date, all obligations  required to\nbe met by  such  date  and  will  in  all  material  respects  comply  with  all\nobligations  to be  satisfied  by them  after  Conversion;  (vi)  no stop  order\nsuspending the  effectiveness of the  Registration  Statement has been initiated\nor, to the best  knowledge  of the  Company or  Association,  threatened  by the\nCommission or any state authority; (vii) no order suspending the Subscription or\nPublic Offerings, the Conversion, the\n\n-20-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::1eef73e4da46", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fa72aaa876bc"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fa72aaa876bc", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.C.(1)(vii)-(viii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent; counsel opinion (representations/warranties)", "path": "8 ➞ 8.C ➞ 8.C.(1) ➞ 8.C.(1)(vii)–8.C.(1)(viii)", "text": "tion,  threatened  by the\nCommission or any state authority; (vii) no order suspending the Subscription or\nPublic Offerings, the Conversion, the\n\n-20-\n\nacquisition  of all of the  shares  of the  Association  by the  Company  or the\neffectiveness  of the  Offering  Prospectus  has  been  issued  and to the  best\nknowledge of the Company or  Association,  no proceedings  for that purpose have\nbeen initiated or threatened by the OTS, the Commission,  the FDIC, or any state\nauthority;  and (viii) to the best of their  knowledge,  no person has sought to\nobtain review of the final action of the OTS approving the Plan.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::eb4956c8b1d0", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f6fd2c3b9a68"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f6fd2c3b9a68", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8(f)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Conditions precedent", "path": "8 ➞ 8(f)", "text": "tate\nauthority;  and (viii) to the best of their  knowledge,  no person has sought to\nobtain review of the final action of the OTS approving the Plan.\n\n(f) Prior to and at the Closing  Date:  (i) in the  reasonable\nopinion of Capital  Resources,  there shall have been no material adverse change\nin the condition,  financial or otherwise,  or in the earnings,  or the business\naffairs or business  prospects of the Company or the Association  independently,\nor of the Company or the  Association,  considered as one enterprise,  since the\nlatest dates as of which such condition is set forth in the Offering Prospectus,\nexcept  as  referred  to  therein;  (ii)  there  shall  have  been  no  material\ntransaction  entered into by the Company or the Association from the latest date\nas of which the  financial  condition of the Company or the  Association  is set\nforth  in  the  Offering  Prospectus  other  than  transactions  referred  to or\ncontemplated  therein;  (iii)  the  Company  or the  Association  shall not have\nreceived  from the OTS or the FDIC any  direction  (oral or written) to make any\nmaterial change in the method of conducting their business with which it has not\ncomplied  (which  direction,  if any,  shall  have  been  disclosed  to  Capital\nResources) and which would reasonably be expected to have a material and adverse\neffect on the  business,  operations  or  financial  condition  or income of the\nCompany or the  Association  taken as a whole;  (iv) neither the Company nor the\nAssociation  shall have been in default (nor shall an event have occurred which,\nwith  notice or lapse of time or both,  would  constitute  a default)  under any\nprovision of and  agreement or instrument  relating to any material  outstanding\nindebtedness;  (v) no action, suit or proceedings, at law or in equity or before\nor by any federal or state  commission,  board or other  administrative  agency,\nshall be  pending,  or, to the  knowledge  of the  Company  or the  Association,\nthreatened  against the Company or the  Association  or  affecting  any of their\nproperties wherein an unfavorable  decision,  ruling or finding would reasonably\nbe expected to have a material and adverse  effect on the business,  operations,\nfinancial  condition  or income of the  Company or the  Association,  taken as a\nwhole;  and (vi) the Shares have been  qualified or registered  for offering and\nsale  under the  securities  or blue sky laws of the  jurisdictions  as  Capital\nResources shall have requested and as agreed to by the Company.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::fa72aaa876bc", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9fc602ccc26e"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9fc602ccc26e", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8(g)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition (delivery of KPMG letter / accounting procedures)", "path": "8 ➞ 8(g)", "text": "g and\nsale  under the  securities  or blue sky laws of the  jurisdictions  as  Capital\nResources shall have requested and as agreed to by the Company.\n\n(g) Concurrently with the execution of this Agreement, Capital\nResources shall receive a letter from KPMG,  dated the date hereof and addressed\nto Capital  Resources:  (i) confirming that KPMG is a firm of independent public\naccountants  within the meaning of the 1933 Act and the 1933 Act Regulations and\n12 C.F.R. ss. 571.2(c)(3) and no information concerning its relationship with or\ninterests in the Company and the  Association is required to be disclosed in the\nOffering Prospectus by the Conversion Regulations or Item 10 of the Registration\nStatement, and stating in effect that in KPMG's opinion the financial statements\nof the Association as are included in the Offering  Prospectus comply as to form\nin all material respects with the applicable accounting requirements of the 1933\nAct and the related published rules and regulations of the Commission thereunder\nand the Conversion  Regulations and generally  accepted  accounting  principles;\n(ii) stating in effect that, on the basis of certain agreed upon procedures (but\nnot  an  audit  examination  in  accordance  with  generally  accepted  auditing\nstandards)  consisting of a reading of the latest  available  unaudited  interim\nfinancial statements of the Association  prepared by the Association,  a reading\nof the  minutes of the  meetings  of the Board of  Directors  and members of the\nAssociation and consultations  with officers of the Association  responsible for\nfinancial and accounting  matters,  nothing came to their attention which caused\nthem to  believe  that:  (A)  such  unaudited  financial  statements  are not in\nconformity  with generally  accepted  accounting  principles  applied on a basis\nsubstantially  consistent with that of the audited financial statements included\nin the Offering Prospectus; or (B) during the period from the date of the latest\nfinancial statements included in the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::f6fd2c3b9a68", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d7d9d8723f6e"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d7d9d8723f6e", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.G.(ii)(B)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition", "path": "8 ➞ 8.G ➞ 8.G.(ii) ➞ 8.G.(ii)(B)", "text": "ed financial statements included\nin the Offering Prospectus; or (B) during the period from the date of the latest\nfinancial statements included in the\n\n-21-\n\nOffering  Prospectus to a specified  date not more than five business days prior\nto the date hereof,  there has been (1) an increase of greater than  $500,000 in\nthe long term debt of the  Association or (2) an increase of $100,000 or more in\nloans past due 90 days or more as of the last day of the month immediately prior\nto such  specified  date or (3) an  increase  of $100,000 or more in real estate\nacquired by  foreclosure  or (4) a decrease of $50,000 or more in the  allowance\nfor loan losses or (5) any decrease in total retained earnings or (6) a decrease", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9fc602ccc26e", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0c7d3cbdb31d"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0c7d3cbdb31d", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "Section 8(g)(ii)-(iii)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition to closing / accountant (KPMG) confirmation and agreed-upon procedures", "path": "8 ➞ 8.(g) ➞ 8.(g)(ii)-(iii)", "text": "foreclosure  or (4) a decrease of $50,000 or more in the  allowance\nfor loan losses or (5) any decrease in total retained earnings or (6) a decrease\n\nin net  income  when  compared  to the like  period in 1995 or (7) any change in\ntotal assets of the Association in an amount greater than  $2,000,000  excluding\nproceeds  from stock  subscriptions;  and (iii) stating that, in addition to the\naudit examination referred to in its opinion included in the Offering Prospectus\nand  the  performance  of the  procedures  referred  to in  clause  (ii) of this\nsubsection  (g), they have compared with the general  accounting  records of the\nCompany and/or the Association, as applicable, which are subject to the internal\ncontrols of the Company and/or the Association, as applicable, accounting system\nand other data prepared by the Company  and/or the  Association,  as applicable,\ndirectly from such accounting  records,  to the extent specified in such letter,\nsuch amounts and/or percentages set forth in the Offering  Prospectus as Capital\nResources  may  reasonably  request;  and  they  have  found  such  amounts  and\npercentages to be in agreement therewith (subject to rounding).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d7d9d8723f6e", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7bc8fa202117"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7bc8fa202117", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(g)-(h)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent (requirements for accountant letters/confirmations)", "path": "8 ➞ 8.(g)-(h)", "text": "pital\nResources  may  reasonably  request;  and  they  have  found  such  amounts  and\npercentages to be in agreement therewith (subject to rounding).\n\n(h) At the Closing  Date,  Capital  Resources  shall receive a\nletter  from KPMG,  dated the  Closing  Date,  addressed  to Capital  Resources,\nconfirming  the  statements  made by its  letter  delivered  by it  pursuant  to\nsubsection (g) of this Section 8, except that the  \"specified  date\" referred to\nin clause (ii)(B) thereof to be a date specified in such letter, which shall not\nbe more than three business days prior to the Closing Date.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0c7d3cbdb31d", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::395cdbc4b0b0"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::395cdbc4b0b0", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(i)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent", "path": "8 ➞ 8.(i)", "text": "ferred to\nin clause (ii)(B) thereof to be a date specified in such letter, which shall not\nbe more than three business days prior to the Closing Date.\n\n(i) The Company and the  Association  shall not have sustained\nsince  the date of the  latest  audited  financial  statements  included  in the\nRegistration Statement and Offering Prospectus any loss or interference with its\nbusiness from fire, explosion,  flood or other calamity,  whether or not covered\nby insurance,  or from any labor dispute or court or governmental  action, order\nor  decree,  otherwise  than as set forth or  contemplated  in the  Registration\nStatement and Offering  Prospectus,  and since the respective  dates as of which\ninformation  is given in the  Registration  Statement  and Offering  Prospectus,\nthere  shall  not have  been any  material  change  in the long term debt of the\nCompany or the Association  other than debt incurred in relation to the purchase\nof Shares by the Company's  Tax-Qualified  Employee Plans, or any change, or any\ndevelopment involving a prospective change, in or affecting the general affairs,\nmanagement, financial position, stockholders' equity or results of operations of\nthe Company or the  Association,  otherwise than as set forth or contemplated in\nthe Registration Statement and Offering Prospectus,  the effect of which, in any\nsuch  case  described  above,  is  in  Capital  Resources'  reasonable  judgment\nsufficiently  material and adverse as to make it impracticable or inadvisable to\nproceed with the  Subscription or Public Offerings or the delivery of the Shares\non the terms and in the manner contemplated in the Offering Prospectus.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7bc8fa202117", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::356237a05ed5"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::356237a05ed5", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(j)-(k)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Conditions precedent / Closing conditions", "path": "8 ➞ 8.(j)-(k)", "text": "oceed with the  Subscription or Public Offerings or the delivery of the Shares\non the terms and in the manner contemplated in the Offering Prospectus.\n\n(j) At or prior to the Closing Date,  Capital  Resources shall\nreceive  (i) a copy  of the  letter  from  the  OTS  authorizing  the use of the\nOffering Prospectus,  (ii) a copy of the order from the Commission declaring the\nRegistration  Statement  effective,  (iii) a copy of a certificate  from the OTS\nevidencing  the good  standing of the  Association,  (iv)  certificates  of good\nstanding from the States of Delaware and New York  evidencing  the good standing\nof the  Company  and from the State of New York  evidencing  that the Company is\nduly qualified to do business and in good standing in New York and (v) a copy of\nthe letter from the OTS approving the Company's Holding Company Application.\n\n(k)      As soon as available after the Closing Date, Capital\nResources shall receive a\n\n-22-\n\ncertified copy of the Association's stock charter.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::395cdbc4b0b0", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7bdba19554aa"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7bdba19554aa", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8.(k)-(l)", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Condition precedent (closing conditions)", "path": "8 ➞ 8.(k) and 8.(l)", "text": "on.\n\n(k)      As soon as available after the Closing Date, Capital\nResources shall receive a\n\n-22-\n\ncertified copy of the Association's stock charter.\n\n(1)  Subsequent  to the  date  hereof,  there  shall  not have\noccurred any of the  following:  (i) a suspension  or  limitation  in trading in\nsecurities  generally on the New York Stock  Exchange or American Stock Exchange\nor in the over-the-counter  market, or quotations halted generally on the NASDAQ\nNational  Market,  or minimum or maximum  prices for  trading  being  fixed,  or\nmaximum  ranges for  prices  for  securities  being  required  by either of such\nexchanges or the NASD or by order of the  Commission  or any other  governmental\nauthority;  (ii) a general  moratorium on the operations of commercial  banks or\nfederal  savings banks or general  moratorium on the withdrawal of deposits from\ncommercial  banks or federal  savings banks  declared by either federal or state\nauthorities; (iii) the engagement by the United States in hostilities which have\nresulted  in the  declaration,  on or  after  the  date  hereof,  of a  national\nemergency  or war;  or (iv) a  material  decline  in the price of equity or debt\nsecurities  if, as to clauses (iii) or (iv),  the effect of such  hostilities or\ndecline, in Capital Resources'  reasonable  judgment,  makes it impracticable or\ninadvisable to proceed with the Subscription or Public Offerings or the delivery\nof the Shares on the terms and in the manner  contemplated  in the  Registration\nStatement and the Offering Prospectus.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::356237a05ed5", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9413a5c47d93"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9413a5c47d93", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Closing conditions / Opinions and Certificates; Representations & Warranties", "path": "8", "text": "blic Offerings or the delivery\nof the Shares on the terms and in the manner  contemplated  in the  Registration\nStatement and the Offering Prospectus.\n\nAll such opinions, certifications, letters and documents shall\nbe in compliance with the provisions  hereof only if they are, in the reasonable\nopinion of Capital Resources and its counsel,  satisfactory to Capital Resources\nand its  counsel.  Any  certificates  signed by an  officer or  director  of the\nCompany or the  Association  and  delivered to Capital  Resources or its counsel\nshall be deemed a representation  and warranty by the Company or the Association\nto Capital Resources as to the statements made therein.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::7bdba19554aa", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::278e746eaeae"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::278e746eaeae", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "8", "section_title": "Conditions to Capital Resources' Obligations", "clause_type": "Conditions / Termination (cancellation of Capital Resources' obligations)", "path": "8", "text": "r its counsel\nshall be deemed a representation  and warranty by the Company or the Association\nto Capital Resources as to the statements made therein.\n\nIf any of the  conditions  specified in this Section shall not\nhave been fulfilled when and as required by this  Agreement,  this Agreement and\nall of Capital  Resources'  obligations  hereunder  may be  canceled  by Capital\nResources by notifying the  Association  of such  cancellation  in writing or by\ntelegram at any time at or prior to the Closing Date, and any such  cancellation\nshall be without  liability  of any party to any other party except as otherwise\nprovided in Sections 2, 7, 9 and 10 hereof.  Notwithstanding  the above, if this", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9413a5c47d93", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9c9fdc7592c4"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9c9fdc7592c4", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9", "section_title": "Indemnification", "clause_type": "Indemnification", "path": "9", "text": "thout  liability  of any party to any other party except as otherwise\nprovided in Sections 2, 7, 9 and 10 hereof.  Notwithstanding  the above, if this\n\nAgreement  is  canceled  pursuant  to  this  paragraph,   the  Company  and  the\nAssociation  jointly and severally agree to reimburse  Capital Resources for all\nout-of-pocket  expenses,  (including without limitation the fees and expenses of\nCapital Resources' counsel) reasonably incurred by Capital Resources and Capital\nResources'  counsel at its normal rates,  in connection  with the preparation of\nthe Registration Statement and the Offering Prospectus,  and in contemplation of\nthe proposed  Subscription  or Public  Offerings  to the extent  provided for in\nSections 2 and 7 hereof.\n\nSECTION 9.  Indemnification.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::278e746eaeae", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::951af71c4b40"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::951af71c4b40", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9.(a)", "section_title": "Indemnification", "clause_type": "Indemnification", "path": "9 ➞ 9.(a)", "text": "ntemplation of\nthe proposed  Subscription  or Public  Offerings  to the extent  provided for in\nSections 2 and 7 hereof.\n\nSECTION 9.  Indemnification.\n\n(a) The Company  and the  Association  jointly  and  severally\nagree to indemnify and hold harmless Capital Resources, its officers, directors,\nagents and  employees  and each person,  if any, who controls or is under common\ncontrol with Capital  Resources within the meaning of Section 15 of the 1933 Act\nor Section 20(a) of the 1934 Act,  against any and all loss,  liability,  claim,\ndamage or expense whatsoever (including but not limited to settlement expenses),\njoint or several,  that Capital  Resources or any of them may suffer or to which\nCapital  Resources  and any such persons  upon  written  demand for any expenses\n(including fees and  disbursements of counsel)  incurred by Capital Resources or\nany of them  in  connection  with  investigating,  preparing  or  defending  any\nactions,  proceedings or claims (whether  commenced or threatened) to the extent\nsuch losses,  claims,  damages,  liabilities  or actions (i) arise out of or are\nbased upon any untrue statement or alleged untrue statement of a material\n\n-23-", "numbers_present": null, "definition_terms": ["Blue Sky Application", "Sales Information"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9c9fdc7592c4", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::517e844a3144"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::517e844a3144", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9(a)", "section_title": "Indemnification", "clause_type": "Indemnification", "path": "9 ➞ 9(a)", "text": "s,  claims,  damages,  liabilities  or actions (i) arise out of or are\nbased upon any untrue statement or alleged untrue statement of a material\n\n-23-\n\nfact  contained in the  Registration  Statement  (or any amendment or supplement\nthereto),  preliminary  or  final  Offering  Prospectus  (or  any  amendment  or\nsupplement thereto),  the Conversion  Application or any Blue Sky application or\nother  instrument  or document of the Company or the  Association  or based upon\nwritten  information  supplied  by the Company or the  Association  filed in any\nstate or  jurisdiction  to  register  or qualify any or all of the Shares or the\nsubscription  rights  applicable  thereto  under  the  securities  laws  thereof\n(collectively,  the  \"Blue  Sky  Application\"),  or  any  application  or  other\ndocument,  advertisement, oral statement, or communication (\"Sales Information\")\nprepared,  made or executed  by or on behalf of the Company  with its consent or\nbased upon written or oral information  furnished by or on behalf of the Company\nor the Association, whether or not filed in any jurisdiction in order to qualify\nor register the Shares under the securities  laws thereof;  (ii) arise out of or\nare based upon the omission or alleged omission to state in any of the foregoing\ndocuments  or  information,  a material  fact  required to be stated  therein or\nnecessary to make the statements  therein,  in light of the circumstances  under\nwhich  they were  made,  not  misleading;  or,  (iii)  arise  from any theory of\nliability  whatsoever relating to or arising from or based upon the Registration\nStatement  (or any  amendment  or  supplement  thereto),  preliminary  or  final\nOffering  Prospectus  (or any amendment or supplement  thereto),  the Conversion\nApplication,   any  Blue  Sky   Application   or  Sales   Information  or  other\ndocumentation distributed in connection with the Conversion;  provided, however,\nthat no  indemnification is required under this paragraph (a) to the extent such\nlosses, claims,  damages,  liabilities or actions arise out of or are based upon\nany untrue  material  statements or alleged  untrue  material  statements in, or\nmaterial omission or alleged material omission from, the Registration  Statement\n(or any amendment or supplement thereto), the Conversion  Application,  any Blue\nSky Application,  the preliminary or final Offering Prospectus (or any amendment\nor  supplement  thereto),  or Sales  Information  made in  reliance  upon and in\nconformity with written information  furnished to the Company or the Association\nby Capital Resources  regarding  Capital  Resources  expressly for use under the\ncaption \"The Conversion - Marketing Arrangements\" in the Offering Prospectus nor\nis  indemnification  required for material  oral  misstatements  made by Capital\nResources,  which are not based upon information  provided by the Association or\nthe  Company  orally or in  writing  or based on  information  contained  in the\nRegistration Statement (or any amendment or supplement thereto),  preliminary or\nfinal  Offering  Prospectus  (or  any  amendment  or  supplement  thereto),  the\nConversion   Application,   any  Blue  Sky  Application  or  Sales   Information\ndistributed in connection with the Conversion.", "numbers_present": null, "definition_terms": ["Blue Sky Application", "Sales Information"], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::951af71c4b40", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::22dd3fe3cc21"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::22dd3fe3cc21", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9(b)", "section_title": "Indemnification", "clause_type": "Indemnity (Capital Resources to Company and Association)", "path": "9 ➞ 9(b)", "text": "lement  thereto),  the\nConversion   Application,   any  Blue  Sky  Application  or  Sales   Information\ndistributed in connection with the Conversion.\n\n(b) Capital  Resources  agrees to indemnify  and hold harmless\nthe Company and the Association,  their directors and officers, agents, servants\nand  employees  and  each  person,  if any,  who  controls  the  Company  or the\nAssociation within the meaning of Section 15 of the 1933 Act or Section 20(a) of\nthe 1934 Act  against  any and all loss,  liability,  claim,  damage or  expense\nwhatsoever (including but not limited to settlement expenses),  joint or several\nwhich they,  or any of them,  may suffer or to which they,  or any of them,  may\nbecome subject under all applicable federal and state laws or otherwise,  and to\npromptly  reimburse  the  Company,  the  Association  and any such  persons upon\nwritten demand for any expenses  (including fees and  disbursements  of counsel)\nincurred by them, or any of them, in connection with investigating, preparing or\ndefending any actions,  proceedings or claims (whether  commenced or threatened)\nto the extent such losses, claims, damages,  liabilities or actions arise out of\nor are based upon any untrue statement or alleged untrue statement of a material\nfact  contained in the  Registration  Statement  (or any amendment of supplement\nthereto),  or the preliminary or final Offering  Prospectus (or any amendment or\nsupplement thereto),  or the Conversion  Application or any Blue Sky Application\nor Sales Information or are based upon the omission or alleged omission to state\nin any of the foregoing  documents a material fact required to be stated therein\nor necessary to make the statements  therein,  in the light of the circumstances\nunder which they were made,  not  misleading;  provided,  however,  that Capital\nResources  obligations  under this  Section 9(b) shall exist only if and only to\nthe", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::517e844a3144", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0a1dbfb3afcb"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0a1dbfb3afcb", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9(b)", "section_title": "Indemnification", "clause_type": "Indemnification", "path": "9 ➞ 9(b)", "text": "y were made,  not  misleading;  provided,  however,  that Capital\nResources  obligations  under this  Section 9(b) shall exist only if and only to\nthe\n\n-24-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::22dd3fe3cc21", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bdd082663517"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bdd082663517", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9(b)", "section_title": "Indemnification", "clause_type": "Indemnification", "path": "9 ➞ 9(b)", "text": "made,  not  misleading;  provided,  however,  that Capital\nResources  obligations  under this  Section 9(b) shall exist only if and only to\nthe\n\n-24-\n\nextent that such untrue  statement or alleged  untrue  statement was made in, or\nsuch material fact or alleged  material fact was omitted from, the  Registration\nStatement (or any amendment or supplement  thereto),  the  preliminary  or final\nOffering Prospectus (or any amendment or supplement thereto),  or the Conversion\nApplication,  any Blue Sky Application or Sales Information in reliance upon and\nin  conformity  with  written  information  furnished  to  the  Company  or  the\nAssociation by Capital Resources  regarding Capital Resources  expressly for use\nunder the caption  \"The  Conversion  - Marketing  Arrangements\"  in the Offering\nProspectus  or in the event of oral  misstatements  made by  Capital  Resources,\nwhich are not based upon information  provided by the Association or the Company\norally or in  writing  or based on  information  contained  in the  Registration\nStatement  (or any  amendment  or  supplement  thereto),  preliminary  or  final\nOffering  Prospectus  (or any amendment or supplement  thereto),  the Conversion\nApplication,  any  Blue Sky  Application  or Sales  Information  distributed  in\nconnection with the Conversion.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::0a1dbfb3afcb", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3eb40695780c"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3eb40695780c", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9.(c)", "section_title": "Indemnification", "clause_type": "Indemnification - Notice and Defense Procedures", "path": "9 ➞ 9.(c)", "text": "supplement  thereto),  the Conversion\nApplication,  any  Blue Sky  Application  or Sales  Information  distributed  in\nconnection with the Conversion.\n\n(c) Each indemnified party shall give prompt written notice to\neach indemnifying party of any action,  proceeding,  claim (whether commenced or\nthreatened),  or suit instituted against it in respect of which indemnity may be\nsought  hereunder,  but  failure to so notify an  indemnifying  party  shall not\nrelieve it from any liability  which it may have on account of this Section 9 or\notherwise.  An  indemnifying  party may  participate  at its own  expense in the\ndefense of such action.  In addition,  if it so elects within a reasonable  time\nafter  receipt of such notice,  an  indemnifying  party,  jointly with any other\nindemnifying  parties  receiving such notice,  may assume defense of such action\nwith  counsel  chosen by it and  approved by the  indemnified  parties  that are\ndefendants in such action,  unless such indemnified parties reasonably object to\nsuch assumption on the ground that there may be legal defenses available to them\nthat are different from or in addition to those  available to such  indemnifying\nparty.  If an  indemnifying  party  assumes  the  defense  of such  action,  the\nindemnifying  parties  shall not be liable for any fees and  expenses of counsel\nfor the indemnified  parties incurred thereafter in connection with such action,\nproceeding or claim,  other than reasonable costs of investigation.  In no event\nshall the indemnifying  parties be liable for the fees and expenses of more than\none  separate  firm of  attorneys  (and any special  counsel  that said firm may\nretain)  for  all  indemnified  parties  in  connection  with  any  one  action,\nproceeding or claim or separate but similar or related  actions,  proceedings or\nclaims in the same jurisdiction  arising out of the same general  allegations or\ncircumstances.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bdd082663517", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::29c7348ce6dd"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::29c7348ce6dd", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9.(d)", "section_title": "Indemnification", "clause_type": "Survival of representations and indemnities", "path": "9 ➞ 9.(d)", "text": "arate but similar or related  actions,  proceedings or\nclaims in the same jurisdiction  arising out of the same general  allegations or\ncircumstances.\n\n(d) The agreements  contained in this Section 9 and in Section\n10  hereof  and  the  representations  and  warranties  of the  Company  and the\nAssociation set forth in this Agreement shall remain operative and in full force\nand effect regardless of: (i) any investigation  made by or on behalf of Capital\nResources or its officers, directors or controlling persons, agents or employees\nor by or on behalf of the Company or the Association or any officers,  directors\nor controlling persons, agents or employees of the Company or the Association or\nany controlling  person,  director or officer of the Company or the Association;\n(ii) delivery of and payment  hereunder for the Shares; or (iii) any termination\nof this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3eb40695780c", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3b478e52f9a3"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3b478e52f9a3", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "9.(e)", "section_title": "Indemnification", "clause_type": "Indemnification limitation / Contribution restriction", "path": "9 ➞ 9.(e)", "text": "ctor or officer of the Company or the Association;\n(ii) delivery of and payment  hereunder for the Shares; or (iii) any termination\nof this Agreement.\n\n(e) No  indemnification  by the Association under Section 9(a)\nhereof nor  contribution  under Section 10 hereof shall be effective if the same\nshall be deemed to be in violation of any law, rule or regulation  applicable to\nthe  Association  including,  without  limitation,  Section  23A of the  Federal\nReserve Act. If the  indemnification  or  contribution by the Association is not\neffective  pursuant  to the  preceding  sentence,  then the  indemnification  by\nCapital  Resources  pursuant to Section 9(b) shall be given only to the Company,\nits  directors  and  officers,  agents,  servants and  employees  and not to the\nAssociation,  its directors and officers, agents, servants and employees and the\nAssociation  shall not be entitled to any  contribution  from Capital  Resources\npursuant to Section 10.\n\n-25-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::29c7348ce6dd", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8149456b7897"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8149456b7897", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "10", "section_title": "Contribution", "clause_type": "Contribution", "path": "10", "text": "agents, servants and employees and the\nAssociation  shall not be entitled to any  contribution  from Capital  Resources\npursuant to Section 10.\n\n-25-\n\nSECTION  10.  Contribution.  In order to provide  for just and\nequitable  contribution in circumstances in which the  indemnification  provided\nfor in  Section 9 is due in  accordance  with its  terms  but is for any  reason\nunavailable  as a result of  Section  9(e) or held by a court to be  unavailable\nfrom the  Company,  the  Association  or Capital  Resources,  the  Company,  the\nAssociation  and Capital  Resources  shall  contribute to the aggregate  losses,\nclaims,  damages and liabilities  (including any investigation,  legal and other\nexpenses  incurred in connection  with, and any amount paid in settlement of any\naction,  suit or  proceeding  of any claims  asserted,  but after  deducting any\ncontribution  received by the Company or the  Association  or Capital  Resources\nfrom  persons  other than the other  party  thereto,  who may also be liable for\ncontribution)  in such  proportion so that Capital  Resources is responsible for\nthat  portion  represented  by the  percentage  that  the fees  paid to  Capital\nResources pursuant to Section 2 of this Agreement (not including expenses) bears\nto the gross proceeds received by the Company from the sale of the Shares in the\nSubscription and Public  Offerings and the Company and the Association  shall be\nresponsible for the balance.  If, however,  the allocation provided above is not\npermitted  by  applicable  law or if the  indemnified  party  failed to give the\nnotice  required  under  Section 9 above,  then each  indemnifying  party  shall\ncontribute  to such  amount  paid or payable by such  indemnified  party in such\nproportion  as is  appropriate  to reflect not only such  relative  fault of the\nCompany and the  Association on the one hand and Capital  Resources on the other", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::3b478e52f9a3", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bbb6d4406498"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bbb6d4406498", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "10", "section_title": "Contribution", "clause_type": "Contribution and liability allocation clause", "path": "10", "text": "as is  appropriate  to reflect not only such  relative  fault of the\nCompany and the  Association on the one hand and Capital  Resources on the other\n\nin connection  with the  statements or omissions  which resulted in such losses,\nclaims,  damages or  liabilities  (or actions,  proceedings or claims in respect\nthereof), but also the relative benefits received by the Company and Association\non the one hand and Capital  Resources on the other from the offering as well as\nany other relevant equitable  considerations.  The relative benefits received by\nthe Company and the  Association  on the one hand and Capital  Resources  on the\nother shall be deemed to be in the same  proportion as the total gross  proceeds\nfrom the Subscription and Public Offerings (before deducting  expenses) received\nby the  Company  bear to the total fees (not  including  expenses)  received  by\nCapital Resources. The relative fault shall be determined by reference to, among\nother things,  whether the untrue or alleged untrue statement of a material fact\nor the  omission  or  alleged  omission  to state a  material  fact  relates  to\ninformation  supplied by the Company  and/or the  Association on the one hand or\nCapital  Resources on the other and the parties'  relative  intent,  good faith,\nknowledge,  access to  information  and  opportunity  to correct or prevent such\nstatement or omission.  The Company, the Association and Capital Resources agree\nthat it would not be just and equitable if contribution pursuant to this Section\n10 were  determined by pro rata  allocation or by any other method of allocation\nwhich does not take account of the equitable considerations referred to above in\nthis Section 10. The amount paid or payable by an indemnified  party as a result\nof the losses, claims, damages or liabilities (or action,  proceedings or claims\nin  respect  thereof)  referred  to above in this  Section 10 shall be deemed to\ninclude any legal or other  expenses  reasonably  incurred  by such  indemnified\nparty in connection with investigating or defending any such action,  proceeding\nor claim. It is expressly agreed that Capital  Resources shall not be liable for\nany loss,  liability,  claim, damage or expense or be required to contribute any\namount which in the aggregate  exceeds the amount paid  (excluding  reimbursable\nexpenses) to Capital  Resources under this Agreement.  It is understood that the\nabove-stated  limitation on Capital Resources' liability is essential to Capital\nResources and that Capital  Resources  relied upon such limitation and would not\nhave entered into this  Agreement if such  limitation  had not been agreed to by\nthe  parties  to this  Agreement.  No  person  found  guilty  of any  fraudulent\nmisrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be\nentitled  to  contribution  from any  person  who was not  found  guilty of such\nfraudulent misrepresentation. The obligations of the Company and the Association\nunder this Section 10 and under  Section 9 shall be in addition to any liability\nwhich the Company and the  Association  may otherwise have. For purposes of this\nSection 10,  each of Capital  Resources',  the  Company's  or the  Association's\nofficers and directors and each person,  if any, who controls Capital  Resources\nor the  Company or the  Association  within the  meaning of the 1933 Act and the\n1934 Act shall  have the same  rights to  contribution  as the  Company  and the\nAssociation.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::8149456b7897", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9281170d4e4a"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9281170d4e4a", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "10", "section_title": "Contribution", "clause_type": "Contribution/Notification", "path": "10", "text": "Association  within the  meaning of the 1933 Act and the\n1934 Act shall  have the same  rights to  contribution  as the  Company  and the\nAssociation.\n\n-26-\n\nAny  party  entitled  to  contribution,  promptly  after  receipt  of  notice of\ncommencement  of any action,  suit,  claim or  proceeding  against such party in\nrespect of which a claim for  contribution  may be made  against  another  party\nunder this  Section 10, will  notify  such party from whom  contribution  may be\nsought,  but the  omission  to so notify  such party shall not relieve the party\nfrom whom  contribution  may be sought  from any  other  obligation  it may have\nhereunder or otherwise than under this Section 10.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::bbb6d4406498", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::1b3c1ceff887"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::1b3c1ceff887", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "11", "section_title": "Survival of Agreements, Representations and Indemnities", "clause_type": "Survival", "path": "11", "text": "relieve the party\nfrom whom  contribution  may be sought  from any  other  obligation  it may have\nhereunder or otherwise than under this Section 10.\n\nSECTION  11.  Survival  of  Agreements,   Representations  and\nIndemnities.  The respective  indemnities of the Company,  the  Association  and\nCapital Resources and the representations and warranties and other statements of\nthe Company and the  Association set forth in or made pursuant to this Agreement\nshall  remain  in full  force  and  effect,  regardless  of any  termination  or\ncancellation  of this  Agreement  or any  investigation  made by or on behalf of\nCapital  Resources,  the Company,  the  Association  or any  indemnified  person\nreferred to in Section 9 hereof,  and shall  survive the issuance of the Shares,\nand any legal  representative,  successor  or assign of Capital  Resources,  the\nAssociation, and any such indemnified person shall be entitled to the benefit of\nthe respective agreements, indemnities, warranties and representations.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::9281170d4e4a", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ba7542dda1c2"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ba7542dda1c2", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "12.(a)", "section_title": "Termination", "clause_type": "Termination", "path": "12 ➞ 12.(a)", "text": "sociation, and any such indemnified person shall be entitled to the benefit of\nthe respective agreements, indemnities, warranties and representations.\n\nSECTION 12.  Termination.  Capital Resources may terminate \nthis Agreement by giving the notice indicated below in this Section at any time\nafter this Agreement becomes effective as follows:\n\n(a) In the event the  Company  fails to sell all of the Shares\nwithin the period  specified,  and in accordance with the provisions of the Plan\nor as required by the Conversion  Regulations and applicable law, this Agreement\nshall terminate upon refund by the Association to each person who has subscribed\nfor or ordered any of the Shares the full amount which it may have received from\nsuch person, together with interest as provided in the Offering Prospectus,  and\nno party to this  Agreement  shall have any  obligation to the other  hereunder,\nexcept  for  payment  by the  Association  and/or  the  Company  as set forth in\nSections 2, 7, 9 and 10 hereof.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::1b3c1ceff887", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::90e112445c02"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::90e112445c02", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "12", "section_title": "Termination", "clause_type": "Termination clause", "path": "12 ➞ 12.(a) ➞ 12.(b) ➞ 12.(c)", "text": "obligation to the other  hereunder,\nexcept  for  payment  by the  Association  and/or  the  Company  as set forth in\nSections 2, 7, 9 and 10 hereof.\n\n(b) If any of the conditions  specified in Section 8 shall not\nhave been  fulfilled when and as required by this  Agreement,  or by the Closing\nDate,  or waived in writing  by Capital  Resources,  this  Agreement  and all of\nCapital Resources  obligations hereunder may be canceled by Capital Resources by\nnotifying the Association of such  cancellation in writing or by telegram at any\ntime at or prior to the  Closing  Date,  and,  any  such  cancellation  shall be\nwithout  Liability of any party to any other party except as otherwise  provided\nin Sections 2, 7, 9 and 10 hereof.\n\n(c) If Capital Resources elects to terminate this Agreement as\nprovided in this section,  the Company and the Association  shall be notified as\nprovided in Section 13 hereof,  promptly by Capital  Resources  by  telephone or\ntelegram, confirmed by letter.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::ba7542dda1c2", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5c96060c96e8"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5c96060c96e8", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "13", "section_title": "Notices", "clause_type": "Notices", "path": "13", "text": "the Association  shall be notified as\nprovided in Section 13 hereof,  promptly by Capital  Resources  by  telephone or\ntelegram, confirmed by letter.\n\nSECTION  13.  Notices.  All  communications  hereunder,  except\nas  herein otherwise specifically provided, shall be mailed in writing and if\nsent to Capital Resources shall be mailed, delivered or telegraphed and \nconfirmed to Capital Resources, Inc.,1701 K Street, N.W., Suite 700, Washington,\nD.C. 20006 Attention:  Catherine Kozlow Rochester (with a copy to Serchuk &\nZelermyer, LLP, 81 Main Street, White Plains, NY 10601, Attention: Clifford S. \nWeber, Esq.) and, if sent to the  Company  and the  Association,  shall be\nmailed,  delivered  or telegraphed  and  confirmed  to the  Company and the \nAssociation  at 161 Church Street, Amsterdam, New York, 12010, (Attention:  John\nM. Lisicki (with a copy to Malizia,  Spidi,  Sloane & Fisch,  P.C.,  1301 K\nStreet,  N.W.,  Suite 700 East Washington, D.C. 20005, Attention: John J. Spidi,\nEsq.)\n\n-27-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::90e112445c02", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d0810343637e"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d0810343637e", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "14", "section_title": "Parties", "clause_type": "Parties / Third-Party Beneficiaries", "path": "14", "text": "copy to Malizia,  Spidi,  Sloane & Fisch,  P.C.,  1301 K\nStreet,  N.W.,  Suite 700 East Washington, D.C. 20005, Attention: John J. Spidi,\nEsq.)\n\n-27-\n\nSECTION 14. Parties.  The Company and the Association shall be\nentitled to act and rely on any request,  notice,  consent,  waiver or agreement\npurportedly  given on behalf of Capital  Resources when the same shall have been\ngiven by the undersigned. Capital Resources shall be entitled to act and rely on\nany request, notice, consent, waiver or agreement purportedly given on behalf or\nthe  Company  or the  Association,  when the same  shall  have been given by the\nundersigned  or any  other  officer  of the  Company  or the  Association.  This\nAgreement  shall  inure  solely to the  benefit  of, and shall be binding  upon,\nCapital Resources and the Company,  the Association and the controlling  persons\nreferred  to in  Section  9  hereof,  and  their  respective  successors,  legal\nrepresentatives  and assigns,  and no other person shall have or be construed to\nhave any legal or equitable right,  remedy or claim under or in respect of or by\nvirtue of this Agreement or any provision herein contained.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::5c96060c96e8", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::cbc028de89b5"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::cbc028de89b5", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "15", "section_title": "Closing", "clause_type": "Closing", "path": "15", "text": "strued to\nhave any legal or equitable right,  remedy or claim under or in respect of or by\nvirtue of this Agreement or any provision herein contained.\n\nSECTION  15.  Closing.  The closing for the sale of the Shares\nshall take place on the Closing Date at the offices of Capital Resources or such\nother location as mutually agreed upon by Capital Resources, the Company and the\nAssociation.  At the closing, the Association shall deliver to Capital Resources\nin next day funds the  commissions,  fees and  expenses due and owing to Capital\nResources  as set  forth  in  Sections  2 and 7  hereof  and  the  opinions  and\ncertificates  required hereby and other documents deemed reasonably necessary by\nCapital  Resources  shall be executed  and  delivered  to effect the sale of the\nShares  as  contemplated  hereby  and  pursuant  to the  terms  of the  Offering\nProspectus.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::d0810343637e", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::48baecba6c35"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::48baecba6c35", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "16-18", "section_title": "Partial Invalidity; Construction; Counterparts", "clause_type": "Boilerplate (Severability; Governing law; Counterparts; Time is of the essence)", "path": "16 ➞ 17 ➞ 18", "text": "ll be executed  and  delivered  to effect the sale of the\nShares  as  contemplated  hereby  and  pursuant  to the  terms  of the  Offering\nProspectus.\n\nSECTION 16.  Partial  Invalidity.  In the event that any term,\nprovision or covenant herein or the application  thereof to any circumstances or\nsituation shall be invalid or unenforceable,  in whole or in part, the remainder\nhereof and the  application  of said term,  provision  or  covenant to any other\ncircumstance  or  situation  shall  not be  affected  thereby,  and  each  term,\nprovision or covenant  herein shall be valid and  enforceable to the full extent\npermitted by law.\n\nSECTION 17.  Construction.  This Agreement shall be construed \nin accordance with the laws of the District of Columbia.\n\nSECTION 18.  Counterparts.  This Agreement may be executed in\nseparate counterparts, each of which so executed and delivered shall be an \noriginal, but all of which together shall constitute but one and the same\ninstrument.\n\nTime shall be of the essence of this Agreement.\n\n-28-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::cbc028de89b5", "next_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::99d7978d8786"}
{"id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::99d7978d8786", "doc_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d", "section_number": "18", "section_title": "Counterparts", "clause_type": "Execution/Counterparts (Miscellaneous) / Signature Block", "path": "18", "text": "ll be an \noriginal, but all of which together shall constitute but one and the same\ninstrument.\n\nTime shall be of the essence of this Agreement.\n\n-28-\n\nIf the foregoing  correctly sets forth the  arrangement  among\nthe Company,  the Association and Capital Resources,  please indicate acceptance\nthereof in the space provided below for that purpose,  whereupon this letter and\nCapital Resources' acceptance shall constitute a binding agreement.\n\nVery truly yours,\n\nAFSALA BANCORP, INC.\n\nBy: ________________________________\n                                                 John M. Lisicki, President and\n                                                 Chief Executive Officer\n\nAMSTERDAM FEDERAL SAVINGS AND\n                                        LOAN ASSOCIATION\n\nBy:  ________________________________\n                                                 John M. Lisicki, President and\n                                                 Chief Executive Officer\n\nAccepted as of the date first above written.\n\nCAPITAL RESOURCES, INC.\n\nBy:  _____________________________________\n         Catherine K. Rochester, President\n\n-29-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "agency agreement", "party_role": ["issuer", "seller", "agent"], "jurisdiction": "US-DC", "governing_law": "US-DC", "industry": "banking"}, "prev_id": "1da02a38-80bf-43e7-90d6-3055205dcc2d::48baecba6c35", "next_id": null}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::14882aeb5f78", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "1", "section_title": "Chrome Services", "clause_type": "Service Description", "path": "1", "text": "Chrome Online Agreement\n\nLast modified: September 17, 2024 | Previous Versions\n\nIf you signed an offline variant of this Agreement for use of the Chrome Services, the\n\nterms below do not apply to you and your offline terms govern your use of the Chrome\n\nServices.\n\nThis Chrome Online Agreement (the \"Agreement\") is entered into between Google and\n\nthe entity agreeing to these terms (\"Customer\"). \"Google\" has the meaning given\n\nat https://cloud.google.com/terms/google-entity.\n\nThis Agreement is effective as of the date Customer clicks to accept it or, if applicable,\n\nthe date the Agreement is countersigned (the \"Effective Date\"). If you are accepting on\n\nbehalf of your employer or another entity, you represent and warrant that: (i) you have full\n\nlegal authority to bind your employer or the applicable entity to these terms; (ii) you have\n\nread and understand this Agreement; and (iii) you agree on behalf of the party that you\n\nrepresent to this Agreement. This Agreement governs Customer's access to and use of\n\nthe Chrome Services as ordered in the applicable Order Form.\n\n1. Chrome Services. Google will provide the Chrome Services ordered in the", "numbers_present": null, "definition_terms": ["Agreement", "Customer", "Google", "Effective Date"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": null, "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::af1cfd290cce"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::af1cfd290cce", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "1", "section_title": "Chrome Services", "clause_type": "Service provision and data transfer (service description; data processing/transfer)", "path": "1 ➞ 1.1 (Facilities and Data Transfer); 1 ➞ 1.2 (No Ads); 1 ➞ 1.3 (New Features for Chrome Services)", "text": "o and use of\n\nthe Chrome Services as ordered in the applicable Order Form.\n\n1. Chrome Services. Google will provide the Chrome Services ordered in the\n\napplicable Order Form. Customer may use the Chrome Services ordered in the \napplicable Order Form in accordance with this Agreement.\n\n1. Facilities and Data Transfer. All facilities used to store and process\n\nCustomer Data will adhere to reasonable security standards no less \nprotective than the security standards at facilities where Google stores \nand processes its own information of a similar type. As part of providing \nthe Chrome Services, Google may transfer, store and process Customer \nData in the United States or any other country in which Google or its \nagents maintain facilities. By using the Chrome Services, Customer \nconsents to this transfer, processing and storage of Customer Data. To \nthe extent applicable, Customer Data will be processed in accordance \nwith the Data Processing Amendment.\n\n2. No Ads. Notwithstanding any other term of the Agreement, Google will\n\nnot process Customer Data for Advertising purposes or serve Advertising \nin the Chrome Services.\n\n3. New Features for Chrome Services. Google may make new", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::14882aeb5f78", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::90ae728516c1"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::90ae728516c1", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "3", "section_title": "New Features for Chrome Services", "clause_type": "Service update / new features availability", "path": "3", "text": "process Customer Data for Advertising purposes or serve Advertising \nin the Chrome Services.\n\n3. New Features for Chrome Services. Google may make new\n\napplications, features or functionality for the Chrome Services available \nfrom time to time, the use of which may be contingent upon Customer's \nagreement to additional terms.\n\n4. Verification to Use Chrome Services. Customer must verify a Domain", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::af1cfd290cce", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::638be7b95f83"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::638be7b95f83", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "4", "section_title": "Verification to Use Chrome Services", "clause_type": "Access/Verification", "path": "4", "text": "use of which may be contingent upon Customer's \nagreement to additional terms.\n\n4. Verification to Use Chrome Services. Customer must verify a Domain\n\nEmail Address or a Domain Name to use the Chrome Services. If \nCustomer does not have audited valid permission to use the Domain \nEmail Address or does not own or control the Domain Name, then Google \nwill have no obligation to provide Customer with the Chrome Services \nand may delete the Account without notice. To use the Chrome Services, \nCustomer will need Cloud Identity. If Customer already has Cloud \nIdentity, Customer can log-in and start using the Chrome Services. If \nCustomer does not have Cloud Identity, Google will provision Customer \nwith access to Cloud Identity. Customer will need to activate Cloud \nIdentity by logging-in to create and complete Customer's Cloud Identity \naccount. Use of Cloud Identity (specifically excluding the Chrome \nServices) is subject to the Cloud Identity Terms.\n\n5. Service Specific Terms. The Service Specific Terms are incorporated\n\nby this reference into the Agreement.\n\n2. Modifications.\n\n1. Modifications to Chrome Services.\n\n1. Deprecation Policy. Google will notify Customer at least 12", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::90ae728516c1", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::4627122228b2"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::4627122228b2", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "2.1.1-2.1.2", "section_title": "Modifications to Chrome Services", "clause_type": "Modification / Deprecation Policy", "path": "2 ➞ 2.1 ➞ 2.1.1-2.1.2", "text": "reference into the Agreement.\n\n2. Modifications.\n\n1. Modifications to Chrome Services.\n\n1. Deprecation Policy. Google will notify Customer at least 12\n\nmonths before a Significant Deprecation unless Google \nreasonably determines that: (i) Google is not permitted to do so \nby law or by contract (including if there is a change in \napplicable law or contract), or (ii) continuing to provide the \nChrome Service that is subject to the Significant Deprecation \ncould create a (A) security risk or (B) substantial economic or \ntechnical burden.\n\n2. Other Modifications. Subject to Section 2.1.1 (Deprecation\n\nPolicy), Google may make changes to the Chrome Services, \nwhich may include adding, updating, or discontinuing any \nChrome Services or portions of feature(s) of the Chrome \nServices. Google will notify Customer of any material change to \nthe Chrome Services.\n\n2. Modifications to the Agreement. Google may change the terms of this", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::638be7b95f83", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::6c972682cb65"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::6c972682cb65", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "2.2-2.3", "section_title": "Modifications to the Agreement; Modifications to URL Terms", "clause_type": "Modification/Amendment (Change of Terms)", "path": "2 ➞ 2.2; 2 ➞ 2.3", "text": "s. Google will notify Customer of any material change to \nthe Chrome Services.\n\n2. Modifications to the Agreement. Google may change the terms of this\n\nAgreement from time to time and will post any such changes \nat https://chromeenterprise.google/terms/chrome-online-agreement . \nThese changes will only take effect at the beginning of Customer's next \nOrder Term, at which time Customer's continued use of the Chrome \nServices will constitute its acceptance of the changes. This Section 2.2 \n(Modifications to the Agreement) does not apply to changes to URL \nTerms.\n\n3. Modifications to URL Terms. Google may update the URL Terms,\n\nprovided the updates do not (a) result in a material degradation of the \noverall security of the Chrome Services, (b) have a material adverse \nimpact on Customer's rights under the URL Terms. Google will notify \nCustomer of any material updates to URL Terms.\n\n3. Customer Obligations.\n\n1. Compliance. Customer will (a) ensure that Customer and its End Users'", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::4627122228b2", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::f91aab04cfaf"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::f91aab04cfaf", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "3", "section_title": "Customer Obligations", "clause_type": "Customer obligations", "path": "3 ➞ 3.1 ➞ 3.2 ➞ 3.2.1", "text": "fy \nCustomer of any material updates to URL Terms.\n\n3. Customer Obligations.\n\n1. Compliance. Customer will (a) ensure that Customer and its End Users'\n\nuse of the Chrome Services, including all access to and use of Customer \nData by it and its End Users, complies with this Agreement and with any \nof its applicable contract terms or policies, including any employment \ncontracts or employer's policies regarding technology usage, security, or \nconfidentiality; (b) use commercially reasonable efforts to prevent \nunauthorized access or use of the Chrome Services; and (c) promptly \nnotify Google of any unauthorized use of, or access to, the Chrome \nServices of which Customer becomes aware. Google reserves the right \nto investigate any potential violation of the AUP by Customer, which may \ninclude reviewing Customer Data.\n\n2. Administration of Chrome Services.\n\n1. Admin Console. Google will provide Customer access to the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::6c972682cb65", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ddf5f353eb87"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ddf5f353eb87", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "3.2", "section_title": "Administration of Chrome Services", "clause_type": "Customer obligations / Administration", "path": "3 ➞ 3.2 ➞ 3.2.1 ➞ 3.2.2 ➞ 3.2.3", "text": "omer, which may \ninclude reviewing Customer Data.\n\n2. Administration of Chrome Services.\n\n1. Admin Console. Google will provide Customer access to the\n\nAdmin Console for the Administrator to manage its use of the \nChrome Services. Customer may use the Admin Console to \nspecify one or more Administrators who will have the rights to \naccess Admin Account(s) and to administer the policies for End \nUsers. Customer is responsible for: (a) maintaining the \nconfidentiality and security of the End User policies and \nassociated passwords; and (b) any use of the End User policies. \nCustomer agrees that Google's responsibilities do not extend \nto the internal management or administration of the policies for \nthe Chrome Services for Customer or any End Users.\n\n2. Consents. Customer will obtain and maintain all required\n\nconsents to permit: (i) Customer's use of the Chrome Services;\n\nand (ii) Google's accessing, storing, and processing of \nCustomer Data under this Agreement.\n\n3. Use Restrictions. Customer will not, and will not allow End Users or third", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::f91aab04cfaf", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::67261575dc37"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::67261575dc37", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "3.3", "section_title": "Use Restrictions", "clause_type": "Use restrictions / prohibitions", "path": "3 ➞ 3.3", "text": "essing, storing, and processing of \nCustomer Data under this Agreement.\n\n3. Use Restrictions. Customer will not, and will not allow End Users or third\n\nparties under its control to: (a) copy, modify, create a derivative work of, \nreverse engineer, decompile, translate, disassemble, or otherwise \nattempt to extract any of the source code of the Chrome Services \n(except to the extent such restriction is expressly prohibited by \napplicable law); (b) license, transfer or distribute any of the Chrome \nServices; (c) sell, resell, or otherwise make the Chrome Services available \nto a third party as part of a commercial offering that does not have \nmaterial value independent of the Chrome Services; or (d) access or use \nthe Chrome Services: (i) for High Risk Activities; (ii) in violation of the \nAUP; (iii) in a manner intended to avoid incurring Fees; (iv) for materials or \nactivities that are subject to the International Traffic in Arms Regulations \n(ITAR) maintained by the United States Department of State; (v) in a \nmanner that breaches, or facilitates the breach of, Export Control Laws; \nor (vi) to transmit, store, or process protected health information subject \nto United States HIPAA regulations except as permitted by an executed \nHIPAA BAA.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ddf5f353eb87", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::21ea781be849"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::21ea781be849", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "3.4", "section_title": "Requesting Additional End User Accounts During Order Term", "clause_type": "Ordering / Account management", "path": "3 ➞ 3.4", "text": "to transmit, store, or process protected health information subject \nto United States HIPAA regulations except as permitted by an executed \nHIPAA BAA.\n\n4. Requesting Additional End User Accounts During Order Term.\n\nCustomer may purchase additional End User Accounts during an Order \nTerm by: (a) executing an additional Order Form with Google or Reseller, \nas applicable, or (b) via the Admin Console, if applicable. Such additional \nEnd User Accounts will have a pro-rated term ending on the last day of \nthe applicable Order Term.\n\n4. Payment.\n\n1. Orders via Reseller. If Customer orders the Chrome Services from", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::67261575dc37", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::2f30c61c8801"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::2f30c61c8801", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "4", "section_title": "Payment", "clause_type": "Payment / Ordering (Reseller and Direct Orders)", "path": "4 ➞ 4.1", "text": "pro-rated term ending on the last day of \nthe applicable Order Term.\n\n4. Payment.\n\n1. Orders via Reseller. If Customer orders the Chrome Services from\n\nReseller, then: (a) fees for the Chrome Services will be set between \nCustomer and Reseller, and any payments will be made directly to \nReseller under the Reseller Agreement; (b) the remaining provisions in \nSection 4.2 (Direct Orders) will not apply to the Chrome Services; (c) \nCustomer may request additional End User Accounts during the Order \nTerm by contacting Reseller; (d) for the purposes of Section 13.1.2 where \nthe event giving rise to Liability is in connection with Chrome Services \nprovided by a Reseller, the term \"Fees\" as it is used under Section 13.1.2 \nrefers to the fees charged by the Reseller under the Reseller Agreement \nand (e) Google may share Customer Confidential Information with \nReseller as a Delegate subject to Section 7.1 (Confidentiality Obligations) \nof this Agreement.\n\n2. Direct Orders. In certain circumstances, Customer may order Chrome\n\nProducts directly from Google via an Order Form or via the Admin", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::21ea781be849", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::68dfc268523b"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::68dfc268523b", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "4.2 (includes 4.2.1–4.2.3)", "section_title": "Direct Orders", "clause_type": "Payment and Billing", "path": "4 ➞ 4.2 ➞ 4.2.1; 4.2.2; 4.2.3", "text": "is Agreement.\n\n2. Direct Orders. In certain circumstances, Customer may order Chrome\n\nProducts directly from Google via an Order Form or via the Admin\n\nConsole directly, in which case, Customer will pay all Fees for the \nChrome Services directly to Google. Google will invoice Customer all \nFees for the Chrome Services. Google may change its offering of billing \noptions, including by limiting or ceasing to offer any billing option, upon \nthirty days' written notice to Customer (which may be by email).\n\n1. Payment. All payments due are in U.S. dollars unless otherwise\n\nindicated on the Order Form or invoice.\n\n2. Credit Card or Debit Card. Fees for orders where Customer is\n\npaying with a credit card, debit card or other non-invoice form \nof payment, are due at the end of the month during which \nCustomer received the Chrome Services. For credit cards, or \ndebit cards, as applicable: (i) Google will charge Customer for \nall applicable Fees when due and (ii) these Fees are considered \noverdue thirty days after the end of the month during which \nCustomer received the Chrome Services.\n\n3. Invoices. Payments for invoices are due thirty days after the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::2f30c61c8801", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::13712616734c"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::13712616734c", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "4.2.3-4.2.5", "section_title": "Invoices; Other Forms of Payment; Overdue Payments", "clause_type": "Payment", "path": "4 ➞ 4.2 ➞ 4.2.3-4.2.5", "text": "days after the end of the month during which \nCustomer received the Chrome Services.\n\n3. Invoices. Payments for invoices are due thirty days after the\n\ninvoice date, unless otherwise specified on the Order Form, \nand are considered overdue after such date.\n\n4. Other Forms of Payment. Unless the payment method is\n\nspecified in the Order Form, Customer may change its \npayment method to those available within the Admin Console. \nGoogle may enable other forms of payment by making them \navailable in the Admin Console. These other forms of payment \nmay be subject to additional terms which Customer may have \nto accept prior to using the additional forms of payment.\n\n5. Overdue Payments. Customer's payment of Fees is overdue if", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::68dfc268523b", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5238990028b9"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5238990028b9", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "4.2.5-4.2.6", "section_title": "Overdue Payments; Taxes", "clause_type": "Payment", "path": "4 ➞ 4.2 ➞ 4.2.5 and 4.2.6", "text": "erms which Customer may have \nto accept prior to using the additional forms of payment.\n\n5. Overdue Payments. Customer's payment of Fees is overdue if\n\nGoogle has not received it by the payment due date. If \nCustomer's payment is overdue, Google may (i) charge interest \non the overdue amount at 1.5% per month (or the highest rate \npermitted by law, if less) from the payment due date until paid \nin full, and (ii) suspend the Chrome Services. Further, Customer \nwill reimburse Google for all reasonable expenses (including \nattorneys' fees) incurred by Google in collecting overdue \npayments, except where such payments are due to Google's \nbilling inaccuracies.\n\n6. Taxes. Taxes are not included in the Fees. Customer will pay\n\nTaxes for the Chrome Services. If legally required, Customer \nwill withhold Taxes from its payments to Google and provide a \nwithholding Tax certificate. Unless Customer provides a timely \nand valid tax exemption certificate, Customer will pay any\n\ninvoiced Taxes for the Chrome Services. Without limiting \nCustomer's obligation to pay Fees, Customer will withhold \nTaxes if legally required.\n\n3. Price Revisions. Google may modify its Prices at any time unless", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::13712616734c", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::6d817679a7c5"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::6d817679a7c5", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "4.3; 5; 6.1", "section_title": "Price Revisions; Technical Support Services; Limitations on Chrome Services Suspension", "clause_type": "Pricing/Price revision; Technical support; Suspension (service availability/security)", "path": "4 ➞ 4.3; 5; 6 ➞ 6.1", "text": "omer's obligation to pay Fees, Customer will withhold \nTaxes if legally required.\n\n3. Price Revisions. Google may modify its Prices at any time unless\n\notherwise expressly agreed in an addendum or Order Form. Google or \nthe Reseller will notify Customer at least 30 days in advance of any Price \nincreases.\n\n5. Technical Support Services. Google will provide TSS to Customer during the\n\nOrder Term in accordance with the TSS Guidelines, if applicable. If Customer \norders the Chrome Services from Reseller, then Customer acknowledges and \nagrees that Reseller may disclose Customer Data to Google as reasonably required \nin order for Reseller to handle any support issues that Customer escalates to or via \nReseller.\n\n6. Suspension.\n\n1. Limitations on Chrome Services Suspension. Google may Suspend\n\nChrome Services as described in Sections 6.2 (AUP Breaches) and 6.3 \n(Emergency Suspension). Any Suspension under those Sections will be \nto the minimum extent and for the shortest duration required to: (a) \nprevent or terminate the offending use, (b) prevent or resolve the \nEmergency Security Issue, or (c) comply with applicable law.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5238990028b9", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::149270a26bfb"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::149270a26bfb", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "6.2, 6.3 and beginning of 7.1", "section_title": "AUP Breaches; Emergency Suspension; Confidentiality (Obligations)", "clause_type": "Service suspension / enforcement provisions and confidentiality obligations", "path": "6 ➞ 6.2; 6 ➞ 6.3; 7 ➞ 7.1", "text": "ion required to: (a) \nprevent or terminate the offending use, (b) prevent or resolve the \nEmergency Security Issue, or (c) comply with applicable law.\n\n2. AUP Breaches. If Google becomes aware that Customer's or any End\n\nUser's use of the Chrome Services breaches the AUP, Google will \nrequest that Customer correct the breach. If Customer fails to correct \nsuch breach within 24 hours of such request, or if Google is otherwise \nrequired by law to take action, then Google may Suspend the Chrome \nServices.\n\n3. Emergency Suspension. Google may immediately Suspend Customer's\n\nuse of the Chrome Services if: (a) there is an Emergency Security Issue, \nor (b) Google is required to Suspend such use to comply with applicable \nlaw. At Customer's request, unless prohibited by law, Google will notify \nCustomer of the basis for the Suspension as soon as is reasonably \npossible.\n\n7. Confidentiality.\n\n1. Obligations. Subject to Section 7.2 (Disclosure of Confidential", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::6d817679a7c5", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::300b1766ba95"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::300b1766ba95", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "7", "section_title": "Confidentiality", "clause_type": "Confidentiality — obligations and disclosure (Legal Process Notification)", "path": "7 ➞ 7.1 ➞ 7.2 ➞ 7.2.1 ➞ 7.2.2", "text": "basis for the Suspension as soon as is reasonably \npossible.\n\n7. Confidentiality.\n\n1. Obligations. Subject to Section 7.2 (Disclosure of Confidential\n\nInformation) the recipient will use the other party's Confidential \nInformation only to exercise rights and fulfill obligations under this \nAgreement. The recipient will use reasonable care to protect against \ndisclosure of the other party's Confidential Information to other parties \nother than the recipient's employees, Affiliates, agents, or professional\n\nadvisors (\"Delegates\") who need to know it and who have a legal \nobligation to keep it confidential. The recipient will ensure that its \nDelegates are also subject to the same non-disclosure and use \nobligations.\n\n2. Disclosure of Confidential Information.\n\n1. General. Regardless of any other provision in the Agreement,\n\nthe recipient or its Affiliates may disclose the other party's \nConfidential Information (i) in accordance with a Legal Process, \nsubject to Section 7.2.2 (Legal Process Notification) or (ii) with \nthe other party's written consent.\n\n2. Legal Process Notification. The recipient will use", "numbers_present": null, "definition_terms": ["Delegates"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::149270a26bfb", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::bd56e82d442f"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::bd56e82d442f", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "8", "section_title": "Intellectual Property", "clause_type": "Intellectual property / Confidentiality disclosure", "path": "7 ➞ 7.2 ➞ 7.2.2; 7 ➞ 7.2 ➞ 7.2.3; 8 ➞ 8.1", "text": "to Section 7.2.2 (Legal Process Notification) or (ii) with \nthe other party's written consent.\n\n2. Legal Process Notification. The recipient will use\n\ncommercially reasonable efforts to notify the other party before \ndisclosing that party's Confidential Information in accordance \nwith Legal Process. Notice is not required before disclosure if \nthe recipient is informed that (i) it is legally prohibited from \ngiving notice or (ii) the Legal Process relates to exceptional \ncircumstances involving danger of death or serious physical \ninjury.\n\n3. Opposition. The recipient and its Affiliates will comply with the\n\nother party's reasonable requests to oppose disclosure of its \nConfidential Information.\n\n8. Intellectual Property.\n\n1. Intellectual Property Rights. Except as expressly stated in the\n\nAgreement, the Agreement does not grant either party any rights, implied \nor otherwise, to the other's content or Intellectual Property. As between \nthe parties, Customer retains all Intellectual Property Rights in Customer \nData, and Google retains all Intellectual Property Rights in the Chrome \nServices.\n\n2. Brand Features. Google will display only those Customer Brand", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::300b1766ba95", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5f5377a3ab18"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5f5377a3ab18", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "8.2 - 8.3 (partial 8.1 and partial 9)", "section_title": "Brand Features; Feedback; (partial) Marketing and Publicity", "clause_type": "Branding / Intellectual Property / Marketing & Publicity", "path": "8 ➞ 8.2; 8 ➞ 8.3; 9", "text": "Data, and Google retains all Intellectual Property Rights in the Chrome \nServices.\n\n2. Brand Features. Google will display only those Customer Brand\n\nFeatures that Customer authorizes Google to display by uploading them \ninto the Chrome Services. Google will display those Customer Brand \nFeatures within designated areas of the web pages displaying the \nChrome Services to Customer or its End Users. Google may also display \nGoogle Brand Features on such web pages to indicate that the Chrome \nServices are provided by Google.\n\n3. Feedback. At its option, Customer may provide Feedback about the\n\nChrome Services to Google. If Customer provides Feedback, then \nGoogle and its Affiliates may use that Feedback without restriction and \nwithout obligation to Customer.\n\n9. Marketing and Publicity. Each party may use the other party's Brand Features in", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::bd56e82d442f", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::63409ce6e0ae"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::63409ce6e0ae", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "9", "section_title": "Marketing and Publicity", "clause_type": "Marketing and Publicity / Brand usage", "path": "9", "text": "Feedback without restriction and \nwithout obligation to Customer.\n\n9. Marketing and Publicity. Each party may use the other party's Brand Features in\n\nconnection with this Agreement only as permitted in the Agreement. Customer \nmay state publicly that it is a Google customer and display Google Brand Features \nin accordance with the Trademark Guidelines. Google may (a) orally state that \nCustomer is a Google customer and (b) include Customer's name or Customer \nBrand Features in a list of Google customers in Google's promotional materials. \nAny use of a party's Brand Features will inure to the benefit of the party holding \nIntellectual Property Rights to those Brand Features. A party may revoke the other \nparty's right to use its Brand Features with written notice to the other party and a \nreasonable period to stop the use.\n\n10. Representations, Warranties and Disclaimers.\n\n1. Representations and Warranties. Each party represents that it: (a) has\n\nfull power and authority to enter into the Agreement; and (b) will comply \nwith all laws and regulations applicable to its provision, or use, of the \nChrome Services, as applicable.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5f5377a3ab18", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::9c0e9bcdc007"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::9c0e9bcdc007", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "10.2; 11; 11.1-11.3", "section_title": "Disclaimers; Term and Termination", "clause_type": "Disclaimers and Termination (warranties & contract term)", "path": "10 ➞ 10.2; 11 ➞ 11.1 ➞ 11.2 ➞ 11.3", "text": "er into the Agreement; and (b) will comply \nwith all laws and regulations applicable to its provision, or use, of the \nChrome Services, as applicable.\n\n2. Disclaimers. Except as expressly provided for in the Agreement, to the\n\nfullest extent permitted by applicable law, Google (a) does not make any \nother warranties of any kind, whether express, implied, statutory or \notherwise, including warranties of merchantability, fitness for a particular \nuse, noninfringement, or error-free or uninterrupted use of the Chrome \nServices; and (b) makes no representation about content or information \nmade accessible through the Chrome Services. Unless otherwise stated \nin Agreement, Customer acknowledges the Chrome Services are not \ncapable of placing or receiving emergency services calls.\n\n11. Term and Termination.\n\n1. Agreement Term. This Agreement will remain in effect for the Term\n\nunless it expires or is terminated in accordance with the Agreement.\n\n2. Renewal. At the end of each Order Term, the Chrome Services will\n\nrenew consistent with Customer's elections on the Order Form or Admin \nConsole.\n\n3. Generally. Customer may alter the number of End User Accounts to be", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::63409ce6e0ae", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d4f8d12ad6bf"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d4f8d12ad6bf", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "11.3-11.4", "section_title": "Generally; Termination for Breach", "clause_type": "Termination and Renewal", "path": "11 ➞ 11.3; 11 ➞ 11.4", "text": "enew consistent with Customer's elections on the Order Form or Admin \nConsole.\n\n3. Generally. Customer may alter the number of End User Accounts to be\n\nrenewed via the Admin Console or elect to renew with the Reseller, as \napplicable. Customer will continue to pay Google or the Reseller the \nthen-current Fees for each renewed End User Account unless Customer \nand Google mutually agree otherwise. If one party does not want the \nChrome Services to renew, then it will provide the other party written \nnotice to this effect at least fifteen days before the end of the then \ncurrent Order Term, unless otherwise specified on the Order Form. This \nnotice of non renewal will be effective upon the conclusion of the then \ncurrent Order Term.\n\n4. Termination for Breach. Either party may terminate the Agreement if the\n\nother party: (a) is in material breach of the Agreement and fails to cure \nthat breach within thirty days after receipt of written notice; or (b) ceases \nits business operations or, to the extent permitted by applicable law, \nbecomes subject to insolvency proceedings and the proceedings are not \ndismissed within ninety days.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::9c0e9bcdc007", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::fe0240f868fd"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::fe0240f868fd", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "11.5; 11.6; 12.1 (partial)", "section_title": "Effects of Termination; Survival; Indemnification", "clause_type": "Termination / Survival / Indemnification", "path": "11 ➞ 11.5; 11 ➞ 11.6; 12", "text": "s or, to the extent permitted by applicable law, \nbecomes subject to insolvency proceedings and the proceedings are not \ndismissed within ninety days.\n\n5. Effects of Termination. If the Agreement terminates or expires, then all\n\nOrder Forms also terminate or expire, as applicable. If the Agreement \nterminates or expires, then: (a) all rights and access to the Chrome \nServices under the Agreement will terminate (including access to \nCustomer Data); and (b) Google or Reseller, as applicable, will send \nCustomer a final invoice.\n\n6. Survival. The following Sections will survive expiration or termination of\n\nthis Agreement: Section 4 (Payment), 7 (Confidentiality), 8 (Intellectual \nProperty), 10.2 (Disclaimers), 11.5 (Effects of Termination), 11.6 (Survival), \n12 (Indemnification), 13 (Liability), 14 (Miscellaneous) and 15 (Definitions).\n\n12. Indemnification.\n\n1. Google Indemnification Obligations. Google will defend Customer and", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d4f8d12ad6bf", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5ee124ca7878"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5ee124ca7878", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "12", "section_title": "Indemnification", "clause_type": "Indemnification", "path": "12 ➞ 12.1; 12 ➞ 12.2; 12 ➞ 12.3", "text": "13 (Liability), 14 (Miscellaneous) and 15 (Definitions).\n\n12. Indemnification.\n\n1. Google Indemnification Obligations. Google will defend Customer and\n\nits Affiliates participating under this Agreement (\"Customer Indemnified \nParties\"), and indemnify them against Indemnified Liabilities in any ThirdParty Legal Proceeding to the extent arising from an allegation that \nCustomer Indemnified Parties' use in accordance with this Agreement of \nany of Google Indemnified Materials infringes the third party's Intellectual \nProperty Rights.\n\n2. Customer Indemnification Obligations. Unless prohibited by applicable\n\nlaw, Customer will defend Google and its Affiliates and indemnify them \nagainst Indemnified Liabilities in any Third-Party Legal Proceeding to the \nextent arising from: (a) any Customer Indemnified Materials; or (b) \nCustomer's or an End User's use of the Chrome Services in violation of \nthe Acceptable Use Policy or the Use Restrictions.\n\n3. Indemnification Exclusions. Sections 12.1 (Google Indemnification", "numbers_present": null, "definition_terms": ["Customer Indemnified Parties"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::fe0240f868fd", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::7a401932453f"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::7a401932453f", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "12.3-12.4.1", "section_title": "Indemnification Exclusions; Indemnification Conditions", "clause_type": "Indemnification", "path": "12 ➞ 12.3; 12 ➞ 12.4 ➞ 12.4.1", "text": "ome Services in violation of \nthe Acceptable Use Policy or the Use Restrictions.\n\n3. Indemnification Exclusions. Sections 12.1 (Google Indemnification\n\nObligations) and 12.2 (Customer Indemnification Obligations) will not \napply to the extent the underlying allegation arises from: (a) the \nindemnified party's breach of the Agreement; or (b) a combination of \nGoogle Indemnified Materials or Customer Indemnified Materials (as \napplicable) with materials not provided by the indemnifying party under \nthe Agreement, unless the combination is required by the Agreement.\n\n4. Indemnification Conditions. Sections 12.1 (Google Indemnification\n\nObligations) and 12.2 (Customer's Indemnification Obligations) are \nconditioned on the following:\n\n1. The indemnified party must promptly notify the indemnifying", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5ee124ca7878", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d47aa67ef83c"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d47aa67ef83c", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "12.4", "section_title": "Indemnification Conditions", "clause_type": "Indemnification (conditions)", "path": "12 ➞ 12.4", "text": ") and 12.2 (Customer's Indemnification Obligations) are \nconditioned on the following:\n\n1. The indemnified party must promptly notify the indemnifying\n\nparty in writing of any allegation(s) that preceded the ThirdParty Legal Proceeding and cooperate reasonably with the \nindemnifying party to resolve the allegation(s) and Third-Party \nLegal Proceeding. If breach of this Section 12.4.1 prejudices the \ndefense of the Third-Party Legal Proceeding, the indemnifying \nparty's obligations under Sections 12.1 (Google Indemnification \nObligations) or 12.2 (Customer Indemnification Obligations) (as \napplicable) will be reduced in proportion to the prejudice.\n\n2. The indemnified party must tender sole control of the\n\nindemnified portion of the Third-Party Legal Proceeding to the \nindemnifying party, subject to the following: (i) the indemnified \nparty may appoint its own non-controlling counsel, at its own \nexpense; and (ii) any settlement requiring the indemnified party \nto admit liability, pay money, or take (or refrain from taking) any \naction, will require the indemnified party's prior written consent, \nnot to be unreasonably withheld, conditioned, or delayed.\n\n5. Remedies.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::7a401932453f", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::76964920cb3c"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::76964920cb3c", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "12.5–12.6; 13.1", "section_title": "Remedies; Sole Rights and Obligations; Limited Liabilities", "clause_type": "Indemnification remedies; indemnification exclusive remedy; limitation of liability (introductory)", "path": "12 ⟶ 12.5; 12 ⟶ 12.6; 13 ⟶ 13.1", "text": "ing) any \naction, will require the indemnified party's prior written consent, \nnot to be unreasonably withheld, conditioned, or delayed.\n\n5. Remedies.\n\n1. If Google reasonably believes the Chrome Services might\n\ninfringe a third party's Intellectual Property Rights, then Google \nmay, at its sole option and expense: (i) procure the right for \nCustomer to continue using the Chrome Services; (ii) modify \nthe Chrome Services to make them non-infringing without \nmaterially reducing their functionality; or (iii) replace the \nChrome Services with a non-infringing, functionally equivalent \nalternative.\n\n2. If Google does not believe the remedies in Section 12.5.1 are\n\ncommercially reasonable, then Google may Suspend or \nterminate the impacted Chrome Services.\n\n6. Sole Rights and Obligations. Without affecting either party's termination\n\nrights and to the extent permitted by applicable law, this Section 12 \n(Indemnification) states the parties' sole and exclusive remedy under this \nAgreement for any third party allegations of Intellectual Property Rights \nInfringement covered by this Section 12 (Indemnification).\n\n13. Liability.\n\n1. Limited Liabilities.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d47aa67ef83c", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::53238ea3b9af"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::53238ea3b9af", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "13", "section_title": "Liability", "clause_type": "Limitation of Liability / Liability Cap", "path": "13 ➞ 13.1", "text": "party allegations of Intellectual Property Rights \nInfringement covered by this Section 12 (Indemnification).\n\n13. Liability.\n\n1. Limited Liabilities.\n\n1. To the extent permitted by applicable law and subject to\n\nSection 13.2 (Unlimited Liabilities), neither party will have any \nLiability arising out of or relating to the Agreement for any: (i)\n\nlost revenues, profits, savings or goodwill; or (ii) indirect, \nspecial, incidental, consequential, or punitive damages.\n\n2. Each party's total Liability for damages arising out of or relating\n\nto the Agreement is limited to the greater of:\n\ni. \nthe Fees paid by Customer under the Agreement \nduring the 12 month period before the event giving \nrise to liability; and\n\nii. \n$25,000.\n\n2. Unlimited Liabilities. Nothing in the Agreement excludes or limits either", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::76964920cb3c", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5dd68409df2b"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5dd68409df2b", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "13.1.2(ii); 13.2; 14; 14.1; 14.2", "section_title": "Limited Liabilities / Unlimited Liabilities; Miscellaneous; Notices; Emails", "clause_type": "Liability and Miscellaneous (Notices / Communications)", "path": "13 ➞ 13.1 ➞ 13.1.2 ➞ 13.1.2(ii); 13 ➞ 13.2; 14 ➞ 14.1; 14 ➞ 14.2", "text": "th period before the event giving \nrise to liability; and\n\nii. \n$25,000.\n\n2. Unlimited Liabilities. Nothing in the Agreement excludes or limits either\n\nparty's Liability for: (a) death or personal injury resulting from its \nnegligence or the negligence of its employees or agents; (b) its fraud or \nfraudulent misrepresentation; (c) obligations under Section 12 \n(Indemnification); (d) its infringement of the other party's Intellectual \nProperty Rights; (e) its payment obligations under the Agreement; or (f) \nmatters for which liability cannot be excluded or limited under applicable \nlaw.\n\n14. Miscellaneous.\n\n1. Notices. Google may provide any notice to Customer by: (a) sending an\n\nemail to Notification Email Address or (b) posting a notice in the Admin \nConsole. Notices to Google must be sent by email to legalnotices@google.com. Notice will be treated as received when (x) the \nemail is sent, whether or not the other party has received the email or (y) \nnotice is posted in the Admin Console. Customer is responsible for \nkeeping its Notification Email Address current throughout the Term.\n\n2. Emails. Under this Agreement, the parties may use emails to satisfy", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::53238ea3b9af", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d5af686a1918"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d5af686a1918", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "14.1-14.5", "section_title": "Miscellaneous", "clause_type": "Boilerplate / Miscellaneous provisions", "path": "14 ➞ 14.1 ➞ 14.2 ➞ 14.3 ➞ 14.4 ➞ 14.5", "text": "sible for \nkeeping its Notification Email Address current throughout the Term.\n\n2. Emails. Under this Agreement, the parties may use emails to satisfy\n\nwritten approval and consent requirements.\n\n3. Assignment. Neither party may assign the Agreement without the\n\nwritten consent of the other party, except to an Affiliate where: (a) the \nassignee agrees in writing to be bound by the terms of the Agreement; \n(b) the assigning party remains liable for obligations incurred under the \nAgreement if the assignee defaults on them; and (c) the assigning party \nhas notified the other party of the assignment. Any other attempt to \nassign is void.\n\n4. Change of Control. If a party experiences a change of Control other than\n\nas part of an internal restructuring or reorganization: (a) that party will \ngive written notice to the other party within 30 days after the change of \nControl; and (b) the other party may immediately terminate the \nAgreement any time within 30 days after it receives that written notice.\n\n5. Force Majeure. Neither party will be liable for failure or delay in", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::5dd68409df2b", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d4e0633638c6"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d4e0633638c6", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "14.5-14.12", "section_title": "Miscellaneous", "clause_type": "Miscellaneous / Boilerplate", "path": "14 ➞ 14.5 ➞ 14.6 ➞ 14.7 ➞ 14.8 ➞ 14.9 ➞ 14.10 ➞ 14.11 ➞ 14.12", "text": "the \nAgreement any time within 30 days after it receives that written notice.\n\n5. Force Majeure. Neither party will be liable for failure or delay in\n\nperformance of its obligations to the extent caused by circumstances \nbeyond its control, including acts of God, natural disaster, terrorism, riots, \nor war.\n\n6. Subcontracting. Google may subcontract obligations under the\n\nAgreement but will remain liable to Customer for any subcontracted \nobligations.\n\n7. No Waiver. Neither party will be treated as having waived any rights by\n\nnot exercising (or delaying the exercise of) any rights under the \nAgreement.\n\n8. Severability. If any Section (or part of a Section) of the Agreement is\n\ninvalid, illegal, or unenforceable, the rest of the Agreement will remain in \neffect.\n\n9. No Agency. The Agreement does not create any agency, partnership or\n\njoint venture between the parties.\n\n10. No Third-Party Beneficiaries. This Agreement does not confer any\n\nbenefits on any third party unless it expressly states that it does.\n\n11. Equitable Relief. Nothing in this Agreement will limit either party's ability\n\nto seek equitable relief.\n\n12. Governing Law.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d5af686a1918", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::19bba0ea849e"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::19bba0ea849e", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "11; 12; 12.1; 12.2; 12.3 (partial)", "section_title": "Equitable Relief; Governing Law", "clause_type": "Equitable relief; Governing law / jurisdiction", "path": "11 ➞ 11. Equitable Relief; 12 ➞ 12.1 (U.S. City, County, and State Government Entities) ➞ 12.2 (U.S. Federal Government Entities) ➞ 12.3 (For All Other Entities) (partial)", "text": "states that it does.\n\n11. Equitable Relief. Nothing in this Agreement will limit either party's ability\n\nto seek equitable relief.\n\n12. Governing Law.\n\n1. U.S. City, County, and State Government Entities. If\n\nCustomer is a U.S. city, county, or state government entity, \nthen the Agreement will be silent regarding governing law and \nvenue.\n\n2. U.S. Federal Government Entities. If Customer is a U.S.\n\nfederal government entity, then the following applies: ALL \nCLAIMS ARISING OUT OF OR RELATING TO THIS \nAGREEMENT OR THE CHROME SERVICES WILL BE \nGOVERNED BY THE LAWS OF THE UNITED STATES OF \nAMERICA, EXCLUDING ITS CONFLICT OF LAWS RULES. \nSOLELY TO THE EXTENT PERMITTED BY FEDERAL LAW, (I) \nTHE LAWS OF THE STATE OF CALIFORNIA (EXCLUDING \nCALIFORNIA'S CONFLICT OF LAWS RULES) WILL APPLY IN \nTHE ABSENCE OF APPLICABLE FEDERAL LAW AND (II) FOR \nALL CLAIMS ARISING OUT OF OR RELATING TO THIS \nAGREEMENT OR THE CHROME SERVICES, THE PARTIES \nCONSENT TO PERSONAL JURISDICTION IN, AND THE \nEXCLUSIVE VENUE OF, THE COURTS IN SANTA CLARA \nCOUNTY, CALIFORNIA.\n\n3. For All Other Entities. If Customer is any entity not identified in", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::d4e0633638c6", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::332a68a1ffec"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::332a68a1ffec", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "13", "section_title": "Amendments", "clause_type": "Amendment", "path": "13", "text": "N, AND THE \nEXCLUSIVE VENUE OF, THE COURTS IN SANTA CLARA \nCOUNTY, CALIFORNIA.\n\n3. For All Other Entities. If Customer is any entity not identified in\n\nSection 14.12.1 (U.S. City, County, and State Government \nEntities) or 14.12.2 (U.S. Federal Government Entities), then the \nfollowing applies: ALL CLAIMS ARISING OUT OF OR \nRELATING TO THIS AGREEMENT OR THE CHROME \nSERVICES WILL BE GOVERNED BY CALIFORNIA LAW, \nEXCLUDING THAT STATE'S CONFLICT OF LAWS RULES, \nAND WILL BE LITIGATED EXCLUSIVELY IN THE FEDERAL OR \nSTATE COURTS OF SANTA CLARA COUNTY, CALIFORNIA, \nUSA; THE PARTIES CONSENT TO PERSONAL JURISDICTION \nIN THOSE COURTS.\n\n13. Amendments. Except as specifically stated otherwise in the Agreement,\n\nany amendment to the Agreement must be in writing, expressly state \nthat it is amending the Agreement and signed by both parties.\n\n14. Independent Development. Nothing in this Agreement will be construed", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::19bba0ea849e", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ea88db04fa89"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ea88db04fa89", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "13-15", "section_title": "Amendments; Independent Development; Entire Agreement", "clause_type": "Amendment clause; Miscellaneous (Independent Development); Entire Agreement (Integration)", "path": "13 ➞ 14 ➞ 15", "text": "pressly state \nthat it is amending the Agreement and signed by both parties.\n\n14. Independent Development. Nothing in this Agreement will be construed\n\nto limit or restrict either party from independently developing, providing, \nor acquiring any materials, services, products, programs, or technology \nthat are similar to the subject of the Agreement; provided, that the party \ndoes not breach its obligations under the Agreement in doing so.\n\n15. Entire Agreement. The Agreement states all terms agreed between the\n\nparties and supersedes any prior or contemporaneous agreements \nbetween the parties relating to the subject matter of this Agreement. In \nentering into the Agreement, neither party has relied on, and neither party \nwill have any right or remedy based on, any statement, representation, or \nwarranty (whether made negligently or innocently), except those \nexpressly stated in the Agreement. The Agreement includes URL links to \nother terms (including the URL Terms), which are incorporated by \nreference into the Agreement. After the Effective Date, Google may \nprovide an updated URL in place of any URL in this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::332a68a1ffec", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::b47352cf3d83"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::b47352cf3d83", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "14.16 - 14.20; 15", "section_title": "Conflicting Terms; Conflicting Languages; Counterparts; Electronic Signatures; Headers; Definitions", "clause_type": "Miscellaneous (boilerplate) and Definitions (heading)", "path": "14 ➞ 14.16; 14 ➞ 14.17; 14 ➞ 14.18; 14 ➞ 14.19; 14 ➞ 14.20; 15", "text": "are incorporated by \nreference into the Agreement. After the Effective Date, Google may \nprovide an updated URL in place of any URL in this Agreement.\n\n16. Conflicting Terms. If there is a conflict between the documents that\n\nmake up this Agreement, the documents will control in the following \norder: the Data Processing Amendment, the Order Form, the Agreement, \nand the URL Terms.\n\n17. Conflicting Languages. If this Agreement is translated into any other\n\nlanguage, and there is a discrepancy between the English text and the \ntext of the other language, the English text will govern.\n\n18. Counterparts. The parties may execute this Agreement in counterparts,\n\nincluding facsimile, PDF or other electronic copies, which taken together \nwill constitute one instrument.\n\n19. Electronic Signatures. The parties consent to electronic signatures.\n\n20. Headers. Headings and captions used in the Agreement are for\n\nreference purposes only and will not have any effect on the interpretation \nof the Agreement.\n\n15. Definitions.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ea88db04fa89", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::1796c89cf419"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::1796c89cf419", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "15", "section_title": "Definitions", "clause_type": "Definitions", "path": "15", "text": "aptions used in the Agreement are for\n\nreference purposes only and will not have any effect on the interpretation \nof the Agreement.\n\n15. Definitions.\n\n\"Acceptable Use Policy\" or \"AUP\" means the acceptable use policy for the \nChrome Services available at https://chromeenterprise.google/terms/aup/.  \n \n\"Account\" means Customer's Google account credentials and correlating access \nto the Chrome Services under this Agreement.  \n \n\"Admin Account\" means a type of End User Account that Customer (or Reseller, if \napplicable) may use to administer the Chrome Services.  \n \n\"Admin Console\" means the online console(s) and tool(s) provided by Google to \nCustomer for administering the Chrome Services.  \n \n\"Admin Console Order\" means an order for Chrome Services placed directly \nthrough the Admin Console and accepted by Google.  \n \n\"Administrators\" mean the Customer-designated technical personnel who \nadminister the Policies for the Chrome Services on Customer's behalf, and may \nhave the ability to access Customer Data.  \n \n\"Advertising\" means online advertisements displayed by Google to End Users, \nexcluding any advertisements Customer expressly chooses to have Google or any \nof its Affiliates display in connection with the Chrome Services under a separate \nagreement (for example, Google AdSense advertisements implemented by \nCustomer on a website created by Customer using the \"Google Sites\" functionality \nwithin the Chrome Services).  \n \n\"Affiliate\" means any entity that directly or indirectly Controls, is Controlled by, or \nis under common Control with a party.  \n \n\"Auto Update Expiration Date\" or \"AUE Date\" means the date set forth on the \napplicable ChromeOS Device or as listed at the following \nlink: https://support.google.com/chrome/a/answer/6220366 (where such content \nmay be updated or modified by Google).  \n \n\"BAA\" or \"Business Associate Agreement\" is an addendum to this Agreement \ncovering the handling of Protected Health Information (as defined in HIPAA).  \n \n\"Brand Features\" means each party's trade names, trademarks, logos, domain \nnames, and other distinctive brand features.", "numbers_present": null, "definition_terms": ["Acceptable Use Policy", "AUP", "Account", "Admin Account", "Admin Console", "Admin Console Order", "Administrators", "Advertising", "Affiliate", "Auto Update Expiration Date", "AUE Date", "BAA", "Business Associate Agreement", "Brand Features"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::b47352cf3d83", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::aa4bbd7368ef"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::aa4bbd7368ef", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "15", "section_title": "Definitions", "clause_type": "Definitions", "path": "15 ➞ Definitions", "text": "on (as defined in HIPAA).  \n \n\"Brand Features\" means each party's trade names, trademarks, logos, domain \nnames, and other distinctive brand features.\n\n\"ChromeOS Device\" means a device using the Chrome Operating System \n(ChromeOS).  \n \n\"ChromeOS Flex Device\" means a non-ChromeOS Device using the ChromeOS \nFlex operating system, which model is included on the Certified Models list \navailable at https://support.google.com/chromeosflex?p=certified_models and only \nprior to its \"Certified until\" date.  \n \n\"Chrome Services\" also referred to as \"Chrome Product\" means Chrome \nEnterprise Upgrade, Chrome Education Upgrade, Chrome Nonprofit Upgrade, or \nKiosk & Signage Upgrade, each of which are described in more detail \nat https://support.google.com/chrome/a/answer/2717664 (as may be updated by \nGoogle from time to time) and are only available for use on either (i) a ChromeOS \nDevice prior to its AUE Date or (ii) a ChromeOS Flex Device prior to its Certified \nUntil date. For clarity, ChromeOS Device(s), the Chrome Operating System \n(ChromeOS), ChromeOS Flex Device(s), and ChromeOS Flex are not Chrome \nServices and are not covered under this Agreement.  \n \n\"Chrome Services Start Date\" means the date Google makes the Chrome \nServices available to Customer.  \n \n\"Cloud Identity\" means the \"Google Cloud Identity – Free\" service described in \nmore detail in https://cloud.google.com/terms/identity/user-features.html.  \n \n\"Cloud Identity Terms\" means the terms which govern use of the Cloud IdentityFree services and which can be found at Service Specific Terms.  \n \n\"Confidential Information\" means information that one party (or Affiliate) \ndiscloses to the other party under the Agreement, and that is marked as \nconfidential or would normally be considered confidential information under the \ncircumstances. Customer Data is Customer's Confidential Information. Confidential \nInformation does not include information that is independently developed by the \nrecipient, is shared with the recipient by a third party without confidentiality \nobligations, or becomes public through no fault of the recipient.  \n \n\"Control\" means control of greater than 50% of the voting rights or equity interests \nof a party.  \n \n\"Customer Data\" means data submitted, stored, sent or received via the Chrome \nServices by Customer, its Affiliates or End Users.  \n \n\"Customer Indemnified Materials\" means the Customer Data and Customer \nBrand Features.", "numbers_present": null, "definition_terms": ["Brand Features", "ChromeOS Device", "ChromeOS Flex Device", "Chrome Services", "Chrome Product", "Chrome Services Start Date", "Cloud Identity", "Cloud Identity Terms", "Confidential Information", "Control", "Customer Data", "Customer Indemnified Materials"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::1796c89cf419", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ee53768933d6"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ee53768933d6", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "15", "section_title": "Definitions", "clause_type": "Definitions", "path": "15 ➞ 15. Definitions", "text": "Chrome \nServices by Customer, its Affiliates or End Users.  \n \n\"Customer Indemnified Materials\" means the Customer Data and Customer \nBrand Features.\n\n\"Data Processing Amendment\" or \"DPA\" means the agreement which governs \nGoogle's processing of Customer Data if Customer is subject to GDPR \nrequirements and which terms can be found at the following \nURL: https://www.google.com/chrome/terms/dpa_terms.html.  \n \n\"Domain Email Address\" means the email address on the Domain Name for use in \nconnection with the Chrome Services.  \n \n\"Domain Name\" means the domain name specified in the Order Form to be used \nin connection with the Chrome Services.  \n \n\"Emergency Security Issue\" means either: (a) Customer's or End Users' use of \nthe Chrome Services in violation of the Acceptable Use Policy, where such use \ncould disrupt: (i) the Chrome Services; (ii) other customers' use of the Chrome \nServices; or (iii) the Google network or servers used to provide the Chrome \nServices; or (b) unauthorized third party access to the Chrome Services.  \n \n\"End User(s)\" means the individuals Customer permits to use a ChromeOS device \nenrolled with Chrome Services managed by an Administrator.  \n \n\"End User Account\" means a Google-hosted account established by Customer \nthrough its Administrator to set the policies for an End User to be included in the \nChrome Services.  \n \n\"Export Control Laws\" means all applicable export and re-export control laws and \nregulations, including (a) the Export Administration Regulations (\"EAR\") maintained \nby the U.S. Department of Commerce, (b) trade and economic sanctions \nmaintained by the U.S. Treasury Department's Office of Foreign Assets Control, \nand (c) the International Traffic in Arms Regulations (\"ITAR\") maintained by the U.S. \nDepartment of State.  \n \n\"Feedback\" means feedback or suggestions about the Chrome Services provided \nto Google by Customer.  \n \n\"Fees\" means the product of the amount of the Chrome Services used or ordered \nby Customer multiplied by the Prices, plus any applicable Taxes.  \n \n\"Google Indemnified Materials\" means the Chrome Services and Google's Brand \nFeatures.  \n \n\"High Risk Activities\" means activities where the use or failure of the Chrome \nServices could lead to death, personal injury, or environmental damage, including \noperation of nuclear facilities, air traffic control, life support systems, or weaponry.", "numbers_present": null, "definition_terms": ["Customer Indemnified Materials", "Data Processing Amendment (DPA)", "Domain Email Address", "Domain Name", "Emergency Security Issue", "End User(s)", "End User Account", "Export Control Laws", "Feedback", "Fees", "Google Indemnified Materials", "High Risk Activities"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::aa4bbd7368ef", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::abb5c8f2af52"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::abb5c8f2af52", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "15", "section_title": "Definitions", "clause_type": "Definitions", "path": "15 ➞ 15 (Definitions)", "text": "o death, personal injury, or environmental damage, including \noperation of nuclear facilities, air traffic control, life support systems, or weaponry.\n\n\"HIPAA\" means the Health Insurance Portability and Accountability Act of 1996, as \nmay be amended from time to time, and any regulations issued thereunder.  \n \n\"including\" means including but not limited to.  \n \n\"Indemnified Liabilities\" means any (i) settlement amounts approved by the \nindemnifying party; and (ii) damages and costs finally awarded against the \nindemnified party and its Affiliates by a court of competent jurisdiction.  \n \n\"Intellectual Property\" or \"IP\" means anything protectable by an Intellectual \nProperty Right.  \n \n\"Intellectual Property Rights\" means all patent rights, copyright, rights in trade \nsecret (if any), trademark rights, design rights, database rights, domain name rights, \nmoral rights, and any other intellectual property rights (registered or unregistered) \nthroughout the world.  \n \n\"Legal Process\" means an information disclosure request made under law, \ngovernmental regulation, court order, subpoena, warrant, governmental regulatory \nor agency request, or other valid legal authority, legal procedure, or similar \nprocess.  \n \n\"Liability\" means any liability, whether under contract, tort (including negligence), \nor otherwise, regardless of whether foreseeable or contemplated by the parties.  \n \n\"Notification Email Address\" means the email address(es) designated by \nCustomer in the Admin Console.  \n \n\"Order Form\" means (i) if Customer orders via a Reseller, the online order page or \npages, or other ordering document acceptable to Google under this Agreement, \nspecifying the Chrome Services that Google will provide to Customer under a \nReseller Agreement; (ii) an order form issued by Google and executed by Customer \nspecifying the Chrome Services that Google will provide to Customer; or (iii) in the \ncase of an Admin Console Order, the order specifying the Chrome Services that \nGoogle will provide to Customer.  \n \n\"Order Term\" means the period of time starting on the Chrome Services Start \nDate for the Chrome Services and (i), continuing for the period indicated on the \nOrder Form, subject to early termination in accordance with this Agreement, or (ii) \nfor orders through the Admin Console, continuing for a period of one year.  \n \n\"Prices\" means the applicable prices stated in an Order Form or amendment.", "numbers_present": null, "definition_terms": ["HIPAA", "including", "Indemnified Liabilities", "Intellectual Property", "IP", "Intellectual Property Rights", "Legal Process", "Liability", "Notification Email Address", "Order Form", "Order Term", "Prices"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::ee53768933d6", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::da1de49d2648"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::da1de49d2648", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "15", "section_title": "Definitions", "clause_type": "Definitions", "path": "15", "text": "orders through the Admin Console, continuing for a period of one year.  \n \n\"Prices\" means the applicable prices stated in an Order Form or amendment.\n\n\"Reseller\" means, if applicable, the authorized non-Affiliate third party reseller that \nsells the Chrome Services to Customer.  \n \n\"Reseller Agreement\" means the separate agreement between Customer and \nReseller regarding the Chrome Services. The Reseller Agreement is independent of \nand outside the scope of this Agreement.  \n \n\"Service Specific Terms\" means the terms specific to one or more other services, \nincluding Cloud Identity, at: https://chromeenterprise.google/terms/service-terms.  \n \n\"Significant Deprecation\" means a material discontinue of or backwards \nincompatible change to the Chrome Services that results in Chrome Services no \nlonger enabling Administrator or End Users, as applicable, to: (1) set or receive \nChrome user policies; and (2) set or receive Chrome device policies.  \n \n\"Suspend\" or \"Suspension\" means the disabling of access to or use of the \nChrome Services, or components of the Chrome Services.  \n \n\"Taxes\" means all government-imposed taxes, except for taxes based on \nGoogle's or Customer's net income, net worth, asset value, property value, or \nemployment.  \n \n\"Term\" means the period starting on the Effective Date and will remain in effect so \nlong as there is an active Order Form, or in the case of direct ordering through the \nAdmin Console, an active order.  \n \n\"Third-Party Legal Proceeding\" means any formal legal proceeding filed by an \nunaffiliated third party before a court or government tribunal (including any \nappellate proceeding).  \n \n\"Trademark Guidelines\" means Google's Brand Terms and Conditions, located \nat http://www.google.com/permissions/trademark/brand-terms.html.  \n \n\"TSS\" means the technical support services provided by Google to Customer \nunder the TSS Guidelines.  \n \n\"TSS Guidelines\" means the then-current support service guidelines \nat: https://support.google.com/googlecloud/answer/6182373?hl=en.  \n \n\"URL Terms\" means the Acceptable Use Policy, Service Specific Terms, and the \nTSS Guidelines.  \n \n\"Use Restrictions\" means the restrictions in Section 3.3 (Use Restrictions) of the \nAgreement.", "numbers_present": null, "definition_terms": ["Prices", "Reseller", "Reseller Agreement", "Service Specific Terms", "Significant Deprecation", "Suspend or Suspension", "Taxes", "Term", "Third-Party Legal Proceeding", "Trademark Guidelines", "TSS", "TSS Guidelines", "URL Terms", "Use Restrictions"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::abb5c8f2af52", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::0f3aa39c3086"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::0f3aa39c3086", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "15", "section_title": "Definitions", "clause_type": "definition", "path": "15 ➞ 15 (Definitions)", "text": "y, Service Specific Terms, and the \nTSS Guidelines.  \n \n\"Use Restrictions\" means the restrictions in Section 3.3 (Use Restrictions) of the \nAgreement.\n\n16. Region-Specific Terms. Customer agrees to the following modifications to the", "numbers_present": null, "definition_terms": ["Use Restrictions"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::da1de49d2648", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::872fd38594a7"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::872fd38594a7", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "16", "section_title": "Region-Specific Terms", "clause_type": "Region-specific modifications (taxes and governing law/arbitration replacements)", "path": "16 ➞ 16. Region-Specific Terms ➞ Asia Pacific - All regions; Asia Pacific - All regions excluding Australia, Japan, India, New Zealand, Singapore", "text": "he restrictions in Section 3.3 (Use Restrictions) of the \nAgreement.\n\n16. Region-Specific Terms. Customer agrees to the following modifications to the\n\nAgreement if Customer orders Chrome Services from the applicable Google entity \nas described below:  \n \nAsia Pacific - All regions  \n \nSection 4.2.6 is replaced as follows:  \n \n4.2.6 Taxes. Google will itemize any invoiced Taxes. If Taxes must be withheld \nfrom any payment to Google, then Customer will increase the payment to Google \nso that the net amount received by Google is equal to the amount invoiced, without \nreduction for Taxes.  \n \nThe definition of \"Taxes\" under Section 15 (Definitions) is replaced as follows:  \n \n15 Definitions.  \n \n\"Taxes\" means all government-imposed taxes, as per the applicable law \nassociated with the rendering and performance of the Chrome Services, including \nbut not limited to any duties, customs duties, and any direct or indirect taxes, \nincluding any related penalties or interest, except for taxes based on Google's \nprofit.  \n \nAsia Pacific - All regions excluding Australia, Japan, India, New Zealand, Singapore  \n \nSection 14.12 (Governing Law) is replaced as follows:  \n \n14.12 Governing Law; Arbitration \n \n(a) ALL CLAIMS ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY \nRELATED GOOGLE PRODUCTS OR SERVICES (INCLUDING ANY DISPUTE \nREGARDING THE INTERPRETATION OR PERFORMANCE OF THE AGREEMENT) \n(\"Dispute\") WILL BE GOVERNED BY THE LAWS OF THE STATE OF CALIFORNIA, \nUSA, EXCLUDING CALIFORNIA'S CONFLICTS OF LAWS RULES.  \n \n(b) The parties will try in good faith to settle any Dispute within 30 days after the \nDispute arises. If the Dispute is not resolved within 30 days, it must be resolved by \narbitration by the American Arbitration Association's International Centre for \nDispute Resolution in accordance with its Expedited Commercial Rules in force as \nof the date of this Agreement (\"Rules\").  \n \n(c) The parties will mutually select one arbitrator. The arbitration will be conducted \nin English in Santa Clara County, California, USA.", "numbers_present": null, "definition_terms": ["Taxes"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::0f3aa39c3086", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::a5aeb095c7d4"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::a5aeb095c7d4", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "14.12(c)-(i); 11.7", "section_title": "Governing Law; Arbitration (subsections c–i) and Termination Waiver", "clause_type": "Governing law and arbitration (regional modification); termination waiver (regional addition)", "path": "14 ➞ 14.12 ➞ 14.12.(c)-(i); 16 ➞ Asia Pacific - Indonesia ➞ 11.7", "text": "ules\").  \n \n(c) The parties will mutually select one arbitrator. The arbitration will be conducted \nin English in Santa Clara County, California, USA.\n\n(d) Either party may apply to any competent court for injunctive relief necessary to \nprotect its rights pending resolution of the arbitration. The arbitrator may order \nequitable or injunctive relief consistent with the remedies and limitations in the \nAgreement.  \n \n(e) Subject to the confidentiality requirements in Subsection (g), either party may \npetition any competent court to issue any order necessary to protect that party's \nrights or property; this petition will not be considered a violation or waiver of this \ngoverning law and arbitration section and will not affect the arbitrator's powers, \nincluding the power to review the judicial decision. The parties stipulate that the \ncourts of Santa Clara County, California, USA, are competent to grant any order \nunder this Subsection 14.12 (e).  \n \n(f) The arbitral award will be final and binding on the parties and its execution may \nbe presented in any competent court, including any court with jurisdiction over \neither party or any of its property.  \n \n(g) Any arbitration proceeding conducted in accordance with this Section 14.12 will \nbe considered Confidential Information under Section 7 (Confidential Information), \nincluding: (i) the existence of, (ii) any information disclosed during, and (iii) any oral \ncommunications or documents related to the arbitration proceedings. In addition to \nthe disclosure rights under Section 7 (Confidential Information), the parties may \ndisclose the information described in this Subsection 14.12 (g) to a competent court \nas may be necessary to file any order under Subsection 14.12 (e) or execute any \narbitral decision, but the parties must request that those judicial proceedings be \nconducted in camera (in private).  \n \n(h) The parties will pay the arbitrator's fees, the arbitrator's appointed experts' fees \nand expenses, and the arbitration center's administrative expenses in accordance \nwith the Rules. In its final decision, the arbitrator will determine the non-prevailing \nparty's obligation to reimburse the amount paid in advance by the prevailing party \nfor these fees.  \n \n(i) Each party will bear its own lawyers' and experts' fees and expenses, regardless \nof the arbitrator's final decision regarding the Dispute.  \n \nAsia Pacific - Indonesia  \n \nA new Section 11.7 is added:  \n \n11.7 Termination Waiver. The parties agree to waive any provisions under any \napplicable laws to the extent that a court decision or order is required for the \ncancellation of this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::872fd38594a7", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::835ef1d31336"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::835ef1d31336", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "16", "section_title": "Region-Specific Terms", "clause_type": "Region-specific modifications / amendments", "path": "16 ➞ 16 (Region-Specific Terms) ➞ Asia Pacific - Indonesia; Asia Pacific - Australia; EMEA - All regions", "text": "e to waive any provisions under any \napplicable laws to the extent that a court decision or order is required for the \ncancellation of this Agreement.\n\nThe Indonesian version of this Agreement is accessible here and Section 14.17 is \nreplaced as follows:  \n \n14.17 Conflicting Languages. This Agreement is made in the Indonesian and the \nEnglish language. Both versions are equally authentic. In the event of any \ninconsistency or different interpretation between the Indonesian version and the \nEnglish version, the parties agree to amend the Indonesian version to make the \nrelevant part of the Indonesian version consistent with the relevant part of the \nEnglish version.  \n \nAsia Pacific - Australia  \n \nA new Section 10.3 is added as follows:  \n \n10.3. This Section 10.3 applies only if the Chrome Services are subject to statutory \nguarantees under the Australian Competition and Consumer Act 2010 (\"ACCA\"). \nApplicable laws, including the ACCA, may confer rights and remedies into this \nAgreement that cannot be excluded, and which are not excluded by this \nAgreement. To the extent that the applicable laws permit Google to limit their \noperation, Google's and its Affiliates' liability under those laws will be limited at its \noption, to the supply of the Chrome Services again, or payment of the cost of \nhaving the Chrome Services supplied again.  \n \nSection 14.12.3 (Governing Law) is amended by inserting the following text at the \nend of that Section: \"IF APPLICABLE LAW PREVENTS A DISPUTE FROM BEING \nRESOLVED IN A CALIFORNIA COURT, THEN CUSTOMER MAY FILE THE \nDISPUTE IN CUSTOMER'S LOCAL COURTS. IF APPLICABLE LAW PREVENTS \nCUSTOMER'S LOCAL COURT FROM APPLYING CALIFORNIA LAW TO RESOLVE \nA DISPUTE, THEN THE DISPUTE WILL BE GOVERNED BY THE APPLICABLE \nLOCAL LAWS OF CUSTOMER'S COUNTRY, STATE, OR OTHER PLACE OF \nRESIDENCE.\"  \n \nSection 14.15 (Entire Agreement) is amended by inserting the following text at the \nend of that Section: \"Nothing in this Agreement excludes a party's liability for prior \nwritten or oral misrepresentation.\"  \n \nEMEA - All regions  \n \nAll instances of the words below are replaced as follows:  \n \n\"unauthorized\" with \"unauthorised\"  \n \n\"authorizes\" with \"authorises\"", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::a5aeb095c7d4", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::cb5e541716f9"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::cb5e541716f9", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "16. EMEA - All regions", "section_title": "EMEA - All regions", "clause_type": "Region-specific modification / replacement", "path": "16 ➞ 16. Region-Specific Terms ➞ EMEA - All regions", "text": "- All regions  \n \nAll instances of the words below are replaced as follows:  \n \n\"unauthorized\" with \"unauthorised\"  \n \n\"authorizes\" with \"authorises\"\n\n\"reorganization\" with \"reorganisation\"  \n \nSection 4.2.1 is replaced as follows:  \n \n4.2.1 Payment. All payments due are in the currency indicated on the Order Form \nor invoice  \n \nSection 4.2.5(i) is replaced as follows:  \n \n(i) charge interest on the overdue amount at 1.5% per year above the base rate of \nBarclays Bank PLC from the payment due date until paid in full, and  \n \nSection 4.2.6 is replaced as follows:  \n \n4.2.6 Taxes. Taxes are not included in the Fees. Customer will pay Taxes for the \nChrome Services.  \n \nSection 13.1.2(ii) is replaced as follows  \n \n(ii) £25,000  \n \nSection 14.12 is replaced as follows:  \n \n14.12 Governing Law.  \n \na. The Agreement and any dispute (contractual or non-contractual) concerning the \nAgreement or its subject matter or formation (a \"Dispute\") is/are governed by \nEnglish law.  \n \nb. Any Dispute will be referred to and finally resolved by arbitration under the rules \nof the LCIA, which rules are deemed to be incorporated by reference into this \nSection. The number of arbitrators will be three. The seat, or legal place, of \narbitration will be London, England. The language to be used in the arbitration will \nbe English.  \n \nc. This Section 14.12 is without prejudice to the right of either party to apply to any \ncourt of competent jurisdiction for emergency, interim or injunctive relief.  \n \nLatin America - all regions  \n \nSection 14.12 is replaced as follows:  \n \n14.12 Governing Law.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::835ef1d31336", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::e3da1fd18b0d"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::e3da1fd18b0d", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "14.12", "section_title": "Governing Law", "clause_type": "Governing Law and Arbitration (Dispute Resolution)", "path": "16 ➞ Region-Specific Terms ➞ Latin America - all regions ➞ 14.12", "text": "iction for emergency, interim or injunctive relief.  \n \nLatin America - all regions  \n \nSection 14.12 is replaced as follows:  \n \n14.12 Governing Law.\n\na. ALL CLAIMS ARISING OUT OR RELATING TO THIS AGREEMENT OR ANY \nRELATED GOOGLE PRODUCTS OR SERVICES (INCLUDING ANY DISPUTE \nREGARDING THE INTERPRETATION OR PERFORMANCE OF THE AGREEMENT) \n(\"Dispute\") WILL BE GOVERNED BY THE LAWS OF THE STATE OF CALIFORNIA, \nUSA, EXCLUDING CALIFORNIA'S CONFLICTS OF LAWS RULES.  \n \nb. The parties will try in good faith to settle any Dispute within 30 days after the \nDispute arises. If the Dispute is not resolved within 30 days, it must be resolved by \narbitration by the American Arbitration Association's International Centre for \nDispute Resolution in accordance with its Expedited Commercial Rules in force as \nof the date of this Agreement (\"Rules\").  \n \nc. The parties will mutually select one arbitrator. The arbitration will be conducted \nin English in Santa Clara County, California, USA.  \n \nd. The arbitrator may not decide by equity.  \n \ne. Subject to the confidentiality requirements in Subsection (g), either party may \npetition any competent court, to issue any order necessary to protect that party's \nrights or property; this petition will not be considered a violation or waiver of this \ngoverning law and arbitration section and will not affect the arbitrator's powers, \nincluding the power to review the judicial decision. The parties stipulate that the \ncourts of Santa Clara County, California, USA, are competent to grant any order \nunder this Subsection (e).  \n \nf. The arbitral award will be final and binding on the parties and its execution may \nbe presented in any competent court, including any court with jurisdiction over \neither party or any of its property.  \n \ng. Any arbitration proceeding conducted in accordance with this Section will be \nconsidered Confidential Information under this Agreement's confidentiality section, \nincluding (i) the existence of, (ii) any information disclosed during, and (iii) any oral \ncommunications or documents related to the arbitration proceedings. The parties \nmay also disclose the information described in this Subsection (g) to a competent \ncourt as may be necessary to file any order under Subsection (e) or execute any \narbitral decision, but the parties must request that those judicial proceedings be \nconducted in camera (in private).  \n \nh. The parties will pay the arbitrator's fees, the arbitrator's appointed experts' fees \nand expenses, and the arbitration center's administrative expenses in accordance \nwith the Rules. In its final decision, the arbitrator will determine the non-prevailing \nparty's obligation to reimburse the amount paid in advance by the prevailing party \nfor these fees.", "numbers_present": null, "definition_terms": ["Dispute", "Rules"], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::cb5e541716f9", "next_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::665c4c647b28"}
{"id": "d2b6e758-5c81-406d-a190-3446dbf0d078::665c4c647b28", "doc_id": "d2b6e758-5c81-406d-a190-3446dbf0d078", "section_number": "14.12(h)-(i)", "section_title": "Governing Law", "clause_type": "Arbitration - allocation of arbitration fees and each party's legal costs", "path": "14 ➞ 14.12 ➞ 14.12(h) ➞ 14.12(i)", "text": "the arbitrator will determine the non-prevailing \nparty's obligation to reimburse the amount paid in advance by the prevailing party \nfor these fees.\n\ni. Each party will bear its own lawyers' and experts' fees and expenses, regardless \nof the arbitrator's final decision regarding the Dispute.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS Agreement", "party_role": "service_provider, customer", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "software"}, "prev_id": "d2b6e758-5c81-406d-a190-3446dbf0d078::e3da1fd18b0d", "next_id": null}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::ebb5d9014f35", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "1.(a)-(c)", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "1 ➞ 1.(a) ➞ 1.(b) ➞ 1.(c)", "text": "CO-BRANDING AND ADVERTISING AGREEMENT\n\nTHIS CO-BRANDING AND ADVERTISING AGREEMENT (the \"Agreement\") is made\nas of June 21, 1999 (the \"Effective Date\") by and between I-ESCROW,\nINC., with its principal place of business at 1730 S. Amphlett\nBlvd., Suite 233, San Mateo, California 94402 (\"i-Escrow\"), and\n2THEMART.COM, INC. having its principal place of business at 18301\nVon Karman Avenue, 7th Floor, Irvine, California 92612 (\"2TheMart\").\n\n1. DEFINITIONS.\n\n(a) \"CONTENT\" means all content or information, in any medium,\nprovided by a party to the other party for use in conjunction\nwith the performance of its obligations hereunder, including\nwithout limitation any text, music, sound, photographs, video,\ngraphics, data or software. Content provided by 2TheMart\nis referred to herein as \"2TheMart Content\" and Content\nprovided by i-Escrow is referred to herein as \"i-Escrow Content.\"\n\n(b) \"CO-BRANDED SITE\" means the web-site accessible through\nDomain Name, for the Services implemented by i-Escrow. The\nhomepage of this web-site will visibly display both\n2TheMart Marks and i-Escrow Marks.\n\n(c) \"CUSTOMERS\" means all users who access Co-Branded Site.", "numbers_present": null, "definition_terms": ["Agreement", "Effective Date", "i-Escrow", "2TheMart", "CONTENT", "2TheMart Content", "i-Escrow Content", "CO-BRANDED SITE", "CUSTOMERS"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": null, "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::247c93f98cbe"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::247c93f98cbe", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "1.(b)-(g)", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "1 ➞ 1.(b) ➞ 1.(c) ➞ 1.(d) ➞ 1.(e) ➞ 1.(f) ➞ 1.(g)", "text": "he\nhomepage of this web-site will visibly display both\n2TheMart Marks and i-Escrow Marks.\n\n(c) \"CUSTOMERS\" means all users who access Co-Branded Site.\n\n(d) \"DOMAIN NAME\" means www.iescrow.com/2TheMart.\n\n(e) \"ESCROW SERVICES\" means services for auction\nsellers and high bidders whereby an agent holds a\nbuyer's money in trust until the buyer approves the\napplicable item that was physically delivered, at\nwhich time the agent releases the buyer's money\nto seller, after subtracting the escrow fees.\n\n(f) \"INFORMATION TRANSFER MECHANISM\" means the\nmechanism by which 2TheMart transfers to i-Escrow\ninformation to populate the applicable i-Escrow\ntransaction and user registration forms.\n\n(g) \"LAUNCH DATE\" means the first date on which the\nCo-Branded Site is pointed to in all references to\ni-Escrow from 2TheMart auction site, and the\nInformation Transfer Mechanism is publicly\ndeployed (post-beta).", "numbers_present": null, "definition_terms": ["CO-BRANDED SITE", "CUSTOMERS", "DOMAIN NAME", "ESCROW SERVICES", "INFORMATION TRANSFER MECHANISM", "LAUNCH DATE"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::ebb5d9014f35", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::cc8c99cfbd7a"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::cc8c99cfbd7a", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "1.(g)-(k)", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "1 ➞ 1.(g) ➞ 1.(h) ➞ 1.(i) ➞ 1.(j) ➞ 1.(k)", "text": "Site is pointed to in all references to\ni-Escrow from 2TheMart auction site, and the\nInformation Transfer Mechanism is publicly\ndeployed (post-beta).\n\n(h) \"MARKS\" means all domain names, trademarks and\nlogos designated by a party for the other party's use in\nconjunction with such other party's performance under\nthis Agreement.  Marks designated by 2TheMart for\ni-Escrow's use are referred to herein as \"2TheMart\nMarks\" and Marks designated by i-Escrow for 2TheMart'\nuse are referred to herein as \"i-Escrow Marks.\"\n\n(i) \"SERVICES\" means i-Escrow's implementation\nand performance of the Escrow Services as of the\nEffective Date, as modified over time.\n\n(j) \"SHADOW SITE\" means the site where Co-Branded Site\nis made available for 2TheMart's testing of the\nInformation Transfer Mechanism prior to being\nmade publicly available.\n\n(k) \"TRANSACTION\" means a transaction utilizing the\nServices that actually closes and that was\ninitiated by a Transaction Inquiry from a Customer.", "numbers_present": null, "definition_terms": ["LAUNCH DATE", "MARKS", "2TheMart Marks", "i-Escrow Marks", "SERVICES", "SHADOW SITE", "TRANSACTION"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::247c93f98cbe", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::e879438008d1"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::e879438008d1", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "2.1", "section_title": "OVERVIEW", "clause_type": "Overview", "path": "2 ➞ 2.1", "text": "e.\n\n(k) \"TRANSACTION\" means a transaction utilizing the\nServices that actually closes and that was\ninitiated by a Transaction Inquiry from a Customer.\n\n(l) \"TRANSACTION INQUIRY\" means a Customer's\nsubmission of i-Escrow's standard New Transaction\nInquiry form (or its successor) on or through the\nCo-Branded Pages.  Currently this means entry of a\ndescription and price of merchandise by a user (buyer\nor seller) who agrees to abide by the terms and\nconditions of the Services, together with email address\nof the other party, regardless of whether or not\nany Transaction is completed.\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999\n\n2. DEVELOPMENT AND IMPLEMENTATION.\n\n2.1 OVERVIEW.  As set forth herein, 2TheMart will promote\nServices to its auction users (buyers and sellers),\nand i-Escrow shall develop Co-Branded Site,\nand develop the Information Transfer\nMechanism working with 2TheMart to make\nServices available seamlessly to Customers.\nUnless otherwise specified, each party shall\nbe responsible for all development, hosting\nand other costs associated with the pages\nresident on their servers and all emails to\nusers they send.", "numbers_present": null, "definition_terms": ["TRANSACTION", "TRANSACTION INQUIRY"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::cc8c99cfbd7a", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::5283152e612d"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::5283152e612d", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "2.2", "section_title": "INITIAL INFORMATION TRANSFER MECHANISM DEVELOPMENT.", "clause_type": "Development / SOW negotiation and implementation; termination right", "path": "2 ➞ 2.2", "text": "all\nbe responsible for all development, hosting\nand other costs associated with the pages\nresident on their servers and all emails to\nusers they send.\n\n2.2 INITIAL INFORMATION TRANSFER MECHANISM DEVELOPMENT.\nThe parties shall negotiate in good faith to determine\nthe initial operation of the Information\nTransfer Mechanism and to describe such\noperation and development fees, in a\nstatement of work (\"SOW\").  Each party shall\nmake available sufficient and qualified\nengineers to negotiate the SOW.  No SOW\nshall be binding on the parties unless\nmutually approved by both parties.  In the\nevent that the parties are unable to agree\nto an SOW within 2 months following the\nEffective Date, either party may, in its\nsole discretion, terminate this Agreement by\nproviding written notice.", "numbers_present": null, "definition_terms": ["SOW"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::e879438008d1", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::eebc9bb8d751"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::eebc9bb8d751", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "2.2–2.3", "section_title": "INITIAL INFORMATION TRANSFER MECHANISM DEVELOPMENT; LAUNCH TIMING", "clause_type": "Development and implementation obligations (Information Transfer Mechanism/SOW) and launch timing/termination right", "path": "2 ➞ 2.2; 2 ➞ 2.3", "text": "o an SOW within 2 months following the\nEffective Date, either party may, in its\nsole discretion, terminate this Agreement by\nproviding written notice.\n\nOnce approved, the parties shall use\ncommercially reasonable efforts to\ndiligently implement their respective\nobligations under the SOW.  Upon completion\nof its duties under the SOW, a party shall\nnotify the other party and provide the other\nparty with the opportunity to test and\nevaluate its work. i-Escrow shall make\navailable the Shadow Site for such testing\nin a timely manner. Each party shall\nreasonably cooperate with the other party in\neffectuating their respective duties under\nthe SOW.  The Information Transfer Mechanism\nshall not go live until its operation has\nbeen approved (\"Approval Date\") by both\nparties, such approval not to be\nunreasonably withheld.\n\n2.3 LAUNCH TIMING.  Each party shall use good faith\nand reasonable efforts to expeditiously develop the\nCo-Branded Pages and the Information\nTransfer Mechanism.  In the event that,\nafter using such efforts, the Launch Date\nhas not occurred within 4 months following\nthe Effective Date, either party may\nterminate this Agreement by providing\nwritten notice.  If", "numbers_present": null, "definition_terms": ["Approval Date"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::5283152e612d", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::ac2cb986b0ea"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::ac2cb986b0ea", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "2.3-2.5", "section_title": "LAUNCH TIMING; RESTRICTIONS ON COMMUNICATIONS; SERVICE PERFORMANCE OF INFORMATION TRANSFER MECHANISM", "clause_type": "Operational/Termination; Advertising Restrictions; Service Level", "path": "2 ➞ 2.3 ➞ 2.4 ➞ 2.5", "text": "Launch Date\nhas not occurred within 4 months following\nthe Effective Date, either party may\nterminate this Agreement by providing\nwritten notice.  If\n\nonly one party has used good faith and reasonable development\nefforts, only that party may exercise the\nforegoing right to terminate.\n\n2.4 RESTRICTIONS ON COMMUNICATIONS.  i-Escrow may place\nbanner advertising on the Co-Branded Site\nupon prior written approval of 2TheMart,\nwhich shall be at the discretion of 2TheMart.  All\nadvertising revenue arising from the banner ads shall be\nsolely i-Escrow's.  i-Escrow shall not run\nbanner advertisements on the Co-Branded Site\nfor any of 2TheMart's competitors. 2TheMart\nshall provide in writing, a list of companies they would\nlike to exclude, including every time\nthey wish to change this list.\n\n2.5 SERVICE PERFORMANCE OF INFORMATION TRANSFER\nMECHANISM.  The parties each shall in good faith work to\nprovide reasonable service levels with respect to the\noperation of the portions of the Information Transfer\nMechanism in their control.\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::eebc9bb8d751", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::83ca70b20127"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::83ca70b20127", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "2.6", "section_title": "PROGRAM REVIEW MEETINGS", "clause_type": "Operational (meetings/procedural)", "path": "2 ➞ 2.6", "text": "els with respect to the\noperation of the portions of the Information Transfer\nMechanism in their control.\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999\n\n2.6 PROGRAM REVIEW MEETINGS.  The parties shall meet, at\nleast once per month either in person, or by telephone, to\ncoordinate the implementation of this agreement over time.\n\n3. PROMOTION.\n\nAfter Launch Date, 2TheMart will widely promote the Services:\n\n(a) To every seller and high bidder through means\nincluding, but not limited to, end of auction\nemails containing links, such that, it shall be\npossible for the buyer or seller to initiate a\nTransaction Inquiry with i-Escrow, without\nhaving to re-enter all their personal or\ntransaction related information.\n\n(b)  By adding links to Co-Branded Site in FAQ\nsection of 2TheMart auctions.\n\n(c) By adding links to Co-Branded Site on the\nseller listing pages of 2TheMart auctions.\n\n(d) By displaying a text or graphic link to a\npage containing information about Services on\nall auction item pages and bidding pages to\neducate bidders about i-Escrow. 2TheMart\nmay use the \"Escrow Services Description\" attached\nin Exhibit A for creating such a page.\n\n5. PAYMENT.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::ac2cb986b0ea", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::7b6e991205b2"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::7b6e991205b2", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "5", "section_title": "PAYMENT", "clause_type": "Payment (Advertising Fees) and Reporting", "path": "5 ➞ 5.1; 5 ➞ 5.2", "text": "ges to\neducate bidders about i-Escrow. 2TheMart\nmay use the \"Escrow Services Description\" attached\nin Exhibit A for creating such a page.\n\n5. PAYMENT.\n\n5.1 ADVERTISING FEES.  After the Launch Date,\ni-Escrow shall pay 2TheMart advertising fees based\non the number of Transaction Inquiries. This advertising\nfees shall consist of a per Transaction Inquiry\namount calculated by multiplying 0.025% by\nthe amount of the average Transaction from\nall Customers in the preceding quarter. The\nformula for arriving at the per Transaction\nInquiry amount may be revised from time to\ntime during the term of this Agreement to\nreflect present market conditions (\"the\nAdjusted Rate\"), but only by mutual\n\nconsent of the parties after good faith discussions.\nThe Adjusted Rate shall be added as an\naddendum to this Agreement.\n\n5.2 REPORTING.  Within two (2) weeks following the\nend of each calendar quarter, i-Escrow shall provide\nto 2TheMart a report, describing for each quarter: the\nnumber of new registrations through the\nCo-Branded Pages; the number of Transaction\nInquiries from Customers; the total number\nof Transactions from such inquiries; the\ntotal dollar value of the Transactions.", "numbers_present": null, "definition_terms": ["Adjusted Rate"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::83ca70b20127", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::fe3886bce1e1"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::fe3886bce1e1", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "5.3", "section_title": "AUDIT RIGHTS", "clause_type": "Audit rights / Recordkeeping", "path": "5 ➞ 5.3", "text": "the number of Transaction\nInquiries from Customers; the total number\nof Transactions from such inquiries; the\ntotal dollar value of the Transactions.\n\n5.3 AUDIT RIGHTS. i-Escrow shall keep for one (1) year proper\nrecords and books of account relating to the\ncomputation of advertising payments owed to\n2TheMart (including, as appropriate, the\ncomputation of the size of average\nTransaction).  Once every twelve (12)\nmonths, 2TheMart through a CPA may inspect\nand audit such records to verify reports.\nAny such inspection will be conducted in a\nmanner that does not unreasonably interfere\nwith i-Escrow's business activities and with\nno less than fifteen (15) days notice.\ni-Escrow shall within two (2) weeks make any\noverdue payments disclosed by the audit.\nSuch inspection shall be at 2TheMart's\nexpense; however, if the audit reveals\noverdue payments in excess of ten percent\n(10%) of the payments owed to date, i-Escrow\nshall immediately pay all cost of such\naudit.\n\n6. RIGHTS AND STANDARDS.\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::7b6e991205b2", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::d32216213849"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::d32216213849", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "6.1", "section_title": "CONTENT", "clause_type": "Content license / mutual rights grant", "path": "6 ➞ 6.1", "text": "e payments owed to date, i-Escrow\nshall immediately pay all cost of such\naudit.\n\n6. RIGHTS AND STANDARDS.\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999\n\n6.1 CONTENT. 2TheMart hereby grants\nto i-Escrow a worldwide,\nnon-exclusive right to use, reproduce,\ndistribute, publicly perform, publicly\ndisplay and digitally perform the 2TheMart\nContent soley with respect to  and in\nconjunction with the Co-Branded Site all\nwith the prior written consent of 2TheMart,\nfor the term of this Agreement.  i-Escrow\nhereby grants to 2TheMart a worldwide,\nnon-exclusive right to use, reproduce,\ndistribute, publicly perform, publicly\ndisplay and digitally perform the i-Escrow\nContent on or in conjunction with 2TheMart\nauctions.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::fe3886bce1e1", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::6c94c384865b"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::6c94c384865b", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "6.2", "section_title": "CONTENT OWNERSHIP", "clause_type": "Content ownership / Intellectual property rights", "path": "6 ➞ 6.2", "text": "use, reproduce,\ndistribute, publicly perform, publicly\ndisplay and digitally perform the i-Escrow\nContent on or in conjunction with 2TheMart\nauctions.\n\n6.2 CONTENT OWNERSHIP.  Except as otherwise provided in\nthis Agreement, as between 2TheMart and i-Escrow:\n(a) 2TheMart and its suppliers retain all\nrights, title and interest in and to all\nintellectual property rights embodied in or\nassociated with the 2TheMart Content, and b)\ni-Escrow and its suppliers retain all\nrights, title and interest in and to all\nintellectual property rights embodied in or\nassociated with the i-Escrow Content and\nCo-Branded Site.  There are no implied\nlicenses under this Agreement, and any\nrights not expressly granted are reserved.\nNeither party shall exceed the scope of the\nrights granted hereunder.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::d32216213849", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::09f4afbb8fa8"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::09f4afbb8fa8", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "6.3–6.4", "section_title": "TRADEMARKS; TRADEMARK RESTRICTIONS", "clause_type": "Trademark license and restrictions", "path": "6 ➞ 6.3; 6 ➞ 6.4", "text": "icenses under this Agreement, and any\nrights not expressly granted are reserved.\nNeither party shall exceed the scope of the\nrights granted hereunder.\n\n6.3 TRADEMARKS.  Subject to the terms and conditions\nof this Agreement: (a) i-Escrow hereby grants to\n2TheMart a non-exclusive, nontransferable\nright to use the i-Escrow Marks (including\nwithout limitation the Domain Name) in links\nto and advertisements and promotions for the\nCo-Branded Pages or the Services; and (b)\n2TheMart hereby grants to i-Escrow a\nnon-exclusive, nontransferable right to use\n2TheMart Marks (including without limitation\nthe Domain Name) on the Co-Branded Pages,\nand for the performance of  Services.\n\n6.4 TRADEMARK RESTRICTIONS.  The Mark owner may\nterminate the foregoing rights if, in its reasonable\ndiscretion, the other party's use of the\nMarks tarnishes, blurs or dilutes the\nquality associated with the Marks or the\nassociated goodwill and such problem is not\ncured within ten (10) days of notice of\nbreach; alternatively, instead of\nterminating the right in total, the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::6c94c384865b", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::42385dc2661d"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::42385dc2661d", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "6.4–6.5", "section_title": "TRADEMARK RESTRICTIONS; LIMITS ON SUBLICENSING", "clause_type": "Trademark restrictions and sublicensing limitations (intellectual property/marks usage clause)", "path": "6 ➞ 6.4 ➞ 6.5", "text": "ociated goodwill and such problem is not\ncured within ten (10) days of notice of\nbreach; alternatively, instead of\nterminating the right in total, the\n\nowner may specify that certain pages of the other\nparty's web-site may not contain the Marks.\nTitle to and ownership of the owner's Marks\nshall remain with the owner.  The receiving\nparty shall use the Marks exactly in the\nform provided and in conformance with any\ntrademark usage policies.  The other party\nshall not take any action inconsistent with\nthe owner's ownership of the Marks, and any\nbenefits accruing from use of such Marks\nshall automatically vest in the owner.  The\nother party shall not form any combination\nmarks with the other party's Marks.\nNotwithstanding the foregoing, to the extent\nthat the Domain Name is deemed a combination\nmark, neither party shall use the Domain\nName for any purpose except as expressly\nprovided herein or attempt to register the\nDomain Name, and the parties will jointly\ncooperate on any enforcement action of\ninfringement of the Domain Name.\n\n6.5 LIMITS ON SUBLICENSING.  All rights (under any\napplicable intellectual property right)\ngranted herein are not sublicenseable,", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::09f4afbb8fa8", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::1984134002e6"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::1984134002e6", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "6.5", "section_title": "LIMITS ON SUBLICENSING.", "clause_type": "Sublicensing/transfer restriction", "path": "6 ➞ 6.5", "text": "of the Domain Name.\n\n6.5 LIMITS ON SUBLICENSING.  All rights (under any\napplicable intellectual property right)\ngranted herein are not sublicenseable,\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999\n\ntransferable or assignable.  Notwithstanding\nthe foregoing, either party may use a third\nparty web host, but all actions or failures\nto act of the web host that would be a\nbreach of this Agreement, were the actions\nor failures to act taken by the applicable\nparty, shall be deemed a breach of this\nAgreement.  In addition, 2TheMart may grant\nsublicenses to companies that 2TheMart has a\nbusiness relationship with to the extent\nthat 2TheMart Content is visible from such\ncompany's web-site through a link or other\nmeans.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::42385dc2661d", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::568d8b260d08"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::568d8b260d08", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "6.6", "section_title": "CONTENT STANDARDS", "clause_type": "Content standards / prohibited content", "path": "6 ➞ 6.6", "text": "t 2TheMart has a\nbusiness relationship with to the extent\nthat 2TheMart Content is visible from such\ncompany's web-site through a link or other\nmeans.\n\n6.6 CONTENT STANDARDS. 2TheMart shall not provide any\n2TheMart Content, and i-Escrow shall not provide any\ni-Escrow Content, that: (a) infringes any\nthird party's copyright, patent, trademark,\ntrade secret or other proprietary rights or\nrights of publicity or privacy; (b) violates\nany law, statute, ordinance or regulation\n(including without limitation the laws and\nregulations governing export control, unfair\ncompetition, antidiscrimination or false\nadvertising); (c) is defamatory, trade\nlibelous, unlawfully threatening or\nunlawfully harassing; (d) is obscene,\nharmful to minors or child pornographic; (e)\ncontains any viruses, Trojan horses, worms,\ntime bombs, cancelbots or other computer\nprogramming routines that are intended to\ndamage, detrimentally interfere with,\nsurreptitiously intercept or expropriate any\nsystem, data or personal information; and\n(f) is materially false, misleading or\ninaccurate.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::1984134002e6", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::079921b4678e"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::079921b4678e", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "6.7", "section_title": "SERVICE STANDARDS", "clause_type": "Service standards / Compliance with law", "path": "6 ➞ 6.7", "text": "erfere with,\nsurreptitiously intercept or expropriate any\nsystem, data or personal information; and\n(f) is materially false, misleading or\ninaccurate.\n\n6.7  SERVICE STANDARDS. i-Escrow will comply with\nall laws and regulations and act as an Independent Escrow\nAgent as per the guidelines of California Escrow Law\n(California Financial Code Section17000 et seq., or its\nsuccessor).  Should any of the terms, conditions or\nprovisions of this Agreement conflict with the California\nEscrow Law, its rules or regulations, which govern\ni-Escrow's business practices, the California\nEscrow Law shall prevail. Notwithstanding the\nforegoing, at any time that i-Escrow reasonably believes\nsuch a conflict exists, i-Escrow will give 2TheMart\nwritten notice of such conflict and the parties\nwill use their best efforts to resolve such conflict.\n\n7. DISCLAIMER OF WARRANTIES.  EACH PARTY PROVIDES ALL\nMATERIALS AND SERVICES TO THE OTHER PARTY \"AS IS.\"  EACH\nPARTY DISCLAIMS ALL WARRANTIES AND CONDITIONS,\nEXPRESS, IMPLIED OR STATUTORY, INCLUDING\nWITHOUT LIMITATION THE IMPLIED WARRANTIES OF\nTITLE, NON-", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::568d8b260d08", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::89ab3839cac3"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::89ab3839cac3", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "8.1", "section_title": "TERM", "clause_type": "Term", "path": "8 ➞ 8.1", "text": "EACH\nPARTY DISCLAIMS ALL WARRANTIES AND CONDITIONS,\nEXPRESS, IMPLIED OR STATUTORY, INCLUDING\nWITHOUT LIMITATION THE IMPLIED WARRANTIES OF\nTITLE, NON-\n\nINFRINGEMENT, MERCHANTABILITY ANDFITNESS FOR A\nPARTICULAR PURPOSE.  Each party acknowledges that it\nhas not entered into this Agreement in reliance upon any\nwarranty or representation except those\nspecifically set forth herein.\n\n8. TERM AND TERMINATION.\n\n8.1 TERM.  The term of this Agreement shall continue for\none (1) year following the Launch Date, unless earlier\nterminated as provided herein. This Agreement may be\nrenewed for any number of successive one (1)\nyear terms by mutual written agreement of\nthe parties prior to the conclusion of the\nterm of this Agreement.  A party wishing to\nrenew this Agreement shall give the other\nparty notice thereof no less than thirty\n(30) days before the expiration of the term\nthen in effect.  In the event that either\nparty does not give such notice, the term of\nthis Agreement shall be automatically\nrenewed for another one (1) year.\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::079921b4678e", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::00d8e94196f2"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::00d8e94196f2", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "8.2", "section_title": "TERMINATION FOR BREACH", "clause_type": "Termination for breach", "path": "8 ⟩ 8.2", "text": "not give such notice, the term of\nthis Agreement shall be automatically\nrenewed for another one (1) year.\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999\n\n8.2 TERMINATION FOR BREACH.  In addition to other remedies that\nmay be available to it, by providing written notice, a party\nmay immediately terminate this Agreement: (a) if the other party\nmaterially breaches this Agreement and fails to cure that\nbreach within sixty (60) days after receiving written\nnotice of the breach, or (b) as provided in Sections 2.2  [INITIAL INFORMATION TRANSFER MECHANISM DEVELOPMENT],\n2.4  [RESTRICTIONS ON COMMUNICATIONS], or 12.4.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::89ab3839cac3", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::fc6be65cd102"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::fc6be65cd102", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "8.2, 8.3, 8.4(a)", "section_title": "8.2 TERMINATION FOR BREACH; 8.3 TERMINATION FOR CHANGE IN COMPANY STRUCTURE; 8.4 TERMINATION FOR BANKRUPTCY", "clause_type": "Termination provisions (breach; change in company structure; bankruptcy)", "path": "8 ➞ 8.2; 8 ➞ 8.3; 8 ➞ 8.4 ➞ 8.4(a)", "text": "the breach, or (b) as provided in Sections 2.2  [INITIAL INFORMATION TRANSFER MECHANISM DEVELOPMENT],\n2.4  [RESTRICTIONS ON COMMUNICATIONS], or 12.4.\n\n8.3 TERMINATION FOR CHANGE IN COMPANY STRUCTURE.  If a\nmajority of the equity securities of either 2TheMart or\ni-Escrow, Inc. (except that i-Escrow may sell all or a\nmajority of its equity securities or voting interests\nto i-Escrow.com, and i-Escrow.com may sell all or a\nmajority of its equity securities or voting interests\nto i-Escrow's existing shareholders, without triggering\nthe foregoing) are acquired by another company during\nthe term of this Agreement either company may terminate\nthis Agreement, without liability, by giving a thirty\n(30) days written notice to the other party.\n\n8.4 TERMINATION FOR BANKRUPTCY. Either party may terminate\nor suspend this Agreement effective immediately and without\nliability upon written notice to the other party if\nany one of the following events occurs:\n\n(a) the other party files a voluntary petition in\nbankruptcy or otherwise seeks protection under any\nlaw for the protection of debtors;", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::00d8e94196f2", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::dc0fc92c005e"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::dc0fc92c005e", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "8.4", "section_title": "TERMINATION FOR BANKRUPTCY", "clause_type": "Termination for Bankruptcy", "path": "8 ➞ 8.4 ➞ 8.4(a)-(g)", "text": "vents occurs:\n\n(a) the other party files a voluntary petition in\nbankruptcy or otherwise seeks protection under any\nlaw for the protection of debtors;\n\n(b) a proceeding is instituted against the\nother party under any provision of any\nbankruptcy laws which is not dismissed within\nninety (90) days;\n\n(c) the other party is adjudged  bankrupt;\n\n(d) a court assumes jurisdiction of all or a\nsubstantial portion of the assets of the other party\nunder a reorganization law;\n\n(e) a trustee or receiver is appointed by a court\nfor all or a substantial portion of the assets\nof the other party;\n\n(f) the other party becomes insolvent, ceases or\nsuspends all or substantially all of its business; or\n\n(g) the other party makes an assignment of the\nmajority of its assets for the benefit of its creditors.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::fc6be65cd102", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::0d6bc943f8ea"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::0d6bc943f8ea", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "8.5", "section_title": "EFFECTS OF TERMINATION", "clause_type": "Termination (Effects of Termination)", "path": "8 ➞ 8.5", "text": "all or substantially all of its business; or\n\n(g) the other party makes an assignment of the\nmajority of its assets for the benefit of its creditors.\n\n8.5 EFFECTS OF TERMINATION.  Upon expiration or termination\nof this Agreement for any reason: (a) all rights granted\nherein shall terminate, (b) i-Escrow shall pay all amounts\nowed to 2TheMart within six (6) weeks of termination,\nand (c) each party shall remove the other party's content\nand Marks from their servers.  Notwithstanding the\nforegoing, unless this Agreement was terminated for a\nmaterial breach, all provisions of this Agreement shall\nsurvive to the extent necessary for i-Escrow to complete\nany Customer transactions which are pending at the time\nof expiration or termination.  Sections 1, 7,  8.5  [EFFECTS OF TERMINATION], 9,\n10, 11 and 12 shall survive expiration or\ntermination of this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::dc0fc92c005e", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::8e6541546bdf"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::8e6541546bdf", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "9", "section_title": "INDEMNITY", "clause_type": "Indemnity", "path": "9", "text": "expiration or termination.  Sections 1, 7,  8.5  [EFFECTS OF TERMINATION], 9,\n10, 11 and 12 shall survive expiration or\ntermination of this Agreement.\n\n9. INDEMNITY.  Each party (the \"Indemnifying Party\") shall\nindemnify the other party (the \"Indemnified Party\")\nagainst any and all claims, losses, costs and expenses,\nincluding reasonable attorneys' fees, which the Indemnified\nParty may incur as a result of claims in any form\nby third parties arising from the Indemnifying Party's\nacts, omissions or misrepresentations to the extent that the\nIndemnified Party is deemed a principal of the Indemnifying\nParty.  In addition, 2TheMart shall indemnify i-Escrow against\nany and all claims, losses, costs and expenses, including\nreasonable attorneys' fees, which i-Escrow may incur as a result\nof claims in any form by third parties arising from 2TheMart\nContent.  In addition, i-Escrow shall indemnify 2TheMart against\nany and all claims, losses, costs and expenses, including\nreasonable attorneys' fees, which 2TheMart may incur as a result\nof claims in any form by third parties arising from i-Escrow\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999", "numbers_present": null, "definition_terms": ["Indemnifying Party", "Indemnified Party"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::0d6bc943f8ea", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::bba225bce644"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::bba225bce644", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "9-10", "section_title": "Indemnity; Limitation on Liability", "clause_type": "Indemnity and Limitation of Liability", "path": "9 ➞ 9.(i)-(iii) ➞ 10", "text": "' fees, which 2TheMart may incur as a result\nof claims in any form by third parties arising from i-Escrow\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999\n\nContent and or the Services provided to Customers.  The\nforegoing obligations are conditioned on the Indemnified Party:\n(i) giving the Indemnifying Party notice of the relevant\nclaim, (ii) cooperating with the Indemnifying Party, at the\nIndemnifying Party's expense, in the defense of such\nclaim, and (iii) giving the Indemnifying Party the right to\ncontrol the defense and settlement of any such claim, except\nthat the Indemnifying Party shall not enter into any\nsettlement that affects the Indemnified Party's rights or\ninterest without the Indemnified Party's prior written approval.\nThe Indemnified Party shall have the right to participate\nin the defense at its expense.\n\n10. LIMITATION ON LIABILITY.  EXCEPT IN THE EVENT OF A\nBREACH OF SECTION 11, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL,\nINCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOST PROFITS\n(HOWEVER ARISING, INCLUDING NEGLIGENCE) ARISING OUT OF OR IN\nCONNECTION WITH THIS AGREEMENT, EVEN IF THE PARTIES ARE\nAWARE OF THE POSSIBILITY OF SUCH DAMAGES.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::8e6541546bdf", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::bc783210851a"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::bc783210851a", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "11", "section_title": "CONFIDENTIAL INFORMATION", "clause_type": "Confidentiality", "path": "11", "text": "ARISING, INCLUDING NEGLIGENCE) ARISING OUT OF OR IN\nCONNECTION WITH THIS AGREEMENT, EVEN IF THE PARTIES ARE\nAWARE OF THE POSSIBILITY OF SUCH DAMAGES.\n\n11. CONFIDENTIAL INFORMATION.  A party's \"Confidential Information\"\nis defined as any confidential or proprietary\ninformation of a party which is disclosed to\nthe other party in a writing marked\nconfidential or, if disclosed orally, is\nidentified as confidential at the time of\ndisclosure and is subsequently reduced to a\nwriting marked confidential and delivered to\nthe", "numbers_present": null, "definition_terms": ["Confidential Information"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::bba225bce644", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::57206ec2fdd7"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::57206ec2fdd7", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "11", "section_title": "CONFIDENTIAL INFORMATION", "clause_type": "Confidentiality (definition and obligations)", "path": "11", "text": "osed orally, is\nidentified as confidential at the time of\ndisclosure and is subsequently reduced to a\nwriting marked confidential and delivered to\nthe\n\nother party within ten (10) days of\ndisclosure.  Each party shall hold the other\nparty's Confidential Information in\nconfidence and shall not disclose such\nConfidential Information to third parties\nnor use the other party's Confidential\nInformation for any purpose other than as\nrequired to perform under this Agreement.\nSuch restrictions shall not apply to\nConfidential Information which (a) is\nalready known by the recipient, (b) becomes,\nthrough no act or fault of the recipient,\npublicly known, (c) is received by recipient\nfrom a third party without a restriction on\ndisclosure or use, or (d) is independently\ndeveloped by recipient without reference to\nthe Confidential Information.  The\nrestriction on disclosure shall not apply to\nConfidential Information which is required\nto be disclosed by a court or government\nagency. Upon expiration or termination of\nthis Agreement, within fourteen (14) days of\nthe other party's request, each party will\nreturn all Confidential Information and\nother deliverables to the requesting party.", "numbers_present": null, "definition_terms": ["Confidential Information"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::bc783210851a", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::1cdec95bbb96"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::1cdec95bbb96", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "12.1-12.2", "section_title": "GENERAL PROVISIONS; GOVERNING LAW; SEVERABILITY; HEADINGS", "clause_type": "Governing law clause; Severability and headings clause (general provisions)", "path": "12 ➞ 12.1; 12 ➞ 12.2", "text": "n fourteen (14) days of\nthe other party's request, each party will\nreturn all Confidential Information and\nother deliverables to the requesting party.\n\n12. GENERAL PROVISIONS.\n\n12.1 GOVERNING LAW.  This Agreement will be governed\nand construed in accordance with the laws of the State of\nCalifornia without giving effect to conflict of laws\nprinciples.  Both parties submit to personal jurisdiction\nin California and further agree that any cause of action\narising under this Agreement shall be brought in a court\nin Orange County, California.\n\n12.2 SEVERABILITY; HEADINGS.  If any provision herein is held\nto be invalid or unenforceable for any reason, the\nremaining provisions will continue in full force without being\nimpaired or invalidated in any way.  The parties agree to replace\nany invalid provision with a valid provision that most\nclosely approximates the intent and economic effect of the\ninvalid provision.  Headings are for reference purposes only and\nin no way define, limit, construe or describe the\nscope or extent of such section.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::57206ec2fdd7", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::adf3895a7128"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::adf3895a7128", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "12.3", "section_title": "PUBLICITY", "clause_type": "Publicity / press release approval", "path": "12 ➞ 12.3", "text": "he\ninvalid provision.  Headings are for reference purposes only and\nin no way define, limit, construe or describe the\nscope or extent of such section.\n\n12.3 PUBLICITY.  Prior to the release of any press releases or other\nsimilar promotional materials related to this Agreement, the\nreleasing party shall submit a written request for approval to the\nother party with a copy of the materials to be released, which\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999\n\nrequest shall be made no less than three (3) business days prior to\nthe requested release date.  A party shall not unreasonably withhold\nor delay the granting of its approval of such materials,\nand such approval shall be provided to the other party within one\n(1) business day of receipt", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::1cdec95bbb96", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::549ff41585cf"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::549ff41585cf", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "12.4–12.5", "section_title": "Force Majeure; Independent Contractors", "clause_type": "Force majeure clause; Independent contractor relationship clause", "path": "12 ➞ 12.4; 12 ➞ 12.5", "text": "or delay the granting of its approval of such materials,\nand such approval shall be provided to the other party within one\n(1) business day of receipt\n\n12.4 FORCE MAJEURE.  Except as otherwise provided, if performance\nhereunder (other than payment) is prevented, restricted or\ninterfered with by any act or condition whatsoever beyond the\nreasonable control of a party (a \"force majeure event\"), the\nparty so affected, upon giving prompt notice to the other party,\nshall be excused from such performance to the extent\nof such prevention, restriction or interference.  However, if a\nforce majeure event interferes with the operation of this\nAgreement for sixty (60) days or more, either party can terminate\nthis Agreement, without penalty.  Notwithstanding the\nforegoing, the occurrence of any force majeure event shall not\nlimit either party's obligations under Section 9 with respect to\nany third party claim as to which the other party seeks\nindemnification.\n\n12.5 INDEPENDENT CONTRACTORS.  The parties are independent\ncontractors, and no agency, partnership, joint venture, employeeemployer or franchisor-franchisee relationship is", "numbers_present": null, "definition_terms": ["force majeure event"], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::adf3895a7128", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::7eff12b08d24"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::7eff12b08d24", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "12.5–12.6", "section_title": "INDEPENDENT CONTRACTORS; NOTICE", "clause_type": "Independent contractor relationship; Notice/Contact", "path": "12 ➞ 12.5; 12 ➞ 12.6", "text": "ACTORS.  The parties are independent\ncontractors, and no agency, partnership, joint venture, employeeemployer or franchisor-franchisee relationship is\n\nintended or created by this Agreement.  Neither party shall\nmake any warranties or representations on behalf of the other\nparty.\n\n12.6 NOTICE.  Any notices hereunder shall be given to the\nappropriate party at the address specified below or at such other\naddress as the party shall specify in writing.  Notice shall\nbe deemed given: upon personal delivery; if sent by fax, upon\nconfirmation of receipt; or if sent by a reputable overnight\ncourier with tracking capabilities, one (1) day after the date of\nmailing:\nTo i-Escrow:            i-Escrow, Inc.\n                        1730 South Amphlett Blvd., #215\n                        San Mateo, CA 94402\n                        Fax no. (650) 638-7890\n                        Attention:  President\n\nWith copy to:           Fred M. Greguras, Esq.\n                        Legal Counsel of i-Escrow\n                        Fenwick & West LLP\n                        Two Palo Alto Square\n                        Palo Alto, CA 94306", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::549ff41585cf", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::8daf95a16fd7"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::8daf95a16fd7", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "11.7; 12.8; 12.9; 12.10", "section_title": "COUNTERPARTS; GOOD FAITH; ADDITIONAL DOCUMENTS/INFORMATION; RIGHTS AND REMEDIES CUMULATIVE", "clause_type": "General provisions / miscellaneous (execution/counterparts, good faith, additional documents, cumulative rights and remedies)", "path": "11 ➞ 11.7; 12 ➞ 12.8; 12 ➞ 12.9; 12 ➞ 12.10", "text": "ounsel of i-Escrow\n                        Fenwick & West LLP\n                        Two Palo Alto Square\n                        Palo Alto, CA 94306\n\nTo 2TheMart:            Dominic J. Magliarditi\n                        President\n                        18301 Von Karman Avenue,\n                        7th Floor\n                        Irvine, CA 92612\n                        Fax no. (949) 477-1221\n\n11.7 COUNTERPARTS.  This Agreement may be executed in one or\nmore counterparts, each of which shall be deemed an original and\nall of which shall be taken together and deemed to be one\ninstrument.\n\n12.8 GOOD FAITH.  The parties agree to act in good faith with\nrespect to each provision of this Agreement and any dispute\nthat may arise related hereto.\n\n12.9 ADDITIONAL DOCUMENTS/INFORMATION. The parties agree to\nsign and/or provide such additional documents and/or information\nas may reasonably be required to carry out the intent of\nthis Agreement and to effectuate its purposes.\n\n12.10 RIGHTS AND REMEDIES CUMULATIVE. The rights and remedies\nprovided herein will be cumulative and not exclusive of any other\nrights or remedies provided by law or otherwise.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::7eff12b08d24", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::9db0c50d0e35"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::9db0c50d0e35", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "12.10–12.11", "section_title": "Rights and Remedies Cumulative; Nonwaiver", "clause_type": "Boilerplate", "path": "12 ➞ 12.10; 12 ➞ 12.11", "text": "CUMULATIVE. The rights and remedies\nprovided herein will be cumulative and not exclusive of any other\nrights or remedies provided by law or otherwise.\n\n12.11 NONWAIVER.   No failure or forbearance by either party to\nexercise any right or insist upon or enforce performance of\nany obligation hereunder shall be deemed a waiver or\nrelinquishment to any extent of that or any other right or\nobligation, in that or any other instance; rather, the\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999\n\nsame shall be and shall remain in full force and effect.\nAny waiver of any right of a party or any obligation of the\nother party hereunder must be made in a writing signed by the\narty waiving such right or obligation.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::8daf95a16fd7", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::b03956c7d7d4"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::b03956c7d7d4", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "12.12", "section_title": "ENTIRE AGREEMENT", "clause_type": "Entire Agreement / Integration clause", "path": "12 ➞ 12.12", "text": "of any right of a party or any obligation of the\nother party hereunder must be made in a writing signed by the\narty waiving such right or obligation.\n\n12.12 ENTIRE AGREEMENT.  This Agreement contains the entire\nunderstanding of the parties hereto with respect to the\ntransactions and matters contemplated hereby, supersedes\nall previous Agreements between i-Escrow and 2TheMart\nconcerning the subject matter (except for the Confidential\nAgreement Dated January 4 1999, which shall survive this\nAgreement).  No amendments or supplements to this Agreement\nwill be effective for any purpose except by a\nwritten Agreement signed by the parties.  No party hereto\nhas relied on any statement, representation or promise of any\nparty or with any other officer, agent, employee or\nattorney for the other party in executing this Agreement\nexcept as expressly stated herein.\n\n2THEMART.COM, INC.:                         I-ESCROW, INC.:\n\nBy:/s/Dominic J. Magliarditi                By:/s/Sanjay Bajaj\nName: Dominic J. Magliarditi                Name: Sanjay Bajaj\nTitle: President                            Title: VP Business Development\nDate: 6/21/99                               Date: 6/11/99\n\nEXHIBIT A", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::9db0c50d0e35", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::24c8563b7ea6"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::24c8563b7ea6", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "EXHIBIT A", "section_title": "ESCROW SERVICES DESCRIPTION", "clause_type": "Exhibit", "path": "EXHIBIT A", "text": "Bajaj\nTitle: President                            Title: VP Business Development\nDate: 6/21/99                               Date: 6/11/99\n\nEXHIBIT A\n\nESCROW SERVICES DESCRIPTION", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::b03956c7d7d4", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::ef94e7b925cc"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::ef94e7b925cc", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "EXHIBIT A", "section_title": "ESCROW SERVICES DESCRIPTION", "clause_type": "Exhibit / Procedural Service Description", "path": "EXHIBIT A ➞ ESCROW SERVICES DESCRIPTION", "text": "Title: VP Business Development\nDate: 6/21/99                               Date: 6/11/99\n\nEXHIBIT A\n\nESCROW SERVICES DESCRIPTION\n\nSuccessful completion of a transaction involves exchange of merchandise\nwith payment. The buyer has to be satisfied he/she received what they\nthought they were getting and the seller has to be sure he/she\ngets paid. i-Escrow holds payment from the buyer in trust until the\nseller sends the merchandise to the buyer. Once the buyer\naccepts the merchandise, i-Escrow forwards the payment to the\nseller by writing a check.  A typical escrow transaction:\nWhen an auction ends, your end of auction email contains links to\ni-Escrow. Once you have signed up with i-Escrow   you go\nthrough the following steps to complete your transaction.\n1.   Start a transaction by entering the description and price of the\nmerchandise along with email address of the other party.\n2.   The other party receives an email from i-Escrow requesting an\nacknowledgement of the terms of the transaction.\n3.   Once the transaction is acknowledged by the other party, the\nbuyer pays i-Escrow the agreed upon price, by credit card or other means.\n4.   i-Escrow informs the seller that payment has been received, requesting\nthem to ship the merchandise directly to the buyer.\n5.   The seller provides i-Escrow with the tracking number of the shipment.\n6.   The buyer receives and accepts the merchandise.\n7.   i-Escrow sends the check to the seller.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::24c8563b7ea6", "next_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::7143383a537e"}
{"id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::7143383a537e", "doc_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1", "section_number": "Exhibit A, 6-7", "section_title": "ESCROW SERVICES DESCRIPTION", "clause_type": "Procedural/Operational", "path": "Exhibit A ➞ ESCROW SERVICES DESCRIPTION ➞ Steps 6-7", "text": "s i-Escrow with the tracking number of the shipment.\n6.   The buyer receives and accepts the merchandise.\n7.   i-Escrow sends the check to the seller.\n\nFor more information about I-Escrow, visit their web-site at www.iescrow.com\n\nSource: 2THEMART COM INC, 10-12G, 8/26/1999", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Co-Branding", "party_role": "licensor, licensee", "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "E-commerce"}, "prev_id": "db3f7425-a9a0-48cb-8d5b-4f2cb78d10c1::ef94e7b925cc", "next_id": null}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a75d8f2518c4", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "1", "section_title": "Service", "clause_type": "Service (Access and Use; Support; User Accounts)", "path": "1 ➞ 1.1 (Access and Use); 1.2 (Support); 1.3 (User Accounts)", "text": "Cloud Service Agreement\n\n1. Service\n\n1. Access and Use. During the Subscription Period and subject to the terms of this\n\nAgreement, Customer may (a) access and use the Cloud Service; and (b) copy \nand use the included Software and Documentation only as needed to access and \nuse the Cloud Service, in each case, for its internal business purposes. If \na Customer Affiliate enters a separate Order Form with Provider, \nthe Customer's Affiliate creates a separate agreement between Provider and that \nAffiliate, where Provider's responsibility to the Affiliate is individual and separate \nfrom Customer and Customer is not responsible for its Affiliates' agreement. \n2. Support. During the Subscription Period, Provider will provide Technical\n\nSupport as described in the Order Form. \n3. User Accounts. Customer is responsible for all actions on Users' accounts and for", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": null, "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::83b9b879c156"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::83b9b879c156", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "1.2-1.5", "section_title": "Support; User Accounts; Feedback and Usage Data; Customer Content", "clause_type": "Service obligations (Support, User Accounts, Feedback and Usage Data)", "path": "1 ➞ 1.2; 1 ➞ 1.3; 1 ➞ 1.4; 1 ➞ 1.5", "text": "will provide Technical\n\nSupport as described in the Order Form. \n3. User Accounts. Customer is responsible for all actions on Users' accounts and for\n\nall Users' compliance with this Agreement. Customer and Users must protect the \nconfidentiality of their passwords and login credentials. Customer will promptly \nnotify Provider if it suspects or knows of any fraudulent activity with its accounts, \npasswords, or credentials, or if they become compromised. \n4. Feedback and Usage Data. Customer may, but is not required to,\n\ngive Provider Feedback, in which case Customer gives Feedback \"AS \nIS\". Provider may use all Feedback freely without any restriction or obligation. In \naddition, Provider may collect and analyze Usage Data, and Provider may freely \nuse Usage Data to maintain, improve, enhance, and promote Provider's products \nand services without restriction or obligation. However, Provider may only disclose \nUsage Data to others if the Usage Data is aggregated and does not \nidentify Customeror Users. \n5. Customer Content. Provider may copy, display, modify, and use Customer", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a75d8f2518c4", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::ef5b66022760"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::ef5b66022760", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "1.5-1.6", "section_title": "Customer Content; Machine Learning", "clause_type": "Data use / Machine Learning", "path": "1 ➞ 1.5; 1 ➞ 1.6", "text": "rs if the Usage Data is aggregated and does not \nidentify Customeror Users. \n5. Customer Content. Provider may copy, display, modify, and use Customer\n\nContent only as needed to provide and maintain the Product and related \nofferings. Customer is responsible for the accuracy and content of Customer \nContent. \n6. Machine Learning. Usage Data and Customer Content may be used to develop,", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::83b9b879c156", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::de16e7bfb864"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::de16e7bfb864", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "1.6", "section_title": "Machine Learning", "clause_type": "Data processing / Machine Learning usage", "path": "1 ➞ 1.6", "text": "stomer is responsible for the accuracy and content of Customer \nContent. \n6. Machine Learning. Usage Data and Customer Content may be used to develop,\n\ntrain, or enhance artificial intelligence or machine learning models that are part \nof Provider's products and services, including third-party components of the \nProduct, and Customer authorizes Provider to process its Usage Data and \nCustomer Content for such purposes. However, (a) Usage Data and Customer \nContent must be aggregated before it can be used for these purposes, and \n(b) Provider will use commercially reasonable efforts consistent with industry \nstandard technology to de-identify Usage Data and Customer Content before such \nuse. Nothing in this section will reduce or limit Provider's obligations regarding \nPersonal Data that may be contained in Usage Data or Customer Content under \nApplicable Data Protection Laws. Due to the nature of artificial intelligence and \nmachine learning, information generated by these features may be incorrect or \ninaccurate. Product features that include artificial intelligence or machine learning \nmodels are not human and are not a substitute for human oversight. \n2. Restrictions & Obligations", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::ef5b66022760", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::50ae63ba948d"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::50ae63ba948d", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "2.1.a", "section_title": "Restrictions on Customer", "clause_type": "Restrictions", "path": "2 ➞ 2.1 ➞ 2.1.a", "text": "include artificial intelligence or machine learning \nmodels are not human and are not a substitute for human oversight. \n2. Restrictions & Obligations\n\n1. Restrictions on Customer.\n\na. Except as expressly permitted by this Agreement, Customer will not (and", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::de16e7bfb864", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::d2a1795d2830"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::d2a1795d2830", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "2.1.a.(i)-(x)", "section_title": "Restrictions on Customer", "clause_type": "Restrictions", "path": "2 ➞ 2.1 ➞ 2.1.a ➞ 2.1.a.(i)-(x)", "text": "an oversight. \n2. Restrictions & Obligations\n\n1. Restrictions on Customer.\n\na. Except as expressly permitted by this Agreement, Customer will not (and\n\nwill not allow anyone else to): (i) reverse engineer, decompile, or attempt to \ndiscover any source code or underlying ideas or algorithms of the Product \n(except to the extent Applicable Laws prohibit this restriction); (ii) provide, \nsell, transfer, sublicense, lend, distribute, rent, or otherwise allow others to \naccess or use the Product; (iii) remove any proprietary notices or labels; (iv) \ncopy, modify, or create derivative works of the Product; (v) conduct \nsecurity or vulnerability tests on, interfere with the operation of, cause \nperformance degradation of, or circumvent access restrictions of the \nProduct; (vi) access accounts, information, data, or portions of the Product \nto which Customer does not have explicit authorization; (vii) use the \nProduct to develop a competing service or product; (viii) use the Product \nwith any High Risk Activities or with any activity prohibited by Applicable \nLaws; (ix) use the Product to obtain unauthorized access to anyone else's \nnetworks or equipment; or (x) upload, submit, or otherwise make available \nto the Product any Customer Content to which Customer and Users do \nnot have the proper rights. \nb. Use of the Product must comply with all Documentation and Use", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::50ae63ba948d", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::f5f37b87baba"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::f5f37b87baba", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "2.1(b) • 2.2 • 3.1", "section_title": "Restrictions on Customer (clause b); Suspension; Privacy & Security — Personal Data", "clause_type": "Restrictions / Suspension / Privacy & Security (Personal Data)", "path": "2 ➞ 2.1 ➞ 2.1(b) ➞ 2.2 ➞ 3 ➞ 3.1", "text": "uct any Customer Content to which Customer and Users do \nnot have the proper rights. \nb. Use of the Product must comply with all Documentation and Use\n\nLimitations. \n2. Suspension. If Customer (a) has an outstanding, undisputed balance on its\n\naccount for more than 30 days; (b) breaches Section 2.1 (Restrictions on \nCustomer); or (c) uses the Product in violation of the Agreement or in a way that \nmaterially and negatively impacts the Product or others, then Provider may \ntemporarily suspend Customer'saccess to the Product with or without notice. \nHowever, Provider will try to inform Customer before \nsuspending Customer's account when practical. Provider will \nreinstate Customer's access to the Product only if Customerresolves the \nunderlying issue. \n3. Privacy & Security\n\n1. Personal Data. Before submitting Personal Data governed by", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::d2a1795d2830", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::411a34c4dec0"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::411a34c4dec0", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "3", "section_title": "Privacy & Security", "clause_type": "Privacy / Security provisions", "path": "3 ➞ 3.1", "text": "s to the Product only if Customerresolves the \nunderlying issue. \n3. Privacy & Security\n\n1. Personal Data. Before submitting Personal Data governed by\n\nGDPR, Customer must enter into a data processing agreement with Provider. If \nthe parties have a DPA, each party will comply with its obligations in the DPA, the \nterms of the DPA will control each party's rights and obligations as to Personal \nData, and the terms of the DPA will control in the event of any conflict with this \nAgreement. \n2. Prohibited Data. Customer will not (and will not allow anyone else to) submit\n\nProhibited Data to the Product unless authorized by the Order Form or Key Terms. \n4. Payment & Taxes\n\n1. Fees. Unless the Order Form specifies a different currency, all Fees are in U.S.\n\nDollars and are exclusive of taxes. Except for the prorated refund of prepaid Fees \nallowed with specific termination rights given in the Agreement, Fees are nonrefundable. \n2. Invoicing. For a Payment Process with invoicing, Provider will send invoices for\n\nusage-based Fees in arrears and for all other Fees in advance, in each case \naccording to the Payment Process. \n3. Automatic Payment. For a Payment Process with automatic", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::f5f37b87baba", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::c387e96b1c10"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::c387e96b1c10", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "4.2-4.6", "section_title": "Payment & Taxes", "clause_type": "Payment & Taxes", "path": "4 ➞ 4.2 ➞ 4.3 ➞ 4.4 ➞ 4.5 ➞ 4.6", "text": "arrears and for all other Fees in advance, in each case \naccording to the Payment Process. \n3. Automatic Payment. For a Payment Process with automatic\n\npayment, Provider will automatically charge the credit card, debit card, or other \npayment method on file for Fees according to the Payment\n\nProcess and Customerauthorizes all such charges. In this case, Provider will \nmake a copy of Customer's bills or transaction history available to Customer. \n4. Taxes. Customer is responsible for all duties, taxes, and levies that apply to Fees,\n\nincluding sales, use, VAT, GST, or withholding, that Provider itemizes and includes \nin an invoice. However, Customer is not responsible for Provider's income taxes. \n5. Payment. Customer will pay Provider Fees and taxes in U.S. Dollars, unless the\n\nOrder Form specifies a different currency, according to the Payment Process. \n6. Payment Dispute. If Customer has a good-faith disagreement about the Fees", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::411a34c4dec0", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::b176fa84d910"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::b176fa84d910", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "4.6; 5; 5.1; 5.2; 5.3", "section_title": "Payment Dispute; Term & Termination (Order Form and Agreement; Framework Terms; Termination)", "clause_type": "Payment dispute and termination/renewal clause", "path": "4 ➞ 4.6; 5 ➞ 5.1; 5 ➞ 5.2; 5 ➞ 5.3", "text": "r Form specifies a different currency, according to the Payment Process. \n6. Payment Dispute. If Customer has a good-faith disagreement about the Fees\n\ncharged or invoiced, Customermust notify Provider about the dispute before \npayment is due, or within 30 days of an automatic payment, and must pay all \nundisputed amounts on time. The parties will work together to resolve the dispute \nwithin 15 days. If no resolution is agreed, each party may pursue any remedies \navailable under the Agreement or Applicable Laws. \n5. Term & Termination\n\n1. Order Form and Agreement. For each Order Form, the Agreement will start on\n\nthe Order Date, continue through the Subscription Period, and automatically \nrenew for additional Subscription Periods unless one party gives notice of nonrenewal to the other party before the Non-Renewal Notice Date. \n2. Framework Terms. These Framework Terms will start on the Effective Date and\n\ncontinue for the longer of one year or until all Order Forms governed by the \nFramework Terms have ended. \n3. Termination. Either party may terminate the Framework Terms or an Order Form\n\nimmediately:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::c387e96b1c10", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::311e58ff7e06"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::311e58ff7e06", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "5.2-5.5", "section_title": "Termination; Force Majeure; Effect of Termination", "clause_type": "Termination / Force Majeure / Consequences of Termination", "path": "5 ➞ 5.2 ➞ 5.3 ➞ 5.3.a ➞ 5.3.b ➞ 5.4 ➞ 5.5", "text": "rder Forms governed by the \nFramework Terms have ended. \n3. Termination. Either party may terminate the Framework Terms or an Order Form\n\nimmediately:\n\na. if the other party fails to cure a material breach of the Framework Terms or\n\nan Order Form following 30 days notice; \nb. upon notice if the other party (i) materially breaches the Framework Terms\n\nor an Order Form in a manner that cannot be cured; (ii) dissolves or stops \nconducting business without a successor; (iii) makes an assignment for the \nbenefit of creditors; or (iv) becomes the debtor in insolvency, receivership, \nor bankruptcy proceedings that continue for more than 60 days. \n4. Force Majeure. Either party may terminate an affected Order Form upon notice if a\n\nForce Majeure Event prevents the Product from materially operating for 30 or more \nconsecutive days. Provider will pay to Customer a prorated refund of any prepaid \nFees for the remainder of the Subscription Period. A Force Majeure Event does \nnot excuse Customer's obligation to pay Fees accrued prior to termination. \n5. Effect of Termination. Termination of the Framework Terms will automatically", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::b176fa84d910", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::ef4b66972793"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::ef4b66972793", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "5.5 – 6.1.a", "section_title": "Effect of Termination; Survival (partial)", "clause_type": "Termination / Post-termination obligations", "path": "5 ➞ 5.5 (a-d); 6 ➞ 6.1.a", "text": "xcuse Customer's obligation to pay Fees accrued prior to termination. \n5. Effect of Termination. Termination of the Framework Terms will automatically\n\nterminate all Order Forms governed by the Framework Terms. Upon any expiration \nor termination:\n\na. Customer will no longer have any right to use the Product. \nb. Upon Customer's request, Provider will delete Customer Content within\n\n60 days. \nc. Each Recipient will return or destroy Discloser's Confidential Information in\n\nits possession or control. \nd. Provider will submit a final bill or invoice for all outstanding Fees accrued\n\nbefore termination and Customerwill pay the invoice according to Section \n4 (Payment & Taxes). \n6. Survival.\n\na. The following sections will survive expiration or termination of the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::311e58ff7e06", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::2aac89b6dea9"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::2aac89b6dea9", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "5.6", "section_title": "Survival", "clause_type": "Survival", "path": "5 ➞ 5.6 ➞ 5.6(a) & 5.6(b)", "text": "will pay the invoice according to Section \n4 (Payment & Taxes). \n6. Survival.\n\na. The following sections will survive expiration or termination of the\n\nAgreement: Section 1.4 (Feedback and Usage Data), Section 1.6 (Machine \nLearning), Section 2.1 (Restrictions on Customer), Section 4 (Payment & \nTaxes) for Fees accrued or payable before expiration or termination, \nSection 5.5 (Effect of Termination), Section 5.6 (Survival), Section 6 \n(Representations & Warranties), Section 7 (Disclaimer of Warranties), \nSection 8 (Limitation of Liability), Section 9 (Indemnification), Section 10 \n(Confidentiality), Section 11 (Reservation of Rights), Section 12 (General \nTerms), Section 13 (Definitions), and the portions of a Cover Page \nreferenced by these sections. \nb. Each Recipient may retain Discloser's Confidential Information in\n\naccordance with its standard backup or record retention policies \nmaintained in the ordinary course of business or as required by Applicable \nLaws, in which case Section 3 (Privacy & Security) and Section 10 \n(Confidentiality) will continue to apply to retained Confidential Information. \n6. Representations & Warranties", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::ef4b66972793", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::610bb44116c9"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::610bb44116c9", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "6", "section_title": "Representations & Warranties", "clause_type": "Representations & Warranties", "path": "6 ➞ 6.1 ➞ 6.2 ➞ 6.3 ➞ 6.4", "text": "3 (Privacy & Security) and Section 10 \n(Confidentiality) will continue to apply to retained Confidential Information. \n6. Representations & Warranties\n\n1. Mutual. Each party represents and warrants to the other that: (a) it has the legal\n\npower and authority to enter into this Agreement; (b) it is duly organized, validly \nexisting, and in good standing under the Applicable Laws of the jurisdiction of its \norigin; (c) it will comply with all Applicable Laws in performing its obligations or \nexercising its rights in this Agreement; and (d) it will comply with the Additional \nWarranties. \n2. From Customer. Customer represents and warrants that it, all Users, and anyone\n\nsubmitting Customer Content each have and will continue to have all rights \nnecessary to submit or make available Customer Content to the Product and to \nallow the use of Customer Content as described in the Agreement. \n3. From Provider. Provider represents and warrants to Customer that it will not\n\nmaterially reduce the general functionality of the Cloud Service during \nthe Subscription Period. \n4. Provider Warranty Remedy. If Provider breaches the warranty in Section 6.3", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::2aac89b6dea9", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::4344bd0fff97"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::4344bd0fff97", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "6.4, 7, 7.1", "section_title": "Provider Warranty Remedy; Disclaimer of Warranties", "clause_type": "Warranty remedy and disclaimer", "path": "6 ➞ 6.4; 7 ➞ 7.1", "text": "ral functionality of the Cloud Service during \nthe Subscription Period. \n4. Provider Warranty Remedy. If Provider breaches the warranty in Section 6.3\n\n(Representations & Warranties from Provider), Customer must \ngive Provider notice (with enough detail for Provider to understand or replicate \nthe issue) within 45 days of discovering the issue. Within 45 days of receiving \nsufficient details of the warranty issue, Provider will attempt to restore the general \nfunctionality of the Cloud Service. If Provider cannot resolve the \nissue, Customer may terminate the affected Order Form and Provider will pay \nto Customer a prorated refund of prepaid Fees for the remainder of \nthe Subscription Period. Provider's restoration obligation, \nand Customer's termination right, are Customer's only remedies if Provider does \nnot meet the warranty in Section 6.3 (Representations & Warranties from Provider). \n7. Disclaimer of Warranties\n\n1. Provider makes no guarantees that the Product will always be safe, secure, or", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::610bb44116c9", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::68bcde93dca5"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::68bcde93dca5", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "7; 8.1(a)-(b)", "section_title": "Disclaimer of Warranties; Limitation of Liability (Liability Caps)", "clause_type": "Disclaimer and Limitation of Liability", "path": "7 ➞ 7.1; 8 ➞ 8.1 ➞ 8.1(a)-(b)", "text": "sentations & Warranties from Provider). \n7. Disclaimer of Warranties\n\n1. Provider makes no guarantees that the Product will always be safe, secure, or\n\nerror-free, or that it will function without disruptions, delays, or imperfections. The \nwarranties in Section 6 (Representations & Warranties) do not apply to any misuse \nor unauthorized modification of the Product, nor to any product or service provided \nby anyone other than Provider. Except for the warranties in Section 6 \n(Representations & Warranties), Provider and Customereach disclaim all other \nwarranties and conditions, whether express or implied, including the implied\n\nwarranties and conditions of merchantability, fitness for a particular purpose, \ntitle, and non-infringement. These disclaimers apply to the maximum extent \npermitted by Applicable Laws. \n8. Limitation of Liability\n\n1. Liability Caps.\n\na. Except as provided in Section 8.4 (Exceptions), each party's total\n\ncumulative liability for all claims arising out of or relating to this \nAgreement will not be more than the General Cap Amount. \nb. If there are Increased Claims, each party's total cumulative liability for", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::4344bd0fff97", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::99e7d45270da"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::99e7d45270da", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "8.1(b)–8.4", "section_title": "Limitation of Liability", "clause_type": "Limitation of Liability / Damages Waiver", "path": "8 ➞ 8.1 ➞ 8.1(b) ➞ 8.2 ➞ 8.3 ➞ 8.4", "text": "lating to this \nAgreement will not be more than the General Cap Amount. \nb. If there are Increased Claims, each party's total cumulative liability for\n\nall Increased Claims arising out of or relating to this Agreement will not \nbe more than the Increased Cap Amount. \n2. Damages Waiver. Except as provided in Section 8.4 (Exceptions), under no\n\ncircumstances will either party be liable to the other for lost profits or \nrevenues (whether direct or indirect), or for consequential, special, indirect, \nexemplary, punitive, or incidental damages relating to this Agreement, even if \nthe party is informed of the possibility of this type of damage in advance. \n3. Applicability. The limitations and waivers contained in Sections 8.1 (Liability\n\nCaps) and 8.2 (Damages Waiver) apply to all liability, whether in tort (including \nnegligence), contract, breach of statutory duty, or otherwise. \n4. Exceptions. The liability cap in Section 8.1(a) does not apply to any Increased", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::68bcde93dca5", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::85a1469105a0"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::85a1469105a0", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "9", "section_title": "Indemnification", "clause_type": "Indemnification", "path": "8 ➞ 8.4 ➞ 9 ➞ 9.1 ➞ 9.2", "text": "ng \nnegligence), contract, breach of statutory duty, or otherwise. \n4. Exceptions. The liability cap in Section 8.1(a) does not apply to any Increased\n\nClaims. Section 8.1 (Liability Caps) does not apply to any Unlimited Claims. \nSection 8.2 (Damages Waiver) does not apply to any Increased Claims or a \nbreach of Section 10 (Confidentiality). Nothing in this Agreement will limit, exclude, \nor restrict a party's liability to the extent prohibited by Applicable Laws. \n9. Indemnification\n\n1. Protection by Provider. Provider will indemnify, defend, and hold\n\nharmless Customer from and against all Provider Covered Claims made by \nsomeone other than Customer, Customer's Affiliates, or Users, and all out-ofpocket damages, awards, settlements, costs, and expenses, including reasonable \nattorneys' fees and other legal expenses, that arise from the Provider Covered \nClaims. \n2. Protection by Customer. Customer will indemnify, defend, and hold", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::99e7d45270da", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::af50308cefaf"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::af50308cefaf", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "9.1-9.3", "section_title": "Indemnification", "clause_type": "Indemnification", "path": "9 ➞ 9.1 / 9 ➞ 9.2 / 9 ➞ 9.3", "text": "ys' fees and other legal expenses, that arise from the Provider Covered \nClaims. \n2. Protection by Customer. Customer will indemnify, defend, and hold\n\nharmless Provider from and against all Customer Covered Claims made by \nsomeone other than Provider or its Affiliates, and all out-of-pocket damages, \nawards, settlements, costs, and expenses, including reasonable attorneys' fees and \nother legal expenses, that arise from the Customer Covered Claims. \n3. Procedure. The Indemnifying Party's obligations in this section are contingent upon", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::85a1469105a0", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::4e724ec8a825"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::4e724ec8a825", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "9.3", "section_title": "Procedure", "clause_type": "Indemnification (Procedure)", "path": "9 ➞ 9.3", "text": "r legal expenses, that arise from the Customer Covered Claims. \n3. Procedure. The Indemnifying Party's obligations in this section are contingent upon\n\nthe Protected Party: (a) promptly notifying the Indemnifying Party of each Covered \nClaim for which it seeks protection; (b) providing reasonable assistance to the \nIndemnifying Party at the Indemnifying Party's expense; and (c) giving the \nIndemnifying Party sole control over the defense and settlement of each Covered \nClaim. A Protected Party may participate in a Covered Claim for which it seeks \nprotection with its own attorneys only at its own expense. The Indemnifying Party \nmay not agree to any settlement of a Covered Claim that contains an admission of \nfault or otherwise materially and adversely impacts the Protected Party without the \nprior written consent of the Protected Party. \n4. Changes to Product. If required by settlement or court order, or if deemed\n\nreasonably necessary in response to a Provider Covered Claim, Provider may: (a)", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::af50308cefaf", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a8a54cb8ca64"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a8a54cb8ca64", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "9.5", "section_title": "Exclusions", "clause_type": "Indemnification - Exclusions", "path": "9 ➞ 9.5", "text": "es to Product. If required by settlement or court order, or if deemed\n\nreasonably necessary in response to a Provider Covered Claim, Provider may: (a)\n\nobtain the right for Customer to continue using the Product; (b) replace or modify \nthe affected component of the Product without materially reducing the general \nfunctionality of the Product; or (c) if neither (a) nor (b) are reasonable, terminate the \naffected Order Form and issue a pro-rated refund of prepaid Fees for the \nremainder of the Subscription Period. \n5. Exclusions.\n\na. Provider's obligations as an Indemnifying Party will not apply to Provider\n\nCovered Claims that result from (i) modifications to the Product that were \nnot authorized by Provider or that were made in compliance \nwith Customer's instructions; (ii) unauthorized use of the Product, including \nuse in violation of this Agreement; (iii) use of the Product in combination \nwith items not provided by Provider; or (iv) use of an old version of the \nProduct where a newer release would avoid the Provider Covered Claim. \nb. Customer's obligations as an Indemnifying Party will not apply", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::4e724ec8a825", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::9c7141462530"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::9c7141462530", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "9.5.b–10.2", "section_title": "Confidentiality", "clause_type": "Confidentiality", "path": "9 ➞ 9.5 ➞ 9.5.b ➞ 9.6 ➞ 10 ➞ 10.1 ➞ 10.2", "text": "rsion of the \nProduct where a newer release would avoid the Provider Covered Claim. \nb. Customer's obligations as an Indemnifying Party will not apply\n\nto Customer Covered Claims that result from the unauthorized use of the \nCustomer Content, including use in violation of this Agreement. \n6. Exclusive Remedy. This Section 9 (Indemnification), together with any termination\n\nrights, describes each Protected Party's exclusive remedy and each Indemnifying \nParty's entire liability for a Covered Claim. \n10. Confidentiality\n\n1. Non-Use and Non-Disclosure. Except as otherwise authorized in the Agreement or\n\nas needed to fulfill its obligations or exercise its rights under this Agreement, \nRecipient will not (a) use Discloser's Confidential Information; nor (b) disclose \nDiscloser's Confidential Information to anyone else. In addition, Recipient will \nprotect Discloser's Confidential Information using at least the same protections \nRecipient uses for its own similar information but no less than a reasonable \nstandard of care. \n2. Exclusions. Confidential Information does not include information that (a) Recipient", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a8a54cb8ca64", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a7244041dc7a"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a7244041dc7a", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "10.2-10.4", "section_title": "Confidentiality", "clause_type": "Confidentiality (Non-use/Non-disclosure; Exclusions; Required and Permitted Disclosures)", "path": "10 ➞ 10.2; 10 ➞ 10.3; 10 ➞ 10.4", "text": "information but no less than a reasonable \nstandard of care. \n2. Exclusions. Confidential Information does not include information that (a) Recipient\n\nknew without any obligation of confidentiality before disclosure by Discloser; (b) is \nor becomes publicly known and generally available through no fault of Recipient; \n(c) Recipient receives under no obligation of confidentiality from someone else who \nis authorized to make the disclosure; or (d) Recipient independently developed \nwithout use of or reference to Discloser's Confidential Information. \n3. Required Disclosures. Recipient may disclose Discloser's Confidential Information\n\nto the extent required by Applicable Laws if, unless prohibited by Applicable Laws, \nRecipient provides Discloser reasonable advance notice of the required disclosure \nand reasonably cooperates, at Discloser's expense, with Discloser's efforts to \nobtain confidential treatment for the Confidential Information. \n4. Permitted Disclosures. Recipient may disclose Discloser's Confidential Information", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::9c7141462530", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::f4eb64ba1a01"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::f4eb64ba1a01", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "11", "section_title": "Reservation of Rights", "clause_type": "Reservation of Rights / Ownership", "path": "11 ➞ 11.1", "text": "obtain confidential treatment for the Confidential Information. \n4. Permitted Disclosures. Recipient may disclose Discloser's Confidential Information\n\nto Users, employees, advisors, contractors, and representatives who each have a \nneed to know the Confidential Information, but only if the person or entity is bound \nby confidentiality obligations at least as protective as those in this Section 10 \n(Confidentiality) and Recipient remains responsible for everyone's compliance with \nthe terms of this Section 10 (Confidentiality). \n11. Reservation of Rights\n\n1. Except for the limited license to copy and use Software and Documentation in\n\nSection 1.1 (Access and Use), Provider retains all right, title, and interest in and to \nthe Product, whether developed before or after the Effective Date. Except for the\n\nlimited rights in Section 1.5 (Customer Content) and 1.6 (Machine \nLearning), Customer retains all right, title, and interest in and to the Customer \nContent. \n12. General Terms\n\n1. Entire Agreement. This Agreement is the only agreement between the parties", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a7244041dc7a", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::8019c4311de4"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::8019c4311de4", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "11.1; 12.1-12.2", "section_title": "General Terms", "clause_type": "Boilerplate (Entire Agreement; Modifications, Severability & Waiver)", "path": "11 ➞ 11.1; 12 ➞ 12.1; 12 ➞ 12.2", "text": "title, and interest in and to the Customer \nContent. \n12. General Terms\n\n1. Entire Agreement. This Agreement is the only agreement between the parties\n\nabout its subject and this Agreement supersedes all prior or contemporaneous \nstatements (whether in writing or not) about its subject. Provider expressly rejects \nany terms included in Customer's purchase order or similar document, which may \nonly be used for accounting or administrative purposes. No terms or conditions in \nany Customer documentation or online vendor portal will apply to Customer's use \nof the Product unless expressly agreed to in a legally binding written agreement \nsigned by an authorized Provider representative, regardless of what such terms \nmay say. \n2. Modifications, Severability, and Waiver. Any waiver, modification, or change to the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::f4eb64ba1a01", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::99e70a198719"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::99e70a198719", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "12.2–12.4", "section_title": "Modifications, Severability, and Waiver; Governing Law and Chosen Courts; Injunctive Relief", "clause_type": "General Terms / Boilerplate", "path": "12 ➞ 12.2; 12 ➞ 12.3; 12 ➞ 12.4", "text": "ovider representative, regardless of what such terms \nmay say. \n2. Modifications, Severability, and Waiver. Any waiver, modification, or change to the\n\nAgreement must be in writing and signed or electronically accepted by each party. \nIf any term of this Agreement is determined to be invalid or unenforceable by a \nrelevant court or governing body, the remaining terms of this Agreement will \nremain in full force and effect. The failure of a party to enforce a term or to exercise \nan option or right in this Agreement will not constitute a waiver by that party of the \nterm, option, or right. \n3. Governing Law and Chosen Courts. The Governing Law will govern all\n\ninterpretations and disputes about this Agreement, without regard to its conflict of \nlaws provisions. The parties will bring any legal suit, action, or proceeding about \nthis Agreement in the Chosen Courts and each party irrevocably submits to the \nexclusive jurisdiction of the Chosen Courts. \n4. Injunctive Relief. Despite Section 12.3 (Governing Law and Chosen Courts), a", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::8019c4311de4", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::83d526ca99ea"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::83d526ca99ea", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "12.3-12.6", "section_title": "Governing Law and Chosen Courts (tail); Injunctive Relief; Non-Exhaustive Remedies; Assignment", "clause_type": "Injunctive relief; Remedies; Assignment (General Terms)", "path": "12 ➞ 12.3; 12 ➞ 12.4; 12 ➞ 12.5; 12 ➞ 12.6", "text": "evocably submits to the \nexclusive jurisdiction of the Chosen Courts. \n4. Injunctive Relief. Despite Section 12.3 (Governing Law and Chosen Courts), a\n\nbreach of Section 10 (Confidentiality) or the violation of a party's intellectual \nproperty rights may cause irreparable harm for which monetary damages cannot \nadequately compensate. As a result, upon the actual or threatened breach of \nSection 10 (Confidentiality) or violation of a party's intellectual property rights, the \nnon-breaching or non-violating party may seek appropriate equitable relief, \nincluding an injunction, in any court of competent jurisdiction without the need to \npost a bond and without limiting its other rights or remedies. \n5. Non-Exhaustive Remedies. Except where the Agreement provides for an exclusive\n\nremedy, seeking or exercising a remedy does not limit the other rights or remedies \navailable to a party. \n6. Assignment. Neither party may assign any rights or obligations under this", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::99e70a198719", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::9bca70b940e7"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::9bca70b940e7", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "12.6-12.8", "section_title": "Assignment; Beta Products; Logo Rights", "clause_type": "Boilerplate (Assignment; Beta Products; Marketing/Logo Rights)", "path": "12 ➞ 12.6; 12 ➞ 12.7; 12 ➞ 12.8", "text": "emedy does not limit the other rights or remedies \navailable to a party. \n6. Assignment. Neither party may assign any rights or obligations under this\n\nAgreement without the prior written consent of the other party. However, either \nparty may assign this Agreement upon notice if the assigning party undergoes a \nmerger, change of control, reorganization, or sale of all or substantially all its equity, \nbusiness, or assets to which this Agreement relates. Any attempted but nonpermitted assignment is void. This Agreement will be binding upon and inure to the \nbenefit of the parties and their permitted successors and assigns. \n7. Beta Products. If Provider gives Customer access to a Beta Product, the Beta\n\nProduct is provided \"AS IS\" and Section 6.3 (Representations & Warranty From \nProvider) does not apply to any Beta Products. Customeracknowledges that Beta \nProducts are experimental in nature and may be modified or removed \nat Provider'sdiscretion with or without notice.\n\n8. Logo Rights. Provider may identify Customer and use Customer's name and logo", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::83d526ca99ea", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::d605a4c3a066"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::d605a4c3a066", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "12.8-12.13", "section_title": "General Terms", "clause_type": "General/Boilerplate", "path": "12 ➞ 12.8-12.13", "text": "modified or removed \nat Provider'sdiscretion with or without notice.\n\n8. Logo Rights. Provider may identify Customer and use Customer's name and logo\n\nin marketing to identify Customer as a user of Provider's products and services. \n9. Notices. Any notice, request, or approval about the Agreement must be in writing\n\nand sent to the Notice Address. Notices will be deemed given (a) upon confirmed \ndelivery if by email, registered or certified mail, or personal delivery; or (b) two days \nafter mailing if by overnight commercial delivery. \n10. Independent Contractors. The parties are independent contractors, not agents,\n\npartners, or joint venturers. Neither party is authorized to bind the other to any \nliability or obligation. \n11. No Third-Party Beneficiary. There are no third-party beneficiaries of this\n\nAgreement. \n12. Force Majeure. Neither party will be liable for a delay or failure to perform its\n\nobligations of this Agreement if caused by a Force Majeure Event. However, this \nsection does not excuse Customer's obligations to pay Fees. \n13. Export Controls. Customer may not remove or export from the United States or", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::9bca70b940e7", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::e5d9f46203cf"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::e5d9f46203cf", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "12.13", "section_title": "Export Controls", "clause_type": "Export Controls / Regulatory Compliance", "path": "12 ➞ 12.13", "text": "r, this \nsection does not excuse Customer's obligations to pay Fees. \n13. Export Controls. Customer may not remove or export from the United States or\n\nallow the export or re-export of the Product or any related technology or materials \nin violation of any restrictions, laws, or regulations of the United States Department \nof Commerce, OFAC, or any other United States or foreign agency or \nauthority. Customerrepresents and warrants that it is not (a) a resident or national \nof an Embargoed Country; (b) an entity organized under the laws of an Embargoed \nCountry; (c) designated on any list of prohibited, restricted, or sanctioned parties \nmaintained by the U.S. government or agencies or other applicable governments or \nagencies, including OFAC's Specially Designated Nationals and Blocked Persons \nList and the UN Security Council Consolidated List; nor (d) 50% or more owned by \nany party designated on any of the above lists. Provider may terminate this \nAgreement immediately without notice or liability to comply, as determined \nin Provider's sole discretion, with applicable export controls and sanctions laws \nand regulations. \n14. Government Rights. The Cloud Service and Software are deemed \"commercial", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::d605a4c3a066", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::02085d1db454"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::02085d1db454", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "12.14-12.16", "section_title": "Government Rights; Anti-Bribery; Titles and Interpretation", "clause_type": "Boilerplate (Government rights, anti-bribery, interpretation)", "path": "12 ➞ 12.14 ➞ 12.15 ➞ 12.16", "text": "on, with applicable export controls and sanctions laws \nand regulations. \n14. Government Rights. The Cloud Service and Software are deemed \"commercial\n\nitems\" or \"commercial computer software\" according to FAR section 12.212 and \nDFAR section 227.7202, and the Documentation is \"commercial computer software \ndocumentation\" according to DFAR section 252.227-7014(a)(1) and (5). Any use, \nmodification, reproduction, release, performance, display, or disclosure of the \nProduct by the U.S. Government will be governed solely by the terms of this \nAgreement and all other use is prohibited. \n15. Anti-Bribery. Neither party will take any action that would be a violation of any\n\nApplicable Laws that prohibit the offering, giving, promising to offer or give, or \nreceiving, directly or indirectly, money or anything of value to any third party to \nassist Provider or Customer in retaining or obtaining business. Examples of these \nkinds of laws include the U.S. Foreign Corrupt Practices Act and the UK Bribery Act \n2010. \n16. Titles and Interpretation. Section titles are for convenience and reference only. All", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::e5d9f46203cf", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::00764fb6e8ac"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::00764fb6e8ac", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "12.16; 12.17; 13.1-13.2", "section_title": "Titles and Interpretation; Signature; Definitions (partial)", "clause_type": "General Terms; Signature; Definitions", "path": "12 ➞ 12.16 | 12 ➞ 12.17 | 13 ➞ 13.1 | 13 ➞ 13.2", "text": "Foreign Corrupt Practices Act and the UK Bribery Act \n2010. \n16. Titles and Interpretation. Section titles are for convenience and reference only. All\n\nuses of \"including\" and similar phrases are non-exhaustive and without limitation. \nThe United Nations Convention for the International Sale of Goods and the Uniform \nComputer Information Transaction Act do not apply to this Agreement. \n17. Signature. This Agreement may be signed in counterparts, including by electronic\n\ncopies or acceptance mechanism. Each copy will be deemed an original and all \ncopies, when taken together, will be the same agreement.\n\n13. Definitions\n\n1. Defining Variables. Variables have the meanings or descriptions given on a Cover\n\nPage. However, if the Order Form and the governing Framework Terms omit or do \nnot define a Variable, the default meaning will be \"none\" or \"not applicable\" and the \ncorrelating clause, sentence, or section does not apply to that Agreement. \n2. \"Affiliate\" means an entity that, directly or indirectly, controls, is under the control", "numbers_present": null, "definition_terms": ["Variable", "Affiliate"], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::02085d1db454", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::cfec80755e58"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::cfec80755e58", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "13.1-13.8", "section_title": "Definitions", "clause_type": "Definitions", "path": "13 ➞ 13.1 ➞ 13.2 ➞ 13.3 ➞ 13.4 ➞ 13.5 ➞ 13.6 ➞ 13.7 ➞ 13.8", "text": "e, sentence, or section does not apply to that Agreement. \n2. \"Affiliate\" means an entity that, directly or indirectly, controls, is under the control\n\nof, or is under common control with a party, where control means having more than \nfifty percent (50%) of the voting stock or other ownership interest. \n3. \"Agreement\" means the Order Form between Provider and Customer as\n\ngoverned by the Framework Terms. \n4. \"Applicable Data Protection Laws\" means the Applicable Laws that govern how\n\nthe Cloud Service may process or use an individual's personal information, \npersonal data, personally identifiable information, or other similar term. \n5. \"Applicable Laws\" means the laws, rules, regulations, court orders, and other\n\nbinding requirements of a relevant government authority that apply to or \ngovern Provider or Customer. \n6. \"Beta Product\" means an early or prerelease feature or version of the Product that\n\nis identified as beta or similar, or a version of the Product that is not generally \navailable. \n7. \"Cloud Service\" means the product described in the Order Form. \n8. \"Confidential Information\" means information in any form disclosed by or on", "numbers_present": null, "definition_terms": ["Affiliate", "Agreement", "Applicable Data Protection Laws", "Applicable Laws", "Beta Product", "Cloud Service", "Confidential Information"], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::00764fb6e8ac", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::fe11e5694cfc"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::fe11e5694cfc", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "13.7-13.11", "section_title": "Definitions", "clause_type": "Defined Terms", "path": "13 ➞ 13.7-13.11", "text": "le. \n7. \"Cloud Service\" means the product described in the Order Form. \n8. \"Confidential Information\" means information in any form disclosed by or on\n\nbehalf of a Discloser, including before the Effective Date, to a Recipient in \nconnection with this Agreement that (a) the Discloser identifies as \"confidential\", \n\"proprietary\", or the like; or (b) should be reasonably understood as confidential or \nproprietary due to its nature and the circumstances of its disclosure. Confidential \nInformation includes the existence of this Agreement and the information on each \nCover Page. Customer's Confidential Information includes non-public Customer \nContent and Provider's Confidential Information includes non-public information \nabout the Product. \n9. \"Cover Page\" means a document that is signed or electronically accepted by the\n\nparties, incorporates these Standard Terms or is governed by the Framework \nTerms, and identifies Provider and Customer. A Cover Page may include an Order \nForm, Key Terms, or both. \n10. \"Covered Claim\" means either a Provider Covered Claim or Customer Covered\n\nClaim. \n11. \"Customer Content\" means data, information, or materials submitted by or on", "numbers_present": null, "definition_terms": ["Cloud Service", "Confidential Information", "Cover Page", "Covered Claim", "Customer Content"], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::cfec80755e58", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::5197a5313735"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::5197a5313735", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "13.11-13.17", "section_title": "Definitions", "clause_type": "Definition", "path": "13 ➞ 13.11 ➞ 13.12 ➞ 13.13 ➞ 13.14 ➞ 13.15 ➞ 13.16 ➞ 13.17", "text": "im\" means either a Provider Covered Claim or Customer Covered\n\nClaim. \n11. \"Customer Content\" means data, information, or materials submitted by or on\n\nbehalf of Customer or Users to the Product but excludes Feedback. \n12. \"Discloser\" means a party to this Agreement when the party is providing or\n\ndisclosing Confidential Information to the other party. \n13. \"Documentation\" means the usage manuals and instructional materials for the\n\nCloud Service or Software that are made available by Provider. \n14. \"Embargoed Country\" means any country or region to or from where Applicable\n\nLaws generally restrict the export or import of goods, services, or money. \n15. \"Feedback\" means suggestions, feedback, or comments about the Product or\n\nrelated offerings. \n16. \"Fees\" means the applicable amounts described in an Order Form. \n17. \"Force Majeure Event\" means an unforeseen event outside a party's reasonable\n\ncontrol where the affected party took reasonable measures to avoid or mitigate the", "numbers_present": null, "definition_terms": ["Covered Claim", "Customer Content", "Discloser", "Documentation", "Embargoed Country", "Feedback", "Fees", "Force Majeure Event"], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::fe11e5694cfc", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a51c740cb970"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a51c740cb970", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "13.17-21", "section_title": "Definitions", "clause_type": "Definitions", "path": "13 ➞ 13.17-13.21", "text": "eure Event\" means an unforeseen event outside a party's reasonable\n\ncontrol where the affected party took reasonable measures to avoid or mitigate the\n\nimpacts of the event. Examples of these kinds of events include unpredicted \nnatural disasters like a major earthquake, war, pandemic, riot, act of terrorism, or \npublic utility or internet failure. \n18. \"Framework Terms\" means these Standard Terms, the Key Terms\n\nbetween Provider and Customer, and any policies and documents referenced in \nor attached to the Key Terms. \n19. \"GDPR\" means European Union Regulation 2016/679 as implemented by local law\n\nin the relevant European Union member nation, and by section 3 of the United \nKingdom's European Union (Withdrawal) Act of 2018 in the United Kingdom. \n20. \"High Risk Activity\" means any situation where the use or failure of the Product\n\ncould be reasonably expected to lead to death, bodily injury, or environmental \ndamage. Examples include full or partial autonomous vehicle technology, medical \nlife-support technology, emergency response services, nuclear facilities operation, \nand air traffic control. \n21. \"Indemnifying Party\" means a party to this Agreement when the party is", "numbers_present": null, "definition_terms": ["Force Majeure Event", "Framework Terms", "GDPR", "High Risk Activity", "Indemnifying Party"], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::5197a5313735", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::b292c50832f4"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::b292c50832f4", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "13.20-13.25", "section_title": "Definitions", "clause_type": "Definitions", "path": "13 ➞ 13.20 ➞ 13.21 ➞ 13.22 ➞ 13.23 ➞ 13.24 ➞ 13.25", "text": "response services, nuclear facilities operation, \nand air traffic control. \n21. \"Indemnifying Party\" means a party to this Agreement when the party is\n\nproviding protection for a particular Covered Claim. \n22. \"Key Terms\" means a Cover Page that includes the key legal details and Variables\n\nfor this Agreement. The Key Terms may include details about Covered Claims, set \nthe Governing Law, or contain other details about this Agreement. \n23. \"OFAC\" means the United States Department of Treasury's Office of Foreign\n\nAssets Control. \n24. \"Order Form\" means a Cover Page that includes the key business details and\n\nVariables for this Agreement that are not defined in the Framework Terms. An \nOrder Form includes the policies and documents referenced in or attached to the \nOrder Form. An Order Form may include details about the level of access and use \ngranted to the Cloud Service, length of Subscription Period, or other details about \nthe Product. \n25. \"Personal Data\" will have the meaning(s) set forth in the Applicable Data", "numbers_present": null, "definition_terms": ["High Risk Activity", "Indemnifying Party", "Key Terms", "OFAC", "Order Form", "Personal Data"], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::a51c740cb970", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::c50859a44ccd"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::c50859a44ccd", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "13.25-13.30", "section_title": "Definitions", "clause_type": "Definitions", "path": "13 ➞ 13.25-13.30", "text": "ce, length of Subscription Period, or other details about \nthe Product. \n25. \"Personal Data\" will have the meaning(s) set forth in the Applicable Data\n\nProtection Laws for personal information, personal data, personally identifiable \ninformation, or other similar term. \n26. \"Product\" means the Cloud Service, Software, and Documentation. \n27. \"Prohibited Data\" means (a) patient, medical, or other protected health\n\ninformation regulated by the Health Insurance Portability and Accountability Act; \n(b) credit, debit, bank account, or other financial account numbers; (c) social \nsecurity numbers, driver's license numbers, or other unique and private \ngovernment ID numbers; (d) special categories of data as defined in the GDPR; and \n(e) other similar categories of sensitive information as set forth in the Applicable \nData Protection Laws. \n28. \"Protected Party\" means a party to this Agreement when the party is receiving\n\nthe benefit of protection for a particular Covered Claim. \n29. \"Recipient\" means a party to this Agreement when the party receives Confidential\n\nInformation from the other party. \n30. \"Software\" means the client-side software or applications made available", "numbers_present": null, "definition_terms": ["Personal Data", "Product", "Prohibited Data", "Protected Party", "Recipient", "Software"], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::b292c50832f4", "next_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::d8e4a4f85470"}
{"id": "79f73805-a51f-472c-88b5-7d50a761f9f8::d8e4a4f85470", "doc_id": "79f73805-a51f-472c-88b5-7d50a761f9f8", "section_number": "13.29-13.34", "section_title": "Definitions", "clause_type": "Definitions", "path": "13 ➞ 13.29-13.34", "text": "when the party receives Confidential\n\nInformation from the other party. \n30. \"Software\" means the client-side software or applications made available\n\nby Provider for Customer to install, download (whether onto a machine or in a \nbrowser), or execute as part of the Product. \n31. \"Standard Terms\" means these Common Paper Cloud Service Agreement\n\nStandard Terms Version 2.1, which are posted \nat https://commonpaper.com/standards/cloud-service-agreement/2.1/.\n\n32. \"Usage Data\" means data and information about the provision, use, and\n\nperformance of the Product and related offerings based on Customer's or User's \nuse of the Product. \n33. \"User\" means any individual who uses the Product on Customer's behalf or\n\nthrough Customer's account. \n34. \"Variable\" means a word or phrase that is highlighted and capitalized, such\n\nas Subscription Period or Governing Law.", "numbers_present": null, "definition_terms": ["Recipient", "Software", "Standard Terms", "Usage Data", "User", "Variable"], "metadata": {"doc_type": "SaaS", "party_role": "provider, customer", "industry": "cloud"}, "prev_id": "79f73805-a51f-472c-88b5-7d50a761f9f8::c50859a44ccd", "next_id": null}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5b86a9e54f87", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": null, "section_title": "TABLE OF CONTENTS", "clause_type": "Table of Contents / Introductory", "path": "Preamble ➞ TABLE OF CONTENTS", "text": "Exhibit 10.3\n\n[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material\nand would likely cause competitive harm to the registrant if publicly disclosed.\n\nExecution Copy\n\nLICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT\n\nDATED AS OF FEBRUARY 4, 2020\n\nBY AND BETWEEN\n\nXENCOR, INC.\n\nAND\n\nAIMMUNE THERAPEUTICS, INC.\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nTABLE OF CONTENTS\n\nPage\nARTICLE 1 Definitions\n1\n\nARTICLE 2 Licenses\n13\n\nARTICLE 3 Development\n16\n\nARTICLE 4 Regulatory\n17\n\nARTICLE 5 Commercialization\n19\n\nARTICLE 6 Supply\n20\n\nARTICLE 7 Payments\n21\n\nARTICLE 8 Payment; Records; Audits\n24\n\nARTICLE 9 Intellectual Property Matters\n26\n\nARTICLE 10 Representations, Warranties and Covenants; Compliance\n31\n\nARTICLE 11 Indemnification\n34\n\nARTICLE 12 Confidentiality\n36\n\nARTICLE 13 Term and Termination\n40\n\nARTICLE 14 Effects of Expiration Or Termination\n40\n\nARTICLE 15 Miscellaneous\n43\n\nSchedule 1.10 Antibody\n50\n\nSchedule 1.79 Xencor General Patents\n51\n\nSchedule 1.81 Xencor Product Specific Patents\n52\n\nSchedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data\n53", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": null, "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cc65e4d1c39a"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cc65e4d1c39a", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": null, "section_title": "RECITALS", "clause_type": "Preamble/Recitals", "path": "Preamble ➞ RECITALS", "text": "encor General Patents\n51\n\nSchedule 1.81 Xencor Product Specific Patents\n52\n\nSchedule 2.7 Xencor Know-How, Regulatory Materials, and Regulatory Data\n53\n\nSchedule 6.1 Initial Product Supply\n54\n\nSchedule 10.2.6 Exceptions\n55\n\nSchedule 12.2 Initial Press Release\n56\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nLICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT\n\nThis License, Development and Commercialization Agreement (this \"Agreement\"), dated as of February 4, 2020 (the \"Effective Date\"), is made by\nand between Xencor, Inc. (\"Xencor\"), and Aimmune Therapeutics, Inc. (\"Aimmune\"). Xencor and Aimmune are sometimes referred to herein\nindividually as a \"Party\" and collectively as the \"Parties\".\n\nRECITALS\n\nWHEREAS, Xencor has developed the Antibody (as defined below);\n\nWHEREAS, Aimmune is interested in further developing and commercializing the Antibody; and\n\nWHEREAS, Xencor wishes to grant a license to Aimmune under certain intellectual property rights related to the Antibody to develop, manufacture\nand commercialize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions\nset forth below.", "numbers_present": null, "definition_terms": ["Agreement", "Effective Date", "Xencor", "Aimmune", "Party", "Parties"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5b86a9e54f87", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a87658d7b019"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a87658d7b019", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.1", "section_title": "Active Ingredient", "clause_type": "Definition", "path": "1 ➞ 1.1", "text": "ize the Product (as defined below), and Aimmune wishes to take such license, in each case in accordance with the terms and conditions\nset forth below.\n\nNO W THEREFORE, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement,\nand for other good and valuable consideration, receipt of which is hereby acknowledged, the Parties agree as follows:\n\nARTICLE 1\nDEFINITIONS\n\nAs used in this Agreement, the following initially capitalized terms shall have the meanings set forth in this ARTICLE 1 or as otherwise defined\nelsewhere in this Agreement:\n\n1.1 \"Active Ingredient\" means any substance (whether chemical or biologic) or mixture of substances intended to be used in the manufacture of a\ndrug (medicinal) product that, when used in the production of such drug, becomes a therapeutically active ingredient of the drug product, and which\nsuch substance or mixture of substances is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment\nor prevention of disease or to affect the structure or function of the body.", "numbers_present": null, "definition_terms": ["Active Ingredient"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cc65e4d1c39a", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0843777a9ff1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0843777a9ff1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.2", "section_title": "Affiliate", "clause_type": "Definition", "path": "1 ➞ 1.2", "text": "vity or other direct effect in the diagnosis, cure, mitigation, treatment\nor prevention of disease or to affect the structure or function of the body.\n\n1.2 \"Affiliate\" means with respect to any person, any other person directly or indirectly controlling, controlled by, or under common control with\nsuch person; provided, that, for purposes of this definition, \"control\" (including, with correlative meanings, the terms \"controlled by\" and \"under\ncommon control with\"), as used with respect to any person, shall mean (i) the possession, directly or indirectly, of the power to direct or cause the\ndirection of the management and policies of such person, whether through the ownership of voting securities or by contract or otherwise, or (ii) the\nownership, directly or indirectly, of fifty percent (50%) or more of the voting securities of such person. For purposes of this Section 1.2, \"person\" means\nmean an individual, corporation, partnership, limited partnership, limited liability company, limited liability partnership, syndicate, person (including a\n\"person\" as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, together with the rules and regulations promulgated\nthereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government.", "numbers_present": null, "definition_terms": ["Affiliate"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a87658d7b019", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ee1f3bdec52f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ee1f3bdec52f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.3-1.7", "section_title": "Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.3-1.7", "text": "and regulations promulgated\nthereunder), trust, association, entity or government or political subdivision, agency or instrumentality of a government.\n\n1\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.3 \"Aimmune Agreement Entities\" means Aimmune's Affiliates and Sublicensees (excluding distributors).\n\n1.4 \"Aimmune Common Stock\" means Aimmune's common stock, par value $0.0001 per share.\n\n1.5 \"Aimmune Field\" means the field of [***].\n\n1.6 \"Aimmune Invention\" means an Invention that is Invented, solely or jointly with a Third Party, by or on behalf of Aimmune or its Affiliates.\n\n1.7 \"Aimmune Know-How\" means any and all Know-How, whether or not patented or patentable, that is Controlled by Aimmune or its Affiliates as\nof the Effective Date or at any time during the Term that is necessary or reasonably useful in connection with the Development, Manufacture,\nCommercialization or other use of the Antibody or Product.", "numbers_present": null, "definition_terms": ["Aimmune Agreement Entities", "Aimmune Common Stock", "Aimmune Field", "Aimmune Invention", "Aimmune Know-How"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0843777a9ff1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e34252b53604"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e34252b53604", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.8–1.11", "section_title": "Article 1 Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.8; 1 ➞ 1.9; 1 ➞ 1.10; 1 ➞ 1.11", "text": "erm that is necessary or reasonably useful in connection with the Development, Manufacture,\nCommercialization or other use of the Antibody or Product.\n\n1.8 \"Aimmune Patent\" means any Patent that (i) (a) is Controlled by Aimmune (or its Affiliates) as of the Effective Date or comes under the\nControl of Aimmune (or its Affiliates) during the Term (other than as a result of the licenses granted by Xencor to Aimmune under this Agreement) and\n(b) that would be infringed by the Development, Manufacture, Commercialization or use of the Antibody or Product or that claims or Covers Aimmune\nKnow-How, or (ii) is an Aimmune Collaboration Patent.\n\n1.9 \"Aimmune Technology\" means Aimmune Know-How and Aimmune Patents.\n\n1.10 \"Antibody\" means Xencor's humanized antibody known as XmAb7195 having the sequence listed in Schedule 1.10.\n\n1.11 \"Anti-Corruption Laws\" means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, as well as\nApplicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.", "numbers_present": null, "definition_terms": ["Aimmune Patent", "Aimmune Technology", "Antibody", "Anti-Corruption Laws"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ee1f3bdec52f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a2180db3549e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a2180db3549e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.12", "section_title": "Applicable Law", "clause_type": "Definition", "path": "1 ➞ 1.12", "text": "ended, the UK Bribery Act 2010, as amended, as well as\nApplicable Law related to the prevention of fraud, racketeering, money laundering or terrorism.\n\n1.12 \"Applicable Law\" means any applicable United States federal, state or local or foreign or multinational law, statute, standard, ordinance, code,\nrule, regulation, resolution or promulgation, or any order, writ, judgment, injunction, decree, stipulation, ruling, determination or award entered by or with\nany Governmental Authority, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force\nor effect of law. For the avoidance of doubt, any specific references to any Applicable Law or any portion thereof, shall be deemed to include all thencurrent amendments thereto or any replacement or successor law, statute, standard, ordinance, code, rule, regulation, resolution, order, writ, judgment,\ninjunction, decree, stipulation, ruling, or determination thereto.\n\n2\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": ["Applicable Law"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e34252b53604", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::233b7278563e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::233b7278563e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.13–1.14", "section_title": "Baseline Quarter Net Sales; Business Day", "clause_type": "Definition", "path": "1 ➞ 1.13; 1 ➞ 1.14", "text": "ution, order, writ, judgment,\ninjunction, decree, stipulation, ruling, or determination thereto.\n\n2\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.13 \"Baseline Quarter Net Sales\" means, on a country-by-country and Product-by-Product basis, the average cumulative Net Sales of such\nProduct in such country during the [***] Calendar Quarters that [***]precede the Calendar Quarter during which a Generic Product with respect to such\nProduct is first commercially sold in such country. For example, if a Generic Product with respect to a given Product is commercially sold in the U.S. for the\nfirst time on [***], then the Baseline Quarter Net Sales with respect to such Product and U.S. are the cumulative Net Sales of such Product in the U.S.\nduring the [***] Calendar Quarters of [***] divided by [***].\n\n1.14 \"Business Day\" means a day other than a Saturday, Sunday, or bank or other public holiday in California.", "numbers_present": null, "definition_terms": ["Baseline Quarter Net Sales", "Business Day"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a2180db3549e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::08ab13d25420"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::08ab13d25420", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.14-1.16", "section_title": "Business Day; Calendar Quarter; Calendar Year", "clause_type": "Definitions", "path": "1 ➞ 1.14; 1 ➞ 1.15; 1 ➞ 1.16", "text": "dar Quarters of [***] divided by [***].\n\n1.14 \"Business Day\" means a day other than a Saturday, Sunday, or bank or other public holiday in California.\n\n1.15 \"Calendar Quarter\" means each three (3) month period commencing January 1, April 1, July 1 or October 1 of any year; provided, however,\nthat (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter, and (b) the last\nCalendar Quarter of the Term shall end upon the expiration or termination of this Agreement.\n\n1.16 \"Calendar Year\" means the period beginning on the 1st of January and ending on the 31st of December of the same year; provided, however,\nthat (a) the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the same year and (b) the last Calendar Year\nof the Term shall commence on January 1 of the Calendar Year in which this Agreement terminates or expires and end on the date of termination or\nexpiration of this Agreement.", "numbers_present": null, "definition_terms": ["Business Day", "Calendar Quarter", "Calendar Year"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::233b7278563e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::73881a877c72"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::73881a877c72", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.17-1.19", "section_title": "Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.17-1.19", "text": "ce on January 1 of the Calendar Year in which this Agreement terminates or expires and end on the date of termination or\nexpiration of this Agreement.\n\n1.17 \"Clinical Trial\" means a clinical trial, including any a Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, or Phase IV Clinical\nTrial, as the case may be, and as any such trial is defined by an applicable Regulatory Authority.\n\n1.18 \"Co-pay Program\" means a program to support patient access to a Product whereby the Product manufacturer makes payments to a Third\nParty equal to all or part of the difference between the price of Product prescribed to a patient and the amount such patient pays for such Product\nthrough such patient's insurance plan.\n\n1.19 \"Combination Product\" means any Product containing an Active Ingredient that is not an Antibody. Such Combination Product shall be\neither (a) priced and sold in a single package containing such multiple products or (b) packaged separately but sold together for a single price.", "numbers_present": null, "definition_terms": ["Clinical Trial", "Co-pay Program", "Combination Product"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::08ab13d25420", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ce156f16407f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ce156f16407f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.20", "section_title": "Commercialize", "clause_type": "Definition", "path": "1 ➞ 1.20", "text": "l be\neither (a) priced and sold in a single package containing such multiple products or (b) packaged separately but sold together for a single price.\n\n1.20 \"Commercialize\" means, with respect to the Product, to promote, market, distribute, sell (and offer for sale or contract to sell), import, export,\nor otherwise commercially exploit or provide product support for the Product and to conduct activities, other than Development or Manufacturing, in\npreparation for conducting the foregoing activities, including activities to produce commercialization support data and to secure and maintain market\naccess and reimbursement. \"Commercializing\" and \"Commercialization\" shall have correlative meanings. For the avoidance of doubt,\nCommercialization does not include Development and Manufacturing.\n\n3\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": ["Commercialize", "Commercializing", "Commercialization"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::73881a877c72", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3037f76420d3"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3037f76420d3", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.21", "section_title": "Commercially Reasonable Efforts", "clause_type": "Definition", "path": "1 ➞ 1.21", "text": "s. For the avoidance of doubt,\nCommercialization does not include Development and Manufacturing.\n\n3\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.21 \"Commercially Reasonable Efforts\" means, with respect to the efforts to be expended by a Party with respect to any objective (e.g.,\nDevelopment Activities and Commercialization hereunder), the level of efforts consistent with the efforts and resources [***] of similar market potential,\nat a similar stage in development or product lifecycle, taking into account the stage of development or product lifecycle of other of [***] product\ncandidates, safety and efficacy, product profile, cost of goods, the competitiveness of the marketplace, such company's patent position with respect to\nsuch product (including such company's ability to obtain or enforce, or have obtained or enforced, such patent rights), the Third Party patent landscape\nrelevant to the product, the regulatory structure involved, the likelihood of regulatory approval, the likelihood and extent of anticipated or actual\nprofitability of the applicable product, and other technical, legal, scientific and medical considerations. Without limiting the foregoing, Commercially\nReasonable Efforts requires, with respect to such obligations, that a Party: (i) promptly assign responsibility for such obligation to specific employee(s)\nwho are held accountable for progress and monitor such progress on an on-going basis, (ii) set objectives for carrying out such obligations, and (iii)\nallocate resources designed to advance progress with respect to such objectives.", "numbers_present": null, "definition_terms": ["Commercially Reasonable Efforts"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ce156f16407f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::255f22fc66c3"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::255f22fc66c3", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.22-1.23", "section_title": "Definitions", "clause_type": "Definition", "path": "1 ➞ 1.22-1.23", "text": "sis, (ii) set objectives for carrying out such obligations, and (iii)\nallocate resources designed to advance progress with respect to such objectives.\n\n1.22 \"Control\" or \"Controlled by\" means, with respect to any Know-How, Invention, Patent, technology, copyright, trademark or other intellectual\nproperty right, possession by a Party or its Affiliates (whether by ownership, license grant or other means) of the legal right to grant the right to access or\nuse, or to grant a license or a sublicense to, such Know-How, Invention, Patent, technology, copyright, trademark or other intellectual property right as\nprovided for herein without violating the proprietary rights of any Third Party or any terms of any agreement or other arrangement between such Party (or\nany of its Affiliates) and any Third Party.\n\n1.23 \"Cover\" or \"Covering\" means, with respect to a particular subject matter at issue and a relevant Patent, that the manufacture, use, sale, offer\nfor sale or importation of such subject matter would, but for the existence of this Agreement, infringe one or more claims in such Patents (or in the case of\na Patent application, would infringe if such application were to issue).", "numbers_present": null, "definition_terms": ["Control/Controlled by", "Cover/Covering"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3037f76420d3", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a1e7eb0a15df"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a1e7eb0a15df", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.24-1.25", "section_title": "Designated Officer; Develop", "clause_type": "Definition", "path": "1 ➞ 1.24; 1 ➞ 1.25", "text": "his Agreement, infringe one or more claims in such Patents (or in the case of\na Patent application, would infringe if such application were to issue).\n\n1.24 \"Designated Officer\" means, with respect to Xencor, the Chief Executive Officer of Xencor (or its designee), and, with respect to Aimmune,\nthe Chief Executive Officer of Aimmune (or its designee).\n\n1.25 \"Develop\" means to research, develop, analyze, test and conduct preclinical trials, Clinical Trials (including, for the avoidance of doubt, Phase\nIV Clinical Trials and any preclinical/clinical/CMC commitments following Regulatory Approval) and all other regulatory trials, for the Product, as well as\nany and all activities pertaining to manufacturing development, formulation development, medical affairs and lifecycle management, including new\nindications, new formulations and all other activities, including regulatory activities, related to securing and maintaining Regulatory Approval for the\nProduct, or otherwise characterizing or understanding the properties and uses of the Antibody or the Product. \"Developing\" and \"Development\" shall\nhave correlative meanings.\n\n4\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": ["Designated Officer", "Develop"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::255f22fc66c3", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::66a9d938353c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::66a9d938353c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.26-1.31", "section_title": "ARTICLE 1 Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.26-1.31", "text": "of the Antibody or the Product. \"Developing\" and \"Development\" shall\nhave correlative meanings.\n\n4\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.26 \"Development Activities\" means those Development activities undertaken by or on behalf of Aimmune with respect to the Product.\n\n1.27 \"Dollar\" or \"$\" means the legal tender of the United States of America.\n\n1.28 \"E.U. Major Countries\" means the United Kingdom, France, Germany, Italy, and Spain.\n\n1.29 \"FDA\" means the United States Food and Drug Administration and any successor Regulatory Authority having substantially the same\nfunction.\n\n1.30 \"FD&C Act\" means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder.\n\n1.31 \"First Commercial Sale\" means, with respect to a Product in any country, the first shipment of such Product to a Third Party in such country\nfor end use or consumption of such Product in such country after Regulatory Approval of such Product in such country or, if earlier, the invoicing of a\nThird Party for such shipment.", "numbers_present": null, "definition_terms": ["Development Activities", "Dollar", "$", "E.U. Major Countries", "FDA", "FD&C Act", "First Commercial Sale"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a1e7eb0a15df", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0477f5c340dd"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0477f5c340dd", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.32", "section_title": "Force Majeure", "clause_type": "Definition", "path": "1 ➞ 1.32", "text": "ch Product in such country after Regulatory Approval of such Product in such country or, if earlier, the invoicing of a\nThird Party for such shipment.\n\n1.32 \"Force Majeure\" means any circumstances whatsoever which are not within the reasonable control of the Party affected thereby, potentially\nincluding an act of God, war, act of terrorism, insurrection, riot, strike or labor dispute, shortage of materials, fire, explosion, flood, earthquake, government\nrequisition or allocation, breakdown of or damage to plant, equipment or facilities, interruption or delay in transportation, fuel supplies or electrical power,\nembargo, boycott, order or act of civil or military authority.", "numbers_present": null, "definition_terms": ["Force Majeure"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::66a9d938353c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1c9a970e9b72"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1c9a970e9b72", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.33", "section_title": "Generic Product", "clause_type": "Definition", "path": "1 ➞ 1.33", "text": "facilities, interruption or delay in transportation, fuel supplies or electrical power,\nembargo, boycott, order or act of civil or military authority.\n\n1.33 \"Generic Product\" means, with respect to a Product and on a country-by-country basis, a product that (a) is marketed for sale in such\ncountry [***], (b) contains or comprises an antibody with the [***], (c) is approved [***], and (d) such product, as and to the extent required, is\napproved through an abbreviated process based in reliance, at least in part, on the safety and efficacy data generated for the prior Regulatory Approval\nof such Product by Aimmune or an Aimmune Agreement Entity in such country (similar, with respect to the United States, to an Abbreviated New Drug\nApplications under Section 505(j) of the FD&C Act (21 USC 355(j))) or is approved as a \"Biosimilar Biologic Product\" under Title VII, Subtitle A Biologics\nPrice Competition and Innovation Act of 2009, Section 42 U.S.C. 262, Section 351 of the PHSA, or, outside the United States, in accordance with European\nDirective 2001/83/EC on the Community Code for medicinal products (Article 10(4) and Section 4, Part II of Annex I) and European Regulation\nEEC/2309/93 establishing the community procedures for the authorization and evaluation of medicinal products, each as amended, and together with all\nassociated guidance, and any counterparts thereof or equivalent process inside or outside of the United States or EU to the foregoing.", "numbers_present": null, "definition_terms": ["Generic Product"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0477f5c340dd", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2f1394c64eda"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2f1394c64eda", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.34", "section_title": "Good Clinical Practices (GCP)", "clause_type": "definition", "path": "1 ➞ 1.34", "text": "gether with all\nassociated guidance, and any counterparts thereof or equivalent process inside or outside of the United States or EU to the foregoing.\n\n1.34 \"Good Clinical Practices\" or \"GCP\" means all applicable Good Clinical Practice standards for the design, conduct, performance, monitoring,\nauditing, recording, analyses and reporting of clinical trials, including, as applicable, (i) as set forth in the International Conference on Harmonisation of\nTechnical Requirements for Registration of\n\n5\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": ["Good Clinical Practices", "GCP"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1c9a970e9b72", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d083e1361f0c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d083e1361f0c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.34", "section_title": "Good Clinical Practices (GCP)", "clause_type": "Definition", "path": "1 ➞ 1.34", "text": "h in the International Conference on Harmonisation of\nTechnical Requirements for Registration of\n\n5\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nPharmaceuticals for Human Use (\"ICH\") Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good\nclinical practice for trials on medicinal products, (ii) the Declaration of Helsinki (1964) as last amended at the 64th World Medical Association in October\n2013 and any further amendments or clarifications thereto, (iii) U.S. Code of Federal Regulations Title 21, Parts 50 (Protection of Human Subjects), 56\n(Institutional Review Boards) and 312 (Investigational New Drug Application), as may be amended from time to time, and (iv) the equivalent Applicable\nLaw in any relevant country, each as may be amended and applicable from time to time and in each case, that provide for, among other things, assurance\nthat the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.", "numbers_present": null, "definition_terms": ["Good Clinical Practices", "GCP"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2f1394c64eda", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cbb1f7c26e8f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cbb1f7c26e8f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.35–1.36", "section_title": "DEFINITIONS", "clause_type": "Definition", "path": "1 ➞ 1.35; 1 ➞ 1.36", "text": "urance\nthat the clinical data and reported results are credible and accurate and protect the rights, integrity, and confidentiality of trial subjects.\n\n1.35 \"Good Laboratory Practices\" or \"GLP\" means all applicable Good Laboratory Practice standards, including, as applicable, (i) as set forth in\nthe then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and (ii) the equivalent\nApplicable Law in any relevant country, each as may be amended and applicable from time to time.\n\n1.36 \"Good Manufacturing Practices\" or \"GMP\" means all applicable Good Manufacturing Practices including, as applicable, (i) the principles\ndetailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Sections 210, 211, 601 and 610, (ii) the principles detailed in the ICH Q7 guidelines,\nand (iii) the equivalent Applicable Law in any relevant country, each as may be amended and applicable from time to time.", "numbers_present": null, "definition_terms": ["Good Laboratory Practices (GLP)", "Good Manufacturing Practices (GMP)"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d083e1361f0c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::acca29d08a46"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::acca29d08a46", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.37", "section_title": "Government Official", "clause_type": "Definition", "path": "1 ➞ 1.37", "text": "ed in the ICH Q7 guidelines,\nand (iii) the equivalent Applicable Law in any relevant country, each as may be amended and applicable from time to time.\n\n1.37 \"Government Official\" means: (i) any official, officer, employee, representative, or anyone acting in an official capacity on behalf of: (a) any\ngovernment or any department or agency thereof; (b) any public international organization (such as the United Nations, the International Monetary\nFund, the International Red Cross, or the World Health Organization), or any department, agency, or institution thereof; or (c) any government-owned or\ncontrolled company, institution, or other entity, including a government-owned hospital or university; (ii) any political party or party official; and (iii) any\ncandidate for political office.", "numbers_present": null, "definition_terms": ["Government Official"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cbb1f7c26e8f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5bf7b1884567"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5bf7b1884567", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.37-1.40", "section_title": "Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.37 - 1.40", "text": "entity, including a government-owned hospital or university; (ii) any political party or party official; and (iii) any\ncandidate for political office.\n\n1.38 \"Governmental Authority\" means any United States federal, state or local, or any foreign, government or political subdivision thereof, or any\nmultinational organization or authority, or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative,\npolice, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or\narbitral body. For clarity, any Regulatory Authority shall be a Governmental Authority.\n\n1.39 \"IFRS\" means international financial reporting standards, or with respect to the U.S., as appropriate, generally accepted accounting principles\nin the U.S. (GAAP), in each case, consistently applied.\n\n1.40 \"IND\" means an investigational new drug application, clinical trial authorization or similar application or submission for approval to conduct\nhuman clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.\n\n6", "numbers_present": null, "definition_terms": ["Government Official", "Governmental Authority", "IFRS", "IND"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::acca29d08a46", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::db04f9608a7e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::db04f9608a7e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.41-1.43", "section_title": "ARTICLE 1 Definitions", "clause_type": "definition", "path": "1 ➞ 1.41; 1 ➞ 1.42; 1 ➞ 1.43", "text": "human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.\n\n6\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.41 \"Invented\" means the acts of (an) inventor(s), as determined in accordance with Applicable Law relating to inventorship set forth in the patent\nlaws of the United States (Title 35, United States Code), in first conceiving an Invention.\n\n1.42 \"Invention\" means any discovery or invention, whether or not patentable, conceived or otherwise made by either Party, or by both Parties, in\nexercising its rights or performing its obligations under this Agreement.\n\n1.43 \"Joint Invention\" means an Invention that is Invented jointly by an employee of, or Person under an obligation of assignment to, each of\nXencor and Aimmune or their respective Affiliates.", "numbers_present": null, "definition_terms": ["Invented", "Invention", "Joint Invention"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5bf7b1884567", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cd8b5825d2f8"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cd8b5825d2f8", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.44-1.46", "section_title": "Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.44-1.46", "text": "that is Invented jointly by an employee of, or Person under an obligation of assignment to, each of\nXencor and Aimmune or their respective Affiliates.\n\n1.44 \"Know-How\" means all technical, scientific, regulatory and other information, results, knowledge, techniques and data, in whatever form and\nwhether or not confidential, patented or patentable, including Inventions, invention disclosures, discoveries, plans, processes, practices, methods,\nknowledge, trade secrets, know-how, instructions, skill, experience, ideas, concepts, data (including biological, chemical, pharmacological, toxicological,\npharmaceutical, physical and analytical, safety, quality control, and preclinical and clinical data), formulae, formulations, compositions, specifications,\nmarketing, pricing, distribution, cost, sales and manufacturing data or descriptions. Know-How does not include any Patent claiming any of the\nforegoing.\n\n1.45 \"Licensed Field\" means the diagnosis, treatment or prevention of human diseases and conditions.\n\n1.46 \"Major Territory\" means the [***].", "numbers_present": null, "definition_terms": ["Know-How", "Licensed Field", "Major Territory"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::db04f9608a7e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7c588850994b"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7c588850994b", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.45-1.48", "section_title": "Definitions", "clause_type": "Definition clause", "path": "1 ➞ ARTICLE 1 ➞ 1.45-1.48", "text": "egoing.\n\n1.45 \"Licensed Field\" means the diagnosis, treatment or prevention of human diseases and conditions.\n\n1.46 \"Major Territory\" means the [***].\n\n1.47 \"Manufacture\" or \"Manufacturing\" or \"Manufactured\" means, with respect to the Antibody and Product, the receipt, handling and storage\nof Active Ingredients, drug substance or drug product, medical devices and other materials, the manufacturing, processing, Packaging and Labeling,\nholding (including storage), quality assurance and quality control testing (including release) of the Antibody and Product (other than quality assurance\nand quality control related to development of the manufacturing process, which activities shall be considered Development Activities) and shipping of\nthe Antibody and Product.\n\n1.48 \"Marketing Authorization Application\" or \"MAA\" means an application to the appropriate Regulatory Authority for approval to sell the\nProduct (but excluding Pricing Approval) in any particular country or regulatory jurisdiction, including a Biologics License Application as described in 21\nC.F.R. §601.2, as amended.", "numbers_present": null, "definition_terms": ["Licensed Field", "Major Territory", "Manufacture/Manufacturing/Manufactured", "Marketing Authorization Application", "MAA"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cd8b5825d2f8", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::41f9766c60e0"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::41f9766c60e0", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.49-1.50", "section_title": "Medical Science Liaison; Net Sales", "clause_type": "Definitions", "path": "1 ➞ 1.49; 1 ➞ 1.50", "text": "pproval) in any particular country or regulatory jurisdiction, including a Biologics License Application as described in 21\nC.F.R. §601.2, as amended.\n\n1.49 \"Medical Science Liaison\" means an individual who is employed by or on behalf of Aimmune or its Affiliates and who provides educational\nservices and other educational efforts directed towards the medical and/or scientific community.\n\n7\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.50 \"Net Sales\" means, with respect to a Product, the gross amount invoiced for sales of a Product by a Selling Party to Third Parties for end use,\nless the following deductions from such gross amounts to the extent attributable to such Product and to the extent actually incurred, allowed, accrued or\nspecifically allocated:\n\n(a) credits or allowances actually granted for damaged Product, returns or rejections of Product, price adjustments and billing errors;\n\n(b) governmental and other rebates (or equivalents thereof) granted to managed health care organizations, pharmacy benefit\nmanagers (or equivalents thereof), federal, state, provincial, local and other governments, their agencies and purchasers and reimbursers or to trade\ncustomers;", "numbers_present": null, "definition_terms": ["Medical Science Liaison", "Net Sales"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7c588850994b", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4ca8ae0490f5"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4ca8ae0490f5", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.50", "section_title": "Net Sales", "clause_type": "Definition", "path": "1 ➞ 1.50", "text": "or equivalents thereof), federal, state, provincial, local and other governments, their agencies and purchasers and reimbursers or to trade\ncustomers;\n\n(c) normal and customary trade, cash and quantity discounts, allowances and credits actually allowed or paid;\n\n(d) payments made as part of a Co-pay Program for a Product; and\n\n(e) sales taxes, VAT taxes and other taxes directly linked to the sales of Product;\n\nall as determined in accordance with IFRS on a basis consistent with the Selling Party's annual audited financial statements.\n\nNet Sales shall not include sales to Affiliates, Sublicensees or contractors engaged by Aimmune to Develop, Manufacture, or Commercialize the\nProduct, solely to the extent that such Affiliate, Sublicensees or contractor purchasing the Product resells such Product to a Third Party. However,\nsubsequent sales of Product by such Aimmune Affiliates, Sublicensees or contractors to a Third Party shall be included in the Net Sales when sold in the\nmarket for end-user use.", "numbers_present": null, "definition_terms": ["Net Sales"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::41f9766c60e0", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::73cd59a12993"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::73cd59a12993", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.50", "section_title": "Net Sales", "clause_type": "Definition", "path": "1 ➞ 1.50", "text": "by such Aimmune Affiliates, Sublicensees or contractors to a Third Party shall be included in the Net Sales when sold in the\nmarket for end-user use.\n\nFurther, any use, supply or provision of Product by Aimmune or Aimmune Agreement Entities at no cost or at a de minimis cost not to exceed\n[***] percent ([***]%) of the fully burdened cost thereof (i) in connection with patient assistance programs, (ii) for charitable or promotional purposes,\n(iii) for preclinical, clinical, regulatory or governmental purposes, or compassionate use or other similar programs, or (iv) for tests or studies reasonably\nnecessary to comply with any Applicable Law, regulation or request by a Regulatory Authority shall not be included in Net Sales of Product. Sale or\ntransfer of Products among the Aimmune Agreement Entities shall not result in any Net Sales, in which case Net Sales shall be based only on any\nsubsequent sales or dispositions to a Third Party; provided that the Aimmune Agreement Entity is not an end user.\n\nIn no event shall any particular amount identified above be deducted more than once in calculating Net Sales (i.e., no \"double counting\" of\nreductions).", "numbers_present": null, "definition_terms": ["Net Sales"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4ca8ae0490f5", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ebc346ecc85e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ebc346ecc85e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.50", "section_title": "Net Sales", "clause_type": "definition", "path": "1 ➞ 1.50", "text": "no event shall any particular amount identified above be deducted more than once in calculating Net Sales (i.e., no \"double counting\" of\nreductions).\n\nIn the event that Product is sold as part of a financial bundle with other products or included in financial package deals to customers and in such\ncase, the price of Product relevant for the calculation of Net Sales will be the average invoiced sales price of Product in the preceding Calendar Quarter\nsold separately less the average discount of all products sold as part of such bundle or package.\n\n8\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": ["Net Sales"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::73cd59a12993", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c22a97b49fa2"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c22a97b49fa2", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.50", "section_title": "Net Sales", "clause_type": "Definition/Calculation", "path": "1 ➞ 1.50", "text": "old separately less the average discount of all products sold as part of such bundle or package.\n\n8\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nFor Net Sales of a Combination Product, the Net Sales applicable to such Combination Product in a country will be determined by multiplying the\ntotal Net Sales of such combined product by the fraction A/(A+B), where A is the actual price of the Product that is included in such Combination\nProduct in the same dosage amount or quantities in the applicable country during the applicable quarter if sold separately, and B is the sum of the actual\nprices of all other products with which such Product is combined in such Combination Product, in the same dosage amount or quantities in the applicable\ncountry during the applicable quarter if sold separately. If A or B cannot be determined because values for such Product or such other products with\nwhich such Product is combined are not available separately in a particular country, then the Parties shall discuss an appropriate allocation for the fair\nmarket value of such Product and such other products with which such Product is combined to mutually determine Net Sales for the relevant transactions\nbased on an equitable method of determining the same that takes into account, in the applicable territory, the relative contribution of each Active\nIngredient, variations in dosage formulation and relative value to the end user of each Active Ingredient.", "numbers_present": null, "definition_terms": ["Net Sales (for a Combination Product — allocation method)", "A (actual price of the Product included in the Combination Product)", "B (sum of the actual prices of all other products in the Combination Product)"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ebc346ecc85e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f7cea27d789e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f7cea27d789e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.51-1.53", "section_title": "Definitions", "clause_type": "Definition clause", "path": "1 ➞ 1.51 ➞ 1.52 ➞ 1.53", "text": "y, the relative contribution of each Active\nIngredient, variations in dosage formulation and relative value to the end user of each Active Ingredient.\n\n1.51 \"Patents\" means any and all (i) issued patents, (ii) pending patent applications, including all provisional applications, substitutions,\ncontinuations, continuations-in-part, divisionals and renewals, and all patents granted thereon, (iii) patents-of-addition, reissues, and reexaminations,\nincluding patent term adjustments, Patent Term Extensions, supplementary protection certificates or the equivalent thereof, (iv) inventor's certificates, (v)\nother forms of government-issued rights substantially similar to any of the foregoing, and (vi) United States and foreign counterparts of any of the\nforegoing.\n\n1.52 \"Patent Term Extension\" means any term extensions, supplementary protection certificates and equivalents thereof offering Patent protection\nbeyond the initial term with respect to any issued Patents.\n\n1.53 \"Person\" means any individual, firm, corporation, partnership, limited liability company, trust, business trust, joint venture, Governmental\nAuthority, association or other entity.", "numbers_present": null, "definition_terms": ["Patents", "Patent Term Extension", "Person"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c22a97b49fa2", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c79238516418"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c79238516418", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.54-1.55", "section_title": "Definitions", "clause_type": "Definition", "path": "1 ➞ 1.54-1.55", "text": "firm, corporation, partnership, limited liability company, trust, business trust, joint venture, Governmental\nAuthority, association or other entity.\n\n1.54 \"Phase I Clinical Trial\" means a study in humans which provides for the first introduction into humans of a product, conducted in normal\nvolunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21\nCFR §312.21(a) or comparable regulations in any country or jurisdiction outside the U.S., and any amended or successor regulations.\n\n1.55 \"Phase II Clinical Trial\" means a study in humans for which a primary endpoint is a preliminary determination of efficacy in patients with the\ndisease being studied, as more fully defined in 21 CFR §312.21(b) or comparable regulations in any country or jurisdiction outside the U.S., and any\namended or successor regulations. Phase II Clinical Trial shall include in all cases any phase I/II clinical trial.", "numbers_present": null, "definition_terms": ["Phase I Clinical Trial", "Phase II Clinical Trial"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f7cea27d789e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::88a01862400e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::88a01862400e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.56", "section_title": "Phase III Clinical Trial", "clause_type": "Definition", "path": "1 ➞ 1.56", "text": "sdiction outside the U.S., and any\namended or successor regulations. Phase II Clinical Trial shall include in all cases any phase I/II clinical trial.\n\n1.56 \"Phase III Clinical Trial\" means a controlled study in humans that is performed after preliminary evidence suggesting effectiveness of a\nproduct has been obtained, and is intended to demonstrate or confirm the therapeutic benefit of such product and to gather the additional information\nabout effectiveness and safety that is needed to evaluate the overall\n\n9\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nbenefit-risk relationship of such product and to provide support for filing for Regulatory Approval and for such product's labeling and summary of\nproduct characteristics, as more fully defined in 21 CFR §312.21(c) or comparable regulations in any country or jurisdiction outside the U.S., and any\namended or successor regulations. For the sake of clarity, with respect to what is commonly called a phase II/III study, the Phase III Clinical Trial\ndefinition is met upon [***], as further defined in Federal Regulation 21 C.F.R. §312.21(c) and its foreign equivalents.", "numbers_present": null, "definition_terms": ["Phase III Clinical Trial"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c79238516418", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d8196ec7fa13"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d8196ec7fa13", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.56-1.58", "section_title": "Phase IV Clinical Trial; Pre-Marketing", "clause_type": "Definitions", "path": "1 ➞ 1.56-1.58", "text": "the Phase III Clinical Trial\ndefinition is met upon [***], as further defined in Federal Regulation 21 C.F.R. §312.21(c) and its foreign equivalents.\n\n1.57 \"Phase IV Clinical Trial\" means a clinical study in humans initiated in a country after receipt of Regulatory Approval for a biopharmaceutical\nproduct in such country, usually within or in support of the approved product labeling.\n\n1.58 \"Pre-Marketing\" means all sales and marketing activities undertaken prior to and in preparation for the launch of the Product. Pre-Marketing\nshall include market research, key opinion leader development, advisory boards, medical education, disease-related public relations, health care economic\nstudies, sales force training and other pre-launch activities prior to the First Commercial Sale of the Product in a given country or other regulatory\njurisdiction.", "numbers_present": null, "definition_terms": ["Phase III Clinical Trial", "Phase IV Clinical Trial", "Pre-Marketing"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::88a01862400e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a7a130463d7e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a7a130463d7e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.59-1.60", "section_title": "Definitions", "clause_type": "Definition", "path": "1 ➞ 1.59-1.60", "text": "force training and other pre-launch activities prior to the First Commercial Sale of the Product in a given country or other regulatory\njurisdiction.\n\n1.59 \"Pricing Approval\" means, with respect to any country where a Governmental Authority authorizes reimbursement or access, or approves or\ndetermines pricing, for biopharmaceutical products, receipt (or, if required to make such authorization, approval of determination effective publication) of\nsuch reimbursement or access authorization or pricing approval or determination (as the case may be).\n\n1.60 \"Product\" means any biopharmaceutical product containing or comprising (i) the Antibody; and (ii) any Variant of the Antibody that: (a)\n[***] and (b) [***]; provided, that a Product does not include any Active Ingredient that is [***], other than the Antibody as described in the foregoing\nsubsections (i) and (ii). For clarity, Product excludes: (1) [***]; (2) [***]; (3) [***]; (4) [***]; (5) [***]; or (6) [***].", "numbers_present": null, "definition_terms": ["Pricing Approval", "Product"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d8196ec7fa13", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::fdf9beff32c5"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::fdf9beff32c5", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.61–1.63", "section_title": "Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.61 ➞ 1.62 ➞ 1.63", "text": "scribed in the foregoing\nsubsections (i) and (ii). For clarity, Product excludes: (1) [***]; (2) [***]; (3) [***]; (4) [***]; (5) [***]; or (6) [***].\n\n1.61 \"Product Approval\" means the approval by a Governmental Authority necessary for the marketing and sale of the Product in a given country\nor regulatory jurisdiction, which may include the approval of an MAA (but shall not include any Pricing Approvals).\n\n1.62 \"Product Complaint\" means any written, verbal or electronic expression of dissatisfaction regarding any Product sold by or on behalf of a\nSelling Party, including reports of actual or suspected product tampering, contamination, mislabeling or inclusion of improper ingredients.\n\n1.63 \"Promotional Materials\" means all written, printed, video or graphic advertising, promotional, educational and communication materials\n(other than the Product labels and package inserts) for marketing, advertising and promoting of the Product, for use (i) by a Sales Representative or a\nMedical Science Liaison or (ii) in advertisements, web sites or direct mail pieces.\n\n10\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": ["Product Approval", "Product Complaint", "Promotional Materials"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a7a130463d7e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1875bf13802d"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1875bf13802d", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.64-1.65", "section_title": "Definitions — Regulatory Approval; Regulatory Authority", "clause_type": "Definition", "path": "1 ➞ 1.64; 1 ➞ 1.65", "text": "tative or a\nMedical Science Liaison or (ii) in advertisements, web sites or direct mail pieces.\n\n10\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.64 \"Regulatory Approval\" means, with respect to any biopharmaceutical product in any regulatory jurisdiction for a given indication, approval\nfrom the applicable Regulatory Authority permitting the manufacture, sale, distribution or Commercialization of such biopharmaceutical product in such\nregulatory jurisdiction for such indication in accordance with Applicable Law, including any Pricing Approvals.\n\n1.65 \"Regulatory Authority\" means, in a particular country or regulatory jurisdiction, any applicable Governmental Authority involved in granting\nRegulatory Approval and/or, to the extent required in such country or regulatory jurisdiction, governmental Pricing Approval of a biopharmaceutical\nproduct in such country or regulatory jurisdiction.", "numbers_present": null, "definition_terms": ["Regulatory Approval", "Regulatory Authority"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::fdf9beff32c5", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9568a7abfcd1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9568a7abfcd1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.66–1.67", "section_title": "Definitions", "clause_type": "Definition", "path": "1 ➞ 1.66 / 1 ➞ 1.67", "text": "d in such country or regulatory jurisdiction, governmental Pricing Approval of a biopharmaceutical\nproduct in such country or regulatory jurisdiction.\n\n1.66 \"Regulatory Data\" means any and all research data, pharmacology data, chemistry, manufacturing and control data, preclinical data, clinical\ndata and all other documentation submitted, or required to be submitted, to Regulatory Authorities in association with regulatory filings for the Product\n(including any applicable Drug Master Files, Chemistry, Manufacturing and Control (\"CMC\") data, or similar documentation).\n\n1.67 \"Regulatory Materials\" means regulatory applications, submissions, notifications, communications, correspondence, meeting minutes,\nregistrations, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority that are necessary in\norder to Develop, Manufacture, obtain marketing authorization, market, sell, distribute or otherwise Commercialize the Product in a particular country or\nregulatory jurisdiction. Regulatory Materials include INDs, MAAs, presentations, responses, and applications for Product Approvals.", "numbers_present": null, "definition_terms": ["Regulatory Data", "Regulatory Materials"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1875bf13802d", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7b34f11f512f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7b34f11f512f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.68–1.73", "section_title": "Article 1 Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.68–1.73", "text": "ticular country or\nregulatory jurisdiction. Regulatory Materials include INDs, MAAs, presentations, responses, and applications for Product Approvals.\n\n1.68 \"Royalty Term\" means, with respect to a Product on a country-by-country basis, the period of time beginning on the First Commercial Sale of\nsuch Product in such country and ending the later of (i) the expiration of the last to expire Valid Claim Covering the Antibody or Product in such country,\nor (ii) [***] ([***]) years from the First Commercial Sale of such Product in such country. Notwithstanding subsections (i) and (ii) above, the Royalty\nTerm for a Product in a country shall not [***].\n\n1.69 \"Sales Representative\" means an individual who is employed by a Party and who performs details and other promotional efforts with respect\nto the Product.\n\n1.70 \"Selling Party\" means Aimmune or another Aimmune Agreement Entity.\n\n1.71 \"Third Party\" means any Person other than Xencor, Aimmune or their respective Affiliates.\n\n1.72 \"United States\" or \"U.S.\" means the United States of America and its possessions and territories.\n\n1.73 \"Upstream Agreement\" means that certain [***] Agreement by and between Xencor and the [***] dated [***].", "numbers_present": null, "definition_terms": ["Royalty Term", "Sales Representative", "Selling Party", "Third Party", "United States or U.S.", "Upstream Agreement"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9568a7abfcd1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::13fe1f858286"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::13fe1f858286", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.73-1.76", "section_title": "Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.73 ➞ 1.74 ➞ 1.75 ➞ 1.76", "text": "ca and its possessions and territories.\n\n1.73 \"Upstream Agreement\" means that certain [***] Agreement by and between Xencor and the [***] dated [***].\n\n11\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.74 \"Valid Claim\" means, with respect to a particular country, (i) a claim of [***] that (a) has not been specifically held permanently revoked,\nunenforceable or invalid by a decision of a court or other Governmental Authority of competent jurisdiction, which decision is unappealed or\nunappealable within the time allowed for appeal, and (b) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or\nunenforceable through reissue, disclaimer or otherwise, or (ii) a bona fide claim of a pending patent application [***] that has not been (a) cancelled,\nwithdrawn or abandoned without being re-filed in another application in the applicable jurisdiction, or (b) finally rejected by an administrative agency\naction from which no appeal can be taken or that has not been appealed within the time allowed for appeal.\n\n1.75 \"Variant\" means [***].\n\n1.76 \"Xencor [***]\" means a [***].", "numbers_present": null, "definition_terms": ["Upstream Agreement", "Valid Claim", "Variant", "Xencor [***]"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7b34f11f512f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8e5401712930"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8e5401712930", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.75-1.78", "section_title": "Article 1: Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.75; 1 ➞ 1.76; 1 ➞ 1.77; 1 ➞ 1.78", "text": "appeal can be taken or that has not been appealed within the time allowed for appeal.\n\n1.75 \"Variant\" means [***].\n\n1.76 \"Xencor [***]\" means a [***].\n\n1.77 \"Xencor Invention\" means an Invention that is Invented solely or jointly with a Third Party, by or on behalf of Xencor or its Affiliates.\n\n1.78 \"Xencor Know-How\" means any and all Know-How, whether or not patented or patentable, (i) to the extent Controlled by Xencor or its\nAffiliates as of the Effective Date, or, if transferred to Aimmune thereafter during the Term of this Agreement, and that is necessary in connection with the\nDevelopment, Manufacture, Commercialization or other use of the Antibody or Product or (ii) constituting a Xencor Invention. Notwithstanding the\nforegoing, in all cases, Xencor Know-How does not include (a) [***], (b) [***], (c) [***], (d) [***], (e) [***], or (f) [***].", "numbers_present": null, "definition_terms": ["Variant", "Xencor [***]", "Xencor Invention", "Xencor Know-How"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::13fe1f858286", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e2c4ad0df1d3"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e2c4ad0df1d3", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.79-1.80", "section_title": "Xencor General Patent; Xencor Patent", "clause_type": "Definitions", "path": "1 ➞ 1.79; 1 ➞ 1.80", "text": "on. Notwithstanding the\nforegoing, in all cases, Xencor Know-How does not include (a) [***], (b) [***], (c) [***], (d) [***], (e) [***], or (f) [***].\n\n1.79 \"Xencor General Patent\" means (i) the Patents identified on Schedule 1.79, including patents issuing from any patent application set forth on\nSchedule 1.79, (ii) with respect to such Patents set forth on Schedule 1.79, all provisional applications, substitutions, continuations, continuations-in-part,\ndivisionals, renewals, patents-of-addition, reissues, reexaminations and extensions, (iii) all international and domestic counterparts of any of the\nforegoing, and (iv) any other Patents Controlled by Xencor that claim inventions necessary for the Development, Manufacture, Commercialization or\nother use of the Antibody or Product as the Antibody and Product exist as of the Effective Date.\n\n1.80 \"Xencor Patent\" means Xencor General Patents and Xencor Product Specific Patents.", "numbers_present": null, "definition_terms": ["Xencor General Patent", "Xencor Patent"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8e5401712930", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1ea17c044b16"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1ea17c044b16", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.80-1.83", "section_title": "Additional Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.80 ➞ 1.81 ➞ 1.82 ➞ 1.83", "text": "ct as the Antibody and Product exist as of the Effective Date.\n\n1.80 \"Xencor Patent\" means Xencor General Patents and Xencor Product Specific Patents.\n\n1.81 \"Xencor Product Specific Patent\" means (i) the Patents identified on Schedule 1.81, including patents issuing from any patent application set\nforth on Schedule 1.81, (ii) with respect to all Patents set forth on Schedule 1.81, all provisional applications, substitutions, continuations, continuationsin-part, divisionals, renewals, patents-of-addition, reissues, reexaminations and extensions, (iii) any [***], and (iv) all international and domestic\ncounterparts of any of the foregoing.\n\n1.82 \"Xencor Technology\" means Xencor Know-How and Xencor Patents.\n\n12\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n1.83 Additional Definitions. The following terms have the meanings set forth in the corresponding Sections of this Agreement:\n\nTerm\nSection\n\"Agreement\"\nPreamble\n\"Bankrupt Party\"\n14.7\n\"Breaching Party\"\n13.2\n[***]\n1.73\n\"Claim\"\n11.1\n\"CMC\"\n1.66\n\"Commercialization Data\"\n5.5\n\"Confidential Information\"\n12.1.1\n\"Controlling Party\"\n9.4.1(a)\n\"Court\"\n15.13.3\n\"Dispute\"\n15.1\n\"Effective Date\"\nPreamble\n\"ICH\"\n1.34", "numbers_present": null, "definition_terms": ["Xencor Patent", "Xencor Product Specific Patent", "Xencor Technology", "Agreement", "Bankrupt Party", "Breaching Party", "[***]", "Claim", "CMC", "Commercialization Data", "Confidential Information", "Controlling Party", "Court", "Dispute", "Effective Date", "ICH", "Indemnified Party", "Indemnifying Party", "Infringement Claim", "Joint Collaboration Patents", "Aimmune", "Aimmune Collaboration Patents", "Xencor", "Xencor Collaboration Patents", "Losses", "Packaging and Labeling", "Party", "Parties", "Product Trade Dress", "Product Trademark", "Recovery", "Shares", "Stock Issuance Agreement", "Sublicensee", "Term", "Third Party Patent", "Upfront Payment", "VAT"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e2c4ad0df1d3", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f6879dd81f6d"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f6879dd81f6d", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "1.83", "section_title": "Additional Definitions", "clause_type": "definitions", "path": "1 ➞ 1.83", "text": "alization Data\"\n5.5\n\"Confidential Information\"\n12.1.1\n\"Controlling Party\"\n9.4.1(a)\n\"Court\"\n15.13.3\n\"Dispute\"\n15.1\n\"Effective Date\"\nPreamble\n\"ICH\"\n1.34\n\nTerm\nSection\n\"Indemnified Party\"\n11.3.1\n\"Indemnifying Party\"\n11.3.1\n\"Infringement Claim\"\n9.4.1\n\"Joint Collaboration Patents\"\n9.1.1\n\"Aimmune\"\nPreamble\n\"Aimmune Collaboration\nPatents\"\n\n9.1.1\n\n\"Xencor\"\nPreamble\n\"Xencor Collaboration Patents\"\n9.1.1\n\"Losses\"\n11.1\n\"Packaging and Labeling\"\n6.2\n\nTerm\nSection\n\"Party\" or \"Parties\"\nPreamble\n\"Product Trade Dress\"\n5.4.1\n\"Product Trademark\"\n5.4.1\n\"Recovery\"\n9.4.2(c)(iv)\n\"Shares\"\n7.1\n\"Stock Issuance Agreement\"\n7.1\n\"Sublicensee\"\n2.3.2\n\"Term\"\n13.1\n\"Third Party Patent\"\n7.3.2(b)\n\"Upfront Payment\"\n7.1\n\"VAT\"\n8.3.3\n\nARTICLE 2\n\nLICENSES", "numbers_present": null, "definition_terms": ["Commercialization Data", "Confidential Information", "Controlling Party", "Court", "Dispute", "Effective Date", "ICH", "Indemnified Party", "Indemnifying Party", "Infringement Claim", "Joint Collaboration Patents", "Aimmune", "Aimmune Collaboration Patents", "Xencor", "Xencor Collaboration Patents", "Losses", "Packaging and Labeling", "Party", "Parties", "Product Trade Dress", "Product Trademark", "Recovery", "Shares", "Stock Issuance Agreement", "Sublicensee", "Term", "Third Party Patent", "Upfront Payment", "VAT"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1ea17c044b16", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1f74ba10876b"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1f74ba10876b", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.1", "section_title": "Grant to Aimmune", "clause_type": "License grant", "path": "2 ➞ 2.1", "text": ".1\n\"Stock Issuance Agreement\"\n7.1\n\"Sublicensee\"\n2.3.2\n\"Term\"\n13.1\n\"Third Party Patent\"\n7.3.2(b)\n\"Upfront Payment\"\n7.1\n\"VAT\"\n8.3.3\n\nARTICLE 2\n\nLICENSES\n\n2.1 Grant to Aimmune. Subject to the terms and conditions of this Agreement, Xencor hereby grants to Aimmune during the Term an exclusive,\nworldwide, payment-bearing license under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents, and a non-exclusive,\npayment bearing license under and with respect to Xencor Know-How, in each case, with the right to sublicense solely in accordance with Section 2.3.2,\nsolely to Develop, Manufacture and Commercialize the Product in and for the Licensed Field; provided that notwithstanding the foregoing, Xencor shall\nretain the right under and with respect to Xencor Patents and Xencor's interest in Joint Collaboration Patents to the extent necessary to perform its\nobligations under this Agreement.\n\n2.2 Additional Licensing Provisions.", "numbers_present": null, "definition_terms": ["Stock Issuance Agreement", "Sublicensee", "Term", "Third Party Patent", "Upfront Payment", "VAT"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f6879dd81f6d", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d79895a81ae4"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d79895a81ae4", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.2", "section_title": "Additional Licensing Provisions", "clause_type": "Licensing provisions (negative covenant; no implied licenses)", "path": "2 ➞ 2.2 ➞ 2.2.1 / 2.2.2", "text": "interest in Joint Collaboration Patents to the extent necessary to perform its\nobligations under this Agreement.\n\n2.2 Additional Licensing Provisions.\n\n2.2.1 Negative Covenant. Aimmune covenants that it will not use or practice any of Xencor's rights to and under the Xencor Patents,\nXencor Know-How or other intellectual property rights licensed (or sublicensed, as applicable) to it under this ARTICLE 2, except for the purposes\nexpressly permitted in the applicable license grant. Aimmune covenants that it will not research or develop (including Develop) the Antibody itself,\nincluding not developing any modification, variant, fragment, progeny or derivatives of such Antibody, in each case, in a way that would produce a\nmolecule that is neither the Antibody nor a molecule that falls within the definition of a Product.\n\n13\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n2.2.2 No Implied Licenses; Retained Rights. Except as explicitly set forth in this Agreement, Xencor does not grant any license, express or\nimplied, under its intellectual property rights to Aimmune, whether by implication, estoppel or otherwise.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1f74ba10876b", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5fa0846fde55"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5fa0846fde55", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.2.3", "section_title": "Upstream Agreement", "clause_type": "Acknowledgement / Compliance (Upstream sublicense obligations)", "path": "2 ➞ 2.2 ➞ 2.2.3", "text": "ncor does not grant any license, express or\nimplied, under its intellectual property rights to Aimmune, whether by implication, estoppel or otherwise.\n\n2.2.3 Upstream Agreement. Aimmune acknowledges, understands and agrees that (i) the Xencor Know-How licensed to Aimmune\npursuant to Section 2.1 includes certain Know-How licensed to Xencor pursuant to the Upstream Agreement, (ii) the license to such Xencor Know-How\nconstitutes a sublicense under the Upstream Agreement, (iii) Aimmune's rights to such Xencor Know-How are subject and subordinate to the terms and\nconditions of the Upstream Agreement, (iv) Aimmune will comply with the Upstream Agreement, including undertaking such activities as Xencor\nreasonably requests to so comply, (v) [***] is responsible for any and all payments due under the Upstream Agreement (following the Effective Date) in\nconnection with Developing, Manufacturing and Commercializing the Product by or on behalf of Aimmune (including by or on behalf of its Affiliates or\nsublicensees), and (vi) Aimmune received a copy of the Upstream Agreement prior to the Effective Date.\n\n2.3 Performance by Affiliates and Sublicensees.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d79895a81ae4", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7703b8a973f1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7703b8a973f1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.3.1", "section_title": "Performance by Affiliates", "clause_type": "Performance / Responsibility clause (affiliate performance and guarantor obligations)", "path": "2 ➞ 2.3 ➞ 2.3.1", "text": "ublicensees), and (vi) Aimmune received a copy of the Upstream Agreement prior to the Effective Date.\n\n2.3 Performance by Affiliates and Sublicensees.\n\n2.3.1 Performance by Affiliates. The Parties recognize that each may perform some or all of its obligations under this Agreement through\nAffiliates; provided, however, that each Party shall remain responsible for and be guarantor of the performance by its Affiliates and shall cause its\nAffiliates to comply with the provisions of this Agreement in connection with such performance. Each Party hereby expressly waives any requirement\nthat the other Party exhausts any right, power or remedy, or proceed against an Affiliate, for any obligation or performance hereunder prior to proceeding\ndirectly against such Party. Wherever in this Agreement the Parties delegate responsibility to Affiliates, the Parties agree that such entities may not make\ndecisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5fa0846fde55", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9e17072a0398"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9e17072a0398", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.3.2", "section_title": "Sublicensees", "clause_type": "Sublicensing obligations / Performance by Affiliates and Sublicensees", "path": "2 ➞ 2.3 ➞ 2.3.2", "text": "that such entities may not make\ndecisions inconsistent with this Agreement, amend the terms of this Agreement or act contrary to its terms in any way.\n\n2.3.2 Sublicensees. Aimmune shall [***] the right (but not the obligation) to sublicense the rights granted to it under Section 2.1 to its\nAffiliates or Third Parties (each, a \"Sublicensee\"); provided, however, that Aimmune shall remain responsible for the performance by any of its direct and\nindirect Sublicensees and shall cause its direct and indirect Sublicensees to comply with the applicable provisions of this Agreement in connection with\nsuch performance. Without limiting the foregoing, Aimmune shall cause its direct and indirect Sublicensees to accept in writing all applicable terms and\nconditions of this Agreement, including the reporting, audit, inspection and confidentiality provisions hereunder and Sections 2.2.1 and 2.4. For the\navoidance of doubt, (a) Aimmune will remain directly responsible for all amounts owed to Xencor under this Agreement, and (b) Aimmune shall cause\neach Sublicensee (including each tier of Sublicensee) to be subject to the negative and restrictive covenants set forth in Sections 2.2.1 and 2.4,\nrespectively. Aimmune hereby expressly waives any requirement that Xencor exhaust any right, power or remedy, or proceed against a subcontractor, for\nany obligation or performance hereunder prior to proceeding directly against Aimmune.", "numbers_present": null, "definition_terms": ["Sublicensee"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7703b8a973f1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::152eb320e72c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::152eb320e72c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.4", "section_title": "Restrictive Covenants", "clause_type": "Restrictive covenant", "path": "2 ➞ 2.4", "text": "right, power or remedy, or proceed against a subcontractor, for\nany obligation or performance hereunder prior to proceeding directly against Aimmune.\n\n2.4 Restrictive Covenants. Aimmune hereby covenants and agrees that it shall not (and shall cause the other Aimmune Agreement Entities\nnot to), either directly or indirectly,\n\n14\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9e17072a0398", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::37e69b673549"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::37e69b673549", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.4", "section_title": "Restrictive Covenants", "clause_type": "Restrictive covenant", "path": "2 ➞ 2.4", "text": "t (and shall cause the other Aimmune Agreement Entities\nnot to), either directly or indirectly,\n\n14\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nDevelop, Manufacture, or Commercialize the Product for use outside the Licensed Field. Furthermore, Xencor hereby covenants and agrees that it shall\nnot (and shall cause its Affiliates not to), either directly or through granting a license or other right to, or otherwise facilitating, a Third Party to (a)\nDevelop, Manufacture or Commercialize the Antibody or the Product during the Term, (b) commence any [***] of any [***] that is not the Antibody or a\nProduct and that [***] for use in the Licensed Field, prior to the [***] ([***]th) anniversary of the Effective Date, or (c) Develop, Manufacture or\nCommercialize any [***] that is not the Antibody or a Product and that [***] for use in the Aimmune Field during the Term. It is the desire and intent of\nthe Parties that the restrictive covenants contained in this Section 2.4 be enforced to the fullest extent permissible under Applicable Laws and public\npolicies applied in each jurisdiction in which enforcement is sought. Xencor and Aimmune believe that the restrictive covenants in this Section 2.4 are\nvalid and enforceable. However, if any restrictive covenant should for any reason become or be declared by a competent court or competition authority to\nbe invalid or unenforceable in any jurisdiction, such restrictive covenant shall be deemed to have been amended to the extent necessary in order that\nsuch provision be valid and enforceable, such amendment shall apply only with respect to the operation of such provision of this Section 2.4 in the\nparticular jurisdiction in which such declaration is made. Further, both Parties agree that [***] of this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::152eb320e72c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0a2c4b258dcf"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0a2c4b258dcf", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.5", "section_title": "Progress Updates", "clause_type": "Reporting / Progress Update Obligation", "path": "2 ➞ 2.5", "text": "vision of this Section 2.4 in the\nparticular jurisdiction in which such declaration is made. Further, both Parties agree that [***] of this Agreement.\n\n2.5 Progress Updates. Aimmune shall keep Xencor informed as to its progress and activities relating to the Development, Manufacture and\nCommercialization of the Product on [***] basis (i.e., every [***] ([***]) months), including by providing updates on the status of studies necessary for\nobtaining Regulatory Approval with respect to the Product, regulatory matters and meetings with Regulatory Authorities with respect to the Product, and\nCommercialization activities commencing no later than [***] ([***]) year prior to the date on which Aimmune estimates the First Commercial Sale of\nProduct will occur. Additionally, to the extent applicable, such updates shall include summaries of Aimmune's Development plans for the Product for the\nensuing [***] ([***]) year time period. Any information disclosed under this Section 2.5 shall be treated as Confidential Information as defined in Section\n12.1.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::37e69b673549", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::139a2047d1ab"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::139a2047d1ab", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.6", "section_title": "Upstream Agreement", "clause_type": "Covenant", "path": "2 ➞ 2.6", "text": "*] ([***]) year time period. Any information disclosed under this Section 2.5 shall be treated as Confidential Information as defined in Section\n12.1.\n\n2.6 Upstream Agreement. During the Term, neither Xencor nor any of its Affiliates shall (a) encumber any GPEx Technology, as defined in the\nUpstream Agreement, to the extent included within the Xencor Technology, or commit any act or permit the occurrence of any omission that would cause\nthe breach or termination of the Upstream Agreement, or otherwise knowingly take actions or permit omissions that would adversely affect the rights\ngranted to Aimmune hereunder with respect to the Xencor Patents and Xencor Know-How, or (b) without Aimmune's prior written consent, amend or\notherwise modify or permit to be amended or modified, the Upstream Agreement in any respect that would adversely affect Aimmune's rights with respect\nto, the Antibody or Products. Xencor shall promptly notify Aimmune upon Xencor's becoming aware of any alleged, threatened, or actual breach of the\nUpstream Agreement by either Party and shall not take any action that would reasonably give rise to the right of the counterparty to terminate the\nUpstream Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0a2c4b258dcf", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8cc351f9e457"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8cc351f9e457", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.7", "section_title": "Technology Transfer", "clause_type": "Obligation (Technology transfer / Commercially Reasonable Efforts)", "path": "2 ➞ 2.7", "text": "nt by either Party and shall not take any action that would reasonably give rise to the right of the counterparty to terminate the\nUpstream Agreement.\n\n2.7 Technology Transfer. Xencor shall use Commercially Reasonable Efforts to transfer, and Aimmune shall use Commercially Reasonable Efforts\nto receive, the Xencor Know-How, Regulatory Materials, and Regulatory Data, in each case, as identified on Schedule 2.7 to\n\n15\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::139a2047d1ab", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::97e4e0ead4fa"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::97e4e0ead4fa", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "2.7", "section_title": "Technology Transfer", "clause_type": "Technology transfer obligations", "path": "2 ➞ 2.7", "text": "-How, Regulatory Materials, and Regulatory Data, in each case, as identified on Schedule 2.7 to\n\n15\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\npermit and enable Aimmune or its Affiliates to Develop and Manufacture the Product pursuant to the terms of this Agreement no later than [***] ([***])\nBusiness Days after the Effective Date. The technology transfer under this Section 2.7 shall occur in an orderly fashion and in a manner reasonably\nagreed by the Parties. The implementation and transfer of information pursuant hereto shall be conducted through electronic, email and teleconference\nconsultation between the Parties. [***] shall be responsible for any Development or Manufacturing related out-of-pocket costs associated with such\ntechnology transfer, including lab runs, pilot scale testing and demo batches. Xencor will allocate adequate appropriately qualified representatives to\nenable Aimmune to practice and understand the Xencor Know-How, Regulatory Materials, and Regulatory Data, including in connection with the\ntransition of Manufacturing responsibility to Aimmune, Xencor's obligations under this Section 2.7 shall not exceed an aggregate of [***] ([***]) fulltime equivalent hours unless the Parties otherwise agree in writing [***].", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8cc351f9e457", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5287182ac4e8"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5287182ac4e8", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "3.1", "section_title": "Overview of Development", "clause_type": "Development obligations", "path": "3 ➞ 3.1", "text": "s under this Section 2.7 shall not exceed an aggregate of [***] ([***]) fulltime equivalent hours unless the Parties otherwise agree in writing [***].\n\nARTICLE 3\nDEVELOPMENT\n\n3.1 Overview of Development. Subject to the terms and conditions of this Agreement, Aimmune shall be responsible for the Development of the\nProduct as set forth herein. Aimmune, itself or with or through its Affiliates and Sublicensees, shall use Commercially Reasonable Efforts to perform the\nDevelopment Activities for the Product to (i) achieve the development milestones set forth in Section 7.2, and (ii) obtain Regulatory Approval for the\nProduct.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::97e4e0ead4fa", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cea8bd608d75"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cea8bd608d75", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "3.2", "section_title": "Compliance", "clause_type": "Compliance covenant", "path": "3 ➞ 3.2", "text": "nt Activities for the Product to (i) achieve the development milestones set forth in Section 7.2, and (ii) obtain Regulatory Approval for the\nProduct.\n\n3.2 Compliance. Aimmune shall conduct the Development Activities in accordance with sound and ethical business and scientific practices, and in\ncompliance with all Applicable Law, including GCPs and GLPs, and also including all applicable data privacy and data protection laws. In addition,\nAimmune shall not use in any capacity, in connection with its Development (or Commercialization) of the Product hereunder, any Person who has been\ndebarred pursuant to Section 306 of the FD&C Act (or similar Applicable Law outside of the U.S.), or who is the subject of a conviction described in such\nsection, and Aimmune shall inform Xencor in writing promptly if it or any Person who is performing services for Aimmune hereunder is debarred or is the\nsubject of a conviction described in Section 306 (or similar Applicable Law outside of the U.S.), or if any action, suit, claim, investigation or legal\nadministrative proceeding is pending or, to Aimmune's knowledge, is threatened, relating to the debarment of Aimmune or any Person used in any\ncapacity by Aimmune in connection with its Development (or Commercialization) of the Product hereunder. Xencor shall not use in any capacity in\nconnection with performing its obligations under this Agreement, any Person who has been debarred pursuant to Section 306 of the FD&C Act (or similar\nApplicable Law outside of the U.S.), or who is the subject of a conviction described in such section. Xencor shall inform Aimmune in writing immediately\npromptly if it or any Person who is performing services for Xencor hereunder is debarred or is the subject of a conviction described in Section 306 (or\nsimilar Applicable Law outside of the U.S.), or if any action, suit, claim, investigation or legal administrative proceeding is pending or, to Xencor's\nknowledge, is threatened, relating to the debarment of Xencor or any Person used in any capacity by Xencor in connection with its Development or\nManufacture of the Product prior to the Effective Date or performance under this Agreement or during the Term in the course of performing Xencor's\nobligations under this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5287182ac4e8", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::044f34bb4eac"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::044f34bb4eac", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "3.3", "section_title": "Development Costs", "clause_type": "Cost allocation (Development expenses)", "path": "3 ➞ 3.3", "text": "or to the Effective Date or performance under this Agreement or during the Term in the course of performing Xencor's\nobligations under this Agreement.\n\n16\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n3.3 Development Costs. As between the Parties, Aimmune shall be solely responsible for one hundred percent (100%) of all Development costs\nincurred with respect to any Development Activities.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cea8bd608d75", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ad96610bfc22"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ad96610bfc22", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "3.4", "section_title": "Records, Reports and Information", "clause_type": "Recordkeeping and Reporting Obligation", "path": "3 ➞ 3.4", "text": "ties, Aimmune shall be solely responsible for one hundred percent (100%) of all Development costs\nincurred with respect to any Development Activities.\n\n3.4 Records, Reports and Information. Aimmune shall, and shall cause each of the other Aimmune Agreement Entities to, maintain current and\naccurate records of all Development Activities conducted by it and all data and other information resulting from such work (which records shall include,\nas applicable, books, records, reports, research notes, charts, graphs, comments, computations, analyses, recordings, photographs, computer programs\nand documentation thereof (e.g., samples of materials and other graphic or written data generated in connection with the Development Activities)). Such\nrecords shall properly reflect all work done and results achieved in the performance of the Development Activities in sufficient detail and in good\nscientific manner appropriate for regulatory and patent purposes. Aimmune shall document all preclinical studies and Clinical Trials to be conducted in\nformal written study reports according to applicable national and international (e.g., ICH, GCP and GLP) guidelines.\n\nARTICLE 4\nREGULATORY", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::044f34bb4eac", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::50b609278697"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::50b609278697", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "4.1.1–4.1.2", "section_title": "Regulatory Filings and Regulatory Approvals", "clause_type": "Regulatory obligations; allocation of responsibilities for preparation, submission, ownership of Regulatory Approvals and Pricing Approvals", "path": "4 ➞ 4.1 ➞ 4.1.1; 4 ➞ 4.1 ➞ 4.1.2", "text": "onducted in\nformal written study reports according to applicable national and international (e.g., ICH, GCP and GLP) guidelines.\n\nARTICLE 4\nREGULATORY\n\n4.1 Regulatory Filings and Regulatory Approvals.\n\n4.1.1 General Responsibilities; Ownership of Regulatory Approvals. Aimmune shall be responsible for the preparation of all Regulatory\nMaterials necessary or desirable for obtaining and maintaining the Regulatory Approvals for the Product and Aimmune shall submit such Regulatory\nMaterials, as applicable, to the applicable Governmental Authorities. For clarity, to the extent allowed by Applicable Law, all Regulatory Approvals for the\nProduct shall be held and owned by Aimmune in its name.\n\n4.1.2 Pricing Approvals. To the extent that a given country or regulatory jurisdiction requires Pricing Approval for sale of the Product,\nAimmune shall (to the extent permitted by Applicable Laws) be solely responsible for (and shall use Commercially Reasonable Efforts toward) obtaining\nand maintaining Pricing Approvals in all such countries and regulatory jurisdictions in which it obtains Regulatory Approval for Product, in its own\nname.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::ad96610bfc22", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::245f793267c2"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::245f793267c2", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "4.1.3–4.1.4", "section_title": "Regulatory Filings and Regulatory Approvals", "clause_type": "Cost allocation and reporting obligations (regulatory)", "path": "4 ➞ 4.1 ➞ 4.1.3–4.1.4", "text": "maintaining Pricing Approvals in all such countries and regulatory jurisdictions in which it obtains Regulatory Approval for Product, in its own\nname.\n\n4.1.3 Cost of Regulatory Activities. All regulatory costs incurred in connection with the preparation of Regulatory Materials, and obtaining\nof Product Approvals, for the Product shall be borne solely by Aimmune. Aimmune shall be responsible for all regulatory costs involved in the\nmaintenance of all Regulatory Approvals for the Product.\n\n4.1.4 Reporting and Review. Pursuant to the updates to be provided to Xencor under Section 2.5, Aimmune shall keep Xencor reasonably\ninformed in connection with the preparation of all material Regulatory Materials, Regulatory Authority review of Regulatory Materials, and Regulatory\nApprovals, in each case with respect to the Product.\n\n17\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::50b609278697", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::337d7305b457"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::337d7305b457", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "4.1.5", "section_title": "Safety Reporting", "clause_type": "Regulatory — Safety reporting obligations", "path": "4 ➞ 4.1 ➞ 4.1.5", "text": "ew of Regulatory Materials, and Regulatory\nApprovals, in each case with respect to the Product.\n\n17\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n4.1.5 Safety Reporting. Aimmune shall provide a [***] safety report in connection with the Development of the Product. Aimmune shall\ndetermine, [***], the contents and frequency of such reports, but in any event such reports will be made as [***] for Xencor to remain informed of the\nsafety status of the Product to assess, monitor and report to Regulatory Authorities information relevant to the safety of Product in connection with\nXencor's efforts to obtain Regulatory Approval of products that are not the Product and that [***], and comply with Applicable Laws. Xencor shall\nprovide a [***] safety report in connection with the development of products (other than Product) that [***]. Xencor shall determine, [***], the contents\nand frequency of such reports, but in any event such reports will be made as [***] for Aimmune to assess, monitor and report to Regulatory Authorities\ninformation relevant to the safety of Product in connection with Aimmune's efforts to obtain Regulatory Approval of the Product and comply with\nApplicable Laws.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::245f793267c2", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::edafe6486c71"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::edafe6486c71", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "4.3.1", "section_title": "Pharmacovigilance", "clause_type": "Regulatory (Pharmacovigilance and safety reporting)", "path": "4 ➞ 4.3 ➞ 4.3.1", "text": "n relevant to the safety of Product in connection with Aimmune's efforts to obtain Regulatory Approval of the Product and comply with\nApplicable Laws.\n\n4.2 No Other Regulatory Filings. Except as otherwise expressly set forth in this ARTICLE 4, Aimmune and Aimmune Agreement Entities shall not\nfile any Regulatory Materials or Regulatory Approvals that are based on any Xencor Technology.\n\n4.3 Pharmacovigilance and Medical Inquiries.\n\n4.3.1 Pharmacovigilance. Subject to Section 4.1.1, Aimmune, as the holder of the Product Approvals, shall be responsible for the\ncollection, review, assessment, tracking and filing of information related to adverse events associated with the Product (whether or not Product Approval\nhas been achieved), in each case in accordance with Applicable Law and this Agreement (and Aimmune shall, in the Development and Commercialization\nof the Product, record, investigate, summarize, notify, report and review all adverse events in accordance with Applicable Law).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::337d7305b457", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d3d326f7883d"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d3d326f7883d", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "4.3.2", "section_title": "Medical Inquiries for the Product", "clause_type": "Regulatory — Medical inquiries / Pharmacovigilance responsibility", "path": "4 ➞ 4.3 ➞ 4.3.2", "text": "and Commercialization\nof the Product, record, investigate, summarize, notify, report and review all adverse events in accordance with Applicable Law).\n\n4.3.2 Medical Inquiries for the Product. Following the Effective Date, subject to Section 4.1.1, Aimmune shall be responsible for handling\nall medical questions or inquiries in each country, including all Product Complaints, with regard to any Product distributed or sold by or on behalf of\nAimmune (or any of the other Aimmune Agreement Entities), in each case in accordance with Applicable Law and this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::edafe6486c71", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6eb7cb2538f3"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6eb7cb2538f3", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "4.3.3", "section_title": "Regulatory Authority Communications", "clause_type": "Regulatory communications/notification", "path": "4 ➞ 4.3 ➞ 4.3.3", "text": "r sold by or on behalf of\nAimmune (or any of the other Aimmune Agreement Entities), in each case in accordance with Applicable Law and this Agreement.\n\n4.3.3 Regulatory Authority Communications. In addition to its obligations under this Agreement, each Party shall disclose to the other\nParty (and each Party shall have the right to subsequently disclose to its Affiliates and subcontractors and licensees, specifically those licensees of the\nProduct in the case of Aimmune, who are bound by obligations of confidentiality substantially consistent with those in ARTICLE 12) the following\nregulatory information: All material information pertaining to material adverse or potentially material adverse actions taken or that may be taken by\nRegulatory Authorities, in connection with the Product or Antibody, including any notice, audit notice, notice of initiation by Regulatory Authorities of\ninvestigations, detentions, seizures or injunctions concerning the Product or Antibody, notice of violation letter (i.e., an untitled letter), warning letter,\nservice of process or other equivalent\n\n18\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d3d326f7883d", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::600410c67b44"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::600410c67b44", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "4.3.3", "section_title": "Regulatory Authority Communications", "clause_type": "Regulatory reporting/notification clause", "path": "4 ➞ 4.3 ➞ 4.3.3", "text": "ation letter (i.e., an untitled letter), warning letter,\nservice of process or other equivalent\n\n18\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\ncommunication or action. Without limiting the generality of the foregoing, each Party shall promptly, but in any event within [***] ([***]) Business Days,\ninform the other Party of any material adverse or potentially material adverse actions taken or that may be taken by Regulatory Authorities in connection\nwith the Product or Antibody, including any notice, audit notice, notice of initiation by Regulatory Authorities of investigations, detentions, seizures or\ninjunctions concerning the Product or Antibody, notice of violation letter (i.e., an untitled letter), warning letter, service of process or other equivalent\ncommunication or action.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6eb7cb2538f3", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5a810f923cc7"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5a810f923cc7", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "4.3.4; Article 5; 5.1; 5.2", "section_title": "Recall, Withdrawal, or Market Notification of Product; Commercialization; Aimmune's Performance", "clause_type": "Regulatory (recall/market notification) and Commercialization obligations (performance and cost allocation)", "path": "4 ➞ 4.3 ➞ 4.3.4; 5; 5 ➞ 5.1; 5 ➞ 5.2", "text": "ct or Antibody, notice of violation letter (i.e., an untitled letter), warning letter, service of process or other equivalent\ncommunication or action.\n\n4.3.4 Recall, Withdrawal, or Market Notification of Product. In the event that any Governmental Authority threatens or initiates any\naction to remove the Product from the market, Aimmune shall notify Xencor of such communication promptly, but in no event later than [***] ([***])\nBusiness Days, after receipt thereof. Aimmune shall [***] any recall, withdrawal or market notification of the Product. As between the Parties, all costs\nand expenses associated with implementing a recall, withdrawal or market notification with respect to the Product shall be borne by [***].\n\nARTICLE 5\nCOMMERCIALIZATION\n\n5.1 Commercialization. During the Term, as between the Parties, Aimmune shall be solely responsible for Commercializing the Product. Aimmune\nshall be responsible for one hundred percent (100%) of the expenses (including Pre-Marketing and other Commercialization expenses) incurred in\nconnection with the Commercialization of the Product.\n\n5.2 Aimmune's Performance.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::600410c67b44", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::90a387ccba91"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::90a387ccba91", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "5.2.1", "section_title": "Specific Commercialization Obligations", "clause_type": "Commercialization obligations / performance covenant", "path": "5 ➞ 5.2 ➞ 5.2.1 ➞ 5.2.1(a)-(b)", "text": "ding Pre-Marketing and other Commercialization expenses) incurred in\nconnection with the Commercialization of the Product.\n\n5.2 Aimmune's Performance.\n\n5.2.1 Specific Commercialization Obligations. Without limiting the generality of the provisions of Section 5.1, in connection with the\nCommercialization of the Product by or on behalf of Aimmune or its Affiliates and Sublicensees hereunder:\n\n(a) Aimmune, itself or with or through its Affiliates and Sublicensees, shall (i) use Commercially Reasonable Efforts to Commercialize\nthe Product in the Licensed Field throughout the Major Territory, (ii) represent the Product accurately and fairly, and (iii) not sell or distribute the Product\nin a bundle with other products at a discount that is not equitably allocated between Product and other products with which the Product is bundled.\n\n(b) Aimmune shall not (i) [***], or (ii) utilize deceptive, misleading or unethical business practices, in each case in the course of\nperforming activities pursuant to this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5a810f923cc7", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3254a587f3f0"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3254a587f3f0", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "5.2(c); 5.3; 5.4; 5.4.1", "section_title": "Commercialization; Reports; Product Trademarks and Product Trade Dress; Product Trademark", "clause_type": "Commercialization obligations; Reporting obligations; Trademark/Trade dress ownership and use", "path": "5 ➞ 5.2 ➞ 5.2(c); 5 ➞ 5.3; 5 ➞ 5.4 ➞ 5.4.1", "text": "or (ii) utilize deceptive, misleading or unethical business practices, in each case in the course of\nperforming activities pursuant to this Agreement.\n\n(c) Aimmune, itself or with or through its Affiliates and Sublicensees, shall be solely responsible for (i) receiving, accepting and filling\norders for the Product, (ii) handling all returns of the Product, (iii) controlling invoicing, order processing and collection of accounts receivable for the\nsales of the Product, and (iv) distributing and managing inventory of the Product.\n\n19\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n5.3 Reports. Without limiting Aimmune's other reporting obligations hereunder, Aimmune shall, during the fourth Calendar Quarter of each\nCalendar Year after the First Commercial Sale of a Product, provide Xencor [***] involving Product during the preceding four (4) Calendar Quarters.\n\n5.4 Product Trademarks and Product Trade Dress.\n\n5.4.1 Product Trademark. Aimmune shall Commercialize the Product under the trademark and the trade dress selected by Aimmune (the\n\"Product Trademark\" and the \"Product Trade Dress\", respectively).", "numbers_present": null, "definition_terms": ["Product Trademark", "Product Trade Dress"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::90a387ccba91", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::db610afaf780"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::db610afaf780", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "5.4.2–5.4.3", "section_title": "Product Trademarks and Product Trade Dress", "clause_type": "Trademark ownership and use", "path": "5 ➞ 5.4 ➞ 5.4.2–5.4.3", "text": "cialize the Product under the trademark and the trade dress selected by Aimmune (the\n\"Product Trademark\" and the \"Product Trade Dress\", respectively).\n\n5.4.2 Use and Ownership of Product Trademarks and Product Trade Dress. All uses of the Product Trademark and Product Trade Dress by\nAimmune (and its other Aimmune Agreement Entities) to identify and/or in connection with the Commercialization of the Product shall be in accordance\nwith Regulatory Approvals and all Applicable Law. Aimmune or the other Aimmune Agreement Entities shall own and retain all rights to the Product\nTrademark and Product Trade Dress (in each case, together with all goodwill associated therewith). Aimmune or the other Aimmune Agreement Entities\nshall also own rights to any internet domain names incorporating the Product Trademark or any variation or part of such trademark as its URL address.\n\n5.4.3 Maintenance of Product Trademark. During the Term, Aimmune or the other Aimmune Agreement Entities will use Commercially\nReasonable Efforts to establish and maintain the Product Trademark and will [***].", "numbers_present": null, "definition_terms": ["Product Trademark", "Product Trade Dress"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3254a587f3f0", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a01ed47994ad"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a01ed47994ad", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "5.4.4–5.5", "section_title": "No Inclusion of Xencor Logos on Packaging and Promotional Materials / Commercialization Data", "clause_type": "Trademark/logo usage restriction; Ownership of commercialization data", "path": "5 ➞ 5.4 ➞ 5.4.4; 5 ➞ 5.5", "text": "mmune or the other Aimmune Agreement Entities will use Commercially\nReasonable Efforts to establish and maintain the Product Trademark and will [***].\n\n5.4.4 No Inclusion of Xencor Logos on Packaging and Promotional Materials. Notwithstanding anything to the contrary herein, Aimmune\nshall not use any Xencor trademark, names, logos or housemark in connection with any Promotional Materials or the Product without Xencor's written\nconsent. Without limiting the foregoing, Aimmune will take no action that will interfere with or diminish Xencor's rights in its respective trademarks,\nnames and logos, and if Xencor reasonably believes that the use of any trademarks, names and logos by Aimmune hereunder is interfering with or\ndiminishing its rights, Xencor shall notify Aimmune thereof in writing and Aimmune shall promptly cease use of such trademarks, names or logos in such\nmanner.\n\n5.5 Commercialization Data. As between the Parties, Aimmune shall own all marketing and sales data and information resulting from its\nCommercialization of the Product during the Term (the \"Commercialization Data\"), including promotional materials, marketing strategies and market\nresearch data.\n\nARTICLE 6\n\nSUPPLY", "numbers_present": null, "definition_terms": ["Commercialization Data"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::db610afaf780", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::97f261b37dd9"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::97f261b37dd9", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "6.1", "section_title": "Initial Product Supply", "clause_type": "Supply/Delivery obligations", "path": "6 ➞ 6.1", "text": "uct during the Term (the \"Commercialization Data\"), including promotional materials, marketing strategies and market\nresearch data.\n\nARTICLE 6\n\nSUPPLY\n\n6.1 Initial Product Supply. Xencor shall provide a [***] supply of Product to Aimmune in the amounts and in the form set forth on Schedule 6.1,\nwhich Aimmune agrees to accept on an as-is basis. Xencor shall make available to Aimmune the quantity of the Product\n\n20\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nspecified on Schedule 6.1 within [***] ([***]) Business Days from the Effective Date or otherwise as agreed to by the Parties, and shall provide\nappropriate documentation at such time (i.e., appropriate certificates of analysis or compliance, as applicable). The Product shall be made available to\nAimmune [***]. For clarity, Aimmune shall bear all costs in connection with such supply of Product related to shipping, taxes, additional testing and\nother matters.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a01ed47994ad", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7394eef6ec1a"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7394eef6ec1a", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "6.2", "section_title": "Packaging and Labeling; Certain Other Manufacturing Activities", "clause_type": "Manufacturing/Supply obligations (packaging, labeling, QC/QA and third-party qualification responsibilities)", "path": "6 ➞ 6.2", "text": "For clarity, Aimmune shall bear all costs in connection with such supply of Product related to shipping, taxes, additional testing and\nother matters.\n\n6.2 Packaging and Labeling; Certain Other Manufacturing Activities. Notwithstanding anything to the contrary contained herein, Aimmune or\nits designated Third Party shall be responsible ([***]) for all final product labeling and packaging (whether in commercial or clinical packaging\npresentation), including materials such as patient inserts, patient medication guides, professional inserts and any other written, printed or graphic\nmaterials accompanying the Product and considered to be part of the finished Product packaging and labeling, and handling, storage, quality control,\nquality assurance, testing and release (collectively, \"Packaging and Labeling\"). Aimmune or its designated Third Party shall ensure that all such\nPackaging and Labeling complies with Applicable Laws, GMPs and the Regulatory Approvals for the Product. To the extent that a Third Party is involved\nin Packaging and Labeling or other activities described in this Section 6.2, [***] shall be [***] responsible for[***], qualifying such Third Party to\nperform such activities.", "numbers_present": null, "definition_terms": ["Packaging and Labeling"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::97f261b37dd9", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d7774e72acb7"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d7774e72acb7", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "7.1", "section_title": "Upfront Payments", "clause_type": "Payment", "path": "7 ➞ 7.1", "text": "or other activities described in this Section 6.2, [***] shall be [***] responsible for[***], qualifying such Third Party to\nperform such activities.\n\nARTICLE 7\nPAYMENTS\n\n7.1 Upfront Payments. Within [***] ([***]) days after the Effective Date of this Agreement, Aimmune shall issue to Xencor shares of Aimmune\nCommon Stock (the \"Shares\") in accordance with that certain Stock Issuance Agreement, dated the date hereof, by and among Xencor and Aimmune\n(the \"Stock Issuance Agreement\"), and pay to Xencor by wire transfer of immediately available funds, into an account designated in writing by Xencor,\nan amount equal to five million Dollars ($5,000,000) (together with the issuance of the Shares, the \"Upfront Payment\"). The Upfront Payment shall be\nnonrefundable and noncreditable against any other payments due hereunder.", "numbers_present": null, "definition_terms": ["Shares", "Stock Issuance Agreement", "Upfront Payment"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7394eef6ec1a", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::bc7342ff6430"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::bc7342ff6430", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "7.2", "section_title": "Milestone Payments", "clause_type": "Payment (Milestone)", "path": "7 ➞ 7.2", "text": "issuance of the Shares, the \"Upfront Payment\"). The Upfront Payment shall be\nnonrefundable and noncreditable against any other payments due hereunder.\n\n7.2 Milestone Payments. Aimmune shall pay to Xencor the one-time milestone payments described in this Section 7.2 following achievement (and\nonly upon the first occurrence) of the corresponding milestone event for a Product. Aimmune shall promptly notify Xencor in writing of, but in no event\nlater than [***] ([***]) days after, the achievement of each such milestone event with respect to a Product. Aimmune shall pay the applicable milestone\npayment by wire transfer of immediately available funds within [***] ([***]) days after the achievement (and only upon the first occurrence) of the\napplicable milestone event into an account designated by Xencor in writing. Each such milestone payment is nonrefundable and noncreditable against\nany other payments due hereunder.\n\n21\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nMilestone\n\nMilestone Event\n\nPayment\nDevelopment Milestone\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\nSales Milestones\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d7774e72acb7", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f502ae09f559"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f502ae09f559", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "7.3.2(a)", "section_title": "Royalty Reductions", "clause_type": "Royalty payments and reductions (financial/payment clause)", "path": "7 ➞ 7.3 ➞ 7.3.2 ➞ 7.3.2(a)", "text": "$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\nSales Milestones\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n[***]\n$\n[***]\n\n7.3 Royalty Payments.\n\n7.3.1 Product. On a Product-by-Product and country-by-country basis during the Royalty Term applicable to such Product and such\ncountry, Aimmune shall pay to Xencor the following royalties on Net Sales of Products, subject to Section 7.3.2:\n\nRoyalty\n\nAggregate Annual Net Sales\n\nRate\n[***]\n[***]%\n[***]\n[***]%\n[***]\n[***]%\n[***]\n[***]%\n[***]\n[***]%\n\n[***].\n\n22\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n7.3.2 Royalty Reductions.\n\n(a) No Valid Claim. On a country-by-country and Product-by-Product basis, if at any time during the Royalty Term with respect to\nsuch country and such Product, such Product is not Covered by any Valid Claim of a [***], the royalty rate applied to Net Sales of such Product shall be\nthe royalty rate in Section 7.3.1 reduced by [***] percent ([***]%) for so long as during the Royalty Term such Product is not Covered by a Valid Claim of\na [***] in such country.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::bc7342ff6430", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cf0baeb676cb"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cf0baeb676cb", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "7.3.2(b)", "section_title": "Third Party Intellectual Property", "clause_type": "Royalty reduction / Third-party license credit", "path": "7 ➞ 7.3 ➞ 7.3.2 ➞ 7.3.2(b)", "text": ".3.1 reduced by [***] percent ([***]%) for so long as during the Royalty Term such Product is not Covered by a Valid Claim of\na [***] in such country.\n\n(b) Third Party Intellectual Property. Aimmune shall have the right (but not the obligation), at its own expense (subject to the\nreduction provided for by this Section 7.3.2(b)), to obtain any licenses from any Third Parties that are not Sublicensees of Aimmune with respect to a\nProduct in such country under any issued Patents that would be infringed by the practice of Xencor Technology licensed under Section 2.1 with respect\nto a given Product in a particular country (each such Patent, a \"Third Party Patent\"). If Aimmune obtains such a license to a Third Party Patent,\nAimmune shall be entitled to credit [***] percent ([***]%) of the royalties paid to such Third Party during a Calendar Quarter against the royalty\npayment otherwise payable by Aimmune to Xencor pursuant to this Section 7.3 with respect to such Product and such country in such Calendar Quarter.\nNotwithstanding the foregoing, Aimmune shall have no right to reduce payments due to Xencor under this Agreement by any amount paid to [***] in\nconnection with the Upstream Agreement or any other agreement entered into between Aimmune and [***].", "numbers_present": null, "definition_terms": ["Third Party Patent"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f502ae09f559", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::541103f2de99"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::541103f2de99", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "7.3.2(c)(i)", "section_title": "Generic Competition", "clause_type": "Royalty reduction", "path": "7 ➞ 7.3 ➞ 7.3.2 ➞ 7.3.2(c) ➞ 7.3.2(c)(i)", "text": "er this Agreement by any amount paid to [***] in\nconnection with the Upstream Agreement or any other agreement entered into between Aimmune and [***].\n\n(c) Generic Competition. On a country-by-country and Product-by-Product basis, if at any time during the Royalty Term with respect\nto such country and such Product there is one or more Generic Product(s) with respect to such Product being sold for [***]) consecutive Calendar\nQuarters, then [***] for such country and such Product, the royalty rate for such Product shall be reduced, after giving effect to any reduction applicable\nto such Product in such country pursuant to [***], on a Calendar Quarter basis as follows:\n\n(i) if the cumulative Net Sales of such Product in such country during such Calendar Quarter are equal to or less than [***]\npercent ([***]%), but are greater than [***] percent ([***]%), of the Baseline Quarter Net Sales, then the royalty rate will be reduced for such Calendar\nQuarter by [***] percent ([***]%); and", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cf0baeb676cb", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::79ad10726af6"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::79ad10726af6", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "7.3.2(c)(i)-(ii)", "section_title": "Royalty Reductions", "clause_type": "Royalty reduction", "path": "7 ➞ 7.3 ➞ 7.3.2 ➞ 7.3.2(c) ➞ 7.3.2(c)(i)-(ii)", "text": "*] percent ([***]%), of the Baseline Quarter Net Sales, then the royalty rate will be reduced for such Calendar\nQuarter by [***] percent ([***]%); and\n\n(ii) if the cumulative Net Sales of such Product in such country during such Calendar Quarter are less than [***] percent\n([***]%) of the Baseline Quarter Net Sales of the Baseline Quarter Net Sales, then the royalty rate for such Calendar Quarter will be reduced by [***]\npercent ([***]%).\n\nprovided, that, for clarity, on a country-by-country and Product-by-Product basis, there will be no royalty rate reduction with respect to a given country\nand Product pursuant to this Section 7.3.2(c) with respect to the initial [***] ([***]) consecutive Calendar Quarter periods during which Generic Product\nentry with respect to such Product and such country is being established.\n\n23\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::541103f2de99", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b6e6a5973683"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b6e6a5973683", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "7.3.2(d)", "section_title": "Royalty Floor", "clause_type": "Royalty floor clause", "path": "7 ➞ 7.3 ➞ 7.3.2 ➞ 7.3.2(d)", "text": "which Generic Product\nentry with respect to such Product and such country is being established.\n\n23\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n(d) Royalty Floor. Notwithstanding any provision set forth in this Agreement to the contrary, none of the permitted reductions to\nroyalties provided in this Section 7.3.2 will reduce any royalty payment payable in a given Calendar Quarter with respect to Net Sales of any Product in\nany country during the Royalty Term by more than [***] percent ([***]%) of the royalties otherwise owed to Xencor pursuant to Section 7.3.1.\n\nARTICLE 8\nPAYMENT; RECORDS; AUDITS", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::79ad10726af6", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::896628fb13da"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::896628fb13da", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "8.1", "section_title": "Royalty Payments and Reports", "clause_type": "Payment and Reporting", "path": "8 ➞ 8.1", "text": "alty Term by more than [***] percent ([***]%) of the royalties otherwise owed to Xencor pursuant to Section 7.3.1.\n\nARTICLE 8\nPAYMENT; RECORDS; AUDITS\n\n8.1 Royalty Payments and Reports. The royalty payments due by Aimmune to Xencor under Section 7.3 shall be calculated, reported and paid for\neach Calendar Quarter within [***] ([***]) days after the end of each Calendar Quarter and shall be accompanied by a report setting forth Net Sales of\nProducts by Aimmune in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including the gross sales and Net Sales of\neach Product, on a country-by-country basis, and the exchange rates used in accordance with Section 8.2. Without limiting the generality of the\nforegoing, Aimmune shall require its Affiliates and other Aimmune Agreement Entities to account for its Net Sales and to provide such reports with\nrespect thereto as if such sales were made by Aimmune.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b6e6a5973683", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b80bc3c60a45"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b80bc3c60a45", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "8.2", "section_title": "Manner and Place of Payment; Taxes", "clause_type": "Payment clause (currency conversion, payment currency and wire transfer) and Taxes header", "path": "8 ➞ 8.2", "text": "other Aimmune Agreement Entities to account for its Net Sales and to provide such reports with\nrespect thereto as if such sales were made by Aimmune.\n\n8.2 Manner and Place of Payment. When conversion of payments from any currency other than U.S. Dollars is required, such conversion shall be\nat an exchange rate equal to the rates of exchange for the currency of the country from which such payments are payable as published by The Wall Street\nJournal, Western U.S. Edition, on the last Business Day of the Calendar Quarter in which the applicable sales were made in such country. All payments\nhereunder shall be payable in U.S. Dollars. All payments owed under this Agreement shall be made by wire transfer in immediately available funds to a\nbank and account designated in writing by Xencor, unless otherwise specified in writing by Xencor.\n\n8.3 Taxes.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::896628fb13da", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e54b40ff2335"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e54b40ff2335", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "8.3.1", "section_title": "Taxes", "clause_type": "Taxes/Tax allocation", "path": "8 ➞ 8.3 ➞ 8.3.1", "text": "fer in immediately available funds to a\nbank and account designated in writing by Xencor, unless otherwise specified in writing by Xencor.\n\n8.3 Taxes.\n\n8.3.1 The Parties acknowledge and agree that it is their mutual objective and intent to minimize, to the extent feasible, taxes payable with\nrespect to their collaborative efforts under this Agreement to cooperate and coordinate with each other to achieve such objective. For the avoidance of\ndoubt, as between the Parties, Aimmune shall be responsible for any Branded Prescription Drug Fees that may be levied under section 9008 of the\nAffordable Care Act with respect to any Product sold.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b80bc3c60a45", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d55708ffa4ae"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d55708ffa4ae", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "8.3.2", "section_title": "Taxes", "clause_type": "Tax withholding and payment allocation", "path": "8 ➞ 8.3 ➞ 8.3.2", "text": "responsible for any Branded Prescription Drug Fees that may be levied under section 9008 of the\nAffordable Care Act with respect to any Product sold.\n\n8.3.2 Subject to this Section 8.3.2, Xencor will pay any and all taxes, including withholdings, levied on account of any payments made to it\nunder this Agreement. If any taxes are paid or required to be withheld by Aimmune for the benefit of Xencor on account of any payments payable to\nXencor under this Agreement, Aimmune will (i) deduct such taxes from the amount of payments otherwise due to Xencor, (ii) timely pay the taxes to the\nproper taxing authority, (iii) send proof of payment to Xencor within [***] ([***]) days following such payment and (iv) cooperate with Xencor in any\nway reasonably required by Xencor to obtain available reductions, credits or refunds of such taxes. Notwithstanding the foregoing, if (a) Aimmune\nassigns its rights or obligations or delegates its rights under this Agreement, (b) as a\n\n24\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e54b40ff2335", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e3f6d3bceb8e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e3f6d3bceb8e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "8.3.2", "section_title": "Taxes", "clause_type": "Tax withholding / payment allocation", "path": "8 ➞ 8.3 ➞ 8.3.2", "text": "immune\nassigns its rights or obligations or delegates its rights under this Agreement, (b) as a\n\n24\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nresult of such assignment or delegation, Aimmune (or its assignee) is required by Applicable Law to withhold taxes from or in respect of any amount\npayable under this Agreement, and (c) such withholding taxes exceed the amount of withholding taxes that would have been applicable but for such\nassignment or delegation, then any such amount payable shall be increased to take into account such withholding taxes as may be necessary so that,\nafter making all required withholdings (including withholdings on the additional amounts payable), the payee receives an amount equal to the sum it\nwould have received had no such increased withholding been made. Each Party shall cooperate with the other Party in any way reasonably requested by\nthe other Party to minimize the withholding tax implications of any such assignment or delegation.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d55708ffa4ae", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3a80df859a01"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3a80df859a01", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "8.3.3-8.3.4", "section_title": "Taxes", "clause_type": "Tax allocation / VAT and withholding", "path": "8 ➞ 8.3 ➞ 8.3.3-8.3.4", "text": "the other Party in any way reasonably requested by\nthe other Party to minimize the withholding tax implications of any such assignment or delegation.\n\n8.3.3 Aimmune shall be responsible for all Value Added Taxes (\"VAT\"), if any, attributable to transactions contemplated by this Agreement\nwithout any offset or reimbursement from Xencor. Xencor shall cooperate with Aimmune in any way reasonably requested by Aimmune to obtain\navailable reductions, credits or refunds of any VAT amounts attributable to transactions contemplated by this Agreement.\n\n8.3.4 [***].", "numbers_present": null, "definition_terms": ["Value Added Taxes", "VAT"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e3f6d3bceb8e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0eae5fba7d48"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0eae5fba7d48", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "8.3.4; 8.4", "section_title": "Records; Audits", "clause_type": "Records and audit rights (recordkeeping; audit access and procedures)", "path": "8 ➞ 8.3 ➞ 8.3.4; 8 ➞ 8.4", "text": "mmune to obtain\navailable reductions, credits or refunds of any VAT amounts attributable to transactions contemplated by this Agreement.\n\n8.3.4 [***].\n\n8.4 Records; Audits. During the Term and for [***] ([***]) years thereafter, Aimmune shall keep, and shall cause its Affiliates and Sublicensees to\nkeep and provide to Xencor, complete and accurate records pertaining to the sale or other disposition of Product in sufficient detail to permit Xencor to\nconfirm the accuracy of payments due hereunder. Xencor shall have the right, upon [***] ([***]) days' prior written notice to Aimmune, to cause an\nindependent, certified international public accounting firm reasonably acceptable to Aimmune or reasonably acceptable to its Affiliates or Sublicensees,\nas applicable, to audit such records during Aimmune's, or its Affiliate's or Sublicensees', as applicable, normal business hours to confirm the number of\nProduct units sold, the gross sales and Net Sales of Product, the royalties payable, the method used to calculate the royalties payable, and the exchange\nrates used in accordance with Section 8.2. The audit shall be limited to pertinent records kept by Aimmune and its Affiliates and Sublicensees for any\nyear ending not more than [***] ([***]) months prior to the date of the written notice. An audit under this Section 8.4 shall not occur more than [***] in\nany Calendar Year, except in the case of any subsequent \"for cause\" audit. The accounting firm shall disclose to Xencor only whether the reports are\ncorrect or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Xencor. The accounting firm shall\nprovide Aimmune with a copy of any disclosures or reports made to Xencor and Aimmune shall have an opportunity to discuss such disclosures or\nreports with Xencor and the accounting firm. Information, disclosures, or reports arising from any such examination shall be Confidential Information of\nAimmune subject to the confidentiality and other obligations of ARTICLE 12. Prompt adjustments shall be made by the Parties to reflect the results of\nsuch audit. Xencor shall bear the full cost of such audit unless such audit discloses an underpayment of more than [***] percent ([***]%) of the\npayments due under this Agreement, in which case, [***].", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3a80df859a01", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9003a3ae0afe"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9003a3ae0afe", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "8.5", "section_title": "Late Payments", "clause_type": "Late payment / interest clause", "path": "8 ➞ 8.5", "text": "audit unless such audit discloses an underpayment of more than [***] percent ([***]%) of the\npayments due under this Agreement, in which case, [***].\n\n8.5 Late Payments. In the event that any payment due under this Agreement is not sent to Xencor when due in accordance with the applicable\nprovisions of Sections 7.1, 7.2, or 8.1, the payment shall accrue interest from the date due at the [***], plus an additional [***]\n\n25\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\npercentage points ([***] ppts); provided, however, that (a) in the event that more than [***] payment due under this Agreement is not received by\nXencor when due, the foregoing rate shall increase to the prime rate plus an additional [***] percentage points ([***] ppts) per year calculated on the\nnumber of days such payment is delinquent, compounded annually and computed on the basis of a three hundred sixty five (365) day year, and (b) in no\nevent shall such rate exceed the maximum legal annual interest rate. The payment of such interest shall not limit Xencor from exercising any other rights it\nmay have as a consequence of the lateness of any payment.\n\nARTICLE 9\nINTELLECTUAL PROPERTY MATTERS", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0eae5fba7d48", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d6682441a7ec"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d6682441a7ec", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.1.1", "section_title": "General", "clause_type": "Ownership (Intellectual Property)", "path": "9 ➞ 9.1 ➞ 9.1.1", "text": "ot limit Xencor from exercising any other rights it\nmay have as a consequence of the lateness of any payment.\n\nARTICLE 9\nINTELLECTUAL PROPERTY MATTERS\n\n9.1 Ownership of Intellectual Property.\n\n9.1.1 General. Subject to the provisions of this Section 9.1.1 and except as expressly set forth otherwise in this Agreement, (i) Xencor shall\nsolely own Patents Covering any Xencor Invention (\"Xencor Collaboration Patents\"), and (ii) Aimmune shall solely own Patents Covering any\nAimmune Invention (\"Aimmune Collaboration Patents\"). All Joint Inventions shall be jointly owned by the Parties, and Patents Covering Joint\nInventions shall be referred to as \"Joint Collaboration Patents\". Each Party shall promptly disclose to the other Party all Xencor Inventions, Aimmune\nInventions and Joint Inventions, as applicable, made by it during the Term. The determination of inventorship for such Inventions shall be made in\naccordance with Applicable Law relating to inventorship set forth in the patent laws of the United States (Title 35, United States Code).", "numbers_present": null, "definition_terms": ["Xencor Collaboration Patents", "Aimmune Collaboration Patents", "Joint Collaboration Patents"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9003a3ae0afe", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b5fab1984e71"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b5fab1984e71", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.1.2", "section_title": "Employees", "clause_type": "Employee invention assignment / IP ownership covenant", "path": "9 ➞ 9.1 ➞ 9.1.2", "text": "l be made in\naccordance with Applicable Law relating to inventorship set forth in the patent laws of the United States (Title 35, United States Code).\n\n9.1.2 Employees. Each Party will require all of its and its Affiliates' employees to assign all Inventions that are developed, made or\nconceived by such employees according to the ownership principles described in Section 9.1.1 free and clear of all liens, encumbrances, charges, security\ninterests, mortgages or other similar restrictions. Each Party will also use its Commercially Reasonable Efforts to require any agents or independent\ncontractors performing an activity pursuant to this Agreement to assign all Inventions that are developed, made or conceived by such agents or\nindependent contractors to the relevant Party, according to the ownership principles described in Section 9.1.1 free and clear of all liens, encumbrances,\ncharges, security interests, mortgages or other similar restrictions.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d6682441a7ec", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5e7a4d2eabff"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5e7a4d2eabff", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.2", "section_title": "Disclosures; Disputes Regarding Inventions", "clause_type": "Intellectual Property - Patent disclosure and dispute resolution", "path": "9 ➞ 9.2", "text": "principles described in Section 9.1.1 free and clear of all liens, encumbrances,\ncharges, security interests, mortgages or other similar restrictions.\n\n9.2 Disclosures; Disputes Regarding Inventions. Each Party shall, before filing a new Patent application (including provisionals and\ncontinuations-in-part) claiming an Invention, promptly disclose such Invention to the other Party and shall provide to the other Party with a copy of the\nproposed patent application at least [***] ([***]) Business Days before filing such application or such shorter time as may be required to preserve Patent\nrights, including the avoidance of a statutory bar or prior publication. If such other Party believes that the first Party's proposed Patent application\ndiscloses such other Party's Confidential Information, such other Party shall so notify the first Party within such [***] ([***]) Business Days after\nreceipt thereof, and such first Party shall amend its proposed application to comply with the confidentiality provisions of this Agreement. If the Parties\nare in agreement as to the designation of the Invention as a Xencor Invention, Joint Invention or Aimmune Invention, as applicable, they can\n\n26", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b5fab1984e71", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::53f0dbfe8fde"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::53f0dbfe8fde", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.2", "section_title": "Disclosures; Disputes Regarding Inventions", "clause_type": "Patent disclosure and dispute resolution", "path": "9 → 9.2", "text": "rties\nare in agreement as to the designation of the Invention as a Xencor Invention, Joint Invention or Aimmune Invention, as applicable, they can\n\n26\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\ncontinue as set forth in Section 9.3. If the Parties disagree as to whether an Invention is a Xencor Invention, Joint Invention or Aimmune Invention, and\nare unable to reach agreement within [***] ([***]) days after commencing discussions, then the provisions of Section 15.1 shall apply to such dispute\nwithout limiting either Party's right to continue with filing such application.\n\n9.3 Patent Filings, Prosecution and Maintenance.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5e7a4d2eabff", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2724bebd1691"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2724bebd1691", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.3", "section_title": "Patent Filings, Prosecution and Maintenance", "clause_type": "Intellectual Property - Patent filings/prosecution", "path": "9 ➞ 9.3 ➞ 9.3.1", "text": "pply to such dispute\nwithout limiting either Party's right to continue with filing such application.\n\n9.3 Patent Filings, Prosecution and Maintenance.\n\n9.3.1 Xencor General Patents. Subject to, and without limiting Aimmune's rights under, Section 9.4 of this Agreement, Xencor shall have\nthe sole right to prepare, file, prosecute and maintain all Xencor General Patents, [***], including by conducting reissues, reexaminations, interferences,\nand/or defending against post grant proceedings, such as inter partes reviews and oppositions and other challenges to the validity or enforceability of\nsuch Xencor General Patents. Xencor shall keep Aimmune generally informed of the status of Xencor General Patents upon Aimmune's request\nreasonable request from time-to-time.\n\n9.3.2 Xencor Product Specific Patent, Aimmune Patents and Joint Collaboration Patents.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::53f0dbfe8fde", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e9c9a135e930"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e9c9a135e930", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.3.2(a)", "section_title": "Xencor Product Specific Patent, Aimmune Patents and Joint Collaboration Patents", "clause_type": "Intellectual Property - Patent prosecution and maintenance", "path": "9 ➞ 9.3 ➞ 9.3.2 ➞ 9.3.2(a)", "text": "s upon Aimmune's request\nreasonable request from time-to-time.\n\n9.3.2 Xencor Product Specific Patent, Aimmune Patents and Joint Collaboration Patents.\n\n(a) Aimmune shall have the first right to prepare, file, prosecute and maintain (i) Xencor Product Specific Patents, (ii) Aimmune\nPatents Covering an Antibody or Product, and (iii) Joint Collaboration Patents, [***], including by conducting reissues, reexaminations, interferences,\nand/or defending against post grant proceedings, such as inter partes reviews and oppositions and other challenges to the validity or enforceability of\nthe relevant Patent; provided that Aimmune shall receive Xencor's prior written approval, not to be unreasonably withheld or delayed, before conducting\nreissues, reexaminations, interferences, and/or defending against post grant proceedings for the [***], such as inter partes reviews and oppositions and\nother challenges to the validity or enforceability of such relevant Patent. [***]. [***]. Aimmune shall keep Xencor informed of the status of Xencor\nProduct Specific Patents, Aimmune Patents Covering an Antibody or Product, and Joint Collaboration Patents [***]. With respect to any material\nsubstantive submissions that Aimmune is required to or otherwise intends to submit to a patent office with respect to a [***], Aimmune shall provide a\ndraft of such submission to Xencor at least [***] ([***]) days (or such time as is possible) prior to the deadline for, or the intended filing date of, such\nsubmission, whichever is earlier (or as soon as reasonably possible if Aimmune has less than [***] ([***]) days' notice of a deadline for submission).\nXencor shall have the right to review and comment upon any such submission by Aimmune to a patent office, and will provide such comments within\n[***] ([***]) days after receiving such submission (provided, that if no comments are received within such [***] ([***]) day period, then Aimmune may\nproceed with such submission). Aimmune shall [***]any suggestions or recommendations of Xencor concerning the preparation, filing, prosecution and\nmaintenance thereof.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2724bebd1691", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7022a895d7b7"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7022a895d7b7", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.3.2(b)", "section_title": "Xencor Product Specific Patent, Aimmune Patents and Joint Collaboration Patents", "clause_type": "Patent prosecution and cooperation", "path": "9 ➞ 9.3 ➞ 9.3.2 ➞ 9.3.2(b)", "text": "submission). Aimmune shall [***]any suggestions or recommendations of Xencor concerning the preparation, filing, prosecution and\nmaintenance thereof.\n\n(b) The Parties shall cooperate reasonably in the prosecution of all Xencor Product Specific Patents, Aimmune Patents Covering an\nAntibody or Product and Joint Collaboration Patents and shall share all material information relating thereto promptly after receipt of such information. If,\nduring the Term, Aimmune (i) intends to allow any Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or Product or Joint\n\n27\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e9c9a135e930", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::65ac2af52d36"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::65ac2af52d36", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.3.2(b)", "section_title": "Xencor Product Specific Patents, Aimmune Patents and Joint Collaboration Patents", "clause_type": "Patent prosecution and maintenance; right to assume responsibility", "path": "9 ➞ 9.3 ➞ 9.3.2 ➞ 9.3.2(b)", "text": "low any Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or Product or Joint\n\n27\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nCollaboration Patent to expire or intends to otherwise abandon any such Xencor Product Specific Patent, Aimmune Patent Covering an Antibody or\nProduct or Joint Collaboration Patent, or (ii) decides not to prepare or file patent applications Covering Aimmune Inventions or Joint Inventions,\nAimmune shall notify Xencor of such intention or decision at least [***] ([***]) days (or as soon as possible if less than [***] ([***]) days) prior to any\nfiling or payment due date, or any other date that requires action, in connection with such Xencor Product Specific Patent, Aimmune Patent Covering an\nAntibody or Product or Joint Collaboration Patent, and Xencor shall thereupon have the right, but not the obligation, to assume responsibility for the\npreparation, filing, prosecution or maintenance thereof [***], in the name of Xencor or Aimmune, as applicable.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7022a895d7b7", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b35519d5fe4f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b35519d5fe4f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.3.3", "section_title": "Cooperation", "clause_type": "Patent prosecution cooperation", "path": "9 ➞ 9.3 ➞ 9.3.3", "text": "tion, to assume responsibility for the\npreparation, filing, prosecution or maintenance thereof [***], in the name of Xencor or Aimmune, as applicable.\n\n9.3.3 Cooperation. The Parties agree to cooperate in the preparation, filing, prosecution and maintenance of all Patents under this Section\n9.3, including obtaining and executing necessary powers of attorney and assignments by the named inventors, providing relevant technical reports to the\nfiling Party concerning the Invention disclosed in such Patent, obtaining execution of such other documents which are needed in the filing and\nprosecution of such Patent, and, as requested by a Party, updating each other regarding the status of such Patent, and shall cooperate with the other\nParty so far as reasonably necessary with respect to furnishing all information and data in its possession reasonably necessary to obtain or maintain\nsuch Patents.\n\n9.4 Infringement of Third Party Patents; Enforcement of Patents.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::65ac2af52d36", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::02606c3073bb"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::02606c3073bb", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.1", "section_title": "Infringement of Third Party Patents", "clause_type": "Intellectual Property – Infringement / Enforcement", "path": "9 ➞ 9.4 ➞ 9.4.1", "text": "and data in its possession reasonably necessary to obtain or maintain\nsuch Patents.\n\n9.4 Infringement of Third Party Patents; Enforcement of Patents.\n\n9.4.1 Infringement of Third Party Patents. Each of the Parties shall promptly, but in any event no later than [***] ([***]) days after receipt\nof notice thereof, notify the other Party in writing in the event of any claims by a Third Party of alleged patent infringement by Aimmune or the other\nAimmune Agreement Entities with respect to the research, development, manufacture, use, sale, offer for sale or importation of the Antibody or Product\n(each, an \"Infringement Claim\"). With respect to any Infringement Claim, the Parties shall attempt to negotiate in good faith a resolution with respect\nthereto. If the Parties cannot settle such Infringement Claim with the appropriate Third Parties within [***] ([***]) days after the receipt of the notice\npursuant to this Section 9.4.1, then the following shall apply:", "numbers_present": null, "definition_terms": ["Infringement Claim"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b35519d5fe4f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c0072378058e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c0072378058e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.1(a)-(b)", "section_title": "Infringement of Third Party Patents", "clause_type": "Infringement defense and control; settlement rights and cooperation", "path": "9 ➞ 9.4 ➞ 9.4.1(a)-(b)", "text": "he appropriate Third Parties within [***] ([***]) days after the receipt of the notice\npursuant to this Section 9.4.1, then the following shall apply:\n\n(a) In the case of any such claim against Aimmune alone or against both Aimmune and Xencor, in each case, with respect to the\nAntibody or Product, then Aimmune shall be deemed to be the \"Controlling Party\" for purposes of such Infringement Claim. In the case of any claim\nagainst Xencor alone, then Xencor shall be deemed to be the \"Controlling Party\" for purposes of such Infringement Claim.\n\n(b) The Controlling Party shall assume control of the defense of such Infringement Claim. The non-Controlling Party, upon request of\nthe Controlling Party, agrees to join in any such litigation, and in any event to reasonably cooperate with the Controlling Party, in each case, at the [***]\nexpense. The non-Controlling Party will have the right to consult with the Controlling Party concerning such Infringement Claim and to participate in and\nbe represented by independent counsel in any litigation in which such non-Controlling Party is a party at its own expense. The Controlling Party shall\nhave the exclusive right to settle any\n\n28", "numbers_present": null, "definition_terms": ["Controlling Party", "Non-Controlling Party"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::02606c3073bb", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::82388cd39b4c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::82388cd39b4c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.1(b) – 9.4.2", "section_title": "Infringement of Third Party Patents; Prosecution of Infringers", "clause_type": "Intellectual Property - Infringement and Enforcement", "path": "9 ➞ 9.4 ➞ 9.4.1(b) ➞ 9.4.2", "text": "y litigation in which such non-Controlling Party is a party at its own expense. The Controlling Party shall\nhave the exclusive right to settle any\n\n28\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nInfringement Claim without the consent of the other Party, unless such settlement would have a material adverse impact on the other Party (in which case\nthe consent of such other Party shall be required). For purposes of this Section 9.4.1(b), any settlement that would involve the waiver of rights (including\nthe rights to receive payments) of such other Party shall be deemed a material adverse impact and shall require the consent of such other Party, such\nconsent not to be unreasonably withheld.\n\n9.4.2 Prosecution of Infringers.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c0072378058e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8bad2b421106"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8bad2b421106", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.2(a)", "section_title": "Prosecution of Infringers (Notice)", "clause_type": "Infringement notification and enforcement procedure", "path": "9 ➞ 9.4 ➞ 9.4.2 ➞ 9.4.2(a)", "text": "rial adverse impact and shall require the consent of such other Party, such\nconsent not to be unreasonably withheld.\n\n9.4.2 Prosecution of Infringers.\n\n(a) Notice. If either Party (i) receives notice of any patent nullity actions, any declaratory judgment actions or any alleged or\nthreatened infringement of patents or patent applications or misappropriation of intellectual property comprising the (w) Joint Inventions, (x) Xencor\nPatents, Xencor Inventions, or Xencor Know-How or (y) Aimmune Patents, Aimmune Inventions, Joint Collaboration Patents or Aimmune Know-How, or\n(ii) learns that a Third Party is infringing or allegedly infringing any Patent within the Xencor Patents, Joint Collaboration Patents or Aimmune Patents, or\nif any Third Party claims that any such Patent is invalid or unenforceable, it will promptly notify the other Party thereof, including providing evidence of\ninfringement or the claim of invalidity or unenforceability reasonably available to such Party. Any matters relating to patent nullity actions, declaratory\njudgment actions or claims of Patent invalidity or unenforceability will be handled as provided in Section 9.3.\n\n(b) Enforcement of Patents.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::82388cd39b4c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3af9782df176"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3af9782df176", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.2(b)(i)", "section_title": "Enforcement of Patents", "clause_type": "Enforcement of Patents", "path": "9 ➞ 9.4 ➞ 9.4.2 ➞ 9.4.2(b) ➞ 9.4.2(b)(i)", "text": "claratory\njudgment actions or claims of Patent invalidity or unenforceability will be handled as provided in Section 9.3.\n\n(b) Enforcement of Patents.\n\n(i) As between the Parties, Aimmune will have the first right (but not the obligation) to take the appropriate steps to enforce\nany Patent within the Xencor Product Specific Patents, Aimmune Patents and Joint Collaboration Patents against infringement by a Third Party, that is, in\neach cause, conducting the manufacture, sale, use, offer for sale or import of any biopharmaceutical product. Aimmune may take any steps it reasonably\nbelieves appropriate to enforce such Patent, including the initiation, prosecution and control of any suit, proceeding or other legal action by counsel of\nits own choice and shall bear the costs of such enforcement, as applicable. Notwithstanding the foregoing, Xencor will have the right, at [***] expense,\nto be represented in any such action by counsel of its own choice.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8bad2b421106", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7409800ac582"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7409800ac582", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.2(b)(ii)", "section_title": "Enforcement of Patents", "clause_type": "Enforcement/Litigation Rights", "path": "9 ➞ 9.4 ➞ 9.4.2 ➞ 9.4.2(b) ➞ 9.4.2(b)(ii)", "text": "cable. Notwithstanding the foregoing, Xencor will have the right, at [***] expense,\nto be represented in any such action by counsel of its own choice.\n\n(ii) If, pursuant to Section 9.4.2(b)(i), Aimmune fails to institute such litigation or otherwise take steps to remedy the\napplicable infringement within [***] ([***]) days of the date one Party has provided notice to the other Party pursuant to Section 9.4.2(a) of such\ninfringement, then Xencor will have the right (but not the obligation), at [***] expense, to bring any such suit, action or proceeding by counsel of its own\nchoice and Aimmune will have the right, at [***] expense, to be represented in any such action by counsel of its own choice.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3af9782df176", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::54719b1ad97a"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::54719b1ad97a", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.2(b)(iii)", "section_title": "Prosecution of Infringers", "clause_type": "Intellectual Property - Enforcement", "path": "9 ➞ 9.4 ➞ 9.4.2 ➞ 9.4.2(b) ➞ 9.4.2(b)(iii)", "text": "ing by counsel of its own\nchoice and Aimmune will have the right, at [***] expense, to be represented in any such action by counsel of its own choice.\n\n(iii) As between the Parties, Xencor will have the sole right (but not the obligation) to take the appropriate steps to enforce\nany Patent within the Xencor General Patents against infringement by a Third Party, that is, in each cause, conducting the manufacture, sale, use, offer for\nsale or import of any biopharmaceutical product. Xencor may take steps including the initiation, prosecution and control of any suit, proceeding or other\nlegal action by counsel of its own choice and shall bear the costs of such enforcement, as applicable.\n\n29\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n(c) Cooperation; Damages.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7409800ac582", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cfa7c577c4c0"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cfa7c577c4c0", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.2(c)(i)-(ii)", "section_title": "Cooperation; Damages.", "clause_type": "Enforcement cooperation (cooperation and damages allocation)", "path": "9 ➞ 9.4 ➞ 9.4.2 ➞ 9.4.2(c) ➞ 9.4.2(c)(i)-(ii)", "text": "choice and shall bear the costs of such enforcement, as applicable.\n\n29\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n(c) Cooperation; Damages.\n\n(i) If one Party brings any suit, action or proceeding under Section 9.4.2(b), the other Party agrees to be joined as party\nplaintiff if necessary to prosecute the suit, action or proceeding and to give the first Party reasonable authority to file and prosecute the suit, action or\nproceeding; provided, however, that neither Party will be required to transfer any right, title or interest in or to any property to the other Party or any\nother party to confer standing on a Party hereunder without the first Party's consent, not to be unreasonably withheld, conditioned or delayed.\n\n(ii) The Party not pursuing the suit, action or proceeding hereunder will provide reasonable assistance to the other Party,\nincluding by providing access to relevant documents and other evidence and making its employees available, subject to the other Party's reimbursement\nof any costs incurred by the non-enforcing or defending Party in providing such assistance.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::54719b1ad97a", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a5c7328d9c3a"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a5c7328d9c3a", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.2(c)(iii)", "section_title": "Cooperation; Damages", "clause_type": "Settlement/consent restriction", "path": "9 ➞ 9.4 ➞ 9.4.2 ➞ 9.4.2(c) ➞ 9.4.2(c)(iii)", "text": "yees available, subject to the other Party's reimbursement\nof any costs incurred by the non-enforcing or defending Party in providing such assistance.\n\n(iii) Aimmune shall not, without the prior written consent of Xencor ([***]), enter into [***] relating to any claim, suit or\naction that it brought under Section 9.4.2 involving a [***]. Xencor shall not, without the prior written consent of Aimmune ([***]), enter into any [***]\nrelating to any claim, suit or action that it brought under Section 9.4.2 involving an [***].", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cfa7c577c4c0", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2d474ea31f8b"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2d474ea31f8b", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.4.2(c)(iv)", "section_title": "Cooperation; Damages", "clause_type": "Settlement and allocation of recoveries (intellectual property enforcement)", "path": "9 ➞ 9.4 ➞ 9.4.2 ➞ 9.4.2(c) ➞ 9.4.2(c)(iv)", "text": "written consent of Aimmune ([***]), enter into any [***]\nrelating to any claim, suit or action that it brought under Section 9.4.2 involving an [***].\n\n(iv) Any settlements, damages or other monetary awards (a \"Recovery\") recovered pursuant to a suit, action or proceeding\nbrought pursuant to Section 9.4.2(b) will be allocated first to the costs and expenses of the Party taking such action, and second, to the costs and\nexpenses (if any) of the other Party, with any remaining amounts (if any) to be allocated as follows: (i) for a suit, action or proceeding controlled by\nAimmune, Aimmune retains [***] percent ([***]%) and Xencor retains [***] percent ([***]%) of such Recovery, and (ii) for a suit, action or proceeding\ncontrolled by Xencor, be allocated between the Parties such that Xencor retains [***] percent ([***]%) and Aimmune retains [***] percent ([***]%) of\nsuch Recovery, provided that, notwithstanding the foregoing clauses (i) or (ii), the portion of any Recoveries from any such actions involving [***].", "numbers_present": null, "definition_terms": ["Recovery"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a5c7328d9c3a", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::267e137f7fd3"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::267e137f7fd3", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.5", "section_title": "Patent Term Extensions", "clause_type": "Intellectual Property - Patent Term Extension", "path": "9 ➞ 9.5", "text": "such Recovery, provided that, notwithstanding the foregoing clauses (i) or (ii), the portion of any Recoveries from any such actions involving [***].\n\n9.5 Patent Term Extensions. As between Xencor and Aimmune, Aimmune shall have the right, but not the obligation, to seek Patent Term\nExtensions (including any supplemental protection certificates and the like available under Applicable Law) in any country in relation to all [***];\nprovided that if, with respect to a given country, Aimmune [***] then Xencor [***]. Aimmune will reasonably consider seeking Patent Term Extensions\nfor [***], and will not [***] for the purpose of [***] under this Agreement. Aimmune and Xencor shall cooperate in connection with all such activities.\nEach Party, its agents and attorneys will give due consideration to all suggestions and comments of the other Party regarding any such activities, but in\nthe event of a disagreement between the Parties, Aimmune will have the final decision making authority as to [***].\n\n30\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2d474ea31f8b", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::df0f60235f0b"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::df0f60235f0b", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "9.6–9.7", "section_title": "Patent Marking; Patent Challenge", "clause_type": "Intellectual Property (patent marking requirement and termination right for patent challenge)", "path": "9 ➞ 9.6; 9 ➞ 9.7; 10 ➞ 10.1 (intro)", "text": "reement between the Parties, Aimmune will have the final decision making authority as to [***].\n\n30\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n9.6 Patent Marking. Aimmune shall mark the Product marketed and sold by Aimmune (or the other Aimmune Agreement Entities) hereunder with\nappropriate patent numbers or indicia.\n\n9.7 Patent Challenge. Xencor will be permitted to terminate this Agreement upon written notice to Aimmune, effective [***] ([***]) days after\nreceipt of written notice thereof by Aimmune, if Aimmune or any of the other Aimmune Agreement Entities, directly or indirectly, (i) [***], or (ii) [***].\n\nARTICLE 10\nREPRESENTATIONS, WARRANTIES AND COVENANTS; COMPLIANCE\n\n10.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as follows, as of the Effective Date:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::267e137f7fd3", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a4c62888880f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a4c62888880f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.1.1", "section_title": "Corporate Existence and Power", "clause_type": "Representation and Warranty", "path": "10 ➞ 10.1 ➞ 10.1.1", "text": "LIANCE\n\n10.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as follows, as of the Effective Date:\n\n10.1.1 Corporate Existence and Power. It is a company or corporation duly organized, validly existing, and in good standing under the laws\nof the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets\nand to carry on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it\nhereunder.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::df0f60235f0b", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2028139a9360"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2028139a9360", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.1.2–10.1.3", "section_title": "Authority and Binding Agreement; No Conflicts", "clause_type": "Representations and Warranties", "path": "10 ➞ 10.1 ➞ 10.1.2; 10 ➞ 10.1 ➞ 10.1.3", "text": "on its business as it is now being conducted and as contemplated in this Agreement, including the right to grant the licenses granted by it\nhereunder.\n\n10.1.2 Authority and Binding Agreement. (i) It has the corporate power and authority and the legal right to enter into this Agreement and\nperform its obligations hereunder, (ii) it has taken all necessary corporate action on its part required to authorize the execution and delivery of this\nAgreement and the performance of its obligations hereunder, and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and\nconstitutes a legal, valid, and binding obligation of such Party that is enforceable against it in accordance with its terms, except as enforcement may be\naffected by bankruptcy, insolvency or other similar laws and by general principles of equity.\n\n10.1.3 No Conflicts. The execution, delivery and performance of this Agreement by it does not (i) conflict with any agreement, instrument\nor understanding, oral or written, to which it is a party and by which it may be bound or (ii) violate any Applicable Law.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a4c62888880f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d642f7c42c5d"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d642f7c42c5d", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.1.4 — 10.2.1", "section_title": "All Consents and Approvals Obtained; Additional Representations, Warranties and Covenants of Xencor", "clause_type": "Representations, Warranties and Covenants", "path": "10 ➞ 10.1 ➞ 10.1.4; 10 ➞ 10.2 ➞ 10.2.1", "text": "h any agreement, instrument\nor understanding, oral or written, to which it is a party and by which it may be bound or (ii) violate any Applicable Law.\n\n10.1.4 All Consents and Approvals Obtained. Except with respect to Regulatory Approvals for the Development, Manufacturing or\nCommercialization of the Product or as otherwise described in this Agreement, (i) all necessary consents, approvals and authorizations of, and (ii) all\nnotices to, and filings by such Party with, all Governmental Authorities and other Persons required to be obtained or provided by such Party as of the\nEffective Date in connection with the execution, delivery and performance of this Agreement have been obtained and provided, except for those\napprovals, if any, not required at the time of execution of this Agreement.\n\n31\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n10.2 Additional Representations, Warranties and Covenants of Xencor. Xencor hereby represents, warrants and covenants to Aimmune that, as of\nthe Effective Date:\n\n10.2.1 Xencor has not filed any Marketing Authorization Applications with a Governmental Authority for the sale of the Product.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2028139a9360", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::84ebd2b84de1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::84ebd2b84de1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.2.1-10.2.5", "section_title": "Additional Representations, Warranties and Covenants of Xencor", "clause_type": "Representations, warranties and covenants", "path": "10 ➞ 10.2 ➞ 10.2.1-10.2.5", "text": "f\nthe Effective Date:\n\n10.2.1 Xencor has not filed any Marketing Authorization Applications with a Governmental Authority for the sale of the Product.\n\n10.2.2 Xencor is the sole owner or licensee of the Xencor Patents existing as of the Effective Date.\n\n10.2.3 There is no Know-How that is owned by or licensed to Xencor that is necessary in connection with the Development, Manufacture,\nCommercialization or other use of the Antibody or Product that is not in the Control of Xencor as the Antibody and Product exist, and as being\nDeveloped and Manufactured, as of the Effective Date.\n\n10.2.4 Schedule 1.79 and Schedule 1.81, when taken together, set forth a true, complete and correct list of all Patents Controlled by Xencor\nor its Affiliates as of the Effective Date that relate to the Antibody or Product and are necessary for Developing, Manufacturing or Commercializing the\nAntibody or Product.\n\n10.2.5 To Xencor's knowledge, Xencor has complied with all Applicable Laws in all material respects, including any disclosure\nrequirements, in connection with the filing, prosecution and maintenance of the Xencor Patents owned by Xencor.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d642f7c42c5d", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9c195250be4a"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9c195250be4a", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.2.6-10.2.9", "section_title": "Additional Representations, Warranties and Covenants of Xencor", "clause_type": "Representations and Warranties", "path": "10 ➞ 10.2 ➞ 10.2.6-10.2.9", "text": "ial respects, including any disclosure\nrequirements, in connection with the filing, prosecution and maintenance of the Xencor Patents owned by Xencor.\n\n10.2.6 Other than as set forth in Schedule 10.2.6, [***] the issued Patents within the Xencor Patents are neither invalid nor unenforceable.\n\n10.2.7 No claim or demand of any Person has been asserted in writing to Xencor or its Affiliates, or to Xencor's knowledge, its licensees or\nsublicensees that challenges the rights of Xencor, its Affiliates, licensees or sublicensees to make, use, sell, exploit or license the Antibody or Product or\nto practice the Xencor Technology.\n\n10.2.8 Neither Xencor nor, to the knowledge of Xencor, its Affiliates, licensees, sublicensees or subcontractors have received written\nnotice of any proceedings pending before or threatened by any Regulatory Authority with respect to the Antibody or Product.\n\n10.2.9 The Upstream Agreement is in full force and effect and, to its knowledge, no facts or circumstances exist that would give either party\nto the Upstream Agreement the right to terminate for the other party's material breach thereof.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::84ebd2b84de1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c76e500f78d2"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c76e500f78d2", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.2.10-10.2.11", "section_title": "Additional Representations, Warranties and Covenants of Xencor", "clause_type": "Representations and Warranties", "path": "10 ➞ 10.2 ➞ 10.2.10; 10 ➞ 10.2 ➞ 10.2.11", "text": "ts or circumstances exist that would give either party\nto the Upstream Agreement the right to terminate for the other party's material breach thereof.\n\n10.2.10 Xencor has not used in any capacity, in connection with its Development or Manufacture of the Product prior to the Effective Date\nany Person who has been debarred pursuant to Section 306 of the FD&C Act (or similar Applicable Law outside of the U.S.), or who is the subject of a\nconviction described in such section.\n\n32\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n10.2.11 Neither Xencor nor its Affiliates or, to the knowledge of Xencor, its licensees, sublicensees or subcontractors have made any\nmaterial misstatements in any regulatory filing with any Regulatory Authority with respect to the Antibody or Product.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9c195250be4a", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::789c91ba1f01"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::789c91ba1f01", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.2.12-10.2.14", "section_title": "Additional Representations, Warranties and Covenants of Xencor", "clause_type": "Representations and Warranties", "path": "10 ➞ 10.2 ➞ 10.2.12-10.2.14", "text": "or subcontractors have made any\nmaterial misstatements in any regulatory filing with any Regulatory Authority with respect to the Antibody or Product.\n\n10.2.12 Neither Xencor nor, to the knowledge of Xencor, its Affiliates, licensees, sublicensees or independent contractors have received\nany notices or claims of noncompliance with Applicable Law relating to activities conducted by or facilities used by, Xencor, its Affiliates, licensees,\nsublicensees or independent contractors in connection with the Development or Manufacture of Antibody or Product, and Xencor is not aware of any\nreasonable basis for any such notices or claims.\n\n10.2.13 [***] as of the Effective Date, neither the Development, Manufacture nor Commercialization of Antibody in the Licensed Field as\nthe Antibody exists as of the Effective Date will infringe or misappropriate any intellectual property rights of any Third Party.\n\n10.2.14 To Xencor's knowledge, Xencor has disclosed to Aimmune all material information in its possession or Control relating to the\nAntibody and Product, and all such information is accurate in all material respects.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c76e500f78d2", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9c9f310eadd1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9c9f310eadd1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.2.15–10.3.2", "section_title": "Additional Representations, Warranties and Covenants of Xencor; Additional Representations, Warranties and Covenants of Aimmune", "clause_type": "Representations, Warranties and Covenants", "path": "10 ➞ 10.2 ➞ 10.2.15–10.2.16; 10 ➞ 10.3 ➞ 10.3.1–10.3.2", "text": "material information in its possession or Control relating to the\nAntibody and Product, and all such information is accurate in all material respects.\n\n10.2.15 Neither Xencor nor its Affiliates have developed or commercialized, and are not developing or commercializing, either directly or\nthrough enabling any Third Party (by license, sublicense or other grant of rights or performance of actions), any antibody [***], other than the Antibody.\n\n10.2.16 The following variations of the Antibody are not required to Develop, Manufacture and Commercialize the Product in the Licensed\nField: (i) [***], (ii) [***], (iii) [***], (iv) [***], (v) [***], or (vi) [***].\n\n10.3 Additional Representations, Warranties and Covenants of Aimmune. Aimmune hereby represents, warrants and covenants to Xencor that, as\nof the Effective Date:\n\n10.3.1 [***]\n\n10.3.2 Aimmune and its Affiliates (a) have not developed or commercialized, and (b) are not developing or commercializing, either directly\nor through enabling any Third Party, any antibody [***] other than the Antibody and Product pursuant to this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::789c91ba1f01", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c326c351d831"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c326c351d831", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.3.3 - 10.5", "section_title": "Additional Representations, Warranties and Covenants of Aimmune; Disclaimer; No Other Representations or Warranties", "clause_type": "Representations and Warranties / Disclaimer / Warranty Exclusion", "path": "10 ➞ 10.3 ➞ 10.3.3; 10 ➞ 10.4; 10 ➞ 10.5", "text": "mmercializing, either directly\nor through enabling any Third Party, any antibody [***] other than the Antibody and Product pursuant to this Agreement.\n\n10.3.3 As of the Effective Date, Aimmune has conducted due diligence in connection with the Development and Manufacture of the\nProduct in the Licensed Field.\n\n10.4 Disclaimer. Aimmune understands that the Product is the subject of ongoing clinical research and development and that Xencor cannot\nensure the safety or usefulness of the Product or that the Product will receive Regulatory Approvals.\n\n33\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n10.5 No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR\nWARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A\nPARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE\nOR GIVEN BY OR ON BEHALF OF A PARTY. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES,\nWHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.\n\n10.6 Compliance.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9c9f310eadd1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0d3831bb9db0"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0d3831bb9db0", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.6.1", "section_title": "Compliance with Anti-Corruption Laws", "clause_type": "Compliance / Anti-Corruption covenant", "path": "10 ➞ 10.6 ➞ 10.6.1", "text": "THIS AGREEMENT, ALL REPRESENTATIONS AND WARRANTIES,\nWHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.\n\n10.6 Compliance.\n\n10.6.1 Compliance with Anti-Corruption Laws. In connection with this Agreement, each Party represents, warrants and covenants to the\nother Party that it has complied and will comply with all Applicable Laws (including Anti-Corruption Laws) and industry codes dealing with government\nprocurement, conflicts of interest, corruption or bribery, including, if applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any laws\nenacted to implement the Organization of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in International\nBusiness Transactions.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c326c351d831", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::34e188d44e66"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::34e188d44e66", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "10.6.2", "section_title": "Prohibited Conduct", "clause_type": "Compliance / Anti‑Corruption covenant", "path": "10 ➞ 10.6 ➞ 10.6.2", "text": "the Organization of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in International\nBusiness Transactions.\n\n10.6.2 Prohibited Conduct. In connection with this Agreement, each Party represents, warrants and covenants to the other Party that it has\nnot made, offered, given, promised to give, or authorized, and will not make, offer, give, promise to give, or authorize, any bribe, kickback, payment or\ntransfer of anything of value, directly or indirectly, to any person or to any Government Official for the purpose of: (i) improperly influencing any act or\ndecision of the person or Government Official; (ii) inducing the person or Government Official to do or omit to do an act in violation of a lawful or\notherwise required duty; (iii) securing any improper advantage; or (iv) inducing the person or Government Official to improperly influence the act or\ndecision of any organization, including any government or government instrumentality, in order to assist such Party in obtaining or retaining business.\n\nARTICLE 11\nINDEMNIFICATION", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0d3831bb9db0", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cd642378e5c9"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cd642378e5c9", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.1", "section_title": "Indemnification by Xencor", "clause_type": "Indemnification", "path": "11 ➞ 11.1", "text": "including any government or government instrumentality, in order to assist such Party in obtaining or retaining business.\n\nARTICLE 11\nINDEMNIFICATION\n\n11.1 Indemnification by Xencor. Xencor hereby agrees to save, indemnify, defend and hold Aimmune, its Affiliates, and their respective directors,\nofficers, agents and employees harmless from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys'\nfees and expenses) (collectively, \"Losses\") arising in connection with any and all charges, complaints, actions, suits, proceedings, hearings,\ninvestigations, claims, demands, judgments, orders, decrees, stipulations or injunctions by a Third Party (each a \"Claim\") resulting or otherwise arising\nfrom (i) any breach by Xencor of any of its representations, warranties, covenants or obligations pursuant to this Agreement, (ii) the Development,\nManufacturing, Commercialization (if applicable, after the Term) or the performance of a Clinical Trial for the Antibody or Product conducted by or on\nbehalf of Xencor (or its Affiliates, licensees (other than Aimmune and its Affiliates and Sublicensees), sublicensees, or independent contractors), prior to\nthe Effective Date or after the Term, provided that this Section (ii) is not intended to extend to strict liability Claims relating to the Product, (iii) [***], and\n(iv) the negligence or willful misconduct by Xencor or its Affiliates, licensees, sublicensees or subcontractors or their respective officers, directors,\nemployees, agents or consultants in performing any obligations under this Agreement, in each case except to the extent that such Losses are subject to\nindemnification by Aimmune pursuant to Section 11.2.", "numbers_present": null, "definition_terms": ["Losses", "Claim"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::34e188d44e66", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c7970d687b6f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c7970d687b6f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.1", "section_title": "Indemnification by Xencor", "clause_type": "Indemnification", "path": "11 ➞ 11.1", "text": "ligations under this Agreement, in each case except to the extent that such Losses are subject to\nindemnification by Aimmune pursuant to Section 11.2.\n\n34\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cd642378e5c9", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4c27984db69e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4c27984db69e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.2", "section_title": "Indemnification by Aimmune", "clause_type": "Indemnification", "path": "11 ➞ 11.2", "text": "the extent that such Losses are subject to\nindemnification by Aimmune pursuant to Section 11.2.\n\n34\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n11.2 Indemnification by Aimmune. Aimmune hereby agrees to save, indemnify, defend and hold Xencor, its Affiliates, and their respective\ndirectors, agents and employees harmless from and against any and all Losses arising in connection with any and all Claims resulting or otherwise arising\nfrom (i) any breach by Aimmune of any of its representations, warranties, covenants or obligations pursuant to this Agreement, (ii) [***], (iii) the\nnegligence or willful misconduct by Aimmune (or its Affiliates, Sublicensees, subcontractors, wholesalers or distributors) or their respective officers,\ndirectors, employees, agents or consultants in performing any obligations under this Agreement, or (iv) the Development, Manufacturing, Packaging and\nLabeling or Commercialization of the Antibody or a Product hereunder during or after the Term (including, for clarity, any product liability Losses\nresulting therefrom) by Aimmune (or its Affiliates, Sublicensees, subcontractors, wholesalers or distributors) or their respective officers, directors,\nemployees, agents or consultants, in each case except to the extent that such Losses are subject to indemnification by Xencor pursuant to Section 11.1.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c7970d687b6f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::58637e4cff51"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::58637e4cff51", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.3", "section_title": "Indemnification Procedures", "clause_type": "Indemnification Procedures", "path": "11 ➞ 11.3", "text": "mployees, agents or consultants, in each case except to the extent that such Losses are subject to indemnification by Xencor pursuant to Section 11.1.\n\n11.3 Indemnification Procedures.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4c27984db69e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::78eea43f644c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::78eea43f644c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.3.1", "section_title": "Indemnification Procedures", "clause_type": "Indemnification procedures", "path": "11 ➞ 11.3 ➞ 11.3.1", "text": "n each case except to the extent that such Losses are subject to indemnification by Xencor pursuant to Section 11.1.\n\n11.3 Indemnification Procedures.\n\n11.3.1 A Party believing that it is entitled to indemnification under, as applicable, Section 11.1 or Section 11.2 (an \"Indemnified Party\") shall\ngive prompt written notification to the other Party (the \"Indemnifying Party\") of the commencement of any Claim for which indemnification may be\nsought or, if earlier, upon the assertion of any such Claim by a Third Party (it being understood and agreed, however, that the failure by an Indemnified\nParty to give notice of a Claim as provided in this Section 11.3.1 shall not relieve the Indemnifying Party of its indemnification obligation under this\nAgreement except and only to the extent that such Indemnifying Party is actually materially prejudiced as a result of such failure to give notice). Within\n[***] ([***]) days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, assume control of\nthe defense of such Claim with counsel reasonably satisfactory to the Indemnified Party. If a Party believes that a Claim presented to it for indemnification\nis one as to which the Party seeking indemnification is not entitled to indemnification under, as applicable, Section 11.1 or Section 11.2, it shall so notify\nthe Party seeking indemnification.", "numbers_present": null, "definition_terms": ["Indemnified Party", "Indemnifying Party"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::58637e4cff51", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6c1c1a105adc"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6c1c1a105adc", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.3.2–11.3.3", "section_title": "Indemnification Procedures", "clause_type": "Indemnification procedure", "path": "11 ➞ 11.3 ➞ 11.3.2 / 11.3.3", "text": "ification is not entitled to indemnification under, as applicable, Section 11.1 or Section 11.2, it shall so notify\nthe Party seeking indemnification.\n\n11.3.2 If the Indemnifying Party elects to assume the defense of such Claim, the Indemnified Party may participate in such defense at its\nown expense; provided, that if the Indemnified Party reasonably concludes, based on advice from counsel, that the Indemnifying Party and the\nIndemnified Party have conflicting interests with respect to such Claim, the Indemnifying Party shall be responsible for the reasonable fees and expenses\nof counsel to the Indemnified Party solely in connection therewith.\n\n11.3.3 The Indemnifying Party shall keep the Indemnified Party advised of the status of such Claim and the defense thereof and shall\nconsider recommendations made by the Indemnified Party with respect thereto.\n\n35\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::78eea43f644c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::968008dc572e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::968008dc572e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.3.4", "section_title": null, "clause_type": "Indemnification — Settlement Consent", "path": "11 ➞ 11.3 ➞ 11.3.4", "text": "thereof and shall\nconsider recommendations made by the Indemnified Party with respect thereto.\n\n35\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n11.3.4 The Indemnified Party shall not agree to any settlement of such Claim without the prior written consent of the Indemnifying Party,\nwhich shall not be unreasonably withheld. The Indemnifying Party shall not agree to any settlement of such Claim or consent to any judgment in respect\nthereof that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto or that imposes any\nliability or obligation on the Indemnified Party or adversely affects the Indemnified Party without the prior written consent of the Indemnified Party, which\nshall not be unreasonably withheld.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6c1c1a105adc", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::447d2347704f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::447d2347704f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.4", "section_title": "Limitation of Liability", "clause_type": "Limitation of Liability clause", "path": "11 ➞ 11.4", "text": "Party or adversely affects the Indemnified Party without the prior written consent of the Indemnified Party, which\nshall not be unreasonably withheld.\n\n11.4 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFITS, OR ANY SPECIAL,\nCONSEQUENTIAL, INCIDENTAL, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT,\nREGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION\n11.4 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1\nor 11.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::968008dc572e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7fae57b03f50"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7fae57b03f50", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "11.5", "section_title": "Insurance", "clause_type": "Insurance", "path": "11 ➞ 11.5", "text": "HTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 11.1\nor 11.2, OR DAMAGES AVAILABLE FOR A PARTY'S BREACH OF CONFIDENTIALITY OBLIGATIONS UNDER ARTICLE 12.\n\n11.5 Insurance. Aimmune shall procure and maintain insurance, including clinical trials insurance and product liability insurance, adequate to cover\nits obligations hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which the\nProduct is being clinically tested in human subjects or commercially distributed or sold by Aimmune pursuant to this Agreement; provided, that any such\nclinical trials insurance coverage shall, prior to the First Commercial Sale of a Product, in no event be less than [***] Dollars ($[***]) per loss occurrence,\nand product liability insurance coverage shall, after such First Commercial Sale, in no event be less than [***] Dollars ($[***]) per loss occurrence. It is\nunderstood that such insurance shall not be construed to create a limit of Aimmune's liability with respect to its indemnification obligations under this\nARTICLE 11. Aimmune shall provide Xencor with written evidence of such insurance prior to commencement of this Agreement and upon expiration of\nany one coverage. Aimmune shall provide Xencor with written notice at least [***] ([***]) days prior to the cancellation, nonrenewal or material change\nin such insurance or self-insurance which materially adversely affects the rights of Xencor hereunder.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::447d2347704f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::77618be9cade"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::77618be9cade", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.1.1", "section_title": "Confidential Information", "clause_type": "Confidentiality / Non-disclosure obligations", "path": "12 ➞ 12.1 ➞ 12.1.1", "text": "the cancellation, nonrenewal or material change\nin such insurance or self-insurance which materially adversely affects the rights of Xencor hereunder.\n\nARTICLE 12\nCONFIDENTIALITY\n\n12.1 Confidential Information.\n\n12.1.1 The Parties agree that during the Term, and for a period of [***] ([***]) years thereafter, a Party receiving Confidential Information\nof the other Party will (X) maintain in confidence such Confidential Information to the same extent such Party maintains its own proprietary information of\nsimilar kind and value, and, in any event, no less than a reasonable standard of care, (Y) not disclose such Confidential Information to any Third Party\nwithout the prior written consent of the other Party, except as otherwise expressly permitted below, and (Z) not use such Confidential Information for any\npurpose except those permitted by this Agreement.\n\n36\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::7fae57b03f50", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e90f1aa682a1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e90f1aa682a1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.1.1", "section_title": "Confidential Information", "clause_type": "Confidentiality (definition and exceptions)", "path": "12 ➞ 12.1 ➞ 12.1.1", "text": "not use such Confidential Information for any\npurpose except those permitted by this Agreement.\n\n36\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nAs used herein, \"Confidential Information\" means all Know-How and other information and materials received by either Party from the other Party or its\nAffiliates pursuant to this Agreement. The foregoing obligations and the other obligations set forth in this Section 12.1 shall not apply with respect to\nany portion of such Confidential Information which:\n\n(a) is publicly disclosed by the disclosing Party, either before or after it becomes known to the receiving Party;\n\n(b) was known to the receiving Party or any or its Affiliates, without any obligation to keep it confidential, prior to when it was\nreceived from the disclosing Party;\n\n(c) is subsequently disclosed to the receiving Party or any of its Affiliates by a Third Party that is lawfully in possession thereof\nwithout obligation to keep it confidential;\n\n(d) has been published by a Third Party or otherwise enters the public domain through no fault of the receiving Party or any of its\nAffiliates in breach of this Agreement; or", "numbers_present": null, "definition_terms": ["Confidential Information"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::77618be9cade", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8a1e7f4aea3d"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8a1e7f4aea3d", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.1.1(d)-(e)", "section_title": "Confidential Information", "clause_type": "Confidentiality exclusions", "path": "12 ➞ 12.1 ➞ 12.1.1 ➞ 12.1.1(d)-(e)", "text": "y a Third Party or otherwise enters the public domain through no fault of the receiving Party or any of its\nAffiliates in breach of this Agreement; or\n\n(e) has been independently developed or acquired by the receiving Party or any of its Affiliates without the aid, application or use of\nthe disclosing Party's Confidential Information.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e90f1aa682a1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::686b57aa9417"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::686b57aa9417", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.1.2", "section_title": "Confidential Information", "clause_type": "Permitted disclosure / compliance with law", "path": "12 ➞ 12.1 ➞ 12.1.2", "text": "ed or acquired by the receiving Party or any of its Affiliates without the aid, application or use of\nthe disclosing Party's Confidential Information.\n\n12.1.2 The receiving Party shall have the right to disclose any Confidential Information provided by the other Party hereunder if, in the\nreasonable opinion of the receiving Party's legal counsel, such disclosure is necessary to comply with the terms and conditions of this Agreement, or the\nrequirements of any law or rule imposed by the U.S. Securities and Exchange Commission or any securities exchange or other Applicable Law, but only to\nthe extent of such necessity or requirements; and no such disclosure shall cause any such information to cease to be Confidential Information hereunder,\nexcept to the extent such disclosure results in a public disclosure of such information. Where reasonably possible, the receiving Party shall notify the\ndisclosing Party of the receiving Party's intent to make such disclosure of Confidential Information pursuant to the preceding sentence sufficiently prior\nto making such disclosure so as to allow the disclosing Party adequate time to take whatever action the disclosing Party may deem to be appropriate to\nprotect the confidentiality of the Confidential Information.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8a1e7f4aea3d", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a0f9368969fd"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a0f9368969fd", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.1.3", "section_title": "Confidential Information (Permitted Disclosures/Access)", "clause_type": "Confidentiality (permitted disclosures/access to confidential information)", "path": "12 ➞ 12.1 ➞ 12.1.3", "text": "adequate time to take whatever action the disclosing Party may deem to be appropriate to\nprotect the confidentiality of the Confidential Information.\n\n12.1.3 Except as set forth above, each Party agrees that it shall provide or permit access to Confidential Information of the other Party only\nto (i) the receiving Party's attorneys, independent accountants and financial advisors for the sole purpose of enabling such attorneys, independent\naccountants and financial advisors to provide advice to the receiving Party and (ii) the receiving Party's Affiliates, directors, officers, employees,\nconsultants, advisors, actual or potential acquirers and permitted subcontractors, sublicensees and subdistributors, and to the directors, officers,\nemployees, consultants, advisors and permitted subcontractors, actual or potential acquirers, sublicensees and subdistributors of such Affiliates, who\nhave a need to know such Confidential Information to assist the receiving Party with the\n\n37\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::686b57aa9417", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::19e69dcd4ac9"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::19e69dcd4ac9", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.1.3", "section_title": "Confidential Information", "clause_type": "Confidentiality - permitted recipients / disclosure", "path": "12 ➞ 12.1 ➞ 12.1.3", "text": "s, who\nhave a need to know such Confidential Information to assist the receiving Party with the\n\n37\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nactivities contemplated or required of it by this Agreement; provided that in each case the Person to whom Confidential Information is being disclosed is\nsubject to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of\nconfidentiality and nonuse of the receiving Party pursuant to this Section 12.1; and provided further, that each Party shall remain responsible for any\nfailure by its attorneys, independent accountants and financial advisors, Affiliates, and its and its Affiliates' respective directors, officers, employees,\nconsultants, advisors, actual or potential acquirers and permitted subcontractors, sublicensees and subdistributors, to treat such Confidential\nInformation as required under this Section 12.1.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a0f9368969fd", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e469c417c622"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e469c417c622", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.1.3", "section_title": "Confidential Information", "clause_type": "Confidentiality; permitted disclosures (recipients and tax-related disclosures)", "path": "12 ➞ 12.1 ➞ 12.1.3", "text": "acquirers and permitted subcontractors, sublicensees and subdistributors, to treat such Confidential\nInformation as required under this Section 12.1.\n\nFor clarity, either Party may disclose without any limitation such Party's U.S. federal income tax treatment and the U.S. federal income tax structure of the\ntransactions relating to such Party that are based on or derived from this Agreement, as well as all materials of any kind (including opinions, other tax\nanalyses, or a complete copy of this Agreement and any amendments thereto) relating to such tax treatment or tax structure, except to the extent that\nnondisclosure of such matters is reasonably necessary in order to comply with applicable securities laws.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::19e69dcd4ac9", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c2a587547f77"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c2a587547f77", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.1.4", "section_title": "Confidential Information", "clause_type": "Injunctive relief / equitable remedies (confidentiality)", "path": "12 ➞ 12.1 ➞ 12.1.4", "text": "or tax structure, except to the extent that\nnondisclosure of such matters is reasonably necessary in order to comply with applicable securities laws.\n\n12.1.4 Each Party acknowledges that a Party in breach of any of its obligations under this Section 12.1 shall cause the non-breaching Party\nirreparable harm, for which monetary damages will be an inadequate remedy. Therefore, notwithstanding anything to the contrary in this Agreement in the\nevent of any such breach, the non-breaching Party shall be entitled, in addition to any other remedy available to it under this Agreement, at law or in\nequity, to injunctive relief, including an accounting for profits, specific performance of the terms hereof and other equitable relief for such breach, without\nthe posting of bond or other security.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e469c417c622", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9f74292fac05"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9f74292fac05", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.2", "section_title": "Publicity", "clause_type": "Publicity / Press Release", "path": "12 ➞ 12.2", "text": "nting for profits, specific performance of the terms hereof and other equitable relief for such breach, without\nthe posting of bond or other security.\n\n12.2 Publicity. Promptly after the Effective Date, the Parties shall each issue the applicable press release in the form attached hereto as\nSchedule 12.2, with respect to this Agreement. Subject to the foregoing, any press releases or other public statements or disclosures regarding the\nsubject matter of this Agreement shall be subject to the express prior written consent of each of the Parties; provided that a disclosure shall be permitted\nwithout the other Party's consent to the extent that it does not contain information beyond that included in a prior disclosure approved in writing by both\nParties. Notwithstanding the foregoing any disclosure which is required by Applicable Law or the rules of the U.S. Securities and Exchange Commission\nor any securities exchange, as reasonably advised by the disclosing Party's counsel, may be made without the prior consent of the other Party, although,\nprior to any such legally required disclosure by a Party, such Party shall use reasonable efforts where practicable to give the other Party reasonable\nnotice and an opportunity to comment on the proposed disclosure.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c2a587547f77", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::30da4ea496f4"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::30da4ea496f4", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.3", "section_title": "Securities Filings", "clause_type": "Securities filing / Public disclosure obligations", "path": "12 ➞ 12.3", "text": "rty shall use reasonable efforts where practicable to give the other Party reasonable\nnotice and an opportunity to comment on the proposed disclosure.\n\n12.3 Securities Filings. In the event either Party proposes to file with the U.S. Securities and Exchange Commission or the securities\nregulators of any state or other jurisdiction under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or any other\napplicable securities law a registration statement or any other disclosure document which describes or refers to this Agreement, such Party shall notify\nthe other Party of such intention and shall provide such other Party with a copy of relevant portions of the proposed filing not less than [***] ([***])\nBusiness Days prior to such filing (or such shorter period of time as may be required in the circumstances, and any revisions to such\n\n38\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9f74292fac05", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0f65eba6230d"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0f65eba6230d", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.3", "section_title": "Securities Filings", "clause_type": "Disclosure / Securities Filings", "path": "12 ➞ 12.3", "text": "such shorter period of time as may be required in the circumstances, and any revisions to such\n\n38\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nportions of the proposed filing a reasonable time prior to the filing thereof), and shall use reasonable efforts where practicable to consider such comments\nto the extent consistent with such Party's disclosure obligations under applicable securities laws or rules of a securities exchange.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::30da4ea496f4", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e44983e7a6e1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e44983e7a6e1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.4", "section_title": "Publications", "clause_type": "Confidentiality (Publication restriction)", "path": "12 ➞ 12.4", "text": "er such comments\nto the extent consistent with such Party's disclosure obligations under applicable securities laws or rules of a securities exchange.\n\n12.4 Publications. Except for disclosures permitted under this Agreement, if Xencor, its Affiliates, or its employee(s) or consultant(s) wishes to\nmake a publication or presentation specific to the Product or which otherwise may reasonably contain Know-How, or other intellectual property, of\nAimmune, Xencor must receive written approval, not to be unreasonably withheld, conditioned or delayed, from Aimmune at least [***] ([***]) days\nprior to submission for publication or presentation. If Aimmune, its Affiliates, or its employee(s) or consultant(s) wishes to make a publication specific to\nthe Product or which otherwise may reasonably contain Xencor Technology, Aimmune shall deliver to Xencor a copy of the proposed written publication\nor an outline of an oral disclosure at least [***] ([***]) days prior to submission for publication or presentation and reasonably consider any comments\nof Xencor thereon; provided that subject to Sections 12.1 through 12.3, to the extent such publication describes or is specific to Xencor Technology,\nAimmune must receive written approval, not to be unreasonably withheld, conditioned or delayed, from Xencor prior to submitting such publication to\nany Third Party.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::0f65eba6230d", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::acd9e6bcb7e9"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::acd9e6bcb7e9", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.5", "section_title": "Use of Names", "clause_type": "Confidentiality/Publicity", "path": "12 ➞ 12.5", "text": "eceive written approval, not to be unreasonably withheld, conditioned or delayed, from Xencor prior to submitting such publication to\nany Third Party.\n\n12.5 Use of Names. Except as otherwise set forth in this Agreement, neither Party shall use the name of the other Party in relation to this\ntransaction in any public announcement, press release or other public document without the written consent of such other Party, which consent shall not\nbe unreasonably withheld; provided, however, that subject to Section 12.3, either Party may use the name of the other Party in any document filed with\nany Regulatory Authority or Governmental Authority, including the Securities and Exchange Commission or the rules of any securities exchange.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e44983e7a6e1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d0af4153123b"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d0af4153123b", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.6", "section_title": "Unauthorized Disclosure of Confidential Information", "clause_type": "Confidentiality (unauthorized disclosure response/notification/remediation)", "path": "12 ➞ 12.6", "text": "led with\nany Regulatory Authority or Governmental Authority, including the Securities and Exchange Commission or the rules of any securities exchange.\n\n12.6 Unauthorized Disclosure of Confidential Information. Each Party shall have a response plan in place for any disclosure of Confidential\nInformation that is not authorized or otherwise permitted under this Agreement. Such plan shall include considerations of, among other things,\nnotification, remediation and retrieval. In the event that a Party becomes aware of an unauthorized disclosure of Confidential Information, then such Party\nshall notify the other Party promptly in writing.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::acd9e6bcb7e9", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e937a443909d"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e937a443909d", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "12.7", "section_title": "Prior CDA", "clause_type": "Confidentiality (prior confidentiality agreement / supersession)", "path": "12 ➞ 12.7", "text": "hat a Party becomes aware of an unauthorized disclosure of Confidential Information, then such Party\nshall notify the other Party promptly in writing.\n\n12.7 Prior CDA. As of the Effective Date, the terms of this ARTICLE 12 shall supersede any prior non-disclosure, secrecy or confidentiality\nagreement between the Parties (or their Affiliates) dealing with the subject of this Agreement, including the Confidentiality Agreement between the\nParties dated [***]. Any information disclosed pursuant to any such prior agreement shall be deemed Confidential Information of the applicable Party for\npurposes of this Agreement, to the extent that such information was deemed to be \"Proprietary Information\" under such prior agreement.\n\n39\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nARTICLE 13\nTERM AND TERMINATION", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d0af4153123b", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a8f41d06ee60"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a8f41d06ee60", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "13.1", "section_title": "Term", "clause_type": "Term/Duration (Termination provisions)", "path": "13 ➞ 13.1", "text": "ed to be \"Proprietary Information\" under such prior agreement.\n\n39\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nARTICLE 13\nTERM AND TERMINATION\n\n13.1 Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this ARTICLE 13, shall remain in\neffect on a Product-by-Product and country-by-country basis until the expiration of the Royalty Term applicable to such Product and country (the\n\"Term\"). Upon expiration of this Agreement with respect to a Product in a country, the licenses granted to Aimmune pursuant to this Agreement shall\ncontinue in full force and effect on a fully-paid basis.", "numbers_present": null, "definition_terms": ["Term"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e937a443909d", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::efc73c527705"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::efc73c527705", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "13.2", "section_title": "Termination for Breach", "clause_type": "Termination for Breach", "path": "13 ➞ 13.2", "text": "t to a Product in a country, the licenses granted to Aimmune pursuant to this Agreement shall\ncontinue in full force and effect on a fully-paid basis.\n\n13.2 Termination for Breach. Either Party may, without prejudice to any other remedies available to it at law or in equity, terminate this Agreement\nupon written notice to the other Party in the event that the other Party (the \"Breaching Party\") shall have materially breached or defaulted in the\nperformance of any of its obligations. The Breaching Party shall have sixty (60) days (thirty (30) days in the event of non-payment) after written notice\nthereof was provided to the Breaching Party by the non-breaching Party to remedy such default. Unless the Breaching Party has cured any such breach\nor default prior to the expiration of such sixty (60) day period (thirty (30) day period for non-payment), such termination shall become effective upon\nreceipt of the written notice of termination by the Breaching Party to be given within ten (10) days of the end of such sixty (60) day period (thirty (30) day\nperiod for non-payment). Notwithstanding the foregoing, in the event that Aimmune as the Breaching Party has materially breached or defaulted in the\nperformance of any of its payment obligations under this Agreement a third time or more in any three (3) year period, then Xencor shall have the right to\nterminate this Agreement immediately by providing written notice Aimmune, without Aimmune having opportunity to cure such breach or default.", "numbers_present": null, "definition_terms": ["Breaching Party"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a8f41d06ee60", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::545849b7e40c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::545849b7e40c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "13.3–13.5; 14.1", "section_title": "Termination as a Result of Bankruptcy; Termination by Aimmune; Termination by Xencor; Effects of Expiration or Termination — Licenses", "clause_type": "Termination and post-termination effects", "path": "13 ➞ 13.3; 13 ➞ 13.4; 13 ➞ 13.5; 14 ➞ 14.1", "text": "right to\nterminate this Agreement immediately by providing written notice Aimmune, without Aimmune having opportunity to cure such breach or default.\n\n13.3 Termination as a Result of Bankruptcy. Each Party shall have the right to terminate this Agreement upon written notice as a result of the\nfiling or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for\nthe benefit of creditors by the other Party; provided that such termination shall be effective only if such proceeding is not dismissed within ninety (90)\ndays after the filing thereof.\n\n13.4 Termination by Aimmune. Aimmune may terminate this Agreement in its entirety at any time for its convenience upon sixty (60) days' prior\nwritten notice to Xencor.\n\n13.5 Termination by Xencor. Without limitation of its rights under this ARTICLE 13, Xencor may also terminate this Agreement in its entirety as\napplicable, pursuant to the provisions of Section 9.7.\n\nARTICLE 14\nEFFECTS OF EXPIRATION OR TERMINATION\n\n14.1 Licenses. Upon the termination of this Agreement:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::efc73c527705", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6901c33f43f0"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6901c33f43f0", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.1.1", "section_title": "Licenses", "clause_type": "Effects of Termination (post-termination licenses and inventory disposition)", "path": "14 ➞ 14.1 ➞ 14.1.1", "text": "e, pursuant to the provisions of Section 9.7.\n\nARTICLE 14\nEFFECTS OF EXPIRATION OR TERMINATION\n\n14.1 Licenses. Upon the termination of this Agreement:\n\n14.1.1 all rights and licenses granted to Aimmune hereunder shall immediately terminate and be of no further force and effect and Aimmune\nshall cease Developing, Commercializing, Manufacturing and Packaging and Labeling such Product in and for all applicable countries; provided, that\nAimmune and its Affiliates will be entitled, during the period\n\n40\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nending on the last day of the [***] following the effective date of such termination, to sell any inventory of Product affected by such termination that\nremains on hand as of the effective date of the termination, so long as Aimmune pays to Xencor all amounts payable hereunder (including milestones)\napplicable to said subsequent sales, as applicable, in accordance with the terms and conditions set forth in this Agreement and otherwise complies with\nthe terms set forth in this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::545849b7e40c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::af2400cd57e1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::af2400cd57e1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.1.2–14.2", "section_title": "Licenses; Assignments", "clause_type": "Post-termination licenses and assignment/transition obligations", "path": "14 ➞ 14.1 ➞ 14.1.2; 14 ➞ 14.2", "text": "applicable, in accordance with the terms and conditions set forth in this Agreement and otherwise complies with\nthe terms set forth in this Agreement.\n\n14.1.2 Aimmune hereby grants to Xencor an exclusive license under and with respect to Aimmune Patents, and a non-exclusive license\nunder and with respect to Aimmune Know-How, in each case, where such license is an irrevocable, perpetual, royalty-bearing license, with the right to\nsublicense, to Develop, Manufacture and Commercialize the Product(s), as the Product(s) exist as of the effective date of such termination, or optimized\nversions thereof that are Products. For clarity, upon the termination of this Agreement, as consideration for such licenses granted under this Section\n14.1.2, Xencor shall [***], and Xencor shall be responsible for [***]; provided further that Xencor shall have the right to terminate such license and\nforgo paying such royalties at its sole discretion upon written notice to Aimmune.\n\n14.2 Assignments. Upon the termination of this Agreement, Aimmune will promptly, in each case within [***] ([***]) days thereafter:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6901c33f43f0", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a885dce4cc76"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a885dce4cc76", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.2", "section_title": "Assignments", "clause_type": "Post-termination assignment of agreements/assets", "path": "14 ➞ 14.2 ➞ 14.2(a)", "text": "otice to Aimmune.\n\n14.2 Assignments. Upon the termination of this Agreement, Aimmune will promptly, in each case within [***] ([***]) days thereafter:\n\n(a) assign to Xencor, [***], all of Aimmune's right, title and interest in and to any agreements (or portions thereof) between Aimmune\nand Third Parties that relate to the Development, Commercialization or Manufacture of the Product, where such assignment is permitted without charge to\nAimmune or its Affiliates and where Xencor shall assume all future payments due under any agreement assigned pursuant to this subsection;", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::af2400cd57e1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f743003296e4"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f743003296e4", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.2(b)", "section_title": "Assignments", "clause_type": "Assignment / post-termination transfer of marketing materials and IP", "path": "14 ➞ 14.2 ➞ 14.2(b)", "text": "ut charge to\nAimmune or its Affiliates and where Xencor shall assume all future payments due under any agreement assigned pursuant to this subsection;\n\n(b) assign to Xencor, [***], and subject to the execution of a standard trademark license between the Parties prior to such\nassignment, all of Aimmune's right, title and interest in and to any (i) Promotional Materials, (ii) copyrights and trademarks (including the Product\nTrademarks and Product Trade Dress), including any goodwill associated therewith, and any registrations and design patents for the foregoing, and (iii)\nany internet domain name registrations for such trademarks and slogans, all to the extent solely related to the Product; provided, however, in the event\nXencor exercises such right to have assigned such Promotional Materials, Aimmune shall grant, and hereby does grant, a royalty-free right and license to\nany housemarks, trademarks, names and logos of Aimmune contained therein for a period of [***] ([***]) months in order to use such Promotional\nMaterials solely in connection with the Commercialization of the Product;", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a885dce4cc76", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f5522f295647"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f5522f295647", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.2(c)-(f)", "section_title": "Assignments", "clause_type": "Post-termination assignments", "path": "14 ➞ 14.2 ➞ 14.2(c)-(f)", "text": "herein for a period of [***] ([***]) months in order to use such Promotional\nMaterials solely in connection with the Commercialization of the Product;\n\n(c) assign to Xencor, [***], the management and continued performance of any Clinical Trials for the Product ongoing hereunder as\nof the effective date of such termination in respect of which Xencor shall assume full financial responsibility from and after the effective date of such\ntermination;\n\n(d) transfer to Xencor all of Aimmune's right, title and interest in and to any and all regulatory filings, Regulatory Approvals and\nother Regulatory Materials for the Product;\n\n41\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n(e) transfer to Xencor all of Aimmune's right, title and interest in and to any and all Development-related data and Commercialization\nData Controlled by Aimmune for the Product; and\n\n(f) provide a copy of (i) the material tangible embodiments of the foregoing and (ii) any other material books, records, files and\ndocuments Controlled by Aimmune solely to the extent related to the Product and which may be redacted to exclude Confidential Information of\nAimmune;", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f743003296e4", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9a31d50d1462"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9a31d50d1462", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.2", "section_title": "Assignments", "clause_type": "Assignment/Transfer (assignment exceptions and required steps upon termination)", "path": "14 ➞ 14.2", "text": "documents Controlled by Aimmune solely to the extent related to the Product and which may be redacted to exclude Confidential Information of\nAimmune;\n\nprovided, however, that to the extent that any agreement or other asset described in this Section 14.2 is not assignable by Aimmune (whether because\nsuch agreement or asset is explicitly non-assignable or because the Third Party consent required for such assignment is not obtained), then such\nagreement or other asset will not be assigned, and upon the request of Xencor, Aimmune will take such steps as may be reasonably necessary to allow\nXencor to obtain and to enjoy the benefits of such agreement or other asset. For purposes of clarity, (1) [***] and (2) to the extent Xencor requests [***].", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f5522f295647", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::bbec97877271"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::bbec97877271", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.3", "section_title": "Disclosure and Delivery", "clause_type": "Post-termination technology transfer / disclosure and delivery obligations", "path": "14 ➞ 14.3", "text": "to obtain and to enjoy the benefits of such agreement or other asset. For purposes of clarity, (1) [***] and (2) to the extent Xencor requests [***].\n\n14.3 Disclosure and Delivery. Upon the termination of this Agreement, Aimmune will promptly transfer to Xencor copies of any physical\nembodiment of any Aimmune Know-How, to the extent then used in connection with the Development or Commercialization of the Product; such transfer\nshall be effected by the delivery of material documents, to the extent such Aimmune Know-How is embodied in such documents, and to the extent that\nAimmune Know-How is not fully embodied in such documents, Aimmune shall make its employees and agents who have knowledge of such Aimmune\nKnow-How in addition to that embodied in documents available to Xencor for interviews, demonstrations and training to effect such transfer in a manner\nsufficient to enable Xencor to practice such Aimmune Know-How but only in a manner as set out as follows in this Section 14.3. The Aimmune KnowHow shall be transferred pursuant to the procedure to transfer Xencor Know-How, Regulatory Materials, and Regulatory Data in Section 2.7 applied\nmutatis mutandis.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::9a31d50d1462", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5b5b2c5212ef"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5b5b2c5212ef", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.4", "section_title": "Disposition of Commercialization Related Materials", "clause_type": "Post-termination transfer obligations", "path": "14 ➞ 14.4", "text": "transferred pursuant to the procedure to transfer Xencor Know-How, Regulatory Materials, and Regulatory Data in Section 2.7 applied\nmutatis mutandis.\n\n14.4 Disposition of Commercialization Related Materials. Upon the termination of this Agreement, Aimmune will promptly deliver to\nXencor in electronic, sortable form (a) a list identifying all wholesalers and other distributors involved in the Commercialization of the Product, will\nreasonably consider providing customer lists (e.g., purchasers), where permitted under Applicable Law and under applicable agreements with Third\nParties, at Xencor's expense, related to the Commercialization of the Product, and (b) all Promotional Materials as well as any items bearing the Product\nTrademark or Product Trade Dress and/or any trademarks or housemarks otherwise associated with the Product or Xencor.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::bbec97877271", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d0e3413a58fc"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d0e3413a58fc", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.5", "section_title": "Accrued Rights", "clause_type": "Termination — Accrued Rights", "path": "14 ➞ 14.5", "text": "as any items bearing the Product\nTrademark or Product Trade Dress and/or any trademarks or housemarks otherwise associated with the Product or Xencor.\n\n14.5 Accrued Rights. Expiration or termination this Agreement for any reason will be without prejudice to any rights that will have accrued\nto the benefit of a Party prior to the effective date of such expiration or termination. Such expiration or termination will not relieve a Party from obligations\nthat are expressly indicated to survive the expiration or termination of this Agreement.\n\n42\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5b5b2c5212ef", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::59c555aeeff6"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::59c555aeeff6", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.6", "section_title": "Survival", "clause_type": "Survival", "path": "14 ➞ 14.6", "text": "ations\nthat are expressly indicated to survive the expiration or termination of this Agreement.\n\n42\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n14.6 Survival. Notwithstanding anything to the contrary contained herein, the following provisions shall survive any expiration or termination of\nthis Agreement: Articles: ARTICLE 1 (to the extent necessary to give effect to the other surviving provisions), ARTICLE 4 (solely with respect to\nremaining inventory of Product that Aimmune continues to sell after the effective date of termination), ARTICLE 7 (with respect to amounts accruing prior\nto expiration or termination of this Agreement), ARTICLE 11, ARTICLE 12 (for the period specified in Section 12.1.1), ARTICLE 14, ARTICLE 15 and\nARTICLE 8 (with respect to amounts accruing prior to expiration or termination of this Agreement) and Sections: 2.2.1, 2.3 (with respect to the applicable\nParty being responsible for its Affiliates or Sublicensee, and the waiver), 2.4, 9.1, 10.2 (for [***] after the effective date of termination or expiration), 10.3\n(for [***] after the effective date of termination or expiration), 10.4, and 10.5. Except as set forth in this ARTICLE 14 or otherwise expressly set forth\nherein, upon expiration or termination of this Agreement all other rights and obligations of the Parties shall cease.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::d0e3413a58fc", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::72510860be35"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::72510860be35", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "14.7", "section_title": "Rights in Bankruptcy", "clause_type": "Bankruptcy / Intellectual Property License Rights", "path": "14 ➞ 14.7", "text": "or otherwise expressly set forth\nherein, upon expiration or termination of this Agreement all other rights and obligations of the Parties shall cease.\n\n14.7 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Xencor and Aimmune are, and shall otherwise\nbe deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to \"intellectual property\" as defined under Section 101 of\nthe U.S. Bankruptcy Code. The Parties agree that each Party, as licensee of certain rights under this Agreement, shall retain and may fully exercise all of\nits rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by\nor against a Party (such Party, the \"Bankrupt Party\") under the U.S. Bankruptcy Code, (a) the other Party shall be entitled to a complete duplicate of (or\ncomplete access to, as appropriate) any intellectual property licensed to such other Party and all embodiments of such intellectual property, which, if not\nalready in such other Party's possession, shall be promptly delivered to it (x) upon any such commencement of a bankruptcy proceeding upon such other\nParty's written request therefore, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement or (y) if not delivered\nunder clause (x), following the rejection of this Agreement by the Bankrupt Party upon written request therefore by the other Party and (b) the Bankrupt\nParty shall not unreasonably interfere with the other Party's rights to intellectual property and all embodiments of intellectual property, and shall assist\nand not unreasonably interfere with the other Party in obtaining intellectual property and all embodiments of intellectual property from another entity. The\n\"embodiments\" of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all\ncompounds and products embodying intellectual property, Products, filings with Regulatory Authorities and related rights and Xencor Know-How in the\ncase that Xencor is the Bankrupt Party and Aimmune Know-How in the case Aimmune is the Bankrupt Party.", "numbers_present": null, "definition_terms": ["Bankrupt Party"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::59c555aeeff6", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a4a227594998"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a4a227594998", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.1", "section_title": "Disputes", "clause_type": "Dispute resolution / escalation", "path": "15 ➞ 15.1", "text": "s and related rights and Xencor Know-How in the\ncase that Xencor is the Bankrupt Party and Aimmune Know-How in the case Aimmune is the Bankrupt Party.\n\nARTICLE 15\nMISCELLANEOUS\n\n15.1 Disputes. The Parties recognize that, from time to time, disputes, controversies or claim may arise which stem from or are related to a Party's\nrespective rights or obligations under this Agreement or a Party's actual or alleged breach of this Agreement (a \"Dispute\"). It is the desire of the Parties\nto establish procedures to facilitate the resolution of Disputes arising under this Agreement in an expedient manner by mutual cooperation and without\nresort to\n\n43\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": ["Dispute"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::72510860be35", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f6f84bc110fa"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f6f84bc110fa", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.1", "section_title": "Disputes", "clause_type": "Dispute resolution / escalation", "path": "15 ➞ 15.1", "text": "arising under this Agreement in an expedient manner by mutual cooperation and without\nresort to\n\n43\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\narbitration or litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Section 15.1 if and when a Dispute arises\nunder this Agreement. If the Parties are unable to resolve any Dispute within [***] ([***]) days after such Dispute is submitted to it, either Party may, by\nwritten notice to the other Party, have such Dispute referred to Designated Officers of each Party for attempted resolution. In the event the Designated\nOfficers or their delegates are not able to resolve such Dispute within such [***] ([***]) day period after receipt of written notice, then each Party is free\nto pursue any remedy at law or in equity available to such Party consistent with Section 15.13.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::a4a227594998", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::07b6bf3162c7"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::07b6bf3162c7", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.2", "section_title": "Entire Agreement; Amendment", "clause_type": "Integration / Entire Agreement and Amendment clause", "path": "15 ➞ 15.2", "text": "ter receipt of written notice, then each Party is free\nto pursue any remedy at law or in equity available to such Party consistent with Section 15.13.\n\n15.2 Entire Agreement; Amendment. This Agreement, together with the Schedules and Exhibits hereto, contains the entire understanding of the\nParties with respect to the subject matter hereof. Any other express or implied agreements and understandings, negotiations, writings and commitments,\neither oral or written, in respect to the subject matter hereof are superseded by the terms of this Agreement. The Schedules and Exhibits to this\nAgreement are incorporated herein by reference and shall be deemed a part of this Agreement. This Agreement may be amended, or any term hereof\nmodified, only by a written instrument duly executed by authorized representatives of each of the Parties.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f6f84bc110fa", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e7d33132ce54"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e7d33132ce54", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.3", "section_title": "Force Majeure", "clause_type": "Force Majeure / Excuse of Performance", "path": "15 ➞ 15.3", "text": "greement may be amended, or any term hereof\nmodified, only by a written instrument duly executed by authorized representatives of each of the Parties.\n\n15.3 Force Majeure. No Party shall be liable for any failure to perform, or be considered in breach of, its obligations under this Agreement (other\nthan obligations to make payments of money) to the extent such performance has been delayed, interfered with or prevented by an event of Force\nMajeure, and the obligations of such Party under this Agreement (other than obligations to make payments of money) whose performance is affected by\nForce Majeure shall be suspended during, but not longer than, the continuance of the event of Force Majeure. Any Party that experiences an event of\nForce Majeure shall provide prompt notice of such event to the other Party, including and an estimate of the likely period of time during which its\nperformance will be affected, and shall use reasonable efforts to remove the condition constituting Force Majeure. In the event of a prolonged condition\nof Force Majeure that makes it unreasonable to continue to perform other activities then being performed by the Parties and their Affiliates pursuant to\nthis Agreement, the Parties shall consult directly as to whether they should appropriately scale back their respective activities in order to avoid waste or\ninappropriate usage of resources under the circumstances.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::07b6bf3162c7", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4f5cb43174d5"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4f5cb43174d5", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.4", "section_title": "Notices", "clause_type": "Notice clause (boilerplate)", "path": "15 ➞ 15.4", "text": "they should appropriately scale back their respective activities in order to avoid waste or\ninappropriate usage of resources under the circumstances.\n\n15.4 Notices. Any notice required or permitted to be given under this Agreement shall be in writing, shall specifically refer to this Agreement and\nshall be deemed to have been sufficiently given for all purposes if; mailed by first class certified or registered mail, postage prepaid (which notice shall be\neffective [***] ([***]) Business Days [***]); express delivery service (which notice shall be effective on the first Business Day after delivery to such\nservice); or personally delivered to the appropriate addresses (which notice shall be effective upon delivery to such addresses) set forth below or to such\nother addresses or numbers for a Party as such Party may inform the other Party by giving [***] ([***]) Business Days' prior written notice:\n\nIf to Xencor:\nXencor, Inc.\n111 West Lemon Avenue\nMonrovia, CA 91016\nAttention: General Counsel\n\n44\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nWith copies to (which shall not constitute notice):", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e7d33132ce54", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::debabbadbf3b"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::debabbadbf3b", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.4 – 15.5", "section_title": "Notices; Maintenance of Records", "clause_type": "Notices and Recordkeeping", "path": "15 ➞ 15.4; 15 ➞ 15.5", "text": "rovia, CA 91016\nAttention: General Counsel\n\n44\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nWith copies to (which shall not constitute notice):\n\nXencor, Inc.\n111 West Lemon Avenue\nMonrovia, CA 91016\nAttention: Chief Executive Officer\n\nMorgan, Lewis & Bockius LLP\n1 Market Street, Spear Street Tower\nSan Francisco, CA 94105\nAttention: Benjamin Pensak\n\nIf to Aimmune:\nAimmune Therapeutics, Inc.\n8000 Marina Boulevard\nSuite 300\nBrisbane, CA 94005\nAttention: General Counsel\n\nWith copies to (which shall not constitute notice):\n\nLatham & Watkins LLP\n140 Scott Drive\nMenlo Park, CA 94025\nAttention: Patrick Pohlen\n\nJudith Hasko\n\n15.5 Maintenance of Records. Aimmune shall keep and maintain all records required by Applicable Law or regulation (including records for\nintellectual property protection purposes) with respect to the Antibody and Product and shall, upon Xencor's written request, allow Xencor reasonable\naccess to make copies of such records, at Xencor's expense. Aimmune must maintain such records for the greater of [***] ([***]) years or the time period\nrequired by Applicable Law.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::4f5cb43174d5", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8b618a24647a"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8b618a24647a", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.6", "section_title": "Assignment", "clause_type": "Assignment", "path": "15 ➞ 15.6", "text": "records, at Xencor's expense. Aimmune must maintain such records for the greater of [***] ([***]) years or the time period\nrequired by Applicable Law.\n\n15.6 Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of\nthe other Party, except that a Party may make such an assignment or transfer without the other Party's written consent to (a) any of its Affiliates, in whole\nor in part, or (b) any Third Party in connection with (i) the acquisition of such Party by or merger or consolidation of such Party with another entity or (ii)\na merger, consolidation, sale of stock, sale of all or substantially all of such Party's assets or other similar transaction in which such Third Party either\nbecomes the owner of all or substantially all of the business and assets of (y) such Party or (z) that portion of such Party's business or business unit\nrelating to this Agreement. Any permitted successor or assignee of rights or obligations hereunder shall, in a writing delivered to the other Party,\nexpressly assume the performance of such rights or obligations. Except as set forth in the immediately preceding sentence, in the event of an assignment\nor transfer as permitted above in this Section 15.6, the assigning or transferring Party shall remain responsible (jointly and severally) with such Affiliate\nfor the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::debabbadbf3b", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::48ec0bd04c7e"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::48ec0bd04c7e", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.6", "section_title": "Assignment", "clause_type": "Assignment / Transfer of Rights and Liability", "path": "15 ➞ 15.6", "text": "permitted above in this Section 15.6, the assigning or transferring Party shall remain responsible (jointly and severally) with such Affiliate\nfor the\n\n45\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8b618a24647a", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5c8dd7f3691d"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5c8dd7f3691d", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.6", "section_title": "Assignment", "clause_type": "Assignment", "path": "15 ➞ 15.6", "text": "transferring Party shall remain responsible (jointly and severally) with such Affiliate\nfor the\n\n45\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nperformance of such assigned or transferred obligations. Any assignment or transfer, or attempted assignment or transfer, by either Party in violation of\nthe terms of this Section 15.6 shall be null and void and of no legal effect. This Agreement shall be binding on, and inure to the benefit of, each Party, its\nsuccessors and permitted assigns. Notwithstanding anything to the contrary in this Agreement, in the event of any permitted assignment, the intellectual\nproperty rights of the acquiring party and its Affiliates (if other than one of the Parties to this Agreement) shall not be included in the technology\nlicensed to the other Party hereunder to the extent held by such acquirer (or its Affiliates) prior to such transaction, or to the extent such technology is\ndeveloped outside the scope of activities conducted with respect to the Antibody or Products, unless the acquired Party practices such intellectual\nproperty rights of the acquirer in connection with its performance of activities pursuant to this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::48ec0bd04c7e", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::84b91aa28d70"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::84b91aa28d70", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.7; 15.8; 15.9", "section_title": "Offset Rights; Severability; Cumulative Remedies", "clause_type": "Miscellaneous / Boilerplate", "path": "15 ➞ 15.7; 15 ➞ 15.8; 15 ➞ 15.9", "text": "cquired Party practices such intellectual\nproperty rights of the acquirer in connection with its performance of activities pursuant to this Agreement.\n\n15.7 Offset Rights. Notwithstanding anything to the contrary in this Agreement, neither Party may, at any time or for any reason, offset any\npayments due to the other Party or its Affiliates under this Agreement.\n\n15.8 Severability. If any one (1) or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent\njurisdiction from which no appeal can be or is taken, such provision shall be considered severed from this Agreement and shall not serve to invalidate\nany remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable\none such that the objectives contemplated by the Parties when entering this Agreement may be realized.\n\n15.9 Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to\nany other remedy referred to in this Agreement or otherwise available under Applicable Law.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::5c8dd7f3691d", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8982fd209838"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8982fd209838", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.10–15.11", "section_title": "Ambiguities; No Presumption / Headings", "clause_type": "Interpretation / Boilerplate (Miscellaneous)", "path": "15 ➞ 15.10; 15 ➞ 15.11", "text": "exclusive, but each shall be cumulative and in addition to\nany other remedy referred to in this Agreement or otherwise available under Applicable Law.\n\n15.10 Ambiguities; No Presumption. Each of the Parties acknowledges and agrees that this Agreement has been diligently reviewed by and\nnegotiated by and between them, that in such negotiations each of them has been represented by competent counsel and that the final agreement\ncontained herein, including the language whereby it has been expressed, represents the joint efforts of the Parties hereto and their counsel. Accordingly,\nin interpreting this Agreement or any provision hereof, no presumption shall apply against any Party hereto as being responsible for the wording or\ndrafting of this Agreement or any such provision, and ambiguities, if any, in this Agreement shall not be construed against any Party, irrespective of\nwhich Party may be deemed to have authored the ambiguous provision.\n\n15.11 Headings. The headings for each Article and Section in this Agreement have been inserted for convenience of reference only and are not\nintended to limit or expand on the meaning of the language contained in the particular article or section.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::84b91aa28d70", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::67c94276235c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::67c94276235c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.12", "section_title": "Interpretation", "clause_type": "Interpretation/Construction (boilerplate)", "path": "15 ➞ 15.12", "text": "r convenience of reference only and are not\nintended to limit or expand on the meaning of the language contained in the particular article or section.\n\n15.12 Interpretation. Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass\nreferences to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words \"include\",\n\"includes\" and \"including\" shall be deemed to be followed by the phrase \"without limitation\", (c) the word \"will\" shall be construed to have the same\nmeaning and effect as the\n\n46\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": ["gender (use of any gender)", "singular/plural", "include/includes/including", "will (construed as shall)", "agreement references (amendments, supplements or modifications)", "person (successors and assigns)", "herein/hereof/hereunder", "Articles/Sections/Exhibits/Schedules references", "notice", "or (inclusive 'and/or')"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8982fd209838", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::383c43f0bcc7"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::383c43f0bcc7", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.12", "section_title": "Interpretation", "clause_type": "Interpretation", "path": "15 ➞ 15.12", "text": "limitation\", (c) the word \"will\" shall be construed to have the same\nmeaning and effect as the\n\n46\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nword \"shall\", (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement,\ninstrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments,\nsupplements or modifications set forth herein), (e) any reference herein to any person shall be construed to include the person's successors and assigns,\n(f) the words \"herein\", \"hereof\" and \"hereunder\", and words of similar import, shall be construed to refer to this Agreement in its entirety and not to any\nparticular provision hereof, (g) all references herein to Articles, Sections, Exhibits or Schedules shall be construed to refer to Articles, Sections, Exhibits\nor Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto, (h) the word \"notice\" means notice in writing\n(whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement,\n(i) provisions that require that a Party or the Parties hereunder to \"agree\", \"consent\" or \"approve\" or the like shall require that such agreement, consent\nor approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding instant messaging), (j)\nreferences to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments\nthereto or any replacement or successor law, rule or regulation thereof, and (k) the term \"or\" shall be interpreted in the inclusive sense commonly\nassociated with the term \"and/or.\"", "numbers_present": null, "definition_terms": ["will", "shall", "include/includes/including", "notice", "herein", "hereof", "hereunder", "person", "Articles", "Sections", "Exhibits", "Schedules", "or"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::67c94276235c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6c780b1992b5"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6c780b1992b5", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.13", "section_title": "Governing Law and Equitable Relief", "clause_type": "Governing law and equitable relief (choice of law; injunctive/equitable remedies)", "path": "15 ➞ 15.13 ➞ 15.13.1 ➞ 15.13.2", "text": "ccessor law, rule or regulation thereof, and (k) the term \"or\" shall be interpreted in the inclusive sense commonly\nassociated with the term \"and/or.\"\n\n15.13 Governing Law and Equitable Relief.\n\n15.13.1 Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of California\napplicable to agreements made and to be performed entirely within such state, without regard to the conflicts of law principles of such state; provided\nthat any matters relating to the construction or effect of any Patent will be governed by the patent laws of the relevant jurisdiction in which such Patent is\ngranted. This Agreement was prepared in the English language, which language shall govern the interpretation of, and any dispute regarding, the terms\nof this Agreement.\n\n15.13.2 Equitable Relief. Notwithstanding anything in this Agreement to the contrary, each Party shall have the right to seek injunctive or\nother equitable relief from a court of competent jurisdiction that may be necessary to avoid irreparable harm or to maintain the status quo.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::383c43f0bcc7", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::078f7821e783"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::078f7821e783", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.13.3", "section_title": "Jurisdiction", "clause_type": "Jurisdiction / Forum selection", "path": "15 ➞ 15.13 ➞ 15.13.3", "text": "nctive or\nother equitable relief from a court of competent jurisdiction that may be necessary to avoid irreparable harm or to maintain the status quo.\n\n15.13.3 Jurisdiction. Each Party (a) irrevocably submits to the exclusive jurisdiction of any United States District Court in California (the\n\"Court\"), for purposes of any action, suit or other proceeding arising out of this Agreement, (b) agrees not to raise any objection at any time to the\nlaying or maintaining of the venue of any such action, suit or proceeding in any of such Court, and (c) irrevocably waives any claim that such action, suit\nor other proceeding has been brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action, suit or\nother proceeding, that such Court does not have any jurisdiction over such Party. Each Party further agrees that service or any process, summons, notice\nor document by U.S. registered mail to such Party's notice address provided for in this Agreement shall be effective service of process for any action, suit\nor proceeding in California with respect to any matters to which it has submitted to jurisdiction in this Section\n\n47", "numbers_present": null, "definition_terms": ["Court"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::6c780b1992b5", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::326291c44d13"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::326291c44d13", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.13.3-15.13.4", "section_title": "Jurisdiction; No Waiver (under Governing Law and Equitable Relief)", "clause_type": "Jurisdiction and waiver (governing law/equitable relief boilerplate)", "path": "15 ➞ 15.13 ➞ 15.13.3 and 15.13.4", "text": "of process for any action, suit\nor proceeding in California with respect to any matters to which it has submitted to jurisdiction in this Section\n\n47\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\n15.13.3. Notwithstanding the forgoing, nothing contained in this Agreement will deny any Party the right to seek injunctive relief or other equitable relief\nfrom a court of competent jurisdiction applying the laws of the court in the context of a bona fide emergency or prospective irreparable harm, and such an\naction may be filed and maintained notwithstanding any other ongoing proceeding.\n\n15.13.4 No Waiver. Any delay in enforcing a Party's rights under this Agreement or any waiver as to a particular default or other matter\nshall not constitute a waiver of such Party's rights to the future enforcement of its rights under this Agreement, except with respect to an express written\nand signed waiver relating to a particular matter for a particular period of time.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::078f7821e783", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1a0f00bb1f1c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1a0f00bb1f1c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.14-15.15", "section_title": "No Third Party Beneficiaries; Independent Contractors", "clause_type": "Miscellaneous / boilerplate provisions", "path": "15 ➞ 15.14; 15 ➞ 15.15", "text": "hts under this Agreement, except with respect to an express written\nand signed waiver relating to a particular matter for a particular period of time.\n\n15.14 No Third Party Beneficiaries. No person or entity other than Aimmune, Xencor and their respective Affiliates, successors and permitted\nassignees hereunder, shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.\n\n15.15 Independent Contractors. It is expressly agreed that Aimmune and Xencor shall be independent contractors and that the relationship\nbetween Aimmune and Xencor shall not constitute a partnership, joint venture or agency. Neither Aimmune nor Xencor shall have the authority to make\nany statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written\nconsent of such other Party.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::326291c44d13", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e37beedcaa7c"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e37beedcaa7c", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "15.16", "section_title": "Counterparts; Facsimile Signatures", "clause_type": "Execution / Signatures (Counterparts and Electronic/Fax Execution)", "path": "15 ➞ 15.16", "text": ", or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written\nconsent of such other Party.\n\n15.16 Counterparts; Facsimile Signatures. This Agreement may be executed in three (3) or more counterparts, each of which shall be deemed an\noriginal, but all of which together shall constitute one (1) and the same instrument. This Agreement may be executed by delivery of electronically scanned\ncopies of original signatures delivered by facsimile or electronic mail, and such signatures shall be deemed to bind each Party as if they were original\nsignatures.\n\n[No Further Text on This Page]\n\n48\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nIN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives as of the date first written above.\nAIMMUNE THERAPEUTICS, INC.\nXENCOR, INC.\n\nBy:\n/s/ Jayson Dallas, M.D\nBy:\n/s/ Bassil Dahiyat, Ph.D.\n\nName:\nJayson Dallas, M.D\nName:\nBassil Dahiyat, Ph.D.\n\nTitle:\nPresident & CEO\nTitle:\nPresident & CEO\n49\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nSchedule 1.10\n\nAntibody\n\nOmitted pursuant to Regulation S-K, Item 601(a)(5)\n\n50", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1a0f00bb1f1c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8bf556541d14"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8bf556541d14", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "Initial Press Release", "clause_type": "Schedule / Press Release", "path": "LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT ➞ Schedules ➞ Schedule 12.2", "text": "President & CEO\n49\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nSchedule 1.10\n\nAntibody\n\nOmitted pursuant to Regulation S-K, Item 601(a)(5)\n\n50\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nSchedule 1.79\nXencor General Patents\n\nOmitted pursuant to Regulation S-K, Item 601(a)(5)\n\n51\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nSchedule 1.81\nXencor Product Specific Patents\n\nOmitted pursuant to Regulation S-K, Item 601(a)(5)\n\n52\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nSchedule 2.7\nXencor Know-How, Regulatory Materials, and Regulatory Data\n\nOmitted pursuant to Regulation S-K, Item 601(a)(5)\n\n53\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nSchedule 6.1\nInitial Product Supply\n\nOmitted pursuant to Regulation S-K, Item 601(a)(5)\n\n54\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nSchedule 10.2.6\n\nExceptions\n\nOmitted pursuant to Regulation S-K, Item 601(a)(5)\n\n55\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nSchedule 12.2\nInitial Press Release\n\n56\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nDistribution on Wednesday, 2/5 @ 8:01 am ET\n\nFOR IMMEDIATE RELEASE\n\nAimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e37beedcaa7c", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cc2cab032d13"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cc2cab032d13", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": null, "section_title": "Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of Next-Generation Food Allergy Treatments", "clause_type": "Press Release (Publicity)", "path": "Schedule 12.2", "text": "/5/2020\n\nDistribution on Wednesday, 2/5 @ 8:01 am ET\n\nFOR IMMEDIATE RELEASE\n\nAimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the\n\nDevelopment of Next-Generation Food Allergy Treatments\n\nBRISBANE, Calif. – February 5, 2020 – Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for\npotentially life-threatening food allergies, today announced it has obtained an exclusive worldwide license to develop and commercialize the\ninvestigational humanized monoclonal antibody XmAb®7195 from Xencor, Inc.\n\nXmAb7195, which has been renamed AIMab7195, was originally developed by Xencor for the treatment of allergic asthma. It uses three distinct\nmechanisms of action to reduce blood serum IgE and suppress IgE-producing cells. Aimmune initially plans to develop AIMab7195 as an adjunctive\ntreatment with select Characterized Oral Desensitized ImmunoTherapy (CODIT™) programs, including PALFORZIA™, to explore treatment outcomes in\npatients with food allergies.", "numbers_present": null, "definition_terms": ["AIMab7195", "CODIT™ (Characterized Oral Desensitized ImmunoTherapy)"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::8bf556541d14", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f035a33fd756"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f035a33fd756", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "Initial Press Release", "clause_type": "Publicity / Press Release", "path": "Schedule 12.2", "text": "Characterized Oral Desensitized ImmunoTherapy (CODIT™) programs, including PALFORZIA™, to explore treatment outcomes in\npatients with food allergies.\n\n\"As we look to the future of food allergy treatments, we are excited to explore the potential of oral immunotherapy to achieve greater levels of\ndesensitization – and perhaps even remission – when combined with adjunctive biologics that target immune pathways,\" said Jayson Dallas, M.D.,\nPresident and CEO of Aimmune. \"In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune's global\nleadership in the evolving therapeutic landscape of food allergy treatments.\"\n\n\"Aimmune's focus, clinical success and regulatory expertise in food allergy demonstrate their capability to advance AIMab7195 with highly\ncomplementary CODIT pipeline programs to create new options for people living with food allergy,\" said Bassil Dahiyat, Ph.D., President and CEO of\nXencor. \"AIMab7195 is designed to reduce levels of IgE, a key mediator of allergic response, and there is strong scientific rationale that this reduction\nwould synergize with the activity of desensitization therapies.\"", "numbers_present": null, "definition_terms": ["Characterized Oral Desensitized ImmunoTherapy (CODIT™)"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::cc2cab032d13", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::034e000a5bbc"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::034e000a5bbc", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "About AIMab7195 (formerly XmAb®7195)", "clause_type": "Press release / Publicity (commercial terms and product description)", "path": "Schedule 12.2 ➞ Initial Press Release ➞ About AIMab7195 (formerly XmAb®7195)", "text": "or of allergic response, and there is strong scientific rationale that this reduction\nwould synergize with the activity of desensitization therapies.\"\n\nUnder the terms of the agreement, Aimmune will make an upfront payment to Xencor of $5 million in cash and $5 million in equity, equivalent to 156,238\nnewly issued shares of Aimmune common stock at $32.0025/share. Xencor also is eligible to receive up to $385 million based on the achievement of\ncertain clinical development, regulatory and commercialization milestones — beginning with the initiation of a Phase 2 clinical trial — and is eligible to\nreceive a high single-digit to mid-teen percentage of royalties upon commercialization of AIMab7195. Aimmune will be solely responsible for costs related\nto the development of AIMab7195 and plans to provide a development plan in the coming months.\n\nAbout AIMab7195 (formerly XmAb®7195)\n\nAIMab7195 is an anti-IgE monoclonal antibody with enhanced binding to the Fc gamma receptor IIb (FcyRIIb). IgE recognizes and interacts with\nallergens and, as a result, can activate immune cells, such as mast cells and basophils, that drive an allergic response", "numbers_present": null, "definition_terms": ["AIMab7195", "XmAb®7195"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::f035a33fd756", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::dbfe8edddc74"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::dbfe8edddc74", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": null, "section_title": "About AIMab7195 (formerly XmAb®7195)", "clause_type": "Informational (press release product description)", "path": "Schedule 12.2 ➞ Press Release ➞ About AIMab7195 (formerly XmAb®7195)", "text": "recognizes and interacts with\nallergens and, as a result, can activate immune cells, such as mast cells and basophils, that drive an allergic response\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nin patients. AIMab7195 is designed to clear IgE rapidly from circulation, to prevent the production of IgE by preventing the activation of IgE-positive B\ncells, and to block IgE from interacting with its receptor on immune cells. AIMab7195 has been evaluated in two Phase 1 studies that enrolled more than\n100 healthy volunteers and patients with allergy and atopic disease.\n\nAbout Aimmune", "numbers_present": null, "definition_terms": ["AIMab7195"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::034e000a5bbc", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c7054a4d97c1"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c7054a4d97c1", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "About Aimmune", "clause_type": "Press Release / Company Description", "path": "Schedule 12.2 ➞ Initial Press Release ➞ About Aimmune", "text": "has been evaluated in two Phase 1 studies that enrolled more than\n100 healthy volunteers and patients with allergy and atopic disease.\n\nAbout Aimmune\n\nAimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for\npatients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments\nfor potentially life-threatening food allergies. The Company's Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to\nprovide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with\ndefined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in\ndevelopment to treat other food allergies. For more information, please visit www.aimmune.com.\n\nForward-Looking Statements", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::dbfe8edddc74", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e9c842136fc4"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e9c842136fc4", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": null, "section_title": "Forward-Looking Statements", "clause_type": "Forward-looking statements disclaimer", "path": "Schedule 12.2 ➞ Initial Press Release ➞ Forward-Looking Statements", "text": "nvestigational therapies in\ndevelopment to treat other food allergies. For more information, please visit www.aimmune.com.\n\nForward-Looking Statements\n\nStatements contained in this press release regarding matters that are not historical facts are \"forward-looking statements\" within the meaning of the\nPrivate Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from\nthose expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune's\nexpectations regarding the potential benefits of AIMab7195; and Aimmune's expectations regarding potential applications of the CODIT™ approach to\ntreating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the\nexpectation that Aimmune will need additional funds to finance its operations; Aimmune's dependence on the success of PALFORZIA; Aimmune's\nreliance on third parties for the manufacture of AIMab7195, PALFORZIA and other product candidates; possible regulatory developments in the United\nStates and foreign countries; and Aimmune's ability to attract and retain senior management personnel. These and other risks and uncertainties are\ndescribed more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the\nquarter ended September 30, 2019. All forward-looking statements contained in this press release speak only as of the date on which they were made.\nAimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were\nmade.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::c7054a4d97c1", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3680b76928b3"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3680b76928b3", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "Initial Press Release", "clause_type": "Publicity/Press Release", "path": "Schedule 12.2", "text": "ne undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were\nmade.\n\nThis press release concerns PALFORZIA (AR101), which has been approved for marketing by the FDA in the United States and has not been approved\nfor marketing by the EMA or Swissmedic. AR101 in Europe is currently limited to investigational use, and no representation is made as to its safety or\neffectiveness for the purposes for which it is being investigated.\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nAIMab7195 TM, PALFORZIA™, AIMMUNE™, AIMMUNE THERAPEUTICS™ and CODIT™ are trademarks of Aimmune Therapeutics, Inc\n\nXencor® and XmAb® are registered trademarks of Xencor, Inc.\n\n###\n\nContacts:\n\nInvestors:\nDeDe Sheel\n(917) 834-1494\ndsheel@aimmune.com\n\nMedia:\nJulie Normart\n(559) 974-3245\njnormart@w2ogroup.com\n\nLauren Barbiero\n(646) 564-2156\nlbarbiero@w2ogroup.com\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nAimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of\n\nNext-Generation Food Allergy Treatments", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::e9c842136fc4", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::62b54503129f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::62b54503129f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "Initial Press Release (Aimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of Next-Generation Food Allergy Treatments)", "clause_type": "Press release / Publicity", "path": "12 ➞ Schedule 12.2", "text": "INC., 8-K, 2/5/2020\n\nAimmune Licenses Exclusive Worldwide Rights to Xencor's XmAb®7195 for the Development of\n\nNext-Generation Food Allergy Treatments\n\nMONROVIA, Calif. – February 5, 2020 – Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal\nantibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive worldwide license to develop and commercialize\nthe investigational humanized monoclonal antibody XmAb®7195 to Aimmune Therapeutics, Inc.\n\nXmAb7195, which has been renamed AIMab7195, was originally developed by Xencor for the treatment of allergic asthma. It uses three distinct\nmechanisms of action to reduce blood serum IgE and suppress IgE-producing cells. Aimmune initially plans to develop AIMab7195 as an adjunctive\ntreatment with select Characterized Oral Desensitized ImmunoTherapy (CODIT™) programs, including PALFORZIA™, to explore treatment outcomes in\npatients with food allergies.", "numbers_present": null, "definition_terms": ["XmAb7195", "AIMab7195", "CODIT™", "PALFORZIA™"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::3680b76928b3", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2d789782687a"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2d789782687a", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": null, "section_title": "Schedule 12.2 - Initial Press Release", "clause_type": "Publicity/Press Release", "path": "Schedule 12.2 ➞ Initial Press Release", "text": "Characterized Oral Desensitized ImmunoTherapy (CODIT™) programs, including PALFORZIA™, to explore treatment outcomes in\npatients with food allergies.\n\n\"As we look to the future of food allergy treatments, we are excited to explore the potential of oral immunotherapy to achieve greater levels of\ndesensitization – and perhaps even remission – when combined with adjunctive biologics that target immune pathways,\" said Jayson Dallas, M.D.,\npresident and CEO of Aimmune. \"In-licensing AIMab7195 demonstrates our commitment to enriching our pipeline and strengthening Aimmune's global\nleadership in the evolving therapeutic landscape of food allergy treatments.\"\n\n\"Aimmune's focus, clinical success and regulatory expertise in food allergy demonstrate their capability to advance AIMab7195 with highly\ncomplementary CODIT pipeline programs to create new options for people living with food allergy,\" said Bassil Dahiyat, Ph.D., President and CEO of\nXencor. \"AIMab7195 is designed to reduce levels of IgE, a key mediator of allergic response, and there is strong scientific rationale that this reduction\nwould synergize with the activity of desensitization therapies.\"", "numbers_present": null, "definition_terms": ["Characterized Oral Desensitized ImmunoTherapy (CODIT™)"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::62b54503129f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b21794d60a2b"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b21794d60a2b", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "Initial Press Release", "clause_type": "Payment/Consideration (upfront payment, equity, milestone and royalty terms)", "path": "Schedule 12.2 ➞ Initial Press Release", "text": "or of allergic response, and there is strong scientific rationale that this reduction\nwould synergize with the activity of desensitization therapies.\"\n\nUnder the terms of the agreement, Aimmune will make an upfront payment to Xencor of $5 million in cash and $5 million in equity, equivalent to 156,238\nnewly issued shares of Aimmune common stock at $32.0025/share, the seven-day volume weighted average price. Xencor also is eligible to receive up to\n$385 million based on the achievement of certain clinical development, regulatory and commercialization milestones – beginning with the initiation of a\nPhase 2 clinical trial – and is eligible to receive a high single-digit to mid-teen percentage of royalties upon commercialization of AIMab7195. Aimmune\nwill be solely responsible for costs related to the development of AIMab7195 and plans to provide a development plan in the coming months.\n\nAbout AIMab7195 (formerly XmAb®7195)", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2d789782687a", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2e742e65882f"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2e742e65882f", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "About AIMab7195 (formerly XmAb®7195)", "clause_type": "Press release — product description", "path": "Schedule 12.2 ➞ About AIMab7195 (formerly XmAb®7195)", "text": "for costs related to the development of AIMab7195 and plans to provide a development plan in the coming months.\n\nAbout AIMab7195 (formerly XmAb®7195)\n\nAIMab7195 is an anti-IgE monoclonal antibody with enhanced binding to the Fc gamma receptor IIb (FcyRIIb). IgE recognizes and interacts with\nallergens and, as a result, can activate immune cells, such as mast cells and basophils, that drive an allergic response in patients. AIMab7195 is designed\nto clear IgE rapidly from circulation, to prevent the production of IgE by preventing the activation of IgE-positive B cells, and to block IgE from\ninteracting with its receptor on immune cells. AIMab7195 has been evaluated in two Phase 1 studies that enrolled more than 100 healthy volunteers and\npatients with allergy and atopic disease.\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nAbout Xencor, Inc.", "numbers_present": null, "definition_terms": ["AIMab7195", "XmAb®7195", "Fc gamma receptor IIb (FcyRIIb)"], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::b21794d60a2b", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1f86dd192820"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1f86dd192820", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "About Xencor, Inc.", "clause_type": "Publicity / Press Release", "path": "Schedule 12.2 ➞ Press Release ➞ About Xencor, Inc.", "text": "more than 100 healthy volunteers and\npatients with allergy and atopic disease.\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020\n\nAbout Xencor, Inc.\n\nXencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune\ndiseases. Currently, 15 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb\nantibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For\nmore information, please visit www.xencor.com.\n\nForward-Looking Statements", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::2e742e65882f", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::de749c938d13"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::de749c938d13", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": "Schedule 12.2", "section_title": "Forward-Looking Statements", "clause_type": "Forward-looking statement disclaimer", "path": "Schedule 12.2 ➞ Forward-Looking Statements", "text": "onoclonal antibodies resulting in new mechanisms of therapeutic action. For\nmore information, please visit www.xencor.com.\n\nForward-Looking Statements\n\nStatements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of applicable\nsecurities laws, including, but not limited to, the quotations from the chief executive officers of Xencor and Aimmune and any expectations relating to the\npotential benefits of AIMab7195; its clinical development, synergies with CODIT™ programs and efficacy; regulatory approval; or commercialization.\nSuch statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the\ntiming of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of\nfuture performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and\ncommercializing drugs that are safe and effective for use as human therapeutics and other risks described in Xencor's public securities filings. For a\ndiscussion of these and other factors, please refer to Xencor's annual report on Form 10-K for the year ended December 31, 2018 as well as Xencor's\nsubsequent filings with the Securities and Exchange Commission. All forward-looking statements are based on Xencor's current information and belief as\nwell as assumptions made by Xencor. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the\ndate hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements\nare qualified in their entirety by this cautionary statement and Xencor undertakes no obligation to revise or update this press release to reflect events or\ncircumstances after the date hereof, except as required by law.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::1f86dd192820", "next_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::eb80964ffebf"}
{"id": "41e4fff0-e869-47c7-b362-eb9c98279e62::eb80964ffebf", "doc_id": "41e4fff0-e869-47c7-b362-eb9c98279e62", "section_number": null, "section_title": "Schedule 12.2 Initial Press Release", "clause_type": "Publicity / Press Release", "path": "Schedule 12.2", "text": "r undertakes no obligation to revise or update this press release to reflect events or\ncircumstances after the date hereof, except as required by law.\n\nAIMab7195™, PALFORZIA™, AIMMUNE™, AIMMUNE THERAPEUTICS™ and CODIT™ are trademarks of Aimmune Therapeutics, Inc\n\nXencor® and XmAb® are registered trademarks of Xencor, Inc.\n\nContacts\n\nCharles Liles\n626-737-8118\ncliles@xencor.com\n\nMedia Contact\nJason I. Spark\nCanale Communications\n619-849-6005\njason@canalecomm.com\n\nSource: AIMMUNE THERAPEUTICS, INC., 8-K, 2/5/2020", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "License agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "biopharmaceutical"}, "prev_id": "41e4fff0-e869-47c7-b362-eb9c98279e62::de749c938d13", "next_id": null}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::b8604b1678ad", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": null, "section_title": "Multiple LINAC and Multi-Modality Distributor Agreement (Preamble/Recitals)", "clause_type": "Preamble/Introductory (Recitals and Parties)", "path": "Preamble", "text": "Exhibit 10.31\n  \nPURSUANT TO 17 C.F.R. § 240.24B-2, CONFIDENTIAL INFORMATION (INDICATED BY {*****}) HAS BEEN OMITTED FROM THIS\n\nDOCUMENT AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A\n\nCONFIDENTIAL TREATMENT APPLICATION FILED WITH THE COMMISSION\n\nACCURAY INCORPORATED \nMULTIPLE LINAC AND MULTI-MODALITY\n\nDISTRIBUTOR AGREEMENT\n\nThis Multiple LINAC and Multi-Modality Distributor Agreement (\"Agreement\") is entered into by and between ACCURAY \nINCORPORATED, a Delaware corporation with its executive offices located at 1310 Chesapeake Terrace, Sunnyvale, California 94089, USA \n(\"Accuray\"), and SIEMENS AKTIENGESELLSCHAFT, a corporation formed under the laws of the Federal Republic of Germany, with its registered \noffices located at Berlin and Munich (\"Siemens\"), as of June 8, 2010 (\"Effective Date\").\n\nRECITALS", "numbers_present": null, "definition_terms": ["Agreement", "Accuray", "Siemens", "Effective Date"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": null, "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fe6467619e27"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fe6467619e27", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": null, "section_title": "RECITALS", "clause_type": "Recitals / Preamble", "path": "RECITALS", "text": "e Federal Republic of Germany, with its registered \noffices located at Berlin and Munich (\"Siemens\"), as of June 8, 2010 (\"Effective Date\").\n\nRECITALS\n\nAccuray manufactures and sells full-body radiosurgery systems using image-guided robotics, including the CyberKnife® Robotic \nRadiosurgery System, which is FDA cleared in the United States to provide treatment planning and image-guided stereotactic radiosurgery and \nprecision radiotherapy for lesions, tumors and conditions anywhere in the body where radiation treatment is indicated.\n\nIn order to achieve its business objectives, Accuray relies on qualified distributors to market and distribute its products and services. \n  \nAccuray and Siemens have entered into that certain Strategic Alliance Agreement, dated as of the date hereof (the \"Strategic Alliance \nAgreement\"), and such agreement provides that Accuray and Siemens shall enter into a distribution agreement for Multiple LINAC and MultiModality Purchases (as defined below).", "numbers_present": null, "definition_terms": ["Effective Date", "Strategic Alliance Agreement"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::b8604b1678ad", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3b8dd8fd620f"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3b8dd8fd620f", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "1.1", "section_title": "Accuray Regions", "clause_type": "Definitions", "path": "1 ➞ 1.1", "text": "reement provides that Accuray and Siemens shall enter into a distribution agreement for Multiple LINAC and MultiModality Purchases (as defined below).\n\nAccuray wishes to appoint Distributor (as defined below) as a non-exclusive, worldwide distributor for the Products and Services to \nCustomer in connection with Multiple LINAC or Multi-Modality Purchases (as defined below), subject to the terms and conditions of this \nAgreement, and Distributor wishes to accept such appointment.\n\nNOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants set forth below, the parties hereto hereby \nagree as follows:\n\n1. DEFINITIONS. Capitalized terms used, but not defined herein, shall have the meaning provided in the Strategic Alliance Agreement. The\n\nfollowing terms, as used herein, have the following meaning:\n\n1.1. \"Accuray Regions\" means Accuray's sales regions (as of the Effective Date) of the Americas (North America and South America),", "numbers_present": null, "definition_terms": ["Accuray Regions"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fe6467619e27", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a978519b009e"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a978519b009e", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "1.1–1.6", "section_title": "Definitions", "clause_type": "Definitions", "path": "1 ➞ 1.1–1.6", "text": "following meaning:\n\n1.1. \"Accuray Regions\" means Accuray's sales regions (as of the Effective Date) of the Americas (North America and South America),\n\nAPAC (Asia Pacific, including Australia and other than India and Japan), EIMEA (Europe, India, Middle East, and Africa), and \nJapan. \n  \n1.2. \"Customer\" means any person or business entity with whom Distributor enters into an agreement for Products or Services in\n\nconnection with a Multiple LINAC or Multi-Modality Purchase pursuant to this Agreement. \n  \n1.3. \"Distributor\" means Siemens, its Affiliates, or any Third Party which has been granted distribution rights whose scope includes the\n\nProducts and/or Services by Siemens. \n  \n1.4. \"Multiple LINAC or Multi-Modality Purchase\" means a Multiple LINAC Purchase or a Multi-Modality Purchase.\n\n1.5. \"Multi-Modality Purchase\" means the purchase, on a single purchase order, of at least one Distributor imaging product (e.g., CT, MR,\n\nPET-CT) and at least one System. \n  \n1.6. \"Multiple LINAC Purchase\" means the purchase, on a single purchase order, of at least one Distributor linear accelerator product and", "numbers_present": null, "definition_terms": ["Accuray Regions", "Customer", "Distributor", "Multiple LINAC or Multi-Modality Purchase", "Multi-Modality Purchase", "Multiple LINAC Purchase"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3b8dd8fd620f", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::25dd897fff88"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::25dd897fff88", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "1.6–1.10", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "1 ➞ 1.6 ➞ 1.7 ➞ 1.8 ➞ 1.9 ➞ 1.10", "text": "System. \n  \n1.6. \"Multiple LINAC Purchase\" means the purchase, on a single purchase order, of at least one Distributor linear accelerator product and\n\nat least one System. \n  \n1.7. \"Product(s)\" means the System and/or related products manufactured by or for Accuray for use in the radiosurgery market, which\n\nhave been approved for sale in the Customer's geographic region. \n  \n1.8. \"Quote\" means a quote provided by Accuray to Distributor pursuant to Section 2.3 that will serve as the basis for the Product\n\nconfiguration, Services, pricing and delivery schedule offered to a Customer by Distributor. \n  \n1.9. \"Service(s)\" means the performance of radiosurgery-related service(s) by Accuray or its distributors, which may include technical\n\nsupport, training or installation of Products as specified in the Quote. \n  \n1.10. \"Service Agreements\" means the Accuray CyberKnife Service Agreement or such other service programs and agreements as may be", "numbers_present": null, "definition_terms": ["Multiple LINAC Purchase", "Product(s)", "Quote", "Service(s)", "Service Agreements"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a978519b009e", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::39157be8ffde"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::39157be8ffde", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "1.10–2.2", "section_title": "DISTRIBUTORSHIP", "clause_type": "Definitions; Distributorship (Appointment & Pricing)", "path": "1 ➞ 1.10 ➞ 1.11 ➞ 1.12 ➞ 1.13 ➞ 2 ➞ 2.1 ➞ 2.2", "text": "ed in the Quote. \n  \n1.10. \"Service Agreements\" means the Accuray CyberKnife Service Agreement or such other service programs and agreements as may be\n\nreleased or modified by Accuray from time to time. \n  \n1.11. \"Spare Parts\" means replacement or additional parts or Products used in connection with the System. \n  \n1.12. \"Specification(s)\" means the current written description of a Product or Service prepared by Accuray and provided to Distributor. \n  \n1.13. \"System(s)\" means the Accuray CyberKnife® Robotic Radiosurgery System or CyberKnife® VSI™ System, as applicable. \n  \n2. DISTRIBUTORSHIP\n\n2.1. Appointment. Accuray hereby appoints Distributor as a non-exclusive, worldwide distributor of Products and Services to Customers\n\nsolely in connection with Multiple LINAC or Multi-Modality Purchases, not to the exclusion of Accuray itself or any of its other \ncurrent or future distributors and subject to the terms and conditions of this Agreement. By way of clarification, this Agreement \ndoes not relate to any Cayman Product, including, without limitation, the distribution or sale thereof or any services related thereto. \n  \n2.2. Pricing.", "numbers_present": null, "definition_terms": ["Service Agreements", "Spare Parts", "Specification(s)", "System(s)"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::25dd897fff88", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::aa4e1d9b8707"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::aa4e1d9b8707", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.2 (includes 2.2.1 and 2.2.2)", "section_title": "Pricing", "clause_type": "Commercial — Pricing / Price lists and quotation validity", "path": "2 ➞ 2.2 ➞ 2.2.1; 2.2.2 (partial)", "text": "s not relate to any Cayman Product, including, without limitation, the distribution or sale thereof or any services related thereto. \n  \n2.2. Pricing.\n\n2.2.1. Pricing of Products and Services shall be based upon Accuray's then current price lists for such Products and Services. The\n\ncurrent price list for Products and Services effective as of the Effective Date will be provided to Distributor \ncontemporaneously with the delivery of this fully executed Agreement to Distributor. Such price lists will be subject to \nchange from time to time in Accuray's sole discretion, and Accuray shall use commercially reasonable efforts to provide \nDistributor with updated pricing on a regular basis, provided that pricing included in a Quote delivered by Accuray to \nDistributor shall reflect Accuray's current up-to-date pricing unless otherwise agreed. Updated price lists shall not apply to \nvalid Quotes\n\n2\n\nissued by Accuray and subject to acceptance by Distributor prior to the effective date of such updated price lists.\n\n2.2.2. Notwithstanding the foregoing or anything to the contrary contained in this Agreement, Distributor may present for approval", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::39157be8ffde", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f78d0883760c"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f78d0883760c", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.2.2", "section_title": "Pricing", "clause_type": "Pricing approval / pricing discretion clause", "path": "2 ➞ 2.2 ➞ 2.2.2", "text": "dated price lists.\n\n2.2.2. Notwithstanding the foregoing or anything to the contrary contained in this Agreement, Distributor may present for approval\n\nto Accuray opportunities for sales of Products and Services at prices that differ from the prices set forth in the then current \nprice list. Accuray may, in its sole and absolute discretion, approve any such opportunity, and if approved in writing by \nAccuray, Distributor shall otherwise be permitted to pursue such opportunity at such prices, which opportunity shall \notherwise be governed by and pursued pursuant to the terms of this Agreement. \n  \n2.3. Quote and Purchase Process. Distributor acknowledges and agrees that Accuray will determine the appropriate quote process to be", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::aa4e1d9b8707", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7597d60875bf"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7597d60875bf", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.3", "section_title": "Quote and Purchase Process", "clause_type": "Procedure/Approval (sales quote and purchase process)", "path": "2 ➞ 2.3 ➞ 2.3.1", "text": "is Agreement. \n  \n2.3. Quote and Purchase Process. Distributor acknowledges and agrees that Accuray will determine the appropriate quote process to be\n\nobserved by the parties under this Agreement and may amend this process (other than the approval rights set forth in Section 2.3.2) \nas notified to the Distributor reasonably in advance. In addition, Distributor acknowledges that each proposed sale of a Product or \nService under this Agreement is subject to the approval rights of Accuray set forth in Section 2.3.2. Accuray and Distributor will \ncomply with the following process for making sales of Products and Services in connection with Multiple LINAC or Multi-Modality \nPurchases:\n\n2.3.1. Opportunity. Once Distributor has identified a Customer opportunity in connection with a Multiple LINAC or Multi-Modality", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f78d0883760c", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::966a0b509b0e"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::966a0b509b0e", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.3.1–2.3.2", "section_title": "Opportunity; Quote", "clause_type": "Procedure", "path": "2 ➞ 2.3 ➞ 2.3.1 ➞ 2.3.2", "text": "Modality \nPurchases:\n\n2.3.1. Opportunity. Once Distributor has identified a Customer opportunity in connection with a Multiple LINAC or Multi-Modality\n\nPurchase, it shall request a Quote from Accuray based on the Product configuration and Services requested by the \nCustomer and the Accuray Region in which the Customer is located, and shall include such other information regarding the \nCustomer and the proposed opportunity as Accuray may reasonably request. \n  \n2.3.2. Quote. Following receipt of Distributor's Quote request, Accuray will determine whether to approve the issuance of a Quote", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7597d60875bf", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::157f4f2f0b1e"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::157f4f2f0b1e", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.3.2", "section_title": "Quote", "clause_type": "Quote approval / Sales process", "path": "2 ➞ 2.3 ➞ 2.3.2", "text": "sonably request. \n  \n2.3.2. Quote. Following receipt of Distributor's Quote request, Accuray will determine whether to approve the issuance of a Quote\n\nrelated to such request. Such determination shall be made in accordance with and subject to the conditions set forth in \nSchedule 2.3.2 attached hereto. If Accuray approves the issuance of a Quote, Accuray shall issue a Quote to Distributor \nbased on the Product configuration and Services requested by the Customer, including pricing for such Products and \nServices as provided in Section 2.2 above. The Quote issued by Accuray in relation to a Customer opportunity shall serve \nas the basis of any offer made by Distributor to that Customer and shall remain valid for at least six months (unless earlier \ndeclined by Distributor), and Distributor shall submit an amended Quote request to Accuray in the event adjustments to a \nQuote are requested by the Customer. Any such amended Quote request from Distributor shall again be subject to the \nAccuray approval process set forth in this Section 2.3.2.\n\n3\n\n2.3.3. Purchase. To purchase Products or Services based on a Quote provided by Accuray, Distributor will issue a purchase order,", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::966a0b509b0e", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2dbc1fcde18c"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2dbc1fcde18c", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.3.3", "section_title": "Purchase", "clause_type": "Purchase Order / Acceptance", "path": "2 ➞ 2.3 ➞ 2.3.3", "text": "is Section 2.3.2.\n\n3\n\n2.3.3. Purchase. To purchase Products or Services based on a Quote provided by Accuray, Distributor will issue a purchase order,\n\nwhich shall include specific references to the quote number of such Quote (the \"Purchase Order\"). Accuray shall either \naccept or reject such Purchase Order within two weeks after receipt thereof, with any failure to approve or disapprove of \nsuch Purchase Order in such period constituting disapproval. Each purchase of Accuray Components and Interfaces shall \nbe accomplished and a Purchase Order may be accepted by the execution of the Purchase Order by an authorized \nrepresentative of Accuray. To the extent of any inconsistency between the Quote and the related Purchase Order, the \nterms and conditions of such Quote shall govern and Distributor acknowledges and agrees that Accuray shall not be \nbound by any terms, conditions or boilerplate language included in a Distributor purchase order submitted to Accuray. \nThe Purchase Order shall be delivered to Accuray via fax, electronic mail, or mail at the following address:", "numbers_present": null, "definition_terms": ["Purchase Order"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::157f4f2f0b1e", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8a3c0f903feb"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8a3c0f903feb", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.3.4", "section_title": "Cancellation; Amendment; Conflict", "clause_type": "Purchase Order cancellation/amendment and contractual precedence", "path": "2 ➞ 2.3 ➞ 2.3.4", "text": "tor purchase order submitted to Accuray. \nThe Purchase Order shall be delivered to Accuray via fax, electronic mail, or mail at the following address:\n\nAccuray Incorporated \nATTN: Contracts Administration \n1310 Chesapeake Terrace \nSunnyvale, CA 94089 \nMain: (408) 716-4600 \nFax: (408) 789-4205 \nEmail: Orders@accuray.com \n  \n2.3.4. Cancellation; Amendment; Conflict. Distributor may cancel the Purchase Order if Accuray has not executed such Purchase\n\nOrder within two weeks of receipt. Any amendment or addition to the Purchase Order shall only be effective if Distributor \nand Accuray confirm such amendment or addition in writing. To the extent of any inconsistency between a Quote or a \nPurchase Order and this Agreement, this Agreement shall prevail, unless such Quote or Purchase Order is signed by both \nthe CFO or General Counsel of Accuray and the CFO of Distributor, expressly refers to this Section 2.3.4, and states that \nthe Quote or Purchase Order is intended to supersede this Agreement. \n  \n2.4. Standard Lead Time. As of the Effective Time and to the best of Accuray's knowledge, Accuray's standard lead time for delivery of\n\nProducts is six months. \n  \n3. DUTIES OF DISTRIBUTOR", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2dbc1fcde18c", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0c5ef822f33d"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0c5ef822f33d", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3; 3.1; 3.2", "section_title": "DUTIES OF DISTRIBUTOR", "clause_type": "Duties / Obligations (Distributor)", "path": "3 ➞ 3.1; 3.2", "text": "ective Time and to the best of Accuray's knowledge, Accuray's standard lead time for delivery of\n\nProducts is six months. \n  \n3. DUTIES OF DISTRIBUTOR\n\n3.1. Independent Distributor. Distributor shall be and must at all times make it clear that it is an independent entity contracting with\n\nAccuray, and is not the employee, representative or agent of Accuray. Distributor does not have the ability or authority to enter \ninto any legal agreements or obligations that would bind Accuray in any manner. \n  \n3.2. Market Knowledge, Promotion and Sales. Distributor will develop a thorough and complete understanding of the Products and\n\nServices. Distributor will use its knowledge and understanding to identify and cultivate potential Customers. Distributor agrees to \nuse commercially reasonable efforts to introduce, promote the sale of, and obtain orders for the Products and Services in connection \nwith Multiple LINAC or Multi-Modality Purchases, including, without limitation, including the Products and Services in each of \nDistributor's\n\n4", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8a3c0f903feb", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2e7d8ad1a320"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2e7d8ad1a320", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.2–3.3", "section_title": "Market Knowledge, Promotion and Sales; Distributor Personnel", "clause_type": "Distributor obligations / duties (marketing, promotion, personnel requirements)", "path": "3 ➞ 3.2; 3 ➞ 3.3", "text": "tion \nwith Multiple LINAC or Multi-Modality Purchases, including, without limitation, including the Products and Services in each of \nDistributor's\n\n4\n\nOncology Care Systems price book and sales operation system, such that all of Distributor's sales representatives can access \nquotations for Products and Services at least as easily as all other systems then available for purchase from Distributor. Moreover, \nDistributor represents and warrants that, on the date hereof and during the Term of this Agreement and any extension thereof, it (i) \npossesses the knowledge, experience, skills, and ability required to properly fulfill its obligations under this Agreement; and (ii) has \nthe required facilities, manpower, capacity, financial strength, and knowledge to market and distribute Accuray's Products and \nServices in connection with Multiple LINAC or Multi-Modality Purchases.\n\n3.3. Distributor Personnel. During the Term of this Agreement and any extension thereof, Distributor agrees to use commercially reasonable", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0c5ef822f33d", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::58f5d19a6c78"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::58f5d19a6c78", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.3-3.5", "section_title": "3.3 Distributor Personnel; 3.4 Distributor Personnel Sales Training; 3.5 Offers", "clause_type": "Distributor obligations / duties (personnel, training, customer offers)", "path": "3 ➞ 3.3; 3 ➞ 3.4; 3 ➞ 3.5", "text": "Purchases.\n\n3.3. Distributor Personnel. During the Term of this Agreement and any extension thereof, Distributor agrees to use commercially reasonable\n\nefforts to employ qualified sales and technical personnel familiar with the Products and Services, including, without limitation, at \nleast one person in Distributor's Oncology Care Systems sales group with a primary responsibility for sales of Products, to perform \nthe marketing and sales requirements as set forth herein. \n  \n3.4. Distributor Personnel Sales Training. Distributor shall use commercially reasonable efforts to cause each of its Oncology Care Systems\n\nsales personnel with any sales duties related to the Systems to attend any training provided by Accuray in such personnel's \nAccuray Region pursuant to Section 4.12. \n  \n3.5. Offers. Distributor shall inform Accuray of all potential Customers for Multiple LINAC or Multi-Modality Purchases during the Term of", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2e7d8ad1a320", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::23fbe21345ec"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::23fbe21345ec", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.5–3.7", "section_title": "Offers; Purchase Schedule; Customer Complaints", "clause_type": "Distributor obligations / Duties", "path": "3 ➞ 3.5 ➞ 3.6 ➞ 3.7", "text": "n 4.12. \n  \n3.5. Offers. Distributor shall inform Accuray of all potential Customers for Multiple LINAC or Multi-Modality Purchases during the Term of\n\nthis Agreement or any extension thereof. Distributor shall offer such potential Customers only those Products or Services described \nin then current price lists, and only in accordance with the applicable Customer Quote and this Agreement. \n  \n3.6. Purchase Schedule. For each sale completed by Distributor, the resulting contract for the sale of Products shall be between Distributor\n\nand the Customer and the Service Agreement, if any, shall be between Accuray and the Customer or Accuray and the Distributor, as \ndetermined pursuant to Section 4.8. For each such sale, Distributor must send a Purchase Order to Accuray at least six (6) months \nprior to the expected shipment date. \n  \n3.7. Customer Complaints. Distributor shall report promptly and in writing to Accuray any complaints or expressions of dissatisfaction by", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::58f5d19a6c78", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::238c3baa5660"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::238c3baa5660", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.7-3.10", "section_title": "DUTIES OF DISTRIBUTOR", "clause_type": "Distributor obligations / operational duties", "path": "3 ➞ 3.7 / 3 ➞ 3.8 / 3 ➞ 3.9 / 3 ➞ 3.10", "text": "nt date. \n  \n3.7. Customer Complaints. Distributor shall report promptly and in writing to Accuray any complaints or expressions of dissatisfaction by\n\nthe Customers to Distributor relating to the Products or Services. Any such reports shall be provided to Accuray via electronic mail \nto the following address: complaints@accuray.com. \n  \n3.8. Warranty. Distributor will not make any warranties or representations in Accuray's name or on Accuray's behalf other than the\n\nwarranty provided by Accuray pursuant to Section 4.6 unless approved in advance in writing by Accuray. \n  \n3.9. Service Agreements. Distributor will make commercially reasonable efforts to sell a Service Agreement to each Customer. For the\n\navoidance of doubt, (i) the obligations of the parties with respect to the Service Agreement are as set forth in Sections 3.6 and 4.8 \nand (ii) the failure of Distributor to sell a Service Agreement to any Customer shall not be deemed to be a breach of this Agreement. \n  \n3.10. Upgrades. Any Product upgrades released by Accuray (other than Bug Fixes and Safety Updates, which are addressed in Section", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::23fbe21345ec", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3413f0d11b47"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3413f0d11b47", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.10–3.11.1", "section_title": "Upgrades; Compliance with Laws (Compliance Generally)", "clause_type": "Distributor obligations / Compliance", "path": "3 ➞ 3.10 ➞ 3.11 ➞ 3.11.1", "text": "this Agreement. \n  \n3.10. Upgrades. Any Product upgrades released by Accuray (other than Bug Fixes and Safety Updates, which are addressed in Section\n\n4.6.3 and 4.6.4 respectively) can be purchased at the discretion of the Distributor pursuant to the procedures set forth in Section 2.3. \nSuch\n\n5\n\nupgrades will be available at the prices listed in the then current price list as of the date of the Quote (unless prior written approval \nby Accuray for application of an earlier price list is obtained) for the upgrade, less any applicable discounts as specified in Exhibit A \nhereto.\n\n3.11. Compliance with Laws.\n\n3.11.1. Compliance Generally. Distributor has and will have during the Term of this Agreement and any extension thereof the ability", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::238c3baa5660", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f544ea3469a0"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f544ea3469a0", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.11.1-3.11.2", "section_title": "Compliance with Laws", "clause_type": "Compliance", "path": "3 ➞ 3.11 ➞ 3.11.1-3.11.2", "text": "liance with Laws.\n\n3.11.1. Compliance Generally. Distributor has and will have during the Term of this Agreement and any extension thereof the ability\n\nto distribute, market and sell the Products and Services in accordance with the terms of this Agreement, in full compliance \nwith all governmental, regulatory and other requirements under any applicable law. Furthermore, Distributor agrees to \ncomply with all applicable international, national, regional and local laws applicable to the performance of its duties \nhereunder or to any transactions involving the Products or Services contemplated hereunder. \n  \n3.11.2. United States Laws. Distributor understands that, because it is distributing the Products and Services of Accuray, a\n\ncorporation subject to the laws of the United States of America, Distributor must, when carrying out its duties pursuant to \nthis Agreement, avoid violations of certain of such laws. These include, but are not necessarily limited to, the following:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3413f0d11b47", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2fa3676e0f52"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2fa3676e0f52", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.11.2.1-3.11.3", "section_title": "United States Laws; No Illegal Activity", "clause_type": "Compliance with Laws / Prohibition on Illegal Activity", "path": "3 ➞ 3.11 ➞ 3.11.2 ➞ 3.11.2.1-3.11.2.3 ➞ 3.11.3", "text": "ut its duties pursuant to \nthis Agreement, avoid violations of certain of such laws. These include, but are not necessarily limited to, the following:\n\n3.11.2.1. Restrictive Trade Practices or Boycotts, U.S. Code of Federal Regulations Title 15, Chapter VII, Part 760. \n  \n3.11.2.2. Foreign Corrupt Practices Act, U.S. Code Title 15, § 78. \n  \n3.11.2.3. Export Controls, imposed by U.S. Executive Order or implementing regulations of the U.S. Departments of\n\nCommerce, Defense or Treasury. \n  \n3.11.3. No Illegal Activity. Neither party (nor their sub-distributors, if any (\"Sub-Distributors\")) shall engage in any illegal activities.", "numbers_present": null, "definition_terms": ["Sub-Distributors"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f544ea3469a0", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d4c20a638266"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d4c20a638266", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.11.3", "section_title": "No Illegal Activity", "clause_type": "Compliance; Prohibition of Illegal Activity; Indemnity; Termination", "path": "3 ➞ 3.11 ➞ 3.11.3", "text": "sury. \n  \n3.11.3. No Illegal Activity. Neither party (nor their sub-distributors, if any (\"Sub-Distributors\")) shall engage in any illegal activities.\n\nA party will not be held responsible for any activities of the other party or the other party's Sub-Distributors that may be \nconsidered to be illegal. For example, neither party supports the practice of bribes or under-the-table payments. Each party \nwill ensure a like clause is included in each agreement it has with its Sub-Distributors, and monitor activities of its SubDistributors closely. In the event a party deems that its good-will has been or may potentially be affected by any such \nillegal activity of the other party or the other party's Sub-Distributors, then such party reserves the right to terminate this \nAgreement or any portion thereof that relates to or is materially affected by such illegal activity with no further liability to \nthe other party or the other party's Sub-Distributors. Such party assumes no liability for such illegal activity and the other \nparty hereby indemnifies and holds such party, its officers and assigns, harmless from any loss, damage and liability \narising from or in connection with such illegal activity. \n  \n3.12. Sales Targets. Distributor shall not be subject to any minimum purchase requirements, but shall agree to the annual sales targets set", "numbers_present": null, "definition_terms": ["Sub-Distributors"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::2fa3676e0f52", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bc4a2f29413e"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bc4a2f29413e", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "3.12; 3.13; 4; 4.1; 4.1.1", "section_title": "Sales Targets; Affiliates; Distributors; DUTIES OF ACCURAY; Fulfillment and Shipment; Fulfillment of Executed Purchase Orders", "clause_type": "Obligations/Duties", "path": "3 ➞ 3.12; 3 ➞ 3.13; 4 ➞ 4.1 ➞ 4.1.1", "text": "ivity. \n  \n3.12. Sales Targets. Distributor shall not be subject to any minimum purchase requirements, but shall agree to the annual sales targets set\n\nforth in Schedule 2.5(d)(i)(2) of the Strategic Alliance Agreement and to using its customary standard sales processes, including, \nwithout limitation, the MTA process, with respect to sales of Systems.\n\n6\n\n3.13. Affiliates; Distributors. Siemens shall cause any of its Affiliates or distributors purchasing Systems or Services pursuant to the terms\n\nof this Agreement to agree to be bound by and comply with the terms and conditions of this Agreement and the provisions of the \nStrategic Alliance Agreement related to or applicable to such purchase, unless such Affiliate or distributor is already party to a \ndistribution agreement for Products with Accuray. \n  \n4. DUTIES OF ACCURAY\n\n4.1. Fulfillment and Shipment.\n\n4.1.1. Fulfillment of Executed Purchase Orders. Accuray is responsible for ensuring that the Products supplied are of good quality as", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d4c20a638266", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1e5fa6919aa4"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1e5fa6919aa4", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.1.1-4.1.2", "section_title": "Fulfillment and Shipment", "clause_type": "Shipping/Delivery (Fulfillment) Obligation", "path": "4 ➞ 4.1 ➞ 4.1.1 and 4.1.2", "text": "t and Shipment.\n\n4.1.1. Fulfillment of Executed Purchase Orders. Accuray is responsible for ensuring that the Products supplied are of good quality as\n\nfurther described below. Accuray will use commercially reasonable efforts to provide to Distributor or Customer, as \napplicable, in a timely manner those Products and Services required to fill confirmed Purchase Orders received from \nDistributor in accordance with the terms of this Agreement. \n  \n4.1.2. Shipment. All shipments shall be made F.C.A. Port of Oakland, California, USA. Transfer of risk from Accuray to Distributor", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bc4a2f29413e", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::e31edf249a44"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::e31edf249a44", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.1.2", "section_title": "Shipment", "clause_type": "Shipping/Delivery", "path": "4 ➞ 4.1 ➞ 4.1.2", "text": "this Agreement. \n  \n4.1.2. Shipment. All shipments shall be made F.C.A. Port of Oakland, California, USA. Transfer of risk from Accuray to Distributor\n\nshall occur at such F.C.A. location as provided in F.C.A. terms and transfer of title shall occur at the same time. Distributor \nmay request Accuray to use a particular freight carrier, and Accuray agrees to do so, if feasible. If not feasible in Accuray's \nreasonable judgment, then Accuray shall promptly advise Distributor of the reasons. If no such request is made, Accuray \nshall ship in accordance with any instructions contained in the Purchase Order or via FedEx ground, with no extra \ninsurance. Accuray shall bill any actual freight costs to Distributor. Any supplementary shipping costs arising from the \nneed to meet the delivery deadline set forth in the Purchase Order by way of expedited delivery shall be borne by Accuray, \nif such delivery deadline was at least six months after the submission of such Purchase Order by Distributor. For example, if \na Purchase Order was submitted on June 1, with a requested delivery date of December 1, any expedited delivery expenses \nrequired in order to ensure delivery by December 1 shall be borne by Accuray, while if the requested delivery date was \nOctober 1, any expedited delivery expenses required in order to ensure delivery by October 1 shall be borne by Distributor. \n  \n4.2. Product and Service Pricing. Accuray will provide its then current U.S. list pricing for its Products and Services to Siemens once per", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1e5fa6919aa4", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bbb562255668"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bbb562255668", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.2-4.4", "section_title": "Product and Service Pricing; Product Specifications and Promotional Literature; Regulatory Clearance", "clause_type": "Duties/Obligations (Accuray obligations)", "path": "4 ➞ 4.2; 4 ➞ 4.3; 4 ➞ 4.4", "text": "butor. \n  \n4.2. Product and Service Pricing. Accuray will provide its then current U.S. list pricing for its Products and Services to Siemens once per\n\nyear during the Term of this Agreement and any extension thereof, or upon request from Siemens. All prices will be stated in US \nDollars, unless another currency is agreed upon in writing by Accuray. \n  \n4.3. Product Specifications and Promotional Literature. Accuray will provide product specifications and promotional literature to Distributor\n\nfrom time to time during the Term of this Agreement and any extension thereof. Distributor may use product specifications and \npromotional literature in Distributor's dealings with Customers. Accuray may introduce changes and upgrades to the Products. \nAccuray will use commercially reasonable efforts to give Distributor as much advance notice of upgrades as is feasible. \n  \n4.4. Regulatory Clearance. Accuray will be responsible for and will bear all expenses related to obtaining and maintaining any approvals,\n\npermits and licenses required under any applicable law in order to sell, market and distribute the Products and Services to a \nCustomer in\n\n7", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::e31edf249a44", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0fb9cf9fcedd"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0fb9cf9fcedd", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.4", "section_title": "Regulatory Clearance", "clause_type": "Regulatory compliance / obligations", "path": "4 ➞ 4.4", "text": "rovals,\n\npermits and licenses required under any applicable law in order to sell, market and distribute the Products and Services to a \nCustomer in\n\n7\n\nconnection with Multiple LINAC or Multi-Modality Purchases, including any upgrades to or expanded usage of the Products; \nprovided, however, that if Accuray does not have a direct presence in or Accuray does not have a distributor for the sales of \nSystems specifically for the country in which the Customer requests delivery, as a condition to any sale of Products or Services to \nsuch Customer, Accuray may require Distributor (solely with the consent of Distributor) to enter into a distribution agreement with \nAccuray pursuant to Section 3.2 of the Strategic Alliance Agreement providing, among other things, that Distributor will be \nresponsible for obtaining all such approvals, permits, and licenses for sales to such Customer. Distributor will provide any \nassistance or documentation reasonably requested by Accuray and at Accuray's expenses to assist Accuray with its obligations \nunder this Section 4.4. Accuray will be registered as the sole owner of any rights, title and interest to any of the Products or Spare \nParts, as the case may be; provided, however, that should any applicable law or regulation require that Distributor alone be entitled \nto such ownership rights, Distributor shall hold this approval as trustee for Accuray and hereby consents to transfer or sublicense \nsuch approval to Accuray free of charge or to support Accuray in its efforts to re-obtain the approval for the benefit of Accuray or a \nthird party named by Accuray upon expiration or termination of this Agreement. Lists indicating, as of the Effective Date, (i) the \ncountries in which Accuray has obtained regulatory approvals for the Products and Services and (ii) the countries in which Accuray \nhas a direct presence or has a distributor for the sales of Systems specifically for such country are being delivered to Siemens \nconcurrently with the execution of this Agreement. Accuray shall provide to Siemens updates of such lists on a quarterly basis.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bbb562255668", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1c7a8d22a46b"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1c7a8d22a46b", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.5", "section_title": "Import License", "clause_type": "Regulatory/Compliance (import license; importer of record obligations)", "path": "4 ➞ 4.5", "text": "delivered to Siemens \nconcurrently with the execution of this Agreement. Accuray shall provide to Siemens updates of such lists on a quarterly basis.\n\n4.5. Import License. Accuray or its distributor will obtain and maintain all required import licenses, and shall serve as importer of record for\n\nall Products and Services delivered in or into any country or region, other than the United States, pursuant to this Agreement; \nprovided, however, that if Accuray does not have a direct presence in or Accuray does not have a distributor specifically for the \nsales of Systems in the country in which the Customer requests delivery, as a condition to any sale of Products or Services to such \nCustomer, Accuray may require Distributor (solely with the consent of Distributor) to enter into a distribution agreement with \nAccuray pursuant to Section 3.2 of the Strategic Alliance Agreement providing, among other things, that Distributor will obtain and \nmaintain all required import licenses and will act as the importer of record for the Products and Services ordered by such Customer. \n  \n4.6. Warranty.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0fb9cf9fcedd", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::99ed3e9f73d6"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::99ed3e9f73d6", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.6.1", "section_title": "Scope of Warranty", "clause_type": "Warranty", "path": "4 ➞ 4.6 ➞ 4.6.1", "text": "aintain all required import licenses and will act as the importer of record for the Products and Services ordered by such Customer. \n  \n4.6. Warranty.\n\n4.6.1. Scope of Warranty. Accuray will provide a warranty to each Customer that the Products will be free from material defects and", "numbers_present": null, "definition_terms": ["Warranty Period", "Installation"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1c7a8d22a46b", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::48e1e342c66f"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::48e1e342c66f", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.6.1", "section_title": "Scope of Warranty", "clause_type": "Warranty", "path": "4 ➞ 4.6 ➞ 4.6.1", "text": "4.6. Warranty.\n\n4.6.1. Scope of Warranty. Accuray will provide a warranty to each Customer that the Products will be free from material defects and\n\nperform substantially in accordance with the written Specifications provided by Accuray as reflected in the regulatory \nclearance at the time of sale for a period of one (1) year following Installation of the Products at Customer's facility, but not \nto exceed eighteen (18) months following shipment of such Products to Distributor (\"Warranty Period\"). \"Installation\" of \nthe System shall occur upon completion by Accuray or the entity installing the System, as applicable, of Accuray's \nacceptance test procedure demonstrating that the System substantially conforms to the written Specifications. If Accuray \ndoes not perform the Installation, Distributor will notify Accuray in writing within ten (10) days following Installation \n(including any testing procedures undertaken by Customer or its installation service provider). In no event shall \nDistributor, Customer or their respective agents use the System (or any portion thereof) for any purpose before Installation \nthereof without the express written approval of Accuray. Distributor\n\n8", "numbers_present": null, "definition_terms": ["Warranty Period", "Installation"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::99ed3e9f73d6", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::af60e672700f"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::af60e672700f", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.6.2", "section_title": "Hardware and Software", "clause_type": "Warranty / Remedies for defective Products (repair, replace or refund)", "path": "4 ➞ 4.6 ➞ 4.6.2", "text": "s use the System (or any portion thereof) for any purpose before Installation \nthereof without the express written approval of Accuray. Distributor\n\n8\n\nshall indemnify and hold Accuray harmless from any such use. Accuray makes no warranty that the operation of any \nsoftware will be uninterrupted or error-free. Except as set forth in the preceding sentences, Accuray makes no warranties or \nrepresentations to Customers or to any other party regarding any Products or Services provided by Accuray. TO THE \nFULLEST EXTENT PERMITTED BY APPLICABLE LAW, ACCURAY DISCLAIMS ALL OTHER WARRANTIES AND \nREPRESENTATIONS, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND ANY WARRANTIES \nARISING OUT OF COURSE OF DEALING OR USAGE OF TRADE.\n\n4.6.2. Hardware and Software. If a Customer notifies Accuray in writing during the Warranty Period of a defect in a Product that", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::48e1e342c66f", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8fb45cd42a5f"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8fb45cd42a5f", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.6.2–4.6.3", "section_title": "Hardware and Software; Software and Bug Fixes", "clause_type": "Warranty (remedies/repair, replacement, refund)", "path": "4 ➞ 4.6 ➞ 4.6.2–4.6.3", "text": "G OR USAGE OF TRADE.\n\n4.6.2. Hardware and Software. If a Customer notifies Accuray in writing during the Warranty Period of a defect in a Product that\n\ncauses the Product to fail to conform to the foregoing warranty, Accuray shall at its option either repair or replace the nonconforming Product or, if in Accuray's opinion such repair or replacement is not commercially reasonable, Accuray shall \nrefund a pro-rated portion of the price paid by the Customer for such Product calculated based on a straight-line \ndepreciation over a 5-year period beginning on the date of delivery. This will be Accuray's sole and exclusive obligation \nand such Customer's sole and exclusive remedy in relation to defective Products and parts. \n  \n4.6.3. Software and Bug Fixes. Notwithstanding Section 4.6.2, for a period of 10 years following Installation of a System, Accuray will", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::af60e672700f", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::19341fcdc0a0"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::19341fcdc0a0", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.6.3", "section_title": "Software and Bug Fixes", "clause_type": "Warranty (software maintenance/bug fixes)", "path": "4 ➞ 4.6 ➞ 4.6.3", "text": "and parts. \n  \n4.6.3. Software and Bug Fixes. Notwithstanding Section 4.6.2, for a period of 10 years following Installation of a System, Accuray will\n\nprovide to Customer, without charge, Bug Fixes with respect to any software included in the System. This is Accuray's \nsole and exclusive obligation and Customer's and Distributor's sole and exclusive remedy in relation to defective software. \nBy way of clarification, Accuray's sole obligation shall be to make such Bug Fixes available to Customer, and Accuray \nshall have no obligation (unless otherwise agreed by the Customer and Accuray) for installation or implementation of such \nBug Fixes at the Customer's site. \"Bug Fix\" means an error correction or minor change in the existing software and/or \nhardware configuration that is required in order to enable the existing software and/or hardware configuration to perform to \nthe existing functional specification(s). \n  \n4.6.4. Safety Updates. Notwithstanding Section 4.6.2 and any obligations according to law, for a period of 10 years following", "numbers_present": null, "definition_terms": ["Bug Fix"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8fb45cd42a5f", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7b89bcd56234"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7b89bcd56234", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.6.4–4.6.5", "section_title": "Safety Updates; Warranty Exclusions", "clause_type": "Warranty (Safety Updates / Warranty exclusions; definition of \"Safety Update\")", "path": "4 ➞ 4.6 ➞ 4.6.4 ➞ 4.6.5", "text": "al specification(s). \n  \n4.6.4. Safety Updates. Notwithstanding Section 4.6.2 and any obligations according to law, for a period of 10 years following\n\nInstallation of a System, Accuray will provide to Customer, without charge, Safety Updates with respect to any hardware or \nsoftware included in the System. This is Accuray's sole and exclusive obligation and Customer's and Distributor's sole \nand exclusive remedy in relation to any Safety Update required to be provided by applicable law in the Customer's \njurisdiction. By way of clarification, Accuray's sole obligation shall be to make such Safety Update available to Customer, \nand Accuray shall have no obligation (unless otherwise agreed by the Customer and Accuray) for installation or \nimplementation of such Safety Update at the Customer's site. \"Safety Update\" means an error correction or change in the \nexisting software and/or hardware configuration that is required for safety in order to enable the existing software and/or \nhardware configuration to perform to the existing functional specification(s) in accordance with applicable law in the \nCustomer's jurisdiction. \n  \n4.6.5. Warranty Exclusions. All warranty replacement of Products and parts shall be limited to malfunctions which are due and", "numbers_present": null, "definition_terms": ["Safety Update"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::19341fcdc0a0", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::da17653dc840"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::da17653dc840", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.6.5, 4.6.6, 4.7", "section_title": "Warranty Exclusions; Warranty Basis; Installation", "clause_type": "Warranty / Limitation of Liability; Installation", "path": "4 ➞ 4.6 ➞ 4.6.5; 4 ➞ 4.6 ➞ 4.6.6; 4 ➞ 4.7", "text": "omer's jurisdiction. \n  \n4.6.5. Warranty Exclusions. All warranty replacement of Products and parts shall be limited to malfunctions which are due and\n\ntraceable to defects in original material or workmanship of Products. The warranties set forth in this Section 4.6 shall be \nvoid\n\n9\n\nand of no further effect in the event of abuse, accident, alteration, misuse or neglect of Products, including but not limited \nto user modification of the operating environment specified by Accuray and user modification of any software.\n\n4.6.6. Warranty Basis. Any limitation of liability under any warranty contained herein shall be an integral part of such warranty,\n\nwhich limits its scope (Section 444, second alternative German Civil Code shall not apply). Any limitation of liability for any \ndefects contained herein shall be void insofar as Accuray has intentionally failed to disclose such defect. \n  \n4.7. Installation. Unless otherwise agreed by Accuray and Distributor (including, without limitation, pursuant to the terms of any", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7b89bcd56234", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9c5ac8fbf796"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9c5ac8fbf796", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.7-4.8", "section_title": "Installation; Service Agreements (partial)", "clause_type": "Obligation/Duty", "path": "4 ➞ 4.7; 4 ➞ 4.8", "text": "se such defect. \n  \n4.7. Installation. Unless otherwise agreed by Accuray and Distributor (including, without limitation, pursuant to the terms of any\n\ndistribution agreement entered into pursuant to Section 3.2 of the Strategic Alliance Agreement), Accuray shall be responsible for \ninstallation of Accuray Products at Customer sites. \n  \n4.8. Service Agreements. Accuray will provide its then current Service Agreements to Distributor from time to time during the Term of this", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::da17653dc840", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ace78842d4d3"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ace78842d4d3", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.8", "section_title": "Service Agreements", "clause_type": "Duties of Accuray / Service Agreement obligation", "path": "4 ➞ 4.8", "text": "sites. \n  \n4.8. Service Agreements. Accuray will provide its then current Service Agreements to Distributor from time to time during the Term of this\n\nAgreement and any extension thereof, or upon request from Distributor. All prices will be stated in US Dollars, unless another \ncurrency is agreed upon in writing by Accuray. Such Service Agreements are to be offered to the Customer on the terms as set forth \nin those agreements, unless otherwise agreed to in writing by an authorized representative of Accuray. Accuray shall execute a \nService Agreement with the Customer upon receipt of (i) a copy of such Service Agreement executed by the Customer, and (ii) any \npayments then due under such Service Agreement; provided, however, that Accuray shall have no obligation to enter into such \nService Agreement if it materially deviates from the form Service Agreement provided to Distributor; provided, further, that if \nAccuray does not have a direct presence in or Accuray does not have a distributor for the sales of Systems specifically for the \ncountry in which the Customer requests Services, as a condition to any sale of Services to such Customer, Accuray may require \nDistributor (solely with the consent of Distributor) to enter into a distribution agreement with Accuray pursuant to Section 3.2 of the \nStrategic Alliance Agreement providing, among other things, that Distributor may (at its sole discretion) enter into such Service \nAgreement with such Customer and will provide directly to such Customer the Services required to be performed under such Service \nAgreement. If Accuray enters into such Service Agreement with such Customer, Accuray will be responsible for and will provide to \nsuch Customer (either directly or through one or more of its distributors) the services required to be performed under such Service \nAgreement. \n  \n4.9. Customer Training. If training of Customer's personnel is included in a Purchase Order confirmed by Accuray, Accuray will provide", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9c5ac8fbf796", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::db673d8b1ff0"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::db673d8b1ff0", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.9", "section_title": "Customer Training", "clause_type": "Operational obligation (training/service obligation)", "path": "4 ➞ 4.9", "text": "Agreement. \n  \n4.9. Customer Training. If training of Customer's personnel is included in a Purchase Order confirmed by Accuray, Accuray will provide\n\nsuch training in accordance with Accuray's then current training offerings and will coordinate with the Customer in order to provide \nsuch training at Accuray's facility in Sunnyvale, California (or such other facility as may be agreed upon by Customer and \nAccuray). For the purposes of such training, Accuray will be responsible for the travel and accommodation expenses of its \npersonnel, while Customer shall be responsible for the travel and accommodation expenses of its personnel. All Customer training \nprovided by Accuray will be conducted in English and, to the extent a Customer or its personnel do not have adequate English \nlanguage reading and comprehension skills, Accuray will provide an interpreter and translation services sufficient to enable the \nCustomer and its personnel to meaningfully and effectively participate in Accuray training courses.\n\n10\n\n4.10. Customer Support. Unless otherwise agreed by Accuray and Distributor (including, without limitation, pursuant to the terms of any", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ace78842d4d3", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8e9aac79bc28"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8e9aac79bc28", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.10-4.12", "section_title": "Customer Support; Additional Support and Training; Distributor Personnel Sales Training", "clause_type": "Duties of Accuray — Support, Training and Customer Assistance obligations", "path": "4 ➞ 4.10 ➞ 4.11 ➞ 4.12", "text": "courses.\n\n10\n\n4.10. Customer Support. Unless otherwise agreed by Accuray and Distributor (including, without limitation, pursuant to the terms of any\n\ndistributorship agreement entered into pursuant to Section 3.2 of the Strategic Alliance Agreement), Accuray will provide guidance \nto billing and reimbursement personnel of each Customer regarding regulatory and billing requirements and reimbursement for \ntreatment provided with Products under radiosurgery reimbursement codes. Accuray will coordinate and assist the Customer with \nroom evaluation, architecture support and quality assurance issues in relation to Customer installation sites. \n  \n4.11. Additional Support and Training. Accuray will provide additional service, support, or training in relation to Products or Services at\n\nCustomer's request, to be ordered separately and directly from Accuray, and priced on a time and materials basis according to \nAccuray's then current price lists. \n  \n4.12. Distributor Personnel Sales Training. Accuray shall provide training of Distributor's sales personnel responsible for sales of Products", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::db673d8b1ff0", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3a92b7c220c3"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3a92b7c220c3", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.12 - 4.13.1", "section_title": "Distributor Personnel Sales Training; Support of Distributor's Efforts", "clause_type": "Obligations (Training and Marketing/Support)", "path": "4 ➞ 4.12; 4 ➞ 4.13 ➞ 4.13.1", "text": "sts. \n  \n4.12. Distributor Personnel Sales Training. Accuray shall provide training of Distributor's sales personnel responsible for sales of Products\n\nand Services to Distributor free of charge. Such training shall be at the times, in such locations, and in the scope agreed upon by \nDistributor and Accuray in good faith; provided, however, that such training shall be provided to such Distributor personnel in \neach Accuray Region at least once per year. Each party shall be responsible for all costs and expenses, including travel and lodging, \nincurred by it or its personnel to attend or provide such training. Accuray will provide additional training to Distributor's personnel \nas may be reasonably requested by Distributor on a time and materials basis according to Accuray's then current price lists. \n  \n4.13. Support of Distributor's Efforts. Accuray shall, at its own expense:\n\n4.13.1. assign a dedicated marketing point of contact for Distributor's marketing and sales personnel, which employee may be based", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8e9aac79bc28", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8ce69e29c0fe"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8ce69e29c0fe", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.13.1–4.14", "section_title": "Support of Distributor's Efforts; Compliance with Laws", "clause_type": "Duties/Obligations (Support and Compliance)", "path": "4 ➞ 4.13 ➞ 4.13.1–4.13.2; 4.14", "text": "t its own expense:\n\n4.13.1. assign a dedicated marketing point of contact for Distributor's marketing and sales personnel, which employee may be based\n\nat any of Distributor's facilities as requested by the Steering Committee; and \n  \n4.13.2. provide global sales and marketing support, including support for individual sales opportunities, to Distributor; provided,\n\nhowever, that the scope, duration, location, availability, and timing of such support shall be subject to commercially \nreasonable limits and shall be determined pursuant to Section 3.3(a)(iii) of the Strategic Alliance Agreement. \n  \n4.14. Compliance with Laws. Accuray will be responsible for complying with (i) applicable U.S. laws, (ii) where Products are being shipped", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3a92b7c220c3", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::217542cc4ab2"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::217542cc4ab2", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.14", "section_title": "Compliance with Laws", "clause_type": "Compliance", "path": "4 ➞ 4.14", "text": "eement. \n  \n4.14. Compliance with Laws. Accuray will be responsible for complying with (i) applicable U.S. laws, (ii) where Products are being shipped\n\nto Distributor and unless otherwise agreed by Accuray and Distributor, applicable laws, codes, registrations, regulations, and \nordinances related to the export of the Products to Distributor, and (iii) any other applicable laws as they pertain to the Products, the \nregulatory clearance, and safety in accordance with Accuray's written Specifications for the intended use. In addition, Accuray \nshall be responsible for compliance with any applicable law, code, registration, regulation, and ordinance related to the export of the \nProducts or Services to Customer and/or Distributor, if any (the \"Export Regulations\"), and Accuray shall be liable for any expenses \nand/or damages incurred by Distributor due to any non-compliance with such Export Regulations by Accuray (unless Accuray is \nnot responsible for such non-compliance). Accuray shall advise Distributor in writing within two weeks of the confirmation of the \nPurchase Order of any information or data required by Accuray to comply with an Export Regulation, including without limitation:", "numbers_present": null, "definition_terms": ["Export Regulations"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8ce69e29c0fe", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::4de4d3ef2909"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::4de4d3ef2909", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.14(a)-(d); 4.15; 5; 5.1", "section_title": "Compliance with Laws (Export Regulations); Spare Parts; Compensation and Payment (Orders)", "clause_type": "Multiple: Export/compliance information; post-termination support (Spare Parts); compensation/payment (Orders)", "path": "4 ➞ 4.14 ➞ 4.14(a)-(d); 4 ➞ 4.15; 5 ➞ 5.1", "text": "confirmation of the \nPurchase Order of any information or data required by Accuray to comply with an Export Regulation, including without limitation:\n\n(a) All applicable export list numbers, including the Export Control\n\n11\n\nClassification Number according to the U.S. Commerce Control List (ECCN); \n  \n(b) The statistical commodity code according to the current commodity classification for foreign trade statistics and the\n\nHS (Harmonized System) coding; \n  \n(c) The country of origin (non-preferential origin); and \n  \n(d) Accuray's declaration of preferential origin (in case of European suppliers) or preferential certificates (in case of\n\nnon-European suppliers). \n  \n4.15. Spare Parts. Upon a termination of this Agreement, Accuray shall continue to make available to Customers support services on\n\ncommercially reasonable terms, including, without limitation, spare parts for the Systems for a minimum period of 10 years after the \nlast shipment of a System pursuant to this Agreement. \n  \n5. COMPENSATION AND PAYMENT\n\n5.1. Orders. Distributor shall make an offer to a Customer based on the Quote provided by Accuray pursuant to the process set forth in", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::217542cc4ab2", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ebab86344dab"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ebab86344dab", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.1–5.2.2", "section_title": "COMPENSATION AND PAYMENT", "clause_type": "Payment/Compensation", "path": "5 ➞ 5.1; 5 ➞ 5.2 ➞ 5.2.1; 5 ➞ 5.2 ➞ 5.2.2", "text": "ON AND PAYMENT\n\n5.1. Orders. Distributor shall make an offer to a Customer based on the Quote provided by Accuray pursuant to the process set forth in\n\nSection 2.3. Submission and acceptance of an order shall be completed pursuant to Section 2.3.3. \n  \n5.2. Purchase Price.\n\n5.2.1. Distributor shall pay the prices listed in the applicable Purchase Order (unless prior written approval by Accuray for\n\napplication of an earlier price list is obtained) for the Products, including any Spare Parts, less any applicable discounts as \nspecified in Exhibit A hereto. Distributor shall receive a commission in the amount specified in Exhibit A hereto for any \nService Agreement entered into by Accuray with Customer pursuant to Section 4.8. \n  \n5.2.2. All costs of delivering the Products to the Distributor or Customer (including, but not limited to, costs for land, air and/or", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::4de4d3ef2909", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f7759e4f7d72"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f7759e4f7d72", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.2.2", "section_title": "Purchase Price", "clause_type": "Pricing / Shipping / Taxes", "path": "5 ➞ 5.2 ➞ 5.2.2", "text": "Section 4.8. \n  \n5.2.2. All costs of delivering the Products to the Distributor or Customer (including, but not limited to, costs for land, air and/or\n\nocean freight, insurance, port, customs and forwarding fees, if any), as well as any rigging and unloading of the Products, \nshall be paid as provided in the F.C.A. terms. Unless advised otherwise, all prices quoted by Accuray include the cost of \npacking and crating for delivery. \n  \n5.2.3. Taxes. By way of clarification, all Accuray prices referenced in this Agreement, and all other amounts payable by Distributor to", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ebab86344dab", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::209014c1d584"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::209014c1d584", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.2.3–5.3", "section_title": "Taxes; Compensation", "clause_type": "Taxes and Compensation (Payment/Financial)", "path": "5 ➞ 5.2 ➞ 5.2.3; 5 ➞ 5.3", "text": "delivery. \n  \n5.2.3. Taxes. By way of clarification, all Accuray prices referenced in this Agreement, and all other amounts payable by Distributor to\n\nAccuray pursuant to this Agreement are net of any value added tax or federal, state, county or municipal sales or use tax, \nexcise or similar charge, withholding tax, or other tax assessment (except for any taxes that are assessed against income) \n(collectively, the \"Taxes\"). The parties agree that it is their intention that Accuray will not bear any economic burden \nrelating to the Taxes. Subject to the foregoing and to compliance with applicable laws, Accuray and Distributor agree to \ncooperate with each other as reasonably requested to establish the responsibilities of the parties relating to the payment \nand withholding of Taxes, filing of documents, and other matters in order to achieve an efficient tax result. \n  \n5.3. Compensation. Except as otherwise provided herein, Distributor's only compensation for its efforts on Accuray's behalf shall be the\n\nmargins it earns on the resale of Products and\n\n12", "numbers_present": null, "definition_terms": ["Taxes"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::f7759e4f7d72", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a8ad17f3a482"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a8ad17f3a482", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.3–5.4.1", "section_title": "Payment", "clause_type": "Payment", "path": "5 ➞ 5.4 ➞ 5.4.1", "text": "provided herein, Distributor's only compensation for its efforts on Accuray's behalf shall be the\n\nmargins it earns on the resale of Products and\n\n12\n\ncommissions on sales of Services, and Distributor shall bear all of the expenses which it incurs in making those efforts. \nNotwithstanding the foregoing, in the event that Accuray does not approve the issuance of a Quote to a potential Customer and \nlater contracts directly (or through one of its distributors) with such potential Customer, of which Accuray shall inform Distributor \nwithout undue delay, Distributor shall receive credit for any sales of Systems to such potential Customer pursuant to and subject to \nthe fulfillment of the conditions set forth in Section 3.4 of the Strategic Alliance Agreement. \n  \n5.4. Payment.\n\n5.4.1. System Purchase Payments. Payment for the purchase of a System shall be made by Distributor to Accuray in US Dollars in", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::209014c1d584", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d99b8c14cd25"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d99b8c14cd25", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.4.1", "section_title": "System Purchase Payments", "clause_type": "Payment", "path": "5 ➞ 5.4 ➞ 5.4.1", "text": "ent. \n  \n5.4. Payment.\n\n5.4.1. System Purchase Payments. Payment for the purchase of a System shall be made by Distributor to Accuray in US Dollars in\n\nthe form of either (1) an irrevocable trade finance letter of credit or (2) wire transfer as further described in Sections 5.4.1.1 \n(Letter of Credit) and 5.4.1.2 (Wire Transfer), respectively below. Accuray shall bear the cost of any bank charges assessed \nby its bank for a letter of credit and any commission charge for a wire transfer. Past due balances on any reasonably \nundisputed amount shall bear interest at the rate of 0.5% per month or, if lower, the maximum amount permitted by \napplicable law. If Distributor is a \"business person\" (as defined in § 14 of the German Civil Code, \"BGB\"), the payment shall \nbe deemed past due only if Distributor fails to pay in response to a payment demand note received after payment becomes \ndue.\n\n5.4.1.1. Letter of Credit. An irrevocable trade finance letter of credit issued by Distributor's bank, confirmed by a bank", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a8ad17f3a482", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ecd9d20bcc29"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ecd9d20bcc29", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.4.1.1 – 5.4.1.2.1", "section_title": "Letter of Credit; Wire Transfer", "clause_type": "Payment terms (Letter of Credit and Wire Transfer schedule)", "path": "5 ➞ 5.4 ➞ 5.4.1 ➞ 5.4.1.1 (Letter of Credit) ➞ 5.4.1.1.1 / 5.4.1.1.2; and 5.4.1.2 (Wire Transfer) ➞ 5.4.1.2.1", "text": "fter payment becomes \ndue.\n\n5.4.1.1. Letter of Credit. An irrevocable trade finance letter of credit issued by Distributor's bank, confirmed by a bank\n\ndesignated by Accuray in all respects and delivered to Accuray upon the acceptance of the Purchase Order \nby Accuray. The letter of credit will provide that Accuray can draw against the letter of credit according to the \nfollowing schedule:\n\n5.4.1.1.1. US $100,000 (non-refundable but, in case of cancellation of the Purchase Order, automatically applied\n\nto Distributor's next purchase of a System) upon Accuray's acceptance of the Purchase \nOrder, which must be at least four (4) months prior to the Distributor's proposed shipment \ndate; and \n  \n5.4.1.1.2. Balance upon presentation of documents by Accuray evidencing shipment of the Products to\n\nDistributor or Customer as designated in the Purchase Order. \n  \n5.4.1.2. Wire Transfer. A wire transfer made in advance of the date payment is due, made in U.S. dollars, to a bank selected\n\nby Accuray, according to the following schedule:\n\n5.4.1.2.1. US $100,000 (non-refundable but, in case of cancellation of the Purchase Order, automatically applied", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d99b8c14cd25", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3a65ed958b74"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3a65ed958b74", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.4.1.2.1–5.4.2", "section_title": "Wire Transfer payment schedule; Tax Exempt Status; Products, Spare Parts and Upgrade Payments", "clause_type": "Payment terms / Wire transfer schedule and tax-exempt condition", "path": "5 ➞ 5.4 ➞ 5.4.1 ➞ 5.4.1.2 ➞ 5.4.1.2.1–5.4.2", "text": "according to the following schedule:\n\n5.4.1.2.1. US $100,000 (non-refundable but, in case of cancellation of the Purchase Order, automatically applied\n\nto Distributor's next purchase of a System) upon Accuray's acceptance of the Purchase \nOrder, which must be at least four (4) months prior to the Distributor's proposed shipment \ndate; and\n\n13\n\n5.4.1.2.2. The remaining balance is due net 30 days after delivery by Accuray at the specified F.C.A. location\n\npursuant to Section 4.1.2 and receipt by Distributor of a reasonably undisputed invoice. \n  \n5.4.1.3. Tax Exempt Status. In the event that Customer claims tax exempt status in the country where the Accuray System is\n\nto be installed, Customer must provide Accuray with sufficient evidence of such tax exempt status prior to \ndelivery of the Accuray System. \n  \n5.4.2. Products, Spare Parts and Upgrade Payments. Full payment of the purchase price for Products (other than Systems), Spare", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ecd9d20bcc29", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::294543d8d8ca"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::294543d8d8ca", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.4.2–5.4.3", "section_title": "Products, Spare Parts and Upgrade Payments / Payments by Customers Direct to Accuray", "clause_type": "Payment terms", "path": "5 ➞ 5.4 ➞ 5.4.2–5.4.3", "text": "the Accuray System. \n  \n5.4.2. Products, Spare Parts and Upgrade Payments. Full payment of the purchase price for Products (other than Systems), Spare\n\nParts and upgrades shall be made by Distributor to Accuray in US Dollars by wire transfer to a bank selected by Accuray \nand is due net 30 days after delivery by Accuray at the specified F.C.A. location pursuant to Section 4.1.2 and receipt by \nDistributor of a reasonably undisputed invoice. Accuray shall bear the cost of any commission charge for a wire transfer. \n  \n5.4.3. Payments by Customers Direct to Accuray. If agreed to in writing by Accuray, Customers may make payments directly to", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3a65ed958b74", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0be7ffaea1e4"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0be7ffaea1e4", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.4.3-5.5", "section_title": "Payments by Customers Direct to Accuray; Collections", "clause_type": "Payment/Collections", "path": "5 ➞ 5.4 ➞ 5.4.3; 5 ➞ 5.5", "text": "e for a wire transfer. \n  \n5.4.3. Payments by Customers Direct to Accuray. If agreed to in writing by Accuray, Customers may make payments directly to\n\nAccuray using the payment methods and schedules set forth in Sections 5.4.1.1 (Letter of Credit), 5.4.1.2 (Wire Transfer) \nand 5.4.2 (Products, Spare Parts and Upgrade Payments) above. Should Customers make such payments to Accuray and \nsuch payment include the Distributor's margin, then Accuray will pay such margin to Distributor once payment is received \nfrom the Customer and cleared by Accuray's designated bank. \n  \n5.5. Collections. Notwithstanding Section 5.4.3 above, Distributor shall be solely responsible for determining the creditworthiness of and", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::294543d8d8ca", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::90092411415c"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::90092411415c", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5.5", "section_title": "Collections", "clause_type": "Payment/Collections", "path": "5 ➞ 5.5", "text": "d bank. \n  \n5.5. Collections. Notwithstanding Section 5.4.3 above, Distributor shall be solely responsible for determining the creditworthiness of and\n\ncollecting payment from its Customers. The risk of non-collection from the Customer will be borne entirely by Distributor, which \nshall be responsible for making timely payment to Accuray for Products whether or not Distributor is successful in collecting from \nits Customer. In the event that full payment is not received by Accuray, Accuray shall not be liable to Distributor for any margin or \ncommission unless and until it has received payment of amounts sufficient to cover the costs incurred by Accuray to provide the \napplicable Products to Distributor and the applicable Services to Customer (\"Accuray Cost\"). Distributor acknowledges and agrees \nthat it shall not be entitled to receive payment of any margin or commission until Accuray has received payment of the Accuray \nCost amount in relation to the applicable Products and Services. \n  \n6. TERM AND TERMINATION\n\n6.1. Term. Unless otherwise agreed in writing by Accuray and Distributor and subject to the termination rights contained in this Agreement,", "numbers_present": null, "definition_terms": ["Accuray Cost"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0be7ffaea1e4", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d85f34893938"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d85f34893938", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "6.1-6.2.2", "section_title": "Termination", "clause_type": "Term and Termination clause", "path": "6 ➞ 6.1; 6 ➞ 6.2 ➞ 6.2.1; 6 ➞ 6.2 ➞ 6.2.2", "text": "RMINATION\n\n6.1. Term. Unless otherwise agreed in writing by Accuray and Distributor and subject to the termination rights contained in this Agreement,\n\nthis Agreement shall begin on the Effective Date and shall continue until the termination of the Strategic Alliance Agreement; \nprovided, however, that if a Termination Election relating to this Agreement is made pursuant to Section 10.3 of the Strategic \nAlliance Agreement prior to such termination, this Agreement shall terminate 36 months after such Termination Election (the \n\"Term\"). \n  \n6.2. Termination.\n\n6.2.1. Breach. If either party commits a material breach of a material provision of this Agreement, if such breach was not excused as a\n\nforce majeure pursuant to Section 12.12, and if the breaching party has not cured such breach to the other party's\n\n14\n\nreasonable satisfaction within 30 days after written notice from the other party specifying the nature of such breach, then \nthe other party shall have the right to terminate this Agreement upon delivery of written notice to the breaching Party.\n\n6.2.2. Bankruptcy. A party may terminate this Agreement effective upon delivery of written notice to the other party if: (i) any", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::90092411415c", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::cc9d4cb4cfbb"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::cc9d4cb4cfbb", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "6.2.2–6.3.1", "section_title": "Bankruptcy; Effect of Termination", "clause_type": "Termination/Bankruptcy", "path": "6 ➞ 6.2 ➞ 6.2.2; 6 ➞ 6.3 ➞ 6.3.1", "text": "the breaching Party.\n\n6.2.2. Bankruptcy. A party may terminate this Agreement effective upon delivery of written notice to the other party if: (i) any\n\nassignment for the benefit of the other party's creditors is made, (ii) the other party voluntarily files a petition in \nbankruptcy or similar proceeding, (iii) the other party has such a petition in bankruptcy or similar proceeding involuntarily \nfiled against it, (iv) the other party is placed in an insolvency proceeding, (v) if an order is entered appointing a receiver or \ntrustee of the other party, or (vi) a levy or attachment is made against a substantial portion of the other party's assets, and, \nwith respect to any event set forth in clauses (iii) through (vi) above, such position, placement, order, levy or attachment is \nnot dismissed or removed within 30 days from the date of such event. \n  \n6.3. Effect of Termination. Upon expiration of the Term (or other termination of this Agreement):\n\n6.3.1. Transition of Activities. Accuray and Distributor agree to negotiate in good faith an orderly transition of Distributor's", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d85f34893938", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::312e0bccc3a3"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::312e0bccc3a3", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "6.3.1-6.4", "section_title": "Effect of Termination; No Termination Compensation", "clause_type": "Termination / Transition", "path": "6 ➞ 6.3 ➞ 6.3.1; 6.3.2; 6.3.3; 6.4", "text": "of this Agreement):\n\n6.3.1. Transition of Activities. Accuray and Distributor agree to negotiate in good faith an orderly transition of Distributor's\n\ndistribution responsibilities and activities to Accuray or a third party designated by Accuray and Distributor agrees to \nassist in the transition. \n  \n6.3.2. Pending Obligations. Each party must continue to fulfill any obligations, including but not limited to pending Quotes, accrued\n\nbefore the effective date of such termination. \n  \n6.3.3. Return of Materials. Distributor shall transfer to Accuray upon Accuray's request: any regulatory clearances, licenses or\n\npermits obtained for conduct of the business pursuant to this Agreement; any Confidential Information; and other items as \nnegotiated in good faith between the parties. Furthermore, each of the parties agree to cooperate fully with the other for \nany reasonable transition assistance required in the case of termination or expiration of this Agreement. \n  \n6.4. No Termination Compensation. Distributor waives any rights it may have to receive any compensation or indemnity upon termination", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::cc9d4cb4cfbb", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9e29c2cd55db"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9e29c2cd55db", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "6.4, 6.5, 7, 8", "section_title": "No Termination Compensation; Accruals; Dispute Resolution; Confidentiality", "clause_type": "Termination / Accruals / Dispute Resolution / Confidentiality", "path": "6 ➞ 6.4; 6 ➞ 6.5; 7; 8", "text": "s Agreement. \n  \n6.4. No Termination Compensation. Distributor waives any rights it may have to receive any compensation or indemnity upon termination\n\nor expiration of this Agreement, other than as expressly provided in this Agreement. Distributor acknowledges that it has no \nexpectation and has received no assurances that any investment by Distributor in the promotion of the Products will be recovered \nor recouped or that Distributor will obtain any anticipated amount of profits by virtue of this Agreement. \n  \n6.5. Accruals. No termination or expiration of this Agreement will terminate any obligation of payment which has accrued prior to the\n\neffective date of such termination or expiration. \n  \n7. DISPUTE RESOLUTION. Any contractual issues or disputes arising out of or related to this Agreement shall be resolved pursuant to the\n\nprocedures set forth in Section 11.3 of the Strategic Alliance Agreement. \n  \n8. CONFIDENTIALITY. Accuray and Distributor agree that all Confidential Information furnished to a party or its Affiliates, employees,\n\nconsultants, and advisors in connection with this Agreement will\n\n15", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::312e0bccc3a3", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1b7c3282be4f"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1b7c3282be4f", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "9", "section_title": "INTELLECTUAL PROPERTY RIGHTS", "clause_type": "Intellectual Property (notice of infringement and third-party claims)", "path": "9 ➞ 9.1 ➞ 9.2", "text": "all Confidential Information furnished to a party or its Affiliates, employees,\n\nconsultants, and advisors in connection with this Agreement will\n\n15\n\nbe subject to and the parties' rights and obligations with respect to such Confidential Information shall be governed by the Confidentiality \nAgreement. \n  \n9. INTELLECTUAL PROPERTY RIGHTS.\n\n9.1. Notice of Infringement. Distributor undertakes to inform Accuray without undue delay if it first becomes aware of any possible\n\ninfringement by third parties of Accuray's proprietary rights, including, without limitation, a duplication of the Products or any other \npatent, trademark or copyright or other infringement of Accuray's intellectual property rights in connection with the Products, and \nto cooperate with Accuray at Accuray's sole expense regarding any legal action in relation to such infringement, which in \nAccuray's judgment, is necessary or desirable. \n  \n9.2. Third Party Claims. If Distributor promptly notifies Accuray of a claim it has received or of which it becomes aware that the Products or", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9e29c2cd55db", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0b2ab9f53642"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0b2ab9f53642", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "9.2", "section_title": "Third Party Claims", "clause_type": "Indemnity / Intellectual Property (infringement remedies)", "path": "9 ➞ 9.2", "text": "le. \n  \n9.2. Third Party Claims. If Distributor promptly notifies Accuray of a claim it has received or of which it becomes aware that the Products or\n\nany part thereof purchased by Distributor hereunder infringes a third party's proprietary rights, then Accuray agrees, at its \ndiscretion, either to (i) defend the claim at its expense, with the cooperation of Distributor, provided, that Accuray shall reimburse \nDistributor for any reasonable costs or expenses actually incurred by Distributor in connection with providing such cooperation, or \n(ii) make changes in the Product or part thereof so that they are at least functionally equivalent and non-infringing or replace the \nProducts with alternatives that are at least functionally equivalent to avoid the claim, or (iii) purchase the right to use such \nproprietary right or (iv) refund to the purchaser the net book value of the Product less a reasonable deduction for use, wear and tear, \nand depreciation upon Accuray taking possession of such Product. Notwithstanding Section 10.1, the foregoing states the entire \nliability of Accuray with respect to infringement of patents or other proprietary rights by the Products or part thereof, or by their \noperation. To remove all doubt, Accuray has no obligation regarding any claim based on any of the following: (a) modification of \nthe Products by any person other than Accuray; (b) combination, operation or use of the Products with other products, parts, \ncomponents, materials or accessories not provided by Accuray; or (c) infringement by a product not manufactured by Accuray. \n  \n9.3. Intellectual Property Ownership and License. Accuray and its licensors retain all intellectual property rights in the Products. Accuray", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1b7c3282be4f", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bc2c0dcff826"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bc2c0dcff826", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "9.3-9.4", "section_title": "Intellectual Property Ownership and License / Product Labeling", "clause_type": "Intellectual Property Rights and Product Labeling", "path": "9 ➞ 9.3 / 9 ➞ 9.4", "text": "uray. \n  \n9.3. Intellectual Property Ownership and License. Accuray and its licensors retain all intellectual property rights in the Products. Accuray\n\nhereby grants Distributor or Customer a nonexclusive, non-transferable, royalty-free right to use the software provided in \nconnection with the Products only in machine readable form and only in combination with the Products with which such software is \nprovided. No such software shall be copied or decompiled in whole or in part by Distributor or Customer, and Distributor or \nCustomer shall not disclose or provide any such software, or any portion thereof, to any third party. Accuray hereby grants to \nCustomers of Products a non-exclusive, non-transferable and royalty-free license under any Patents owned by Accuray or the \nlicensing of which is controlled by Accuray that, but for this license, would be infringed by the use of such Products in accordance \nwith the applicable Specification. All rights in intellectual property not expressly granted hereunder are reserved by the owner of \nsuch intellectual property. \n  \n9.4. Product Labeling. Products shall be labeled and identified at point of manufacture. Accuray shall be responsible for compliance with all", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::0b2ab9f53642", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7ab746b6bb0c"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7ab746b6bb0c", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "9.4", "section_title": "Product Labeling", "clause_type": "Obligation/Compliance (Product labeling and identification)", "path": "9 ➞ 9.4", "text": "rty. \n  \n9.4. Product Labeling. Products shall be labeled and identified at point of manufacture. Accuray shall be responsible for compliance with all\n\napplicable local laws and regulations relating to labeling. Such labeling and identification shall be only as acceptable to Accuray and \nmay be altered or added to by Distributor only as previously agreed upon in writing by Accuray. The failure of Distributor to \ncomply with these provisions shall be considered a material default under the terms of this Agreement.\n\n16\n\n9.5. Trademarks. Distributor acknowledges the validity and proprietary value of Accuray's trademarks including, but not limited to,", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bc2c0dcff826", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ead506fe4062"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ead506fe4062", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "9.5", "section_title": "Trademarks", "clause_type": "Trademarks", "path": "9 ⟶ 9.5", "text": "is Agreement.\n\n16\n\n9.5. Trademarks. Distributor acknowledges the validity and proprietary value of Accuray's trademarks including, but not limited to,\n\n\"CyberKnife.\" Accuray shall retain sole ownership of all goodwill associated with the Products, as represented and symbolized by \nthe associated trademarks, and Distributor shall not register any of Accuray's trademarks in its name. Distributor undertakes to \ndisplay Accuray's trademarks solely in connection with identifying Accuray in the sale and marketing of Products hereunder. \nDistributor shall not remove copyright notices or any trademarks from the Products. Distributor shall not be entitled to use said \ntrademarks in conjunction with Distributor's own trademarks or for any other purpose, except in the manner authorized by Accuray, \nwhich authorization will not be unreasonably withheld and in compliance with distribution standards and specifications established \nby Accuray. If Accuray determines in its sole discretion that Distributor is not meeting such standards and specifications, \nDistributor shall immediately, at Accuray's instructions, take all steps necessary to ensure that such standards and specifications \nare met or cease all further use and display of the trademarks. In the event of expiration or termination of this Agreement, Distributor \nshall immediately discontinue all use of Accuray's trademarks except for the sale of Distributor's inventory of Products. \n  \n10. INDEMNITIES.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::7ab746b6bb0c", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::13933d7c8876"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::13933d7c8876", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "10.1", "section_title": "Accuray Indemnity", "clause_type": "Indemnity", "path": "10 ➞ 10.1", "text": "ibutor \nshall immediately discontinue all use of Accuray's trademarks except for the sale of Distributor's inventory of Products. \n  \n10. INDEMNITIES.\n\n10.1. Accuray Indemnity. Accuray will defend or settle any action brought against Distributor and shall indemnify and hold Distributor", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ead506fe4062", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::32649f424731"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::32649f424731", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "10.1", "section_title": "Accuray Indemnity", "clause_type": "Indemnity", "path": "10 ➞ 10.1", "text": ". INDEMNITIES.\n\n10.1. Accuray Indemnity. Accuray will defend or settle any action brought against Distributor and shall indemnify and hold Distributor\n\nharmless from any liability, damages and expenses (including court costs and reasonable attorneys' fees) to the extent that it is \nbased upon a third-party claim that a Product, as provided by Accuray to Distributor under this Agreement, infringes any patent \nissued in the United States, Germany, or in the country in which the Customer requested delivery of the Product or any copyright or \nmisappropriates any trade secret, and will pay any costs and damages made in settlement or awarded against Distributor in final \ndecision resulting from any such claim, provided that Distributor: (i) gives Accuray prompt notice of any such claim; (ii) gives \nAccuray sole control of the defense and any related settlement of any such claim; and (iii) gives Accuray, at Accuray's expense, all \nreasonable information, assistance and authority in connection with the foregoing. Accuray will not be bound by any settlement or \ncompromise that Distributor enters into without Accuray's express prior written consent. \n  \n10.2. Products Liability Indemnity. Accuray will defend or settle any action brought against Distributor and shall indemnify and hold", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::13933d7c8876", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fb9b9db3790d"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fb9b9db3790d", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "10.2", "section_title": "Products Liability Indemnity", "clause_type": "Indemnity", "path": "10 ➞ 10.2", "text": "ten consent. \n  \n10.2. Products Liability Indemnity. Accuray will defend or settle any action brought against Distributor and shall indemnify and hold\n\nDistributor harmless from any liability, damages and expenses (including court costs and reasonable attorneys' fees) to the extent \nthat it is based upon a third-party claim that a Product, as provided by Accuray to Distributor under this Agreement is unsafe when \nused according to Accuray's written Specifications for its intended use, and will pay any costs and damages made in settlement or \nawarded against Distributor in final decision resulting from any such claim, provided that Distributor: (i) gives Accuray prompt \nnotice of any such claim; (ii) gives Accuray sole control of the defense and any related settlement of any such claim; and (iii) gives \nAccuray, at Accuray's expense, all reasonable information, assistance and authority in connection with the foregoing. Accuray will \nnot be bound by any settlement or compromise that Distributor enters into without Accuray's express prior written consent. \n  \n10.3. Injunctions. If Distributor's rights to use and distribute a Product under the terms of this Agreement are, or in Accuray's opinion are", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::32649f424731", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::935cb5a539ed"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::935cb5a539ed", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "10.3", "section_title": "Injunctions", "clause_type": "Injunctions / Remedies (Indemnity-related)", "path": "10 ➞ 10.3", "text": "ent. \n  \n10.3. Injunctions. If Distributor's rights to use and distribute a Product under the terms of this Agreement are, or in Accuray's opinion are\n\nlikely to be, enjoined due to the type of claim specified in Section 10.1 (Accuray Indemnity), then Accuray may, at its sole option \nand expense: (i) procure for Distributor the right to continue to use and distribute such Product under the terms of this Agreement; \n(ii) replace or modify such Product so that it is non-\n\n17\n\ninfringing; or (iii) if options (i) and (ii) above cannot be accomplished despite Accuray's reasonable efforts, then Accuray or \nDistributor may terminate this Agreement with respect to such Product and Accuray shall credit to Distributor a pro-rated portion of \nthe amount paid for such Product based on a straight-line depreciation calculated over a 5-year period beginning on the date of \ndelivery of the Product, provided that all units of such Product are returned to Accuray in an undamaged condition. \n  \n10.4. Indemnity Exclusions. Notwithstanding the foregoing, Accuray will have no obligation under Sections 10.1 (Accuray Indemnity) or", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fb9b9db3790d", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ba32fa246fbf"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ba32fa246fbf", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "10.4", "section_title": "Indemnity Exclusions", "clause_type": "Indemnity - Exclusions", "path": "10 ➞ 10.4", "text": "d condition. \n  \n10.4. Indemnity Exclusions. Notwithstanding the foregoing, Accuray will have no obligation under Sections 10.1 (Accuray Indemnity) or\n\n10.2 (Products Liability Indemnity) for any third-party claim to the extent that such claim results from: (i) use of any Products not in \naccordance with Accuray's written Specifications; (ii) use or combination of the Products with other items, such as other equipment, \nprocesses, programming applications or materials not furnished by Accuray; (iii) compliance by Accuray with Distributor's or \nCustomers' designs, specifications or instructions; (iv) modifications to a Product not made by or at the express written direction of \nAccuray; (v) Distributor's failure to use updated or modified Products provided by Accuray, provided that such updated or \nmodified Products would have avoided the basis for such claim; or (vi) Distributor's use or distribution of a Product other than in \naccordance with this Agreement. The foregoing clauses (i) to (vi) are referred to collectively as \"Indemnity Exclusions\". \n  \n10.5. Limitation. WITHOUT AFFECTING STRICT PRODUCT LIABILITY UNDER MANDATORY APPLICABLE LAW, THE FOREGOING", "numbers_present": null, "definition_terms": ["Indemnity Exclusions"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::935cb5a539ed", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ed8caad652f7"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ed8caad652f7", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "10.5-11.2", "section_title": "Limitation; Distributor Indemnity; Liability; Liability for Death or Injury; Limitation on Liability", "clause_type": "Indemnity and Limitation of Liability", "path": "10 ➞ 10.5; 10 ➞ 10.6; 11 ➞ 11.1 ➞ 11.2", "text": "collectively as \"Indemnity Exclusions\". \n  \n10.5. Limitation. WITHOUT AFFECTING STRICT PRODUCT LIABILITY UNDER MANDATORY APPLICABLE LAW, THE FOREGOING\n\nPROVISIONS OF THIS SECTION SET FORTH ACCURAY'S SOLE AND EXCLUSIVE LIABILITY AND DISTRIBUTOR'S SOLE \nAND EXCLUSIVE REMEDY FOR ANY CLAIMS OF INFRINGEMENT OR MISAPPROPRIATION OF INTELLECTUAL PROPERTY \nRIGHTS OR PROPRIETARY RIGHTS OF ANY KIND. \n  \n10.6. Distributor Indemnity. Distributor will defend or settle, indemnify and hold Accuray harmless from any liability, damages and expenses\n\n(including court costs and reasonable attorneys' fees) to the extent based upon a third-party claim based on or otherwise \nattributable to: (i) Distributor's acts or omissions not in accordance with this Agreement or (ii) any misrepresentations made by \nDistributor with respect to Accuray or the Products or Services. \n  \n11. LIABILITY.\n\n11.1. Liability for Death or Injury. The liability of any party with respect to death or injury to any person is subject to and governed by the\n\nprovisions of applicable law. \n  \n11.2. Limitation on Liability. WITHOUT AFFECTING STRICT PRODUCT LIABILITY UNDER MANDATORY APPLICABLE LAW,", "numbers_present": null, "definition_terms": ["Indemnity Exclusions"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ba32fa246fbf", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1ec411f2bc89"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1ec411f2bc89", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "11.2", "section_title": "Limitation on Liability", "clause_type": "Limitation of liability", "path": "11 ➞ 11.2", "text": "ed by the\n\nprovisions of applicable law. \n  \n11.2. Limitation on Liability. WITHOUT AFFECTING STRICT PRODUCT LIABILITY UNDER MANDATORY APPLICABLE LAW,\n\nSECTION 10, OR THE RESPECTIVE OBLIGATIONS OF THE PARTIES UNDER THE CONFIDENTIAILITY AGREEMENT AND \nEXCEPT FOR BREACHES ASSOCIATED WITH THE UNAUTHORIZED USE OF INTELLECTUAL PROPERTY, IN NO EVENT \nSHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR \nTORT DAMAGES, INCLUDING WITHOUT LIMITATION, ANY DAMAGES RESULTING FROM LOSS OF USE, LOSS OF DATA, \nLOSS OF PROFITS OR LOSS OF BUSINESS ARISING OUT OF OR IN CONNECTION WITH THE MATTERS CONTEMPLATED \nBY THIS AGREEMENT, WHETHER OR NOT A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.\n\n18\n\n11.3. Liability Cap. Without affecting Section 10 or the respective obligations of the parties under the Confidentiality Agreement and except", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ed8caad652f7", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::6525d3e90054"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::6525d3e90054", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "11.3", "section_title": "Liability Cap", "clause_type": "Limitation of liability", "path": "11 ➞ 11.3", "text": "ES.\n\n18\n\n11.3. Liability Cap. Without affecting Section 10 or the respective obligations of the parties under the Confidentiality Agreement and except\n\nfor any liability (i) relating to any breach associated with the unauthorized use of Intellectual Property, (ii) arising from the \nintentional breach or willful misconduct of a party, or (iii) arising from the non-compliance with any mandatory applicable law or \nregulation, the total aggregate liability of one party to another party for any claim relating to any breach of this Agreement (or any \nPurchase Order or other agreement entered into in connection with this Agreement) (a \"Claim\") shall be limited to the aggregate \namount of the purchase prices paid by Distributor to Accuray for Products pursuant to this Agreement (or any Purchase Order or \nother Agreement entered into in connection with this Agreement) during the twelve calendar months preceding the date of the \nnotification to the other party of such Claim less any amounts paid or payable in respect of any other Claim of which the other party \nwas notified during such twelve month period. \n  \n11.4. Notice; No Waiver. Each party shall not unreasonably delay notification to the other party of any Claim. Nothing in this Section 11", "numbers_present": null, "definition_terms": ["Claim"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1ec411f2bc89", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a00685cad2f4"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a00685cad2f4", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "11.4 – 12.2", "section_title": "Notice; No Waiver / Miscellaneous Provisions", "clause_type": "Miscellaneous (Notice; Governing Law; Modification)", "path": "11 ➞ 11.4 ➞ 12 ➞ 12.1 ➞ 12.2", "text": "period. \n  \n11.4. Notice; No Waiver. Each party shall not unreasonably delay notification to the other party of any Claim. Nothing in this Section 11\n\nshall be deemed a waiver by any party of any right to injunctive relief to the extent it is available to such party. \n  \n12. MISCELLANEOUS PROVISIONS\n\n12.1. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the Federal Republic of Germany\n\nexcluding the United Nations Convention on Contracts of International Sale of Goods (CISG) and the provisions of German private \ninternational law. \n  \n12.2. Modification. Notwithstanding any provision to the contrary in this Agreement, Distributor and Accuray may agree, by execution of a", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::6525d3e90054", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d71c96e02dc9"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d71c96e02dc9", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.2–12.4", "section_title": "Modification; Publicity; Goodwill", "clause_type": "Miscellaneous / Boilerplate", "path": "12 ➞ 12.2 ➞ 12.3 ➞ 12.4", "text": "nal law. \n  \n12.2. Modification. Notwithstanding any provision to the contrary in this Agreement, Distributor and Accuray may agree, by execution of a\n\nwritten agreement, to modify any term or provision of this Agreement, including, without limitation, the duties of the parties, the \nQuote and Purchase Order approval procedure, the pricing of the Products and Services, and the payment terms, with respect to any \nsingle or number of Customer opportunities, Quotes, or Purchase Orders. \n  \n12.3. Publicity. Both parties may not use the other party's name or trademarks on its literature, signs, or letterhead, nor may it make press\n\nreleases or other public statements disclosing its relationship under this Agreement or otherwise without the prior written consent \nof the other party, which shall not be unreasonably withheld or delayed. \n  \n12.4. Goodwill. Distributor agrees that it will help develop and work to preserve the goodwill of Accuray, and will not unreasonably harm", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a00685cad2f4", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::04603e8f6d99"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::04603e8f6d99", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.4, 12.5, 12.6", "section_title": "Goodwill; Titles; Assignment", "clause_type": "Miscellaneous provisions", "path": "12 ➞ 12.4; 12 ➞ 12.5; 12 ➞ 12.6", "text": "delayed. \n  \n12.4. Goodwill. Distributor agrees that it will help develop and work to preserve the goodwill of Accuray, and will not unreasonably harm\n\nthat goodwill. In the event of termination of this Agreement for any reason, Distributor will not do anything to unreasonably harm \nthe goodwill of Accuray. \n  \n12.5. Titles. Titles of the various paragraphs and sections of this Agreement are for ease of reference only and are not intended to change\n\nor limit the language contained in those paragraphs and sections. \n  \n12.6. Assignment. Neither this Agreement, nor any of the rights, interests, or obligations under this Agreement may be assigned or\n\ndelegated, in whole or in part, by operation of law or otherwise, by any party without the prior written consent of the other party, \nand any such assignment without such prior written consent shall be null and void; provided, however, that this Agreement may be \nassigned by a Party in connection with a Change in Control of such party, subject to the specific termination and other rights set \nforth in the Strategic\n\n19", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d71c96e02dc9", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3accb315a343"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3accb315a343", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.7.1", "section_title": "Conduct", "clause_type": "Conduct/Compliance", "path": "12 ➞ 12.7 ➞ 12.7.1", "text": "by a Party in connection with a Change in Control of such party, subject to the specific termination and other rights set \nforth in the Strategic\n\n19\n\nAlliance Agreement upon such Change in Control; provided, further, that Siemens may assign its rights and obligations under this \nAgreement to any Distributor that agrees, in writing, to be bound by and comply with the terms and conditions of this Agreement \nand the provisions of the Strategic Alliance Agreement, provided, that no such assignment shall relieve Siemens of its obligations \nhereunder or thereunder if such Distributor does not perform such obligations. Subject to the foregoing, this Agreement will be \nbinding upon, inure to the benefit of, and be enforceable by, the parties and their respective successors and permitted assigns.\n\n12.7. Conduct.\n\n12.7.1. Both parties prohibit the harassment of their employees and contractors in any form. They consider harassment of, or", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::04603e8f6d99", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a855d9763298"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a855d9763298", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.7 (12.7.1-12.7.3)", "section_title": "Conduct", "clause_type": "Conduct / Code of Conduct / Compliance", "path": "12 ➞ 12.7 ➞ 12.7.1-12.7.3; 12 ➞ 12.8 (header present)", "text": "assigns.\n\n12.7. Conduct.\n\n12.7.1. Both parties prohibit the harassment of their employees and contractors in any form. They consider harassment of, or\n\ndiscrimination against, their employees and affiliated persons a very serious matter and will investigate all complaints of \ninappropriate conduct. Where the investigation uncover harassment or discrimination, the other party may take \nreasonable corrective action, including, without limitation, termination of this Agreement for material breach. \n  \n12.7.2. During the Term, Accuray shall comply, in all material respects, with Siemens' Code of Conduct, attached hereto as Exhibit B\n\n(the \"Code of Conduct\"). Siemens shall give Accuray written notice of any change to its Code of Conduct as soon as \nreasonably practicable. \n  \n12.7.3. During the Term, Distributor shall comply, in all material respects, with the Business Conduct Guidelines of Siemens and all\n\nother Siemens internal regulations and guidelines. \n  \n12.8. Quality Assurance Agreement. During the Term and in connection with its performance of its duties under this Agreement, Accuray", "numbers_present": null, "definition_terms": ["Code of Conduct"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3accb315a343", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::6f54a529f400"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::6f54a529f400", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.8-12.9", "section_title": "Quality Assurance Agreement; Notices", "clause_type": "Miscellaneous (Quality Assurance; Notices)", "path": "12 ➞ 12.8; 12 ➞ 12.9", "text": "guidelines. \n  \n12.8. Quality Assurance Agreement. During the Term and in connection with its performance of its duties under this Agreement, Accuray\n\nshall comply, in all material respects, with Siemens' Quality Assurance Agreement attached hereto as Exhibit C, with the exception of \nany provisions thereof related to barcoding. \n  \n12.9. Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly given (a) on the date of delivery\n\nif delivered personally, (b) if by facsimile, upon written or electronic confirmation of receipt (if sent during business hours of the \nrecipient, otherwise on the next business day following such confirmation), (c) on the first business day following the date of \ndispatch if delivered utilizing a next-day service by a recognized next-day courier, (d) on the earlier of confirmed receipt or the fifth \nbusiness day following the date of mailing if delivered by registered or certified mail, return receipt requested, postage prepaid. All \nnotice hereunder shall be delivered to the addresses set forth below:\n\n20\n\nTo Distributor: \n  \n    \nAccuray Incorporated\n\nTo Accuray:\n\nSiemens AG \nAttention: Chief Financial Officer", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a855d9763298", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fbb9367534f8"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fbb9367534f8", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.10–12.12", "section_title": "Waiver; Severability; Survival", "clause_type": "Miscellaneous / Boilerplate", "path": "12 ➞ 12.10; 12 ➞ 12.11; 12 ➞ 12.12", "text": "ered to the addresses set forth below:\n\n20\n\nTo Distributor: \n  \n    \nAccuray Incorporated\n\nTo Accuray:\n\nSiemens AG \nAttention: Chief Financial Officer\n\nHenkestr. 127 \n1310 Chesapeake Terrace\n\n91054 Erlangen \nSunnyvale, CA 94089\n\nGermany \nFacsimile: +1 (408) 789-4205\n\nAttn: Healthcare General Counsel, Ritva Sotamaa \nwith cc to: General Counsel\n\nFacsimile: + 49/### - ## - ####\n\n12.10. Waiver. The waiver of any breach or default of any provision of this Agreement will not constitute a waiver of any other right\n\nhereunder or of any subsequent breach or default. \n  \n12.11. Severability. If any provision of this Agreement is held invalid or unenforceable by a court of competent jurisdiction, the remaining\n\nprovisions of the Agreement will remain in full force and effect, and the provision affected will be construed so as to be enforceable \nto the maximum extent permissible by law. \n  \n12.12. Survival. The expiration or termination of this Agreement for any reason will not release either party from any liabilities or obligations", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::6f54a529f400", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::5175fd3cbfe2"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::5175fd3cbfe2", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.12", "section_title": "Survival", "clause_type": "Survival clause (post-termination obligations)", "path": "12 ➞ 12.12", "text": "12.12. Survival. The expiration or termination of this Agreement for any reason will not release either party from any liabilities or obligations\n\nset forth herein which (i) the parties have expressly agreed will survive any such expiration or termination; or (ii) remain to be \nperformed or by their nature would be intended to be applicable following any such termination or expiration. In addition to the \nforegoing, the following provisions shall survive any termination or expiration of this Agreement: Section 3.8 (Warranty); Section \n3.11 (Compliance with Laws); Section 4.6 (Warranty); Section 6.2 (Effect of Termination); Section 6.3 (No Termination \nCompensation); Section 6.4 (Accruals); Section 7 (Dispute Resolution); Section 8 (Confidentiality); Section 9 (Intellectual Property \nRights); Section 10 (Indemnities), Section 11 (Liability) and Section 12 (Miscellaneous Provisions). \n  \n12.13. Force Majeure. Neither party will be responsible for any failure or delay in its performance under this Agreement (except for the", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::fbb9367534f8", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9718309147d4"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9718309147d4", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.13-12.16", "section_title": "Force Majeure; Amendments; English Language Requirement; Foreign Currency", "clause_type": "Boilerplate / Miscellaneous", "path": "12 ➞ 12.13; 12 ➞ 12.14; 12 ➞ 12.15; 12 ➞ 12.16", "text": "visions). \n  \n12.13. Force Majeure. Neither party will be responsible for any failure or delay in its performance under this Agreement (except for the\n\npayment of money) due to causes beyond its reasonable control, including, but not limited to, labor disputes, strikes, lockouts, \nshortages of or inability to obtain labor, energy, raw materials or supplies, war, acts of terror, riot, acts of God or governmental \naction. \n  \n12.14. Amendments. Any amendment or modification of this Agreement must be made in writing and signed by duly authorized\n\nrepresentatives of each party. For Accuray, a duly authorized representative must be any of the following: CEO, CFO, General \nCounsel or Associate General Counsel. \n  \n12.15. English Language Requirement. This Agreement is written in the English language as spoken and interpreted in the United States of\n\nAmerica, and such language and interpretation shall be controlling in all respects. \n  \n12.16. Foreign Currency. Distributor acknowledges and agrees that it shall assume all risk associated with any fluctuation of foreign", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::5175fd3cbfe2", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d1bd023211b3"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d1bd023211b3", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "12.16, 12.17, 12.18", "section_title": "Foreign Currency; Entire Agreement; Counterparts", "clause_type": "Miscellaneous / Boilerplate provisions", "path": "12 ➞ 12.16; 12 ➞ 12.17; 12 ➞ 12.18", "text": "ll respects. \n  \n12.16. Foreign Currency. Distributor acknowledges and agrees that it shall assume all risk associated with any fluctuation of foreign\n\ncurrency exchange rates associated with its pricing of Products and Services to Customers in a currency other than US Dollars. All \npayments made by Distributor to Accuray shall be in US Dollars. \n  \n12.17. Entire Agreement. This Agreement and the Strategic Alliance Agreement contain the entire agreement of the parties hereto with\n\nrespect to the subject matter hereof, and supersedes all prior understandings, representations and warranties, written and oral. If \nany part of the terms and conditions stated herein are held void or unenforceable, such part will be treated\n\n21\n\nas severable, leaving valid the remainder of the terms and conditions. In case of any contradiction between this Agreement and the \nStrategic Alliance Agreement, the terms of this Agreement shall prevail.\n\n12.18. Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together\n\nwill constitute one and the same instrument.\n\nSIGNATURE PAGE FOLLOWS\n\n22", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9718309147d4", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::19aead50d717"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::19aead50d717", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "Schedule 2.3.2", "section_title": "ACCEPTANCE PROCESS", "clause_type": "Signature Block / Schedule Heading", "path": "Agreement ➞ Signature Page ➞ Schedule 2.3.2", "text": "erparts, each of which will be deemed an original, but all of which together\n\nwill constitute one and the same instrument.\n\nSIGNATURE PAGE FOLLOWS\n\n22\n\nIN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the Effective Date by their duly authorized representatives. \nThe parties acknowledge and agree that this Agreement does not become effective until it has been signed by all parties indicated below.\n\nACCURAY INCORPORATED: \n  \n  \n    \n  \nBy: \n/s/ Christian Klaussner\n\nDISTRIBUTOR:\n\nBy: \n/s/ Euan Thompson \n  \n  \n    \n  \nPrint name: \nChristian Klaussner\n\nPrint name: Euan Thomson \n  \n  \n    \n  \nTitle: \nHIM OCS CFO\n\nTitle: \nPresident and Chief Executive Officer \n  \n  \n    \n  \nDate: \nJune 8, 2010\n\nDate: \nJune 7, 2010 \n  \n  \n    \n  \n  \n  \n    \n  \nBy: \n/s/ Holger Schmidt\n\nBy: \n/s/ Darren Milliken \n  \n  \n    \n  \nPrint name: \nHolger Schmidt\n\nPrint name: Darren Milliken \n  \n  \n    \n  \nTitle: \nHIM OCS CEO\n\nTitle: \nSenior Vice President and General Counsel \n  \n  \n    \n  \nDate: \nJune 8, 2010\n\nDate: \nJune 7, 2010\n\nSIGNATURE PAGE TO MULTIPLE LINAC AND MULTI-MODALITY DISTRIBUTOR AGREEMENT\n\nSCHEDULE 2.3.2\n\nACCEPTANCE PROCESS", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d1bd023211b3", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::003f8f387a21"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::003f8f387a21", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "Schedule 2.3.2", "section_title": "ACCEPTANCE PROCESS", "clause_type": "Approval/Acceptance process", "path": "2 ➞ 2.3 ➞ 2.3.2 ➞ Schedule 2.3.2", "text": "ate: \nJune 8, 2010\n\nDate: \nJune 7, 2010\n\nSIGNATURE PAGE TO MULTIPLE LINAC AND MULTI-MODALITY DISTRIBUTOR AGREEMENT\n\nSCHEDULE 2.3.2\n\nACCEPTANCE PROCESS\n\n· Accuray shall have 5 Business Days from date of the submission of a proposed Multiple LINAC Purchase or Multi-Modality Purchases by\n\nSiemens in which to either give or withhold approval of such purchase, with any failure to approve or disapprove of such purchase in \nsuch period constituting disapproval; \n  \n· Such approval may be given by either Accuray's applicable General Regional Manager or a corporate representative of Accuray, expressly\n\ndesignated with such approval authority in writing by Accuray to Siemens; \n  \n· Siemens' shall provide any information concerning such proposed purchase and the proposed purchaser as is reasonably requested by\n\nAccuray; \n  \n· Such approval of any such proposed purchase must not be unreasonably withheld or delayed; \n  \n· In determining whether to grant such approval, Accuray may consider, at a minimum:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::19aead50d717", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1330ca67af0d"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1330ca67af0d", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "Exhibit A", "section_title": "DISTRIBUTOR DISCOUNTS ON PRODUCTS AND SERVICES", "clause_type": "Exhibit (Pricing / Discount Schedule) and approval criteria (schedule continuation)", "path": "2 ➞ 2.3 ➞ 2.3.2 ➞ Schedule 2.3.2 ➞ Exhibit A", "text": "oposed purchase must not be unreasonably withheld or delayed; \n  \n· In determining whether to grant such approval, Accuray may consider, at a minimum:\n\n· Existing exclusivity arrangements between Accuray and Third Parties; \n  \n· Prior and current contact with the proposed purchaser by either Party; \n  \n· Other commercial relationships that either Party may have with the proposed purchaser; \n  \n· Bona fide concerns about the suitability of the proposed purchaser; and \n  \n· Whether Accuray or any of its distributors have obtained any required regulatory clearances and/or import licenses required in\n\nconnection with the proposed purchase.\n\nEXHIBIT A\n\nDISTRIBUTOR DISCOUNTS ON PRODUCTS AND SERVICES\n\nList Price\n\nRange\n\nVolume  \nDiscount\n\nDistributor\n\nDiscount Type\n\nDiscount* \nVolume Discounts - Tier # 1\n\nUSD\n\n{*****} \nVolume Discounts - Tier # 2\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 3\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 4\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 5\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 6\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 7\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 8\n\n{*****}", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::003f8f387a21", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ec5f637c0858"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ec5f637c0858", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "Exhibit A (Volume Discounts) / Exhibit B", "section_title": "Volume Discounts (Tiers) / Siemens Code of Conduct", "clause_type": "Exhibit (Pricing / Discounts) and Exhibit (Supplier Code of Conduct)", "path": "Exhibit A ➞ Volume Discounts (Tier #6 - Tier #12) ➞ Pricing Formula; Exhibit B ➞ Code of Conduct for Siemens Suppliers", "text": "Volume Discounts - Tier # 6\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 7\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 8\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 9\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 10\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 11\n\n{*****}\n\n{*****}\n\n{*****} \nVolume Discounts - Tier # 12\n\n{*****}\n\n{*****}\n\n{*****}\n\n{*****}\n\n{*****}\n\n* Siemens distributor channel discount. \n  \nSiemens Bundled Sales Price= (List Price (1- (Volume Discount + Distributor Discount))\n\nEXHIBIT B\n\nSIEMENS CODE OF CONDUCT\n\nSIEMENS \n  \nCode of Conduct for Siemens Suppliers \n  \nThis Code of Conduct defines the basic requirements placed on Siemens' suppliers of goods and services concerning their responsibilities \ntowards their stakeholders and the environment. Siemens reserves the right to reasonably change the requirements of this Code of Conduct due to \nchanges of the Siemens Compliance Program. In such event Siemens expects the supplier to accept such reasonable changes. \n  \nThe supplier declares herewith:\n\n· Legal compliance", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::1330ca67af0d", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9e1d4d613790"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9e1d4d613790", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": null, "section_title": null, "clause_type": "Supplier Code of Conduct / Compliance Declaration", "path": "12 ➞ 12.7 ➞ 12.7.2 ➞ Exhibit B (Supplier Declaration)", "text": "pliance Program. In such event Siemens expects the supplier to accept such reasonable changes. \n  \nThe supplier declares herewith:\n\n· Legal compliance\n\n·  to comply with the laws of the applicable legal system(s). \n  \n·  Prohibition of corruption and bribery\n\n· to tolerate no form of and not to engage in any form of corruption or bribery, including any payment or other form of benefit conferred\n\non any government official for the purpose of influencing decision making in violation of law. \n  \n·  Respect for the basic human rights of employees\n\n· to promote equal opportunities for and treatment of its employees irrespective of skin color, race, nationality, social background,", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::ec5f637c0858", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9fab72212b3a"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9fab72212b3a", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "Exhibit B", "section_title": "Code of Conduct (Employee Standards)", "clause_type": "Code of Conduct / Behavioral Standards", "path": "12 ➞ 12.7 ➞ Exhibit B (Code of Conduct)", "text": "ts of employees\n\n· to promote equal opportunities for and treatment of its employees irrespective of skin color, race, nationality, social background,\n\ndisabilities, sexual orientation, political or religious conviction, sex or age; \n· to respect the personal dignity, privacy and rights of each individual; \n· to refuse to employ or make anyone work against his will; \n· to refuse to tolerate any unacceptable treatment of employees, such as mental cruelty, sexual harassment or discrimination; \n· to prohibit behavior including gestures, language and physical contact, that is sexual, coercive, threatening, abusive or exploitative; \n· to provide fair remuneration and to guarantee the applicable national statutory minimum wage; \n· to comply with the maximum number of working hours laid down in the applicable laws; \n· to recognize, as far as legally possible, the right of free association of employees and to neither favor nor discriminate against\n\nmembers of employee organizations or trade unions.  \n  \n· Prohibition of child labor\n\n· to employ no workers under the age of 15 or, in those countries subject to the developing country exception of the ILO Convention", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9e1d4d613790", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d81fff2d30f0"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d81fff2d30f0", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": null, "section_title": null, "clause_type": "Code of Conduct / supplier conduct obligations", "path": null, "text": "on of child labor\n\n· to employ no workers under the age of 15 or, in those countries subject to the developing country exception of the ILO Convention\n\n138, to employ no workers under the age of 14.  \n  \n· Health and safety of employees\n\n· to take responsibility for the health and safety of its employees; \n· to control hazards and take the best reasonably possible precautionary measures against accidents and occupational diseases; \n· to provide training and ensure that employees are educated in health and safety issues; \n· to set up or use a reasonable occupational health & safety management system(1)\n\n· Environmental protection\n\n· to act in accordance with the applicable statutory and international standards regarding environmental protection; \n· to minimize environmental pollution and make continuous improvements in environmental protection; \n· to set up or use a reasonable environmental management system(1)\n\n·  Supply chain\n\n·  to use reasonable efforts to promote among its suppliers compliance with this Code of Conduct; \n· to comply with the principles of non discrimination with regard to supplier selection and treatment.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::9fab72212b3a", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a60ba3e087f1"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a60ba3e087f1", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "Exhibit C", "section_title": "Siemens Quality Assurance Agreement", "clause_type": "Exhibit / Quality Assurance Agreement (Table of Contents)", "path": "Exhibit C ➞ Siemens Quality Assurance Agreement ➞ Contents", "text": "uppliers compliance with this Code of Conduct; \n· to comply with the principles of non discrimination with regard to supplier selection and treatment.\n\n(1) For further information see www.siemens.com/procurement/cr/code-of-conduct\n\nEXHIBIT C\n\nSIEMENS QUALITY ASSURANCE AGREEMENT\n\nPlease see attached.\n\nSIEMENS\n\nFor internal use only \nCopyright © Siemens AG 2002. All rights reserved.\n\nQuality Requirement Med\n\nIdentification of Products and basic\n\nrequirements for packaging \nRequirements for Suppliers\n\nQR Med 1 A1\n\nSiemens Medical Solutions\n\nand affiliated Companies\n\nIssued by Med Quality Management & Regulatory Affairs\n\nReleased 2007-09-28 by the Med Quality Steering Board (QSB)\n\nValid from 2007-11-01\n\n04798372 AND 02S 04\n\n1\n\nContents\n\n1 \nPurpose and scope \n3\n  \n  \n \n2 \nDefinitions and abbreviations \n3\n\n2.1 \nMaterial No. \n3\n\n2.2 \nRevision \n3\n\n2.3 \nSerial No. \n3\n\n2.4 \nData Identifier \n3\n\n2.5 \nExpiration date \n4\n\n2.6 \nBatch \n4\n\n2.7 \nShelf life  \n4\n    \n  \n \n3 \nReference documents \n4\n  \n  \n \n4 \nRequirements \n4\n\n4.1 \nIdentification of parts, components and systems \n4\n\n4.2 \nLabeling of parts, components, systems and its packaging \n4", "numbers_present": null, "definition_terms": ["Material No.", "Revision", "Serial No.", "Data Identifier", "Expiration date", "Batch", "Shelf life"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d81fff2d30f0", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a31eaef03164"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a31eaef03164", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4", "section_title": "Requirements", "clause_type": "Table of Contents", "path": "4 ➞ 4.1 ➞ 4.2 ➞ 4.3 ➞ 5 ➞ 6 ➞ 7 ➞ 8 ➞ 9", "text": "4 \nRequirements \n4\n\n4.1 \nIdentification of parts, components and systems \n4\n\n4.2 \nLabeling of parts, components, systems and its packaging \n4\n\n4.3 \nSpacing  \n6\n    \n  \n \n5 \nBasic requirements for packaging \n7\n  \n  \n \n6 \nLiterature \n7\n  \n  \n \n7 \nTransition and retrospective measures \n7\n  \n  \n \n8 \nChanges to prior version \n7\n  \n  \n \n9 \nAttachments \n7\n\nAuthor:\n\nGabriele Franz\n\nAX QP \n  \n    \nReviewer:\n\nVolker Glahn\n\nQM&RA \nPhilippe Hoxter\n\nCSQ\n\n2", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a60ba3e087f1", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::57911ae68bbb"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::57911ae68bbb", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "1-2.2", "section_title": "Purpose and scope; Definitions and abbreviations", "clause_type": "Purpose/Scope and Definitions", "path": "1 ➞ 2 ➞ 2.1 ➞ 2.2", "text": "Changes to prior version \n7\n  \n  \n \n9 \nAttachments \n7\n\nAuthor:\n\nGabriele Franz\n\nAX QP \n  \n    \nReviewer:\n\nVolker Glahn\n\nQM&RA \nPhilippe Hoxter\n\nCSQ\n\n2\n\n1 Purpose and scope \n  \nFor Siemens Medical Solutions it is a basic requirement that any part, component or system is identified the same way worldwide. This document \nlists the minimum requirements for suppliers of Siemens Medical Solutions describing \n· how parts, components and systems are identified with their attributes and \n· how attributes are labeled both as plain text as well as barcode on products and its packaging. Detailed specifications with regards to the labeling \nof products are defined for the individual product concerned. \n  \n2 Definitions and abbreviations  \n  \n2.1 Material No. \n  \nThe Siemens Medical Solutions Material No. is used to uniquely identify products (parts, components and systems). It consists of an 8-digit \nidentification no. assigned by Siemens Medical Solutions. \n  \nPreviously, the term \"Part no.\" was also used; it is replaced by the term \"Material No.\".  \n  \n2.2 Revision \n  \nThe Revision (abbreviated \"Rev.\") serves to distinguish between different update statuses of hardware. It is assigned by Siemens Medical \nSolutions.", "numbers_present": null, "definition_terms": ["Material No.", "Part no.", "Revision"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::a31eaef03164", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8227c005938b"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8227c005938b", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": null, "section_title": null, "clause_type": "Definition", "path": null, "text": "The Revision (abbreviated \"Rev.\") serves to distinguish between different update statuses of hardware. It is assigned by Siemens Medical \nSolutions.\n\nThe English term \"Revision\" replaces the German term \"Erzeugnisstand\" (abbreviated \"ES\") and \"Ausführungsstand\" (abbreviated \"AS\").", "numbers_present": null, "definition_terms": ["Revision", "Rev.", "Erzeugnisstand", "ES", "Ausführungsstand", "AS"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::57911ae68bbb", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bf059d4269d1"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bf059d4269d1", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.3", "section_title": "Serial No.", "clause_type": "definition/specification", "path": "2 ➞ 2.3", "text": "dical \nSolutions.\n\nThe English term \"Revision\" replaces the German term \"Erzeugnisstand\" (abbreviated \"ES\") and \"Ausführungsstand\" (abbreviated \"AS\").\n\n2.3 Serial No. \n  \nThe Serial No. is an identifying attribute used to uniquely identify hardware or software with the same Material No. . \n  \nFor suppliers the Serial No. can consist of up to 15 alphanumeric digits; it is however recommended to use only a 6 digit numerical Serial No. where \npossible. \n  \nThe Serial No. may contain a dash (-) or a slash (/), but no other special characters (e.g. # + * ?). Spaces, lower-case letters or language-specific \ncharacters (e.g. Ä, Ö, Ü) are not allowed within the Serial No. . \n  \nThe characters \"L\", \"SxxL\" or \"Sxx\" at the end or the beginning of the Serial No. should be avoided (xx = any alphanumerical character). \n  \nFor any Serial No. that is numeric only (i.e. has no letters) it is allowed to omit printing of leading zeros („0\"). \n  \nIt is recommended to use the Serial No. of the supplier if it complies with the principles described above. \n  \n2.4 Data Identifier \n  \nData Identifiers are used in the barcode to indicate that the information following the Data Identifier is data of a certain attribute. The Data \nIdentifier enables the barcode reading program to recognize that the following information represents a certain type of attribute. \n  \nData Identifiers to be used:", "numbers_present": null, "definition_terms": ["Revision", "Erzeugnisstand", "ES", "Ausführungsstand", "AS", "Serial No.", "Data Identifier"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::8227c005938b", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::78c5bd8ebca1"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::78c5bd8ebca1", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "2.5–4.1", "section_title": "Expiration date; Batch; Shelf life; Reference documents; Requirements; Identification of parts, components and systems", "clause_type": "Quality assurance / Identification requirements (procedural specification)", "path": "2 ➞ 2.5 ➞ 2.6 ➞ 2.7 ➞ 3 ➞ 4 ➞ 4.1", "text": "ables the barcode reading program to recognize that the following information represents a certain type of attribute. \n  \nData Identifiers to be used:\n\n1P\n\nRevision (for packaging only) \nS\n\nMaterial No.\n\n2P\n\nQuantity (for packaging only) \n14D\n\nSerial No.\n\nQ\n\nExpiration date (for packaging only)\n\nT\n\nBatch (for packaging only)\n\n3\n\n2.5 Expiration date \n  \nThe format of the expiration date shall be definite and specified as follows: YYYYMMDD \n  \n2.6 Batch \n  \nThe batch is an alphanumeric ident number with 10 digits, used to identify parts manufactured or shipped together. Is no batch provided on the \npacking but required, a batch is initiated in the stock. \n  \n2.7 Shelf life \n  \nIf a shelf life is defined for parts the shelf life has to be filed in calendar days. (365 days per year) \n  \n3 Reference documents \n  \nn.a. \n  \n4 Requirements \n  \n4.1 Identification of parts, components and systems \n  \nNon-serialized parts (including spare parts) and components are identified using a Material No. . If necessary, different statuses of a part, \ncomponent or system can be distinguished via the Revision.", "numbers_present": null, "definition_terms": ["Data Identifiers", "Revision", "Material No.", "Quantity", "Serial No.", "Expiration date", "Batch", "Shelf life", "Non-serialized parts"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::bf059d4269d1", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::966eec76ab88"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::966eec76ab88", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.2", "section_title": "Labeling of parts, components, systems and its packaging", "clause_type": "Operational / Labeling requirement", "path": "4 ➞ 4.2", "text": "mponents are identified using a Material No. . If necessary, different statuses of a part, \ncomponent or system can be distinguished via the Revision.\n\nSerialized parts, components and systems are identified using the combination of Material No. and Serial No. . In addition, the Revision may be \nused to distinguish between different statuses of hardware.\n\n4.2 Labeling of parts, components, systems and its packaging \n  \nIn general, requirements with respect to labeling have to be defined for the product concerned. However, minimum requirements are specified in \norder to allow proper identification throughout all processes involved. This chapter lists those minimum requirements. \n  \nFor all material numbers specified by Siemens the parts and its packaging have to be labeled according to the requirements listed below. The label \ndepends on whether a part/component/system \n  \n· is serialized \n· contains a revision level \n· is classified as an IVK (\"Installed Volume Component\") \n· shall be handled by expiration date or batch\n\nSiemens defines those requirements per individual Material No. .\n\n4\n\nColor", "numbers_present": null, "definition_terms": ["Material No.", "Serial No.", "Revision", "IVK (Installed Volume Component)"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::78c5bd8ebca1", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::26c0863374ad"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::26c0863374ad", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": null, "section_title": null, "clause_type": "Technical specification (labeling / barcode requirements)", "path": null, "text": "stalled Volume Component\") \n· shall be handled by expiration date or batch\n\nSiemens defines those requirements per individual Material No. .\n\n4\n\nColor\n\nUsually white label with black printing other colors are allowed as long as barcode/plain text \ncan be read \n  \n    \nBarcode content\n\n1P <Material No. >\n\nS <Serial No.> \n  \n    \nAdditionally for packaging only\n\n2P <product Revision>\n\nQ <quantity of products in this packaging (numeric only), usually 1>\n\nIt is not allowed to label Revision and Quantity on product identification labels!\n\ne.g.: 1P01234567 as barcode *) \n(1P) Model No. 01234567\n\nS1001 as barcode *) \n(S) Serial No. 1001\n\nEach symbol structure with start and stop character including Data Identifier (e.g. \"1P\" or \n\"S\"), but without symbol check character.\n\nNo space allowed between Data Identifier and attribute.\n\nIt is not allowed to print any other information in the barcode fields described above. \n  \n    \nBarcode type\n\nCode 39 according to ISO/IEC 16388 \n  \n    \nNarrow element (bar or space)\n\nMin. 0,17 mm \n  \n    \nRatio of wide element to narrow element\n\nMin. 2,25 : 1 \n  \n    \nBarcode height\n\nMin. 2 mm, typical 4mm \n  \n    \nPlain text (below barcode)", "numbers_present": null, "definition_terms": ["1P", "S", "2P", "Q", "Material No.", "Serial No.", "product Revision", "quantity", "Data Identifier", "Code 39", "Narrow element", "Barcode height", "Plain text"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::966eec76ab88", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::b1100ca35331"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::b1100ca35331", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": null, "section_title": "Barcode and Product Identification Label Requirements", "clause_type": "Labeling specification", "path": null, "text": "mm \n  \n    \nRatio of wide element to narrow element\n\nMin. 2,25 : 1 \n  \n    \nBarcode height\n\nMin. 2 mm, typical 4mm \n  \n    \nPlain text (below barcode)\n\n(1P) Model No.: \n<Material No.>\n\n(S) \nSerial No.: \n<Serial No.> \n  \n    \nAdditionally for packaging only\n\n(2P) Revision: \n<product Revision>\n\n(Q) Quantity: \n<quantity of products in this packaging (numeric only), usually 1>\n\nIt is not allowed to label Revision and Quantity on product identification labels!\n\nData Identifier (e.g. \"1P\" or \"S\") in brackets in front of data element title (e.g. ''Model No.\" \nor \"Serial No.\") in plain text!\n\ne.g.: (1P) Model No.: 01234567 *) \n(1p) Model No. 01234567\n\n(S) Serial No.: 1001 *) \n(S) Serial No. 1001\n\nNote: Due to 21CFR1020.30 section e) the term \"Model No.\" shall be used instead of the \nterm \"Material No.\" in plain text on all labels.\n\nIt is not allowed to print any other information near the data fields described above. If any \nother information is printed, it must be printed in a manner so that it can't be misinterpreted \nas being part of the fields described above; this can be done by printing other information at \nthe very right side of the label. \n  \n    \nAdditionally for products only", "numbers_present": null, "definition_terms": ["Data Identifier", "Model No.", "Material No.", "Serial No.", "Revision", "Quantity", "Plain text (below barcode)"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::26c0863374ad", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d463f3dfee62"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d463f3dfee62", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.3", "section_title": "Spacing", "clause_type": "Technical specification (labeling/packaging/formatting requirements)", "path": "4 ➞ 4.3", "text": "e fields described above; this can be done by printing other information at \nthe very right side of the label. \n  \n    \nAdditionally for products only\n\nFor IVKs or System IVKs, the text \"IVK\" or \"SYSTEM IVK\" shall be printed on the very \nright side of the label. It has to be ensured that this text can't be misinterpreted as being part \nof the Serial No. ; this can be done by printing this text on a different level. [Siemens \nMedical Solutions decides and specifies whether a product is an IVK or System IVK.]\n\n5\n\nAdditionally for packing only\n\nThe Expiration date of parts with Shelf life is fixed below the quantity as following:\n\nExpiration date: <date of expiration> YYYYMMDD\n\nFor parts which require a Batch, the batch is fixed below the Expiration date as following: \nAAAAAAAAAA\n\nFor a transition period the batch can also be fixed above the material number \n  \n    \nFont\n\nUniverse, if not possible use similar font (e.g. Helvetica)\n\n*) In case of limited space, it is possible to print the bar code next to (and not under) the clear text. \n  \n4.3 Spacing  \n  \nMinimum distances are:\n\n(A)\n\n>5 mm \n(B)\n\nHorizontal distance from edge (quiet zone)\n\n>2 mm \n(C)\n\nVertical distance from edge", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::b1100ca35331", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d96045798c9c"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d96045798c9c", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "4.3", "section_title": "Spacing", "clause_type": "Specification (label/printing requirements)", "path": "4 ⟩ 4.3", "text": "ext. \n  \n4.3 Spacing  \n  \nMinimum distances are:\n\n(A)\n\n>5 mm \n(B)\n\nHorizontal distance from edge (quiet zone)\n\n>2 mm \n(C)\n\nVertical distance from edge\n\nVertical distance between printing areas\n\n>1 mm\n\nLegend: \n \na) printing area for barcode\n\nb) printing area for plain text\n\n5) Expiration date and 6) Batch can be printed in barcode additionally.\n\nFor a transition period the batch can also be fixed above the material number\n\n6", "numbers_present": null, "definition_terms": ["printing area for barcode", "printing area for plain text"], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d463f3dfee62", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::706f3f78aca2"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::706f3f78aca2", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "5-8", "section_title": "Basic requirements for packaging; Literature; Transition and retrospective measures; Changes to prior version", "clause_type": "Technical requirements / Packaging specification and revision history", "path": "5 ➞ 6 ➞ 7 ➞ 8", "text": "Expiration date and 6) Batch can be printed in barcode additionally.\n\nFor a transition period the batch can also be fixed above the material number\n\n6\n\n5 Basic requirements for packaging \n  \nEspecially for spare parts appropriate packaging are required for the global shipping process. Should those packaging contain wood, generally \n\"non wood-packaging\" according IPPC (International Plant Protection Convention) shall be used, but fumigation of such packaging is not \nallowed. \n  \nPackaging shall be designed in a suitable way to protect the packed good against transportation load according to IEC 60721-3-2 class's 2M2/2K4 \n  \nInternational pictograms following the IEC 60601 series shall be used for parts which fall under specific restrictions for transport or storage. \n  \nThe specification of packaging especially for spare parts is within the responsibility of the Business Unit responsible for the product. \n  \n6 Literature \n  \nISO/IEC 16388 \"Information technology — Automatic identification and data capture techniques — Bar code symbology specifications — Code \n39\". \n  \nIEC 60721-3-2 Classification of environmental conditions — Part 3: Classification of groups of environmental parameters and their severities — \nSection 2: Transportation \n  \n7 Transition and retrospective measures \n  \nn.a. \n  \n8 Changes to prior version \n  \nCR-No.: 2007-005 \nChanges to previous edition 04798372 AND 02S 03: \n  \n· Chapter 2: Reference document IEC 60721-3-2 added  \n· Chapter 5: Design of packaging changed \n  \nCR-No. 2006-008 (CR N06/0207) \nChanges to previous edition 04798372 AND 02S 02: \n  \n· Title: Added: and basic requirements for packaging \n· Chapter 3.4 Data Identifier for Expiration Date and Batch added \n· Chapter 3.5 — 3.7: Completely new \n· Chapter 4.2 Added: Expiration date and batch \n· Chapter 4.3. Added: labeling of Expiration Date and Batch, \n· Chapter 5: Completely new \n  \nCR-No. 2006-01, 2006-02 \nChanges to previous edition 4798372 AND 02S 01: \n  \n· Chapter 2, 4.2 : EN 800 replaced by ISO/IEC 16388 \n· Chapter 4.2 : general requirements at the beginning stated more clearly, footnote added", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::d96045798c9c", "next_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3169b94cc5d9"}
{"id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::3169b94cc5d9", "doc_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6", "section_number": "01", "section_title": null, "clause_type": "Amendment/Revision Note", "path": null, "text": "01: \n  \n· Chapter 2, 4.2 : EN 800 replaced by ISO/IEC 16388 \n· Chapter 4.2 : general requirements at the beginning stated more clearly, footnote added\n\n9 Attachments\n\nn.a.\n\n7", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Distributor Agreement", "party_role": "manufacturer, distributor", "jurisdiction": "DE", "governing_law": "DE", "industry": "medical devices"}, "prev_id": "3b2cd484-91d6-4be7-8182-74ad7f2971f6::706f3f78aca2", "next_id": null}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::3925221715b3", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "SECTION ONE", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "SECTION ONE", "text": "EXHIBIT 10.1   ENDORSEMENT AGREEMENT   This Endorsement Agreement (\"Agreement\") made October 30, 2017, between National Football League Alumni - Northern California Chapter (\"NFLA-NC\"), a charitable corporation organized under the laws of California, having its principal office at 1311 Madison Avenue, Redwood CA 94061; National Football League Alumni, Inc. (\"NFLA\"), a charitable corporation organized under the laws of Florida, having its principal office at 8000 Midlantic Drive, 130 S., Mount Laurel, NJ. 08054 and Food For Athletes, Inc. a corporation organized under the laws of California / Gridiron BioNutrients™, a corporation organized under the laws of Nevada having their principal office(s) at 1119 West 1st Ave., STE G, Spokane, WA 99201 (collectively the \"Company\").   RECITALS   A. Whereas, NFLA is a nationwide group of former National Football League players, coaches, and other employees whose mission is to serve, assist and inform players and their families. The association offers a variety of medical, financial and social programs to help members lead healthy, productive and connected lives.    B. Whereas, NFLA-NC is a local Chapter of the NFLA and supports the organizations \"Caring for Kids\" initiative through fundraising for youth-related charities.    C. The Company desires to obtain the rights to use the Pro Football Legends Logo of the NFLA in connection with the advertisement and promotion of certain of its products. An image of the Pro Football Legends Logo is depicted in Exhibit A.    D. The NFLA agrees to license such rights to the Company.   In consideration of the matters described above, and of the mutual benefits and obligations set forth in this Agreement, the parties agree as follows:   SECTION ONE. DEFINITIONS   As used in this Agreement, the following terms shall be defined as follows:   A. \"Contract Period\" shall mean that period of time of three (3) years commencing on November 1st, 2017 and concluding November 2nd, 2020, unless terminated sooner or extended as provided in this Agreement.    B. \"Contract Territory\" shall mean worldwide.    C. \"Contract Year\" shall mean each of the consecutive 12-month periods beginning on the effective date of the Agreement of the Contract Period.   1", "numbers_present": null, "definition_terms": ["Agreement", "NFLA-NC", "NFLA", "Company", "Contract Period", "Contract Territory", "Contract Year"], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": null, "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::1e37a88d7850"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::1e37a88d7850", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "1.C", "section_title": "Contract Year", "clause_type": "Definition", "path": "1 ➞ 1.C", "text": "C. \"Contract Year\" shall mean each of the consecutive 12-month periods beginning on the effective date of the Agreement of the Contract Period.   1\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": ["Contract Year"], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::3925221715b3", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::fbc65113d64d"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::fbc65113d64d", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "1.D-I", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "1 ➞ 1.D ➞ 1.E ➞ 1.F ➞ 1.G ➞ 1.H ➞ 1.I", "text": "ive 12-month periods beginning on the effective date of the Agreement of the Contract Period.   1\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nD. \"Gross Sales\" shall mean total revenues, under generally accepted accounting principles, from sales of the Licensed Products, but does not include any revenue from sales, use or other transaction taxes, duties, handling, graphics, embroidery or shipping.    E. \"Net Sales\" shall mean Gross Sales less Product returns, trade discounts, samples, allowances, value added services, markdowns, customer charge backs and liquidation sales (substantially discounted and out of ordinary distribution channel) of Licensed Products.    F. \"Licensed Products\" shall mean BlackMP Living Water, BlackMP Concentrate, Zezel Probiotic Water, Zayin Sports Water, Gridiron MVP™ and Gridiron MVP™ Concentrate using the Pro Football Legends Logo on the Licensed Products' affixed labels, hang-tags or packaging. Other products of the Company may be added to the list of Licensed Products during the Contract Period by written amendment to this Agreement. All amendments to this Agreement must be signed by all parties to this Agreement.    G. \"Products\" shall mean goods manufactured, distributed or otherwise sold by the Company.    H. \"Licensed Marks\" shall mean in connection with the rights and benefits granted to Company hereunder as set forth in General Terms. Company may utilize only the logo and other trademarks listed on Exhibit A (the \"Licensed Marks\") during the Term and within the Territory solely in connection with advertising and promotional materials that identify Company as a sponsor of the Pro Football Legends, provided that NFLA first approves all such uses in writing. Any use of the Licensed Marks will bear the trademark and/or copyright notices required by NFLA to facilitate its trademark protection program and will be a \"work made for hire\" for NFLA. All of Company's uses of the Licensed Marks shall inure to the benefit of the NFLA. After the expiration or termination of this Agreement, Company will refrain from further use of the Licensed Marks used pursuant to this Agreement. Company will not sublicense pass-through or otherwise grant to any third parties the rights granted to Company hereunder without the NFLA prior written consent, including but not limited to the right to use the Licensed Marks. Company acknowledges that this Agreement does not grant Company any rights with respect to any other NFLA Marks (defined below), the name, likeness, signature, or other attributes of any NFLA member or other individual, or any audio or video of any NFLA event. Company agrees that the quality of all services offered by Company under the Licensed Marks will conform to Licensor's written quality control standards and that Company will annually provide to NFLA samples of any advertising and marketing materials that use the Licensed Marks.    I. \"Trademark Protection\" for the purposes of this agreement, \"NFLA MARKS\" means the names, symbols, emblems, designs, and colors of the NFLA, including but not limited to the Licensed Marks. Company acknowledges and agrees that all right, title and interest in and to the NFLA marks belongs to the NFLA. Company agrees that NFLA marks possesses a special, unique and extraordinary character that makes difficult assessment of the monetary damages that would be sustained by their unauthorized use. Company recognizes that irreparable injury would be caused by unauthorized use of any of the NFLA marks, and agrees that injunctive and other equitable relief would be appropriate in the event of such unauthorized use, and that such remedy would not be exclusive of other legal remedies available to NFLA. Company recognizes that great value and goodwill associated with NFLA marks belongs to the NFLA and that the NFLA marks have secondary meaning.   2", "numbers_present": null, "definition_terms": ["Gross Sales", "Net Sales", "Licensed Products", "Products", "Licensed Marks", "Trademark Protection", "NFLA MARKS"], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::1e37a88d7850", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::274f6618ddc1"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::274f6618ddc1", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "1.I.A", "section_title": "Trademark Protection", "clause_type": "acknowledgment", "path": "1 ➞ 1.I ➞ 1.I.A", "text": "A. Company recognizes that great value and goodwill associated with NFLA marks belongs to the NFLA and that the NFLA marks have secondary meaning.   2\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::fbc65113d64d", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::04f778ccaa16"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::04f778ccaa16", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "1.J, 1.K; 2; 3", "section_title": "DEFINITIONS; GRANT OF RIGHTS; PRIOR APPROVAL", "clause_type": "Definitions; Grant of Rights; Approval", "path": "1 ➞ 1.J ➞ 1.K ➞ 2 ➞ 3", "text": "ssociated with NFLA marks belongs to the NFLA and that the NFLA marks have secondary meaning.   2\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nJ. \"NFLA Identification\" means the right to use, subject to the provisions of this Agreement, the NFLA name, and Pro Football Legends Logo and any other means of endorsement by the NFLA used in connection with the advertisement and promotion of the Company and the Licensed Products.    K. \"One (1) Unit\" shall represent $0.05 (1 Unit = $0.05USD) for purposes of defining the monetary donation allocation of the Company's sold products to the NFLA-NC, specific to the terms of this Agreement. A Licensed Product in no circumstance shall be valued at less than one (1) full Unit and under no circumstance shall a Unit be fractionalized (if required rounded up to the nearest whole number). SECTION TWO. GRANT OF RIGHTS   In consideration of the remuneration to be paid to the NFLA-NC pursuant to this Agreement, the NFLA grants to Company and to its authorized distributors and sublicenses the right and license during the Contract Period to use the NFLA Identification solely in connection with the advertisement, marketing and promotion of the Products within the Contract Territory as set forth in this Agreement. NFLA agrees not to grant the right to use the NFLAs Identification to anyone other than Company in connection with the advertisement and promotion of Products. It is understood that Company, its authorized distributors and sublicenses may not use the name of the NFLA in connection with any items for sale or resale, other than the Products as specified in this Agreement. The foregoing rights to use the name of the NFLA is limited to television, radio and print advertising, advertising published over the Internet (provided that such material is limited to advertising or Product promotion only), public relations and marketing materials, point-of-sale displays, free standing inserts, videos shown to customers and consumers, catalogs for customers and consumers, direct mail (including e-mail) and billboards. Company shall ensure that all uses of the name of the NFLA comply with applicable law.   SECTION THREE. PRIOR APPROVAL   Company agrees that no use of the name of the NFLA Identification nor any item used in connection with the name of NFLA Identification (including any Licensed Product) will be made under this Agreement unless and until the same is approved by the NFLA. The NFLA agrees that any material, advertising or otherwise, submitted for approval as provided in this section may be deemed by Company to have been approved under this section if the same is not disapproved in writing within ten (10) business days after receipt of the material. The NFLA agrees that it will reasonably cooperate with Company and that any material submitted under this section will not be unreasonably disapproved and, if it is disapproved, that Company will be advised of the specific grounds for disapproval. If Company desires immediate approval of advertising material, Company shall have the right to directly contact the NFLA's authorized agent to obtain such approval. Company agrees to protect, indemnify and hold harmless the NFLA and their authorized agents, or any of them, from and against any and all expenses, damages, claims, suits, actions, judgments and costs whatsoever, arising out of, or in any way connected with any advertising material furnished by, or on behalf of Company, except with respect to any inaccurate information furnished by them expressly for use in such advertising.   3", "numbers_present": null, "definition_terms": ["NFLA Identification", "One (1) Unit"], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::274f6618ddc1", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::176ecbf84e36"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::176ecbf84e36", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "3", "section_title": "PRIOR APPROVAL", "clause_type": "Indemnity", "path": "3", "text": "furnished by, or on behalf of Company, except with respect to any inaccurate information furnished by them expressly for use in such advertising.   3\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::04f778ccaa16", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::38473f352e26"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::38473f352e26", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "SECTION FOUR", "section_title": "REMUNERATION", "clause_type": "Remuneration/Payment", "path": "4 ➞ 4.A ➞ 4.B ➞ 4.C", "text": "espect to any inaccurate information furnished by them expressly for use in such advertising.   3\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nSECTION FOUR. REMUNERATION   In consideration of the endorsement rights granted under this Agreement, Company shall provide the following remuneration:   A. An initial one-time license fee of $35,000.00USD (Thirty-Five Thousand Dollars) payable to the NFLA-NC;    B. A one-time $10,000USD (Ten Thousand Dollars) promotional fee payable to NFLA. The $10,000 promotional fee shall be payable in four (4) quarterly payments beginning in 2018: Q1 ($2500); Q2 ($2500); Q3 ($2500); Q4 ($2500). Each payment shall be delivered by no later than the 10t h day of the first month of each quarter.    C. A *donation of $0.05 per Unit sold of Licensed Products within the Contract Territory payable to the **NFL Alumni Northern California Chapter. Donated amounts will be allocated and dispersed to the Northern California Chapter beginning on the first full quarter [three (3) month period] of the Agreement and continue on a quarterly basis thereafter for the term of this Agreement. Where the following per Unit conversion shall apply for the term of this Agreement:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::176ecbf84e36", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::a3f2534fec28"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::a3f2534fec28", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "4.C", "section_title": "REMUNERATION", "clause_type": "Remuneration (donation per-unit conversion)", "path": "4 ➞ 4.C ➞ 4.C.a-f", "text": "ue on a quarterly basis thereafter for the term of this Agreement. Where the following per Unit conversion shall apply for the term of this Agreement:\n\na. (1) Bottle of BlackMP LivingWater = 1 Unit\n\nb. (1 )  4oz  bo t t l e  o f  BlackMPConcentrate = 30 Units\n\nc. (1) Bottle of Zezel ProbioticWater = 1 Unit\n\nd. (1) Bottle of Zayin Sports Water = 1 Unit  e. (1) Bottle Gridiron MVP™ Water= 1 Unit\n\nf. (1) 4oz bottle of Gridiron MVP™Concentrate = 30 Units\n\n_____________    * The NFLA-NC will donate 15% of the above described proceeds to the NFLA.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::38473f352e26", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bacb9e43f414"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bacb9e43f414", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "SECTION FOUR (4.C.(f); 4.D; 4.E; 4.F)", "section_title": "REMUNERATION", "clause_type": "Remuneration and Commitments (donation/unit schedule, product commitment, affiliated partnership, marketing commitment)", "path": "4 ➞ 4.C ➞ 4.C.(f) ➞ 4.D ➞ 4.E ➞ 4.F", "text": "f. (1) 4oz bottle of Gridiron MVP™Concentrate = 30 Units\n\n_____________    * The NFLA-NC will donate 15% of the above described proceeds to the NFLA.\n\n** The Company will provide to the NFLA-NC upon request the most recent quarterly sales report of the Company'sLicensed Products.   D. Product Commitment. Up to Two-thousand (2,000) 4oz bottles of BlackMP Living Water Concentrate to be used as a \"value appeal\"  for  annual  membership renewal  (up to  a  $220,000 value)  a l located to  the  NFLA and provide a combination/assortment of bottle water to NFLA-NC for display and use though out the term of the Agreement at the NFLA-NC facilities. The Company agrees to pay for all shipping costs of the Products under the Product Commitment to the fulfillment center, currently Sharp Marketing, located in Fort Lauderdale, FL and to any subsequent fulfillment center that is contracted by the NFLA to provide distribution to existing and new NFLA members.    E. Affiliated Partnership Commitment. Company agrees to facilitate and provide in good-faith their affiliated partnership discount program benefits and access to applicable health and wellness research, information and protocols to NFLA members (Current partnership benefit includes providing NFLA members with a 15% discount on all Kraski's Nutrition Real Products For Real People); and    F. Marketing Commitment. Company agrees that it will continue in good-faith to produce and market Licensed Products in the same manner that it is currently producing and marketing such items as of September 2017, unless Company and the NFLA/NFLA-NC believe it is not commercially reasonable to continue to produce and market the Licensed Products.   4", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::a3f2534fec28", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::dda61ef140b9"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::dda61ef140b9", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "4.F", "section_title": "Marketing Commitment", "clause_type": "Marketing commitment", "path": "4 ➞ 4.F", "text": "ember 2017, unless Company and the NFLA/NFLA-NC believe it is not commercially reasonable to continue to produce and market the Licensed Products.   4\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bacb9e43f414", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::ab8ad2c90bca"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::ab8ad2c90bca", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "5; 6.A-E", "section_title": "SERVICES OF COMPANY; SERVICES OF NFLA-NC", "clause_type": "Services / Performance obligations", "path": "5 ➞ 5.A; 6 ➞ 6.A ➞ 6.B ➞ 6.C ➞ 6.D ➞ 6.E", "text": "ve it is not commercially reasonable to continue to produce and market the Licensed Products.   4\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nSECTION FIVE. SERVICES OF COMPANY   A. Resource Call Center. For the term of this Agreement Company shall provide a call in center whereby NFLA members can call for information, ask questions, and consult with Company's staff on details and specifics of the Company's Products and replenishment program.   SECTION SIX. SERVICES OF NFLA-NC   A. If Company desires to use the services of the NFLA-NC and/or any of its officers and members as a model in connection with Company advertising to promote its Products or as a part of a special promotional appearance for the Company, the NFLA-NC agrees, at the request of Company, to provide a good faith effort services of the officers or members of the NFLA for a reasonable amount of time as mutually agreed upon by all parties and at places reasonably convenient to each parties schedule. Each day shall not exceed a reasonable number of hours unless otherwise mutually agreed upon. The Company agrees that it will reimburse the NFLA-NC and if applicable the NFLA or its officers/members for all reasonable travel, lodging and meal expenses incurred by the NFLA / NFLA-NC or its officers/members in connection with such services. The Company understands that failure to use services of a member of the NFLA / NFLA-NC pursuant to this section shall not result in any reduction in payments to NFLA-NC under this Agreement. The obligations of the NFLA / NFLA-NC to provide services of its officers/members under this Agreement are subject to the condition that payments to NFLA-NC are current and up to date.    B. Should Company use any member of the NFLA-NC in television advertising to promote Company's Products, Company will make all applicable required union scale and pension and welfare payments.    C. During the Contract Period, NFLA-NC shall make a good faith effort to assure that its members shall wear Company Products at all professional and promotional events and at all media appearances where appropriate, and when not in conflict with its members existing agreements. It is agreed that the logo or name of Company (the \"Company Logo\") shall be affixed to an appropriate location (i.e. shoulder-sleeve and/or back] of all Company Products that members of the NFLA-NC wear. Company agrees that it will be responsible for, and the cost of, affixing the Company Logo on all such Company Products. Company acknowledges that other locations on the NFLA-NC Products are reserved for NFLA-NC's other sponsors. Furthermore, Company understands that if the NFLA-NC or its Officers/members participate in a special team event where there is an official uniform, then representatives of the NFLA-NC are permitted to wear such uniform during such event.    D. The NFLA shall list the Company as a sponsor on all of its promotional materials, websites or other electronic media. The NFLA shall allow the Company to participate in local and national NFLA functions (i.e. Super Bowl Parties, Award Ceremonies, Banquets, etc…) at the Company's own expense.    E. The NFLA shall promote Company and Company's products to NFLA database and audience by deliverables listed in Exhibit B.   5", "numbers_present": null, "definition_terms": ["Company Logo"], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::dda61ef140b9", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::02972baa4927"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::02972baa4927", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "6.E", "section_title": "SERVICES OF NFLA-NC", "clause_type": "Promotional obligation", "path": "6 ➞ 6.E", "text": "pany's own expense.    E. The NFLA shall promote Company and Company's products to NFLA database and audience by deliverables listed in Exhibit B.   5\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::ab8ad2c90bca", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bb8e4fff1c50"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bb8e4fff1c50", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "SECTION SEVEN; SECTION EIGHT", "section_title": "PAYMENTS; AUTHORIZED AGENT", "clause_type": "Payment; Notices/Authorized Agent", "path": "7 ➞ SECTION SEVEN; 8 ➞ SECTION EIGHT", "text": "any and Company's products to NFLA database and audience by deliverables listed in Exhibit B.   5\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nSECTION SEVEN. PAYMENTS   All payments shall be made by wire transfer drawn to the account of NFLA-NC no later than ten (10) business days after the end of each quarter as follows:   $0.05 per Unit as described herein of Company's Products sold in the Contract Territory payable to NFLA-NC. Donated amounts will be allocated and dispersed to the NFLA-NC beginning on the first full quarter (three month period) of the Agreement and continue on a quarterly basis thereafter for the term of this Agreement.   Past due payments under this Agreement shall bear interest at the rate of: (a) 1% per month; or (b) the maximum interest rate permissible under law, whichever is less. All amounts in this section are in United States dollars.   SECTION EIGHT. AUTHORIZED AGENT   Each party shall designate its authorized agent for all purposes under this Agreement. All notices or submissions to be made or delivered by the Company, the NFLA or the NFLA-NC pursuant to this Agreement shall be delivered to the agent's address below, free of all charges (for example, shipping charges and customs charges). If any such shipping charges are paid by another party or by its authorized agent, the corresponding party agrees to make prompt reimbursement. All notices or submissions to be made or delivered to Company pursuant to this Agreement shall be delivered to:   The Company Food For Athletes/Gridiron BioNutrients™ Attention: Darren Long 1147 N Roseburg Ct STE A, Visalia CA, 93291   NFLA-NC National Football League Alumni - Northern California Chapter Attention: Russell Isaacson - Comptroller 1311 Madison Avenue Redwood CA 94061   NFLA National Football League Alumni, Inc. Attention: Elvis Gooden 8000 Midlantic Drive, 130 S. Mount Laurel, NJ. 08054   6", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::02972baa4927", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::a7d989094564"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::a7d989094564", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "8", "section_title": "AUTHORIZED AGENT", "clause_type": "Notices/Authorized Agent", "path": "8", "text": "Avenue Redwood CA 94061   NFLA National Football League Alumni, Inc. Attention: Elvis Gooden 8000 Midlantic Drive, 130 S. Mount Laurel, NJ. 08054   6\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bb8e4fff1c50", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bf843ccf6b19"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bf843ccf6b19", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "9; 10", "section_title": "DEFAULT; USE OF THE NFLA/NFLA-NC's IDENTIFICATION AFTER TERMINATION", "clause_type": "Default clause; Post-termination use / liquidation and disposition of inventory clause", "path": "9 ➞ 9.A (i),(ii) ➞ 9.B ➞ 10 ➞ 10.A ➞ 10.A.1 ➞ 10.A.2", "text": "gue Alumni, Inc. Attention: Elvis Gooden 8000 Midlantic Drive, 130 S. Mount Laurel, NJ. 08054   6\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nSECTION NINE. DEFAULT   A. If either party at any time during the Contract Period shall: (i) fail to make any payment of any sum of money specified in this Agreement to be made; or (ii) fail to observe or perform any of the covenants, agreements or obligations under this Agreement (other than the payment of money), the non-defaulting party may terminate this Agreement as follows: As to a default under clause (i) above, if such payment is not made within 10 business days after the defaulting party shall have received written notice of such failure to make payment; or, as to a default under clause (ii) above, if such other default is not cured within 30 days after the defaulting party shall have received written notice specifying in reasonable detail the nature of such default. In order to be a sufficient notice under this section, any such written notice shall specify in detail each item of default and shall specify the provision of this Agreement which applies to each item of default, and shall specify in detail the action the defaulting party is required to take in order to cure each item of default. The termination rights set forth in this section shall not constitute the exclusive remedy of the non-defaulting party under this Agreement, however, and if default is made by either party under this Agreement, the other party may resort to such other remedies as such party would have been entitled to if this section had been omitted from this Agreement, subject to the terms of this Agreement. Termination under the provisions of this section shall be without prejudice to any rights or claims which the terminating party may otherwise have against the defaulting party, and if Company is the defaulting party, Company shall be responsible for any and all payments due under the terms of this Agreement in addition to other liabilities set forth above.    B. If Company shall become bankrupt or insolvent, or if Company's business shall be placed in the hands of a receiver, assignee or trustee, whether by voluntary act of Company or otherwise, the Contract Period, at the election of NFLA, shall immediately terminate.   SECTION TEN. USE OF THE NFLA/NFLA-NC's IDENTIFICATION AFTER TERMINATION   A. Except as provided in paragraph B of this SECTION TEN, from and after the termination of the Contract Period, all of the rights of Company to the use of the name of the NFLA shall cease absolutely and Company subsequently shall not use or refer to the NFLA in advertising or promotion in any manner whatsoever. Except as provided in paragraph B below, it is further agreed that following termination of the Contract Period, Company shall not advertise, promote, distribute or sell any item whatsoever in connection with the use of any name, figure, design, logo, trademark or trade name similar to or suggestive of the NFLA.    1. Company may liquidate and sell its inventory of Licensed Products (including any inventory then in production) for a period of ninety (90) days after the termination date of the Contract Period, subject to the Company's continued obligation to pay the Fee as provided above, and will deliver the Sales Report with respect to such liquidation sales within 30 days following the end of the first reached full quarter following termination.      2. If Company has not disposed of all Licensed Products as provided in subparagraph 1 above by the end of the 90 day period, Company, at its option, may either: (a) remove or obliterate entirely from such Licensed Products (and any labels, tags, riders and the like) all references to any NFLA Identification, and then sell the same; or (b) destroy all such remaining Licensed Products.   7", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::a7d989094564", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::128c934faaab"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::128c934faaab", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "10.A.2", "section_title": "USE OF THE NFLA/NFLA-NC's IDENTIFICATION AFTER TERMINATION", "clause_type": "Post-termination use / liquidation of inventory", "path": "10 ➞ 10.A ➞ 10.A.2", "text": "tags, riders and the like) all references to any NFLA Identification, and then sell the same; or (b) destroy all such remaining Licensed Products.   7\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::bf843ccf6b19", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::6de6f0ec9119"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::6de6f0ec9119", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "11", "section_title": "TRADEMARKS", "clause_type": "Trademark registration restriction", "path": "11", "text": "Identification, and then sell the same; or (b) destroy all such remaining Licensed Products.   7\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nSECTION ELEVEN. TRADEMARKS   Company agrees that it will not file, during the Contract Period or afterward, any application for trademark registration or otherwise obtain or attempt to obtain ownership of any trademark or trade name within the Contract Territory or in any other country of the world which consists of the NFLA Identification or any mark, design or logo intended to obtain any rights to the name of the NFLA or to identify products as being endorsed b the NFLA.   SECTION TWELVE. RESERVATION OF RIGHTS   All rights not specifically granted in this Agreement to Company shall remain the property of the NFLA to be used in any manner the NFLA deems appropriate. Company understands that the NFLA has reserved the right to authorize others to use the name of the NFLA within the Contract Territory and during the Contract Period in connection with all tangible and intangible items and services other than Products themselves. NFLA is not aware of any such rights that would conflict with the nature or image of Company Products.   SECTION THIRTEEN. INDEMNITY   Company agrees to protect, indemnify and hold harmless the NFLA / NFLA-NC and their authorized agents, or any of them, from and against any and all expenses, damages, claims, suits, actions, judgments and costs whatsoever, including reasonable attorney's fees, arising out of, or in any way connected with, actions or omissions of Company, any advertising material furnished by, or an behalf of, Company, or any claim or action for personal injury, death or other cause of action involving alleged defects in Company's Products or services. Company agrees to provide and maintain, at its own expense, general commercial and product liability insurance.   SECTION FOURTEEN. SPECIAL RIGHT OF TERMINATION   Company shall have the right to terminate this Agreement, upon written notice to the NFLA / NFLA-NC, if the commercial value of the NFLA's endorsement is substantially reduced because an officer of the NFLA / NFLA-NC: (i) has been charged with illegal or immoral conduct which could result in a felony conviction and such charges have not been dismissed or terminated within 90 days. Any termination pursuant to this section shall become effective on the business day next following the date of receipt by NFLA of Company's written notice to so terminate.   SECTION FIFTEEN. CONTRACT EXTENSION   Due to long product development lead times, Company and NFLA-NC agree to begin discussions for the renewal of this Agreement by no later than June 1st, 2020. All terms of this Agreement will automatically commence on November 1st, 2017, and expire on November 2nd, 2020.   8", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::128c934faaab", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::550e37ad87f8"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::550e37ad87f8", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "SECTION FIFTEEN", "section_title": "CONTRACT EXTENSION", "clause_type": "Term/Extension", "path": "15", "text": "by no later than June 1st, 2020. All terms of this Agreement will automatically commence on November 1st, 2017, and expire on November 2nd, 2020.   8\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::6de6f0ec9119", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::e5f7df53b78b"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::e5f7df53b78b", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "SECTION SIXTEEN - SECTION TWENTY-ONE", "section_title": "LIMITED LIABILITY; WAIVER; SEVERABILITY; ASSIGNMENT; GOVERNING LAW; ARBITRATION; HEADINGS", "clause_type": "Boilerplate (limitation of liability; waiver; severability; assignment; governing law & arbitration; headings)", "path": "16 ➞ SECTION SIXTEEN; 17 ➞ SECTION SEVENTEEN; 18 ➞ SECTION EIGHTEEN; 19 ➞ SECTION NINETEEN; 20 ➞ SECTION TWENTY; 21 ➞ SECTION TWENTY-ONE", "text": "greement will automatically commence on November 1st, 2017, and expire on November 2nd, 2020.   8\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nSECTION SIXTEEN. LIMITED LIABILITY   Notwithstanding anything to the contrary in this Agreement, if Company incurs any expenses, damages or other liabilities (including but not limited to reasonable attorney's fees) in connection with the performance or nonperformance of any term or provision of this Agreement, NFLA's liability to Company shall not exceed the remuneration, excluding reimbursement of expenses, actually paid to NFLA by Company. In no event will NFLA be liable for any indirect, incidental, reliance, special or consequential damages arising out of the performance or nonperformance of this Agreement, whether or not NFLA had been advised of the possibility of such damages.   SECTION SEVENTEEN. WAIVER   The failure of either party at any time or times to demand strict performance by the other party of any of the terms, covenants or conditions set forth in this Agreement shall not be construed as a continuing waiver or relinquishment of the same and each party may at any time demand strict and complete performance by the other party of such terms, covenants and conditions. Any waiver of such rights must be set forth in writing.   SECTION EIGHTEEN. SEVERABILITY   If any provision of this Agreement shall be declared illegal, invalid, void or unenforceable by any judicial or administrative authority, the validity of any other provision and of the entire Agreement shall not be affected by such declaration.   SECTION NINETEEN. ASSIGNMENT   This Agreement shall bind and inure to the benefit of Company and NFLA and their respective successors and assigns.   SECTION TWENTY. GOVERNING LAW; ARBITRATION   This Agreement shall be governed by, and its provisions enforced in accordance with, the laws of California without regard to its principles of conflicts of laws. If a dispute arises under this Agreement which cannot be resolved, such dispute shall be submitted to arbitration and resolved by a single arbitrator (who shall be a lawyer not employed by or associated with either party to this Agreement) in accordance with the Commercial Arbitration Rules of the American Arbitration Association then in effect. All such arbitration shall take place at the office of the American Arbitration Association located within 225 miles of Hayward, California. Each party is entitled to depose one fact witness and all expert witnesses retained by the other party, and to conduct such other discovery as the arbitrator deems appropriate. The award or decision rendered by the arbitrator shall be final, binding and conclusive and judgment may be entered upon such award by any court.   SECTION TWENTY-ONE. HEADINGS   Section headings contained in this Agreement are solely for the purpose of aiding in speedy location of subject matter and are not in any sense to be given weight in the construction of this Agreement. Accordingly, in case of any question with respect to the construction of this Agreement, it is to be construed as though such section headings had been omitted.   9", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::550e37ad87f8", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::dae0fc51ae87"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::dae0fc51ae87", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "21", "section_title": "SECTION TWENTY-ONE. HEADINGS", "clause_type": "heading/interpretation", "path": "21 ➞ 21. HEADINGS", "text": "n case of any question with respect to the construction of this Agreement, it is to be construed as though such section headings had been omitted.   9\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::e5f7df53b78b", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::310d9ac36069"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::310d9ac36069", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "SECTION TWENTY-TWO; SECTION TWENTY-THREE", "section_title": "NO JOINT VENTURE; ENTIRE AGREEMENT", "clause_type": "No joint venture / relationship clause; Entire agreement (integration) clause", "path": "22 ➞ SECTION TWENTY-TWO; 23 ➞ SECTION TWENTY-THREE", "text": "on of this Agreement, it is to be construed as though such section headings had been omitted.   9\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nSECTION TWENTY-TWO. NO JOINT VENTURE   This Agreement does not constitute and shall not be construed as constituting an association, partnership, joint venture or relationship of principal and agent, or employer and employee, between NFLA and Company. Neither party shall have any right to obligate or bind the other party in any manner whatsoever except as expressly set forth in this Agreement, nothing contained in this Agreement shall give, or is intended to give, any rights of any kind to any person.   SECTION TWENTY-THREE. ENTIRE AGREEMENT   This writing constitutes the entire agreement between the parties to this Agreement and may not be changed or modified except by a writing signed by the party or parties to be charged by such change or modification.   The parties have executed this Agreement on October 30, 2017.   Food For Athletes, Inc. / Gridiron BioNutrients™   By: /s/ Darren Long    Darren Long - CEO     The National Football League Alumni, Inc.     By: /s/ Elvis Gooden    Elvis Gooden - President     NFL Alumni - Northern California Chapter   By: /s/ Eric Price    Eric Price - President     10", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::dae0fc51ae87", "next_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::385fb00e03cc"}
{"id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::385fb00e03cc", "doc_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8", "section_number": "EXHIBIT B", "section_title": "NFLA agrees to promote Company and Company's products to NFLA database by:", "clause_type": "Exhibit - Promotional Obligations", "path": "EXHIBIT B", "text": "By: /s/ Elvis Gooden    Elvis Gooden - President     NFL Alumni - Northern California Chapter   By: /s/ Eric Price    Eric Price - President     10\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nEXHIBIT A PRO FOOTBALL LEGENDS LOGO\n\n11\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017\n\nEXHIBIT B   NFLA agrees to promote Company and Company's products to NFLA database by:    1. E-blasts: NFLA to send a minimum of two (2) dedicated e-blasts per year to NFLA database. All e-blast communications must be approved in writing by Company;      2. Newsletter: NFLA to feature Company in Weekly Newsletter \"Partner Spotlight\" a minimum of four (4) times per year. All newsletter communications must be approved in writing by Company; and      3. Social Media: NFLA to feature Company on all social media channels a minimum of four (4) times per year. All newsletter communications must be approved in writing by Company.     12\n\nSource: GRIDIRON BIONUTRIENTS, INC., 8-K, 12/6/2017", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Endorsement Agreement", "party_role": ["licensor", "licensee"], "jurisdiction": "US-CA", "governing_law": "US-CA", "industry": "beverages"}, "prev_id": "7e17f0f6-5c43-4fa4-a8e4-4e43f0f440e8::310d9ac36069", "next_id": null}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::e3e7a13df9cc", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "1", "section_title": "Description of the Promotion", "clause_type": "Preamble and Section Heading", "path": "Agreement ➞ 1", "text": "Promotion Agreement Between                     PageMaster Corporation and Go Call, Inc.\n\nAGREEMENT                                     ---------\n\nThis Promotion Agreement (herein \"Agreement\") dated March 12,1999, by and between Go Call, Inc. (herein \"Go Call\") located at 15 Queen Street East, Cambridge Ontario, Canada N3C2A7 and PageMaster Corporation located at 100 E. Thousand Oaks Blvd. Suite 297, Thousand Oaks, CA 91360, shall set forth the Terms and conditions pursuant to which Go Call and PageMaster Corporation shall create a promotion as more fully described below.\n\nWHEREAS, Go Call seeks to increase its sales and website activity; and         WHEREAS. PageMaster Corporation seeks to promote the contracting of         paging service to clients;         NOW THEREFORE, Go Call and PageMaster Corporation in consideration of         the mutual obligations set forth herein and other good and valuable         consideration, the receipt and sufficiency of which the parties         acknowledge, hereby agree as follows:\n\n1.      Description of the Promotion         ----------------------------", "numbers_present": null, "definition_terms": ["Agreement", "Go Call"], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": null, "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::c5cccc103605"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::c5cccc103605", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "1, 2, 3", "section_title": ["Description of the Promotion", "Consumer Cost Description", "Term"], "clause_type": "Promotion description / Consumer cost / Term", "path": "1 ➞ 2 ➞ 3", "text": "ficiency of which the parties         acknowledge, hereby agree as follows:\n\n1.      Description of the Promotion         ----------------------------\n\nPageMaster Corporation in conjunction with Go Call, shall offer free new Motorola \"Wordline Alphanumeric\" (or equal) pagers with no activation fee to all customers responding to this promotion who purchase twelve (12) months of numeric paging and airtime products and services from PageMaster Corporation (\"Purchase Customers\").\n\n2.      Consumer Cost Description         -------------------------\n\nEach Purchase Customer will be required to purchase twelve months of local numeric airtime at a rate of $10.33 per month through a designated nationwide airtime provider, prepaid in advance. The purchased airtime shall be non-refundable to the consumer. Additionally, Purchase Customers will be required to pay for shipping and handling costs and applicable sales taxes based on their locations.\n\n3.      Term         ----\n\nThis promotion shall begin on June 1,1999 and shall terminate June 1, 2000 (herein \"Term\") This term shall be extended for a 1 year period provided 3000 pagers per month are distributed to Purchase customers.", "numbers_present": null, "definition_terms": ["Purchase Customers", "Term"], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::e3e7a13df9cc", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0126d3ee8f94"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0126d3ee8f94", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "4", "section_title": "Responsibilities of PageMaster Corporation", "clause_type": "Responsibilities/Obligations", "path": "4 ➞ 4.a ➞ 4.b", "text": "ate June 1, 2000 (herein \"Term\") This term shall be extended for a 1 year period provided 3000 pagers per month are distributed to Purchase customers.\n\n4.      Responsibilities of PageMaster Corporation         ------------------------------------------\n\nPageMaster Corporation shall be responsible for providing the following:\n\na.     For Purchase Customers to participate in the promotion,                PageMaster Corporation shall establish and maintain a toll-free                telephone number for this promotion beginning June 1,1999 and                continuing until September 1, 2000 unless otherwise requested by                Go Call and agreed upon by PageMaster Corporation.\n\nb.     PageMaster Corporation shall provide a minimum of 100,000 up to                500,000 pagers for the fulfillment of this promotion to all                Purchase Customers who prepay their annual airtime.", "numbers_present": null, "definition_terms": ["Term"], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::c5cccc103605", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::d681ac44682e"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::d681ac44682e", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "4.b–4.c", "section_title": "Responsibilities of PageMaster Corporation", "clause_type": "Responsibilities/Obligations", "path": "4 ➞ 4.b–4.c", "text": "00 up to                500,000 pagers for the fulfillment of this promotion to all                Purchase Customers who prepay their annual airtime.\n\nc.     PageMaster Corporation shall be responsible for all fulfillment                obligations of this promotion relating to paging services,                including, but not limited to, timely delivery of pagers, paging                services, defective goods handling, subcontracting, deadlines,                and handling of consumer and regulatory inquiries and complaints.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0126d3ee8f94", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::78797f06d859"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::78797f06d859", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "4.d", "section_title": "Responsibilities of PageMaster Corporation", "clause_type": "Responsibilities / Fulfillment", "path": "4 ➞ 4.d", "text": "services, defective goods handling, subcontracting, deadlines,                and handling of consumer and regulatory inquiries and complaints.\n\nd.     PageMaster Corporation will contract with a nationwide airtime                service provider to fulfill and to ship Purchasing Customer                orders direct to the Purchase Customers to fulfill this promotion                in a timely manner. PageMaster Corporation has chosen for the                purpose of this promotion, MetroCall Inc. to provide pager and                airtime services where the nationwide airtime service provider                has the facilities and the requisite governmental authority to                provide such services. All Purchase Customers shall become                customers of the nationwide airtime service provider. The                nationwide airtime service provider shall be allowed to market                additional pagers arid enhanced services to all Purchase                Customers, and to charge for over-calls with respect to any                account with a Purchase Customer. The nationwide airtime service                provider shall be able to discontinue or terminate service to any                Purchase Customer in accordance with the terms of the contract                between the nationwide airtime service provider and the Purchase                Customer. Notwithstanding the foregoing, PageMaster Corporation                shall remain solely responsible for the fulfillment of all                services and obligations set forth in this Agreement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::d681ac44682e", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::220c338c9382"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::220c338c9382", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "4.e–5.c", "section_title": "Responsibilities of PageMaster Corporation; Responsibilities of Go Call", "clause_type": "Responsibilities / Obligations", "path": "4 ➞ 4.e; 4 ➞ 4.f; 5 ➞ 5.a; 5 ➞ 5.b; 5 ➞ 5.c", "text": "oration                shall remain solely responsible for the fulfillment of all                services and obligations set forth in this Agreement.\n\ne.     PageMaster Corporation shall not engage in the same or similar                promotion with any other On-Line Casinos from June 1, 1999                through June 1, 2000.\n\nf.     PageMaster Corporation will provide at no charge programming                software that will allow Go Call to broadcast any and all                messages of 125 characters or less to all Go Call consumers who                have redeemed pagers on this promotion.\n\n5.      Responsibilities of Go Call         ---------------------------\n\na.     Go Call shall prepare and distribute at its own expense, all                advertising materials to be used for this promotion.\n\nb.     Go Call, shall submit in advance, all artwork and advertising to                PageMaster Corporation for approval as provided in Paragraph 8.\n\nc.     Go Call shall not engage in the same or similar promotions during                the Term of this Agreement with any other entity providing paging                services, equipment or other related products and services.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::78797f06d859", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9c272f50ef7f"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9c272f50ef7f", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "6", "section_title": "Payment Made As Deposit On Pagers", "clause_type": "Payment/Deposit/Refund", "path": "6 ➞ 6.a", "text": "the Term of this Agreement with any other entity providing paging                services, equipment or other related products and services.\n\n6.      Payment Made As Deposit On Pagers         ---------------------------------\n\nUpon the execution of this Agreement, Go Call shall forward to PageMaster Corporation a deposit in the sum of $100,000.00 to secure the availability of 100,000 pagers to all Purchase Customers who prepay their annual airtime for this promotion. The deposit is non-refundable except as follows:\n\na.     PageMaster Corporation shall refund to Go Call, $1.00 per pager                on all pagers delivered to Purchase Customers pursuant to this                promotion (net return) up to the maximum refund of $100,000.00.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::220c338c9382", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::efd6e16bf308"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::efd6e16bf308", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "6.b", "section_title": "Payment Made As Deposit On Pagers", "clause_type": "Payment/Refund and Audit", "path": "6 ➞ 6.b", "text": "on all pagers delivered to Purchase Customers pursuant to this                promotion (net return) up to the maximum refund of $100,000.00.\n\nb.     On the last day of each month, the refund of Go Call's portion of                the deposit shall be calculated by PageMaster Corporation for the           &bbsp;    prior month and will be forwarded to Go Call by check, along with                an extended accounting of all pagers and customers until                September 1, 2000, unless otherwise instructed by Go Call. Go                Call, upon ten (10) days written notice, shall have the right to                examine the books and records of PageMaster Corporation to verify                the sales resulting from this promotion. Such examination shall                be made at the regular place of business of PageMaster                Corporation where such books and records are maintained during                normal business hours and shall be conducted at Go Call's expense                by a certified public accountant or other Go Call executive so                designated by Go Call.\n\n7.      Co-Op Marketing Funds         ---------------------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9c272f50ef7f", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::e9b9a317b869"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::e9b9a317b869", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "7", "section_title": "Co-Op Marketing Funds", "clause_type": "Payment/Marketing funds", "path": "7", "text": "ied public accountant or other Go Call executive so                designated by Go Call.\n\n7.      Co-Op Marketing Funds         ---------------------\n\nPageMaster Corporation shall pay to Go Call, Co-Op Marketing funds for the promotion. PageMaster Corporation will pay Go Call $3.00 per pager (beginning with pager # 1) and 5% of all airtime renewal revenue for each pager redeemed for this promotion consistent with the terms of paragraph 6b of this Agreement.\n\n8.      Representation and Warranties         -----------------------------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::efd6e16bf308", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9ce2d51ce16d"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9ce2d51ce16d", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "8.", "section_title": "Representation and Warranties", "clause_type": "Representations and warranties", "path": "8", "text": "is promotion consistent with the terms of paragraph 6b of this Agreement.\n\n8.      Representation and Warranties         -----------------------------\n\nPageMaster Corporation warrants and represents that it has a license to advertise and use the trademarks, logos, etc. of Motorola, Inc., PageMaster Promotions and such other third parties as may be necessary to advertise this promotion. At least sixty (60) days prior to the commencement of the promotion, PageMaster Corporation in its sole discretion shall have the unconditional right to approve the accuracy of the description of the pager promotion and use of corporate logos and photographs and descriptions of products and services provided by designated airtime carriers or any third parties participating in the promotion; in the event of disapproval, Go Call shall not proceed with the promotion until the revised artwork or presentation is subsequently approved by PageMaster Corporation in writing. Upon termination or expiration of this Agreement, Go Call agrees not to use or advertise any trademarks, logos or other property rights of PageMaster Corporation or any third parties participating in the promotion. Any advertising, artwork, presentation, or other promotional activities (collectively \"Advertising\") concerning the pager Promotion not pre-approved in writing by PageMaster Corporation shall be deemed to be unauthorized by PageMaster Corporation and shall constitute a breach of this Agreement. In addition to the duty to indemnify PageMaster Corporation as provided in Paragraph 9 hereof, Go Call shall also have the duty to indemnify Motorola, Inc. or any affiliated entity from and against any and all claims, expense, suits or demands arising from such unauthorized Advertising by Go Call, or its agent, affiliate, licensee, franchisee or any other third party.", "numbers_present": null, "definition_terms": ["Advertising"], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::e9b9a317b869", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::341ad3a365b9"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::341ad3a365b9", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "9", "section_title": "Indemnity", "clause_type": "Indemnity", "path": "9", "text": "pense, suits or demands arising from such unauthorized Advertising by Go Call, or its agent, affiliate, licensee, franchisee or any other third party.\n\n9.      Indemnity         ---------\n\nEach party shall indemnify and hold harmless the other from any loss or damages, including reasonable attorneys' fees incurred by the other because of claims, suits or demands based on personal injury, death or property damage or third party claims, suits or demands of any kind to the extent such loss or damage is caused by or results from the negligent or willful acts or omissions of the other or its employees or agents, including but not limited to the unauthorized use of the trademark, logos, or other property of third parties without the consent and approval of PageMaster Corporation. PageMaster Corporation's participation in the promotion does not constitute an endorsement of the products or services of Go Call nor does Go Call's participation in the promotion constitute an endorsement of PageMaster Corporations or any third party's products or services.\n\n10.     Force Majeure         -------------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9ce2d51ce16d", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9fb773286916"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9fb773286916", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "10", "section_title": "Force Majeure", "clause_type": "Force Majeure", "path": "10", "text": "promotion constitute an endorsement of PageMaster Corporations or any third party's products or services.\n\n10.     Force Majeure         -------------\n\nNeither party will be responsible for any delay or failure in performance of any part of&bbsp;this Agreement to the extent that such delay or failure is caused by any event beyond its control, which may include, but not be limited to, fire, flood, explosion, war, strike, embargo, government requirement, civil or military authority, and acts of God (\"Conditions\"). If any such Condition occurs, the party delayed or unable to perform shall promptly give notice to the other party and, if such Condition remains at the end of thirty (30) days thereafter, the party affected by the other party's delay or inability to perform may elect to terminate or suspend this Agreement or part thereof, and resume performance of this Agreement once the Condition ceases, with an option for the affected party to extend the period of this Agreement up to the length of time the Condition endured. PageMaster Corporation make no warranties, either express or implied, concerning the pagers or the transmission of pages by the airtime service provider, including warranties of merchantability or fitness for particular purpose. The parties agree that", "numbers_present": null, "definition_terms": ["Conditions"], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::341ad3a365b9", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::c36692abbdcc"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::c36692abbdcc", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "10.", "section_title": "Force Majeure", "clause_type": "Force Majeure", "path": "10", "text": "ansmission of pages by the airtime service provider, including warranties of merchantability or fitness for particular purpose. The parties agree that\n\nPageMaster Corporation shall not be liable for service interruptions in the telecommunications industry, capacity constraints or related problems, or for any act or omission of any other entity furnishing products or services to PageMaster Corporation. PageMaster Corporations' liability shall in no event exceed an amount equivalent to the amounts received by PageMaster Corporation hereunder.\n\n11.     Choice Of Law         -------------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::9fb773286916", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::f8a60ae12f6c"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::f8a60ae12f6c", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "11", "section_title": "Choice Of Law", "clause_type": "Choice of law, venue and indemnification notice requirement", "path": "11", "text": "hall in no event exceed an amount equivalent to the amounts received by PageMaster Corporation hereunder.\n\n11.     Choice Of Law         -------------\n\nThis Agreement will be governed by and construed in accordance with the laws of the State of California, exclusive of conflicts of law principles, and will, to the maximum extent practicable, be deemed to call for performance in Los Angeles County, California. Los Angeles County, California shall be the sole and exclusive venue for any litigation or dispute resolution relating to or arising out of the Agreement. To seek or receive indemnification hereunder (i) the party seeking indemnification must have properly notified the other party of any claim or litigation of which it is aware to which the indemnification relates; and the party seeking indemnification must have afforded the other the opportunity to participate in any compromise, settlement, litigation or other resolution or disposition of such claim or litigation.\n\n12.     Dispute Resolution         ------------------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::c36692abbdcc", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::12e4af90b460"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::12e4af90b460", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "12.a", "section_title": "Dispute Resolution", "clause_type": "Alternative dispute resolution", "path": "12 ➞ 12.a", "text": "promise, settlement, litigation or other resolution or disposition of such claim or litigation.\n\n12.     Dispute Resolution         ------------------\n\na.     The parties desire to resolve disputes arising out of this                Agreement without litigation. Accordingly, except for an action                seeking a temporary restraining order or injunction related to                the purposes of this Agreement, or a suit to compel compliance                with this dispute resolution process, the parties agree to use                the following alternative dispute resolution procedure as their                sole remedy with respect to any controversy or claim arising out                of or relating to this Agreement or its breach.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::f8a60ae12f6c", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::370ffc4d85c6"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::370ffc4d85c6", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "12.b", "section_title": "Dispute Resolution", "clause_type": "Negotiation and confidentiality (dispute resolution)", "path": "12 ➞ 12.b", "text": "s their                sole remedy with respect to any controversy or claim arising out                of or relating to this Agreement or its breach.\n\nb.     At the written request of a party, each party shall appoint a                knowledgeable, responsible representative to meet and negotiate                in good faith to resolve any dispute arising under this                Agreement. The parties intend that these negotiations be                conducted by non-lawyer, business representatives. The                discussions shall be left to the discretion of the                representatives. Upon agreement, the representatives may utilize                other alternative dispute resolution procedures such as mediation                to assist in the negotiations. Discussions and correspondence                among the representatives for purposes of these negotiations                shall be treated as confidential information developed for                purposes of settlement, exempt from discovery and production,                which shall not be admissible in the arbitration described below                or in any lawsuit without the concurrence of all parties.                Documents identified in or provided with such communications,                which are not prepared for purposes of the negotiations, are not                so exempted and may, if otherwise admissible, be admitted in                evidence in the arbitration or lawsuit.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::12e4af90b460", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0620ee18c550"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0620ee18c550", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "12.c", "section_title": "Dispute Resolution", "clause_type": "Arbitration — procedural (discovery limits and hearing rules)", "path": "12 ➞ 12.c", "text": "gotiations, are not                so exempted and may, if otherwise admissible, be admitted in                evidence in the arbitration or lawsuit.\n\nc.     If the negotiations do not resolve the dispute within sixty (60)                days of the initial written request, the dispute shall be                submitted to binding arbitration by a single arbitrator pursuant                to the Commercial Arbitration Rules of the American Arbitration                Association. A party may demand such arbitration in accordance                with the procedures set out in those rules. Discovery shall be                controlled by the arbitrator and shall be permitted to the extent                set out in this Section. Each party may submit in writing to a                party, and that party shall so respond, to a maximum of any                combination of thirty-five (35) (none of which may have subparts)                of the following: interrogatories, demands to produce documents                and requests for admission. Each party is also entitled to take                the oral deposition of one (1) individual of another party.                Additional discovery may be permitted upon mutual agreement of                the parties. The arbitration hearing shall be commenced within                sixty (60) days of the demand for arbitration and the arbitration                shall be held in Los Angeles, CA. The arbitrator shall control                the scheduling so as to process the matter expeditiously. The", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::370ffc4d85c6", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::3162af1d8f45"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::3162af1d8f45", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "12.c-d", "section_title": "Dispute Resolution", "clause_type": "Arbitration / Dispute Resolution (costs and discovery)", "path": "12 ➞ 12.c / 12.d", "text": "shall be held in Los Angeles, CA. The arbitrator shall control                the scheduling so as to process the matter expeditiously. The\n\nparties may submit written briefs. The arbitrator shall rule on\n\nthe dispute by issuing a written opinion within thirty (30) days                after the close of hearings. The times specified in this                paragraph may be extended upon mutual agreement of the parties or                by the arbitrator upon a showing of good cause. Judgment upon the                award rendered by the arbitrator may be entered in any court                having jurisdiction.\n\nd.     Each party shall bear its own cost of these procedures. A party                seeking discovery shall reimburse the responding party the cost                of production of the documents (to include search time and                reproduction time costs). The parties shall equally share the                fees of the arbitration and the arbitrator.\n\n13.     Notices         -------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0620ee18c550", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0e60b85311ec"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0e60b85311ec", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "13", "section_title": "Notices", "clause_type": "Notice", "path": "13", "text": "roduction time costs). The parties shall equally share the                fees of the arbitration and the arbitrator.\n\n13.     Notices         -------\n\nAny notice or demand given to either party under the Terms of this Agreement or pursuant to statute shall be in writing and shall be given or made by telegram, facsimile transmission, certified or registered mail, express mail or other overnight delivery service or hand delivery, proper postage or other charges prepaid and addressed or directed to the respective parties as follows:\n\nPAGEMASTER CORPORATION 100 E. Thousand Oaks Blvd. Suite 297 Thousand Oaks, CA 91360 ATTN:    Marc Resnick, CEO\n\nGO CALL, INC. 15 Queen Street East Cambridge Ontario, Canada N3C2A7 ATTN:    Ian Smith, President\n\nSuch notice or demand shall be deemed to have been given or made when actually received or seventy-two (72) hours after being sent, whichever occurs first. The address for notice set out above may be changed at any time by giving thirty (30) days prior written notice in the manner above.\n\n14.     Agreement Expiration         --------------------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::3162af1d8f45", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0b635dcf4406"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0b635dcf4406", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "14-16", "section_title": "Agreement Expiration; Entire Agreement; Nonwaiver", "clause_type": "Boilerplate / Miscellaneous (Expiration, Integration, Nonwaiver)", "path": "14 ➞ 15 ➞ 16", "text": "be changed at any time by giving thirty (30) days prior written notice in the manner above.\n\n14.     Agreement Expiration         --------------------\n\nUnless this Agreement is signed by an authorized representative of Go Call and a signed copy delivered in person by mail or facsimile and personally received by an authorized representative of PageMaster Corporation by 12:01 p.m. PST, on or before March 26, 1999, this Agreement shall be deemed terminated and shall be of no further force or effect and the parties shall have no liability to one another. At PageMaster Corporation's option, an additional agreement(s) may be prepared to further negotiate this or similar promotions with Go Call.\n\n15.     Entire Agreement         ----------------\n\nThis Agreement represents the entire agreement and understanding of the parties hereto with respect to its subject matter hereof, and supersedes all previous representations, understandings or agreements between the parties hereto. No waiver, modification or cancellation of any term or condition of this Agreement shall be effective unless executed in writing by the party charged therewith.\n\n16.     Nonwaiver         ---------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0e60b85311ec", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::91deaba12cf3"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::91deaba12cf3", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "16-19", "section_title": "Nonwaiver; Counterparts; Successors and Assigns; Confidentiality", "clause_type": "Boilerplate", "path": "15 ➞ 16 ➞ 17 ➞ 18 ➞ 19", "text": "term or condition of this Agreement shall be effective unless executed in writing by the party charged therewith.\n\n16.     Nonwaiver         ---------\n\nEither parties failure to enforce any of the provisions of this Agreement shall in no way be deemed to affect the validity of this Agreement.\n\n17.     Counterparts         ------------\n\nThis Agreement may be executed in duplicate counterparts, all of which together shall constitute a single instrument, and each of which shall be deemed an original of this Agreement for all purposes.\n\n18.     Successors and Assigns         ----------------------\n\nThis Agreement shall be binding upon, and shall inure to the benefit of the successors, heirs, administrators, trustees and assigns of the parties.\n\n19.     Confidentiality         ---------------", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::0b635dcf4406", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::ab55265cf340"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::ab55265cf340", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "19", "section_title": "Confidentiality", "clause_type": "Confidentiality", "path": "19", "text": "l inure to the benefit of the successors, heirs, administrators, trustees and assigns of the parties.\n\n19.     Confidentiality         ---------------\n\nThe parties acknowledge that preparation for and execution of the promotion necessitates the exchange of confidential and proprietary information relating and belonging to the parties to this Agreement, as well as to other third parties integral to the promotion, including, without limitation, the pager manufacturer and the airtime supplier (herein \"Information\"). Each party agrees (1) to review, examine, inspect, obtain or utilize the information only for the purpose of this promotion, (2) to otherwise hold such Information strictly confidential, (3) to prevent the disclosure of such Information to nonessential third parties without a \"need to know\", and (4) to insure that each party's employees, agents and representatives and those of any integral third party understand and are bound by the confidentiality obligations of this Agreement. Each party shall indemnify the other party with respect to any loss or damage arising from the unauthorized disclosure or use of the Information by their respective employees, agents and representatives, or by those of any third", "numbers_present": null, "definition_terms": ["Information"], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::91deaba12cf3", "next_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::4a8470df02e4"}
{"id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::4a8470df02e4", "doc_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726", "section_number": "19", "section_title": "Confidentiality", "clause_type": "Confidentiality; Execution/Signature", "path": "19 ➞ 19. Confidentiality", "text": "arising from the unauthorized disclosure or use of the Information by their respective employees, agents and representatives, or by those of any third\n\nparty to whom such Information was disclosed. The agreements contained in this Paragraph shall survive the expiration, or termination of this Agreement. The panics hereby agree that subsequent to the expiration or termination of this Agreement, each party consents to the other party's use of its name only in connection with advertising to their respective trade or industry.\n\nIN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date set forth below.\n\nGO CALL, Inc.\n\nDated:  3/13/99                         By:  /s/ Michael Ruge                -------------------      &sbsp;           ----------------------------                                                      Michael Ruge\n\nPAGEMASTER CORPORATION\n\nDated:  3/13/99                         By:  /s/ Marc B. Resnick                -------------------                  ----------------------------                                                      Marc B. Resnick                                                      CE0", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Promotion Agreement", "party_role": "promoter, fulfillment provider", "jurisdiction": "US-CA (Los Angeles County)", "governing_law": "US-CA", "industry": "telecommunications"}, "prev_id": "a91ee621-f62b-4877-abd7-d3ad3c08f726::ab55265cf340", "next_id": null}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::bc64c69391f2", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "A", "section_title": "Distributor Information", "clause_type": "Agreement Preamble and Distributor Information", "path": "Agreement ➞ A", "text": "EXHIBIT 10.9     GLOBAL MUSIC INTERNATIONAL, INC. DBA IMNTV CONTENT LICENSE AGREEMENT\n\nThis Content License Agreement (\"Agreement\") is between Global Music International, Inc. d/b/a Independent Music Network (IMNTV), located at 20 Old Stagecoach Road, Redding, Connecticut, 06896 (\"IMNTV\"), and Distributor, as set forth below, and describes the terms and conditions under which Distributor will distribute Programming provided by IMNTV as described herein. Distributor's distribution of the Programming is subject to the Master Terms of Service (\"MTS\") attached hereto as Exhibit A. All capitalized terms shall have the meaning set forth on the MTS. In consideration for the mutual promises and covenants contained herein, the parties agree as follows:\n\nDistributor's authorized signature, is REQUIRED:\n\nA. Distributor Information N/A   Provider Name: MobileVision Communications Ltd.\n\nAddress: 100 Ba Li Zhuang Xi Li, Suite 907, ZhuBang2000 Plaza, East Building, Beijing, China\n\nCOUNTRY PROVINCE: P.R.China\n\nWeb Site www.looklook.cn\n\nTax ID #: N/A\n\nBusiness Contact: Name: MengDi Xu\n\nPhone: +86 135 010 37211\n\nEmail: xumengdi@looklook.cn\n\nMarketing Contact: Name: BaoQing (Angel) Song", "numbers_present": null, "definition_terms": ["Agreement", "IMNTV", "MTS"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": null, "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::4d1bce3550ec"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::4d1bce3550ec", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "A", "section_title": "Distributor Information", "clause_type": "Contact Information", "path": "A", "text": "Tax ID #: N/A\n\nBusiness Contact: Name: MengDi Xu\n\nPhone: +86 135 010 37211\n\nEmail: xumengdi@looklook.cn\n\nMarketing Contact: Name: BaoQing (Angel) Song\n\nPhone: +86 13911178981\n\nEmail: angelsong@looklook.cn\n\nTechnical Contact: Name: WeiLi Cheng\n\nPhone: +86 13011813916\n\nEmail: chengwl@mobiledata.com.cn\n\nBilling contact: Name: RuoXian Qi\n\nPhone: +86 13161502302\n\nEmail: ruoxian@looklook.cn\n\nBilling Address: (if different from above)   Customer Service Contact: Name: Liang (Dean) Wang\n\nPhone: +86 136 2131 5977\n\nEmail: deanwang@looklook.cn\n\nNotice Contact: Name: RuoXian Qi\n\nPhone: +86 13161502302\n\nEmail: ruoxian@looklook.cn\n\nNotice Address: (if different from above)\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nB. Term", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::bc64c69391f2", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::b0321957d91b"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::b0321957d91b", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "B", "section_title": "Term", "clause_type": "Term", "path": "Agreement ➞ B ➞ B. Term", "text": "13161502302\n\nEmail: ruoxian@looklook.cn\n\nNotice Address: (if different from above)\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nB. Term\n\nThis Agreement is effective as of the last date signed below (\"Effective Date\"). The initial term of this Agreement will begin on the Effective Date and end twelve (12) months after the Launch (the \"Term\"). IMNTV will extend the Agreement on the same terms and conditions for additional one-year terms, providing Distributor and IMNTV agree, predicated on satisfactory performance by both parties IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized representatives.     DISTRIBUTOR\n\nMOBILEVISION COMMUNICATIONS LTD.   By: Name Andrew Zhang   Title PRESIDENT   Signature /s/ Andrew Zhang   Date 13/07/05\n\nGLOBAL MUSIC INTERNATIONAL, INC. D/B/A INDEPENDENT MUSIC NETWORK (IMNTV)\n\nBy: Name Corinne Fallacaro   Title PRESIDENT   Signature /s/ Corinne Fallacaro    Date 13/07/05\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nEXHIBIT A\n\nGLOBAL MUSIC INTERNATIONAL, INC. DBA IMNTV MASTER TERMS OF SERVICE\n\n1. DEFINITIONS", "numbers_present": null, "definition_terms": ["Effective Date", "Term"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::4d1bce3550ec", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::d75115f756eb"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::d75115f756eb", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "1", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "EXHIBIT A ➞ 1", "text": "urce: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nEXHIBIT A\n\nGLOBAL MUSIC INTERNATIONAL, INC. DBA IMNTV MASTER TERMS OF SERVICE\n\n1. DEFINITIONS\n\nThe following capitalized terms will have the meanings set forth below:   \"Bundles\" means, any version of the Mobile Product that includes IMNTV content bundled with any other product or service.", "numbers_present": null, "definition_terms": ["Bundles"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::b0321957d91b", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::18a1a1d67961"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::18a1a1d67961", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "1.", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "EXHIBIT A ➞ 1.", "text": "meanings set forth below:   \"Bundles\" means, any version of the Mobile Product that includes IMNTV content bundled with any other product or service.\n\n\"Confidential Information\" means the confidential or proprietary technical or business information of a party, including without limitation (a) proposals or research related to possible new products or services; (b) financial statements and other financial information; (c) reporting information; (d) the material terms of this Agreement and the relationship between the parties; and (e) planned launch dates. All of the information will be considered confidential only if it is conspicuously designated as \"Confidential,\" or if provided orally, identified at the time of disclosure as confidential. \"Confidential Information\" does not include information that (i) is in or enters the public domain without breach of this Agreement, (ii) the receiving party lawfully receives from a third party without restriction on disclosure and without breach of a nondisclosure obligation, or (iii) the receiving party knew prior to receiving such information from the disclosing party or develops independently.", "numbers_present": null, "definition_terms": ["Bundles", "Confidential Information"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::d75115f756eb", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::4123d953a501"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::4123d953a501", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "1", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "EXHIBIT A ➞ 1 ➞ 1. DEFINITIONS", "text": "a nondisclosure obligation, or (iii) the receiving party knew prior to receiving such information from the disclosing party or develops independently.\n\n\"Content\" means generally text, images, video, audio, and other material.\n\n\"Fees\" means Subscription Fees that include IMNTV content..\n\n\"Internet Protocol\" means any protocol used to route data on the Internet, or on any portion of the Internet, including all versions currently in existence or developed or implemented in the future.\n\n\"Landing Page\" means the destination web page for a Special Link, created and hosted by Distributor, from where individuals may begin the Registration Process for the Subscription Service or a Bundle, at such individual's election.\n\n\"Launch\" means the date that the Programming is made generally available for purchase by consumers under the terms and conditions of the Agreement.\n\n\"Programming\"means IMNTV's Content, as specifically described on Section B (1) of the Agreement. As used herein, \"Programming\" also includes any promotional and marketing Content provided by Provider for IMNTV's promotional and marketing activities as described herein.", "numbers_present": null, "definition_terms": ["Content", "Fees", "Internet Protocol", "Landing Page", "Launch", "Programming"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::18a1a1d67961", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::da9b97716356"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::da9b97716356", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "1", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "1 ➞ 1.DEFINITIONS", "text": "amming\" also includes any promotional and marketing Content provided by Provider for IMNTV's promotional and marketing activities as described herein.\n\n\"Programming Bundle Fee\" means the fee actually paid by a Subscriber for a Programming Bundle that includes IMNTV content provided in accordance with this Agreement.\n\n\"Distributor Marks\" means the trademarks, service marks, brands, logos and trade names of Distributor.\n\n\"Distributor Portal\" means, collectively, the Distributor's Site and any other web site or property from where Distributor promotes the Programming.\n\n\"Distributor Site\" means Distributor's Internet web site intended to promote the availability of any Distributor Content, including the Programming, via mobile and wireless networks. Distributor Site is more fully described in Section A of the Agreement.\n\n\"Subscription Fee\" means the fee actually paid by a Subscriber for the applicable Mobile Content.", "numbers_present": null, "definition_terms": ["Programming", "Programming Bundle Fee", "Distributor Marks", "Distributor Portal", "Distributor Site", "Subscription Fee"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::4123d953a501", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a5c0b0a86777"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::a5c0b0a86777", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "1.", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "EXHIBIT A ➞ 1. DEFINITIONS", "text": "more fully described in Section A of the Agreement.\n\n\"Subscription Fee\" means the fee actually paid by a Subscriber for the applicable Mobile Content.\n\n\"Subscriber\" means any individual who purchases mobile content programming and: (a) who actually pays the applicable Subscription Fee; and (b) does not receive a refund of such Subscription Fee for any reason within thirty (30) days from the end of the payment period for which the Subscription Fee was paid. A Subscriber remains a \"Subscriber\" for the purposes of this Agreement so long as such individual continues to pay the applicable Subscription Fee.\n\n\"Registration Process\" means the download, payment, installation, and electronic registration process of the Programming, a Bundle or the applicable Software. \"Registration Process\" may include an online registration form\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005", "numbers_present": null, "definition_terms": ["Subscription Fee", "Subscriber", "Registration Process"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::da9b97716356", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::77c8767e661f"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::77c8767e661f", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "1", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "EXHIBIT A ➞ 1 ➞ 1. DEFINITIONS", "text": "or the applicable Software. \"Registration Process\" may include an online registration form\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nprovided, hosted, and managed by Distributor, and may also, at Distributor's discretion, include other methods by which a Subscriber may affirmatively request access to the Programming, a Bundle, or the Software.   \"IMNTV Marks\" means the trademarks, service marks, brands, logos and trade names of IMNTV and/or Global Music International.\n\n\"IMNTV Portal\" means the IMNTV Sites where IMNTV promotes the Programming.\n\n\"IMNTV Sites\" means the Internet web sites owned and operated by IMNTV.\n\n\"Special Link\"means a formatted or \"tagged\" link that tracks traffic from the Distributor Portal to the Landing Page.\n\n\"Subscribers\" means, collectively, end users who have completed the Registration Process for any of the Subscription Products described herein. \"Subscribers\" includes \"Recurring Subscribers.\"\n\n\"Subscription Products\" means, collectively Products and Bundles that include IMNTV content.", "numbers_present": null, "definition_terms": ["Registration Process", "IMNTV Marks", "IMNTV Portal", "IMNTV Sites", "Special Link", "Subscribers", "Subscription Products"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a5c0b0a86777", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::08d128b68a9e"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::08d128b68a9e", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "1", "section_title": "DEFINITIONS", "clause_type": "Definitions", "path": "EXHIBIT A ➞ 1. DEFINITIONS", "text": "herein. \"Subscribers\" includes \"Recurring Subscribers.\"\n\n\"Subscription Products\" means, collectively Products and Bundles that include IMNTV content.\n\n\"IMNTV Mobile Product\" means an IMNTV branded subscription product distributed to mobile and wireless devices, which includes services, products and Content from one or a variety of third parties, and includes any derivative, follow-on, repackaged, or substantially similar product offered by Distributor that includes IMNTV Programming.\n\n\"Bundle Fee\" means the fee actually paid by a Subscriber for the Mobile Product Bundle that includes provider content provided in accordance with this Agreement.\n\n\"IMNTV Mobile Product Fee\" means the fee actually paid by a Subscriber for the IMNTV Mobile Product.\n\n\"Recurring Subscriber\" for the purpose of this Agreement so as long as such individual continues to pay the applicable Subscription Fee, so long as IMNTV actually receives such fee.\n\n\"Territory\" means China. Other territories are subject to approval by IMNTV.\n\n2. DISTRIBUTOR OBLIGATIONS.", "numbers_present": null, "definition_terms": ["Subscribers", "Subscription Products", "IMNTV Mobile Product", "Bundle Fee", "IMNTV Mobile Product Fee", "Recurring Subscriber", "Territory"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::77c8767e661f", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::5f48c9be11bb"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::5f48c9be11bb", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "2.1(a)-(b)", "section_title": "Subscription Transactions", "clause_type": "Distributor Obligations", "path": "1 ➞ Territory; 2 ➞ 2.1 ➞ 2.1(a) ➞ 2.1(b)", "text": "o long as IMNTV actually receives such fee.\n\n\"Territory\" means China. Other territories are subject to approval by IMNTV.\n\n2. DISTRIBUTOR OBLIGATIONS.\n\n2.1 Subscription Transactions. Distributor will provide the following services to market, launch and distribute the Programming using its existing infrastructure as follows:\n\n(a) Fulfillment. Each individual who purchases a Subscription must complete the Registration Process, where such individual will be prompted to provide certain personally identifiable information including a valid major credit card (e.g. Visa, MasterCard, Discover, American Express) to receive the Programming. Support for additional payment methods and additional credit cards may be developed by Distributor, with IMNTV's prior written approval.\n\n(b) Customer Support. Distributor will provide customer support in target Territory in a workmanlike and professional manner.", "numbers_present": null, "definition_terms": ["Territory"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::08d128b68a9e", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::cb736664e3ce"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::cb736664e3ce", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "2.1(b); 2.2; 2.3", "section_title": "Customer Support; Distribution Channels; Hosting Services", "clause_type": "Distributor obligations (customer support, distribution channels, hosting services)", "path": "2 ➞ 2.1(b); 2 ➞ 2.2; 2 ➞ 2.3", "text": "prior written approval.\n\n(b) Customer Support. Distributor will provide customer support in target Territory in a workmanlike and professional manner.\n\n2.2 Distribution Channels. Distributor and IMNTV may create, sell and market Bundles that include the IMNTV Programming. Distributor may offer the Programming and any Bundles through all wireless distribution channels in target Territory. To enable all Subscribers to have access to the Programming, the Programming may be distributed in whole or in part via Internet Protocol in a manner that enables the Programming to be received and played back by mobile devices in the target Territory.\n\n2.3 Hosting Services. Hosting of on-demand Programming will be provided at no cost to IMNTV in a format acceptable to local Territory wireless devices. Distributor will provide reports of aggregated Subscriber access and usage data concerning the Programming on a monthly basis, together with reports described in Section 6.5, below.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::5f48c9be11bb", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a79247146f53"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::a79247146f53", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "2.4", "section_title": "Promotion of Programming", "clause_type": "Marketing/Promotion", "path": "2 ➞ 2.4", "text": "s of aggregated Subscriber access and usage data concerning the Programming on a monthly basis, together with reports described in Section 6.5, below.\n\n2.4 Promotion of Programming. Distributor may use the Programming and IMNTV's Marks to market, advertise and promote the Programming in the Mobile Software Application(s), the Distributor's Portal, and in other on and off-line marketing efforts as follows: (a) promoting the Programming in directories, listings, and keyword searches; (b) deep linking to the Programming; (c) featuring Programming in various areas within the Distributor's Software and Distributor's Portal, (d) communicating to users via Distributor's consumer marketing channels such as on-line messages, member newsletters or email campaigns; (e) featuring excerpts, screenshots of Programming in marketing collateral and advertisements; (f) featuring the Programming in product demonstrations relating to Distributor's\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::cb736664e3ce", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::8f66a34e349c"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::8f66a34e349c", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "2.4", "section_title": "Promotion of Programming", "clause_type": "Marketing/Promotion obligation", "path": "2 ➞ 2.4 ➞ 2.4.(f)-(h)", "text": "isements; (f) featuring the Programming in product demonstrations relating to Distributor's\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nsoftware or subscription products at trade shows and conferences; (g) creating collateral for joint promotional efforts between Distributor and third parties; (h) promoting the Programming in television, radio and print media. IMNTV may use Distributor's logos and marks in the marketing of the Product, subject to pre- approved trademark usage policy and Brand Standards to be provided by Distributor to IMNTV.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a79247146f53", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::d6f373b152c8"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::d6f373b152c8", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "2.5", "section_title": "Distributor Support and Operational Responsibilities", "clause_type": "Obligations", "path": "2 ➞ 2.5", "text": "and marks in the marketing of the Product, subject to pre- approved trademark usage policy and Brand Standards to be provided by Distributor to IMNTV.\n\n2.5 Distributor Support and Operational Responsibilities. Distributor will provide all \"middleware\" programming to facilitate connection of the content delivery platform to local Territory wireless networks. Distributor will perform localization of any software components to make the program possible to use in the local Territory. This is to include language translations or interface design changes. Provider will act as liaison with local Territory wireless carriers. This will include content review to insure content meets local broadcast standards and meets any local regulatory requirements. Distributor also agrees to secure necessary governmental approvals or permits necessary to operate in the Territory and to secure permission to enable distribution of IMNTV's share of Subscription Fees to IMNTV in the United States. Distributor is solely responsible for monitoring, performance and ensuring the availability of the Programming and will notify IMNTV immediately of planned and unplanned Programming delays or outages.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::8f66a34e349c", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a81b3fe9b081"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::a81b3fe9b081", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "2.6", "section_title": "Privacy", "clause_type": "Distributor obligation (Privacy/Compliance)", "path": "2 ➞ 2.6", "text": "performance and ensuring the availability of the Programming and will notify IMNTV immediately of planned and unplanned Programming delays or outages.\n\n2.6 Privacy. Distributor is responsible for complying with all applicable laws, rules and regulations relating to its collection and use of personal information from users of the Distributor Portal. At a minimum, Distributor must adopt, implement and comply with a Privacy Policy that: (a) is easy to find, read and understand; (b) is prominently posted at the time that any personally identifiable information is collected or requested; and (c) clearly states what information is being collected, what the information will be used for, whether such information will be provided to third parties, and the choices available regarding collection, use and distribution of the collected information.\n\n3. IMNTV OBLIGATIONS.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::d6f373b152c8", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::de222d042f50"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::de222d042f50", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "3.1", "section_title": "Grant of License", "clause_type": "License grant", "path": "3 ➞ 3.1", "text": "e provided to third parties, and the choices available regarding collection, use and distribution of the collected information.\n\n3. IMNTV OBLIGATIONS.\n\n3.1 Grant of License. During the Term, for the activities described in this Agreement, IMNTV hereby grants Distributor non-exclusive rights and licenses necessary within the Territory to: (a) copy, store digitally, host and stream the Programming; (b) publicly perform, publicly display, electronically transmit, distribute and broadcast the Programming; (c) promote the Programming and use IMNTV Marks for Distributor's promotion of the Programming as activities described in Section 2.4 above; (d) archive the Programming on Distributor's servers; (e) encode, copy, and create continuous Programming excerpts of up to sixty (60) seconds and transmit, publicly perform, distribute, and redistribute such excerpts to end users via the Distributor's Portal for marketing purposes only(f) deep link to the Programming.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a81b3fe9b081", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::f1a033721e2a"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::f1a033721e2a", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "3.1(f) - 3.6", "section_title": "IMNTV OBLIGATIONS", "clause_type": "Obligations / License rights", "path": "3 ➞ 3.1 ➞ 3.2 ➞ 3.3 ➞ 3.4 ➞ 3.5 ➞ 3.6", "text": "orm, distribute, and redistribute such excerpts to end users via the Distributor's Portal for marketing purposes only(f) deep link to the Programming.\n\n3.2 Right of distribution N/A   3.3 Removed N/A   3.4 Programming Obligations. IMNTV will create and maintain it's programming content and will deliver same to Distributor in a format suitable for the distribution over wireless networks in Distributor's Territory on a regular basis.\n\n3.5 Logo Trademarks. Distributor may use IMNTV logos and marks in the marketing of the Product, subject to pre-approved trademark usage policy and Brand Standards.\n\n3.6 Dedicated Personnel. Throughout the Term, IMNTV shall designate at least one (1) staff member to provide Distributor with all reasonably necessary assistance, information and support relating to its obligations herein including, but not limited to, updating and maintaining the Programming.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::de222d042f50", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::b6f796fefc75"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::b6f796fefc75", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "3.7; 4; 5", "section_title": "Responsibility for Programming; ADVERTISING; OWNERSHIP", "clause_type": "Obligations (responsibility for programming); Advertising restriction; Ownership heading", "path": "3 ➞ 3.7; 4; 5", "text": "essary assistance, information and support relating to its obligations herein including, but not limited to, updating and maintaining the Programming.\n\n3.7 Responsibility for Programming. Except as expressly set forth herein, IMNTV is solely responsible for all costs, activities, obligations and liabilities associated with: (a) obtaining all rights and licenses necessary for the authorized use and distribution of the IMNTV Programming as described herein including, but not limited to, all copyright, trademark rights, rights of publicity and rights of privacy, and any broadcast, rebroadcast, or retransmission rights or permissions; and (b) obtaining all necessary permissions and/or release documentation from all persons associated with the distribution of the Programming as described herein, including, without limitation, all performers.\n\n4. ADVERTISING   The IMNTV Programming will not contain any advertising, either integrated or before or after each clip, except IMNTV I'Ds and IMNTV commercials for solicitation of Chinese music videos,without the prior written approval of both parties.\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\n5. OWNERSHIP.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::f1a033721e2a", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::b811904e0900"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::b811904e0900", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "5.1", "section_title": "By IMNTV", "clause_type": "Ownership / Intellectual Property", "path": "5 ➞ 5.1", "text": "of Chinese music videos,without the prior written approval of both parties.\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\n5. OWNERSHIP.\n\n5.1 By IMNTV. As between Distributor and IMNTV, IMNTV owns or has the necessary licenses to all copyright, trademark, patent and other intellectual property rights in and to, and all other right, title and interest in and to the Programming, the Trademarks and the IMNTV Portal. Except as expressly provided herein, IMNTV retains the right to distribute the Programming in any medium now known or hereafter developed. As between IMNTV and Distributor (excluding the Programming and other Provider intellectual property), IMNTV owns all copyright, trademark, patent and other intellectual property rights therein, and all other right, title and interest in and to or associated with the Subscription Products, the IMNTV Sites, the IMNTV Marks, and the System and Subscriber data.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::b6f796fefc75", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::2f2ffab63ecb"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::2f2ffab63ecb", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "5.3", "section_title": "Trademarks", "clause_type": "Trademarks / Intellectual Property", "path": "5 ➞ 5.3", "text": "ight, title and interest in and to or associated with the Subscription Products, the IMNTV Sites, the IMNTV Marks, and the System and Subscriber data.\n\n5.3 Trademarks. Each party: (a) will not create a unitary composite mark involving a trademark of the other party without the prior written approval of such other party; (b) will display symbols and notices clearly and sufficiently indicating the trademark status and ownership of the other party's trademarks in accordance with applicable trademark law and practice; (c) acknowledges that its utilization of the other party's trademarks will not create in it, nor will it represent it has, any right, title or interest in or to such trademarks other than the licenses expressly granted herein; (d) agrees not to do anything contesting or impairing the trademark rights of the other party; (e) agrees to promptly notify the other party of any unauthorized use of the other party's trademarks of which it has actual knowledge; and (f) will have the sole right and discretion to bring proceedings alleging infringement of its trademarks or unfair competition related thereto; provided, however, that each party agrees to provide the other party, at such other party's expense, with its reasonable cooperation and assistance with respect to any such infringement proceedings", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::b811904e0900", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::713123d5dffd"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::713123d5dffd", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "6.1", "section_title": "Mobile Product Payments", "clause_type": "Fees/Royalties (Payment)", "path": "6 ➞ 6.1", "text": "ovide the other party, at such other party's expense, with its reasonable cooperation and assistance with respect to any such infringement proceedings\n\n6. FEES AND ROYALTIES\n\n6.1 Mobile Product Payments. Subscription fee in Territory is to be determined based on market research performed by Distributor with pricing to be agreed upon jointly and in writing Each quarter, Distributor will make royalty payments to IMNTV based on a Structure as follows:", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::2f2ffab63ecb", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::0e92034cfb21"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::0e92034cfb21", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "6.1", "section_title": "Mobile Product Payments", "clause_type": "Fees and royalties (payment/royalty terms)", "path": "6 ➞ 6.1", "text": "r with pricing to be agreed upon jointly and in writing Each quarter, Distributor will make royalty payments to IMNTV based on a Structure as follows:\n\n55% of subscriber revenue for the subscription based services broadcasting IMNTV content only, net of telecom percentage provided in accordance with this Agreement.   (\"Programming Payments\"), subject to the following: The parties acknowledge that some mobile carriers may bill end users for a full month in a single billing, and that others may bill for partial months or pro-rate the billing of Recurring Subscribers. For each full month of Fees received from a Recurring Subscriber, Distributor will pay IMNTV based on the Rate Structure (the \"Full Month Payment\"). To the extent that Distributor receives a partial month's Fee or pro-rated Fee from a Recurring Subscriber as a result of a carrier's billing practices, Distributor will pay IMNTV a proportionate or pro-rated portion of such Full Month Payment based on the amount received by Distributor.\n\n6.2 Payments. All payments hereunder shall be payable to IMNTV in United States Dollars on a quarterly basis upon receipt from the wireless carriers in the Territory, except as follows:", "numbers_present": null, "definition_terms": ["Programming Payments", "Full Month Payment"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::713123d5dffd", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::e566ddd09474"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::e566ddd09474", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "6.2", "section_title": "Payments", "clause_type": "Payments/Payment schedule", "path": "6 ➞ 6.2 ➞ 6.2(a)-(c)", "text": "r shall be payable to IMNTV in United States Dollars on a quarterly basis upon receipt from the wireless carriers in the Territory, except as follows:\n\n(a) First Payment. The first payment to IMNTV will be payable upon receipt at the end of the first calendar quarter after Launch, and will include any amounts due, pro-rated based on the number of days in such period of time; and\n\n(b) Last Payment. The last payment to IMNTV will be payable upon receipt at the end of the first full month after the termination or expiration of this Agreement, and will include any amounts due: for the last month that the Programming is available, prorated based on the number of days in such final period.\n\n(c) Other Exceptions. All payments hereunder are exclusive of: (i) any trial or promotional periods during which a Subscriber receives access to the Programming before such Subscriber's credit card is charged; and (ii) refunds, charge backs and fees attributable to contested credit card transactions", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::0e92034cfb21", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::791a70775d95"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::791a70775d95", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "6.2(c)-(e); 6.3", "section_title": "Payments; Provider Payment Location", "clause_type": "Payments", "path": "6 ➞ 6.2 ➞ 6.2(c), 6.2(d), 6.2(e); 6 ➞ 6.3", "text": "rogramming before such Subscriber's credit card is charged; and (ii) refunds, charge backs and fees attributable to contested credit card transactions\n\n(d) Summary of Timing. The parties acknowledge the following that establishes timing of payments: (1) Distributor receives a carrier statement saying how much Distributor will be paid; (2) 30-45 days later the Carrier pays Distributor; (3) when Distributor is paid by a carrier, Distributor makes royalty payments to IMNTV.\n\n(e) Exchange Rate. Payments to IMNTV will be converted from local currency to US Dollars at the official exchange rate posted on the day payments are made to IMNTV via wire transfer provided that currency exchange is approved by the relevant Chinese currency exchange administrative agency.\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\n6.3 Provider Payment Location. Distributor will remit such payments a bank account specifically named by IMNTV..", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::e566ddd09474", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::c71951874cc0"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::c71951874cc0", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "6.3–7.1", "section_title": "Provider Payment Location; Taxes; Reporting; Termination; General Termination Rights", "clause_type": "Payments/Taxes/Reporting/Termination", "path": "6 ➞ 6.3; 6 ➞ 6.4; 6 ➞ 6.5; 7 ➞ 7.1", "text": "LOGIES GROUP, INC., 10KSB, 9/28/2005\n\n6.3 Provider Payment Location. Distributor will remit such payments a bank account specifically named by IMNTV..\n\n6.4 Taxes. Distributor will collect and remit to the appropriate taxing authority, or require Subscribers to pay, any sales, use or similar taxes applicable to any retail sale or distribution of the Programming. Except for the foregoing, each party is solely and separately responsible for its own taxes, user fees, or similar levies.\n\n6.5 Reporting. Distributor will provide IMNTV with a quarterly report or monthly report if available, summarizing the data relevant to the payment obligations herein within five (5) business days from the end of the calendar quarter. The reports will contain sufficient information to permit Provider to verify payments hereunder.\n\n7. TERMINATION\n\n7.1 General Termination Rights. Either party may terminate the Agreement at any time in the event of a material breach by the other party that remains uncured after thirty (30) days written notice of the breach.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::791a70775d95", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::1bc640b1126d"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::1bc640b1126d", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "7.2", "section_title": "Termination for Programming Deficiency", "clause_type": "Termination", "path": "7 ➞ 7.2", "text": "e Agreement at any time in the event of a material breach by the other party that remains uncured after thirty (30) days written notice of the breach.\n\n7.2 Termination for Programming Deficiency. Distributor reserves the right to issue a warning immediately to Subscribers, to temporarily or indefinitely suspend the availability of the Programming, or to terminate this Agreement (the \"Remedies\") if IMNTV breaches this Agreement. In the event that Distributor exercises any of its rights set forth in this Section 7.2, Distributor will notify IMNTV of the Programming Deficiency, Distributor's elected Remedy, and the available cure options, and will provide IMNTV with a reasonable period of time in which IMNTV may cure the Programming Deficiency (the \"Cure Period\"). During the Cure Period, if commercially reasonable, the Distributor may help IMNTV cure the Programming Deficiency, but is under no affirmative obligation to do so. If IMNTV fails to cure the Programming Deficiency within the Cure Period, Distributor may terminate this Agreement immediately upon written notice. In the event of a suspension or termination under this Section 7.2, Distributor will notify Subscribers that the Programming is no longer available. Distributor will be solely liable for any refunds pertaining to the Programming that are issued to Subscribers as a result of termination under this Section 7.2.", "numbers_present": null, "definition_terms": ["Remedies", "Cure Period"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::c71951874cc0", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::7e522bde89ae"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::7e522bde89ae", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "7.3", "section_title": "Termination for Bankruptcy/Insolvency.", "clause_type": "Termination", "path": "7 ➞ 7.3", "text": "will be solely liable for any refunds pertaining to the Programming that are issued to Subscribers as a result of termination under this Section 7.2.\n\n7.3 Termination for Bankruptcy/Insolvency. Either party may terminate this Agreement immediately following written notice to the other party if the other party: (a) ceases to do business in the normal course; (b) becomes or is declared insolvent or bankrupt; (c) is the subject of any proceeding related to its liquidation or insolvency (whether voluntary or involuntary) which is not dismissed within ninety (90) calendar days; or (d) makes an assignment for the benefit of creditors.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::1bc640b1126d", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::42c61c23acc5"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::42c61c23acc5", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "7.4", "section_title": "Effect of Termination", "clause_type": "Termination", "path": "7 ➞ 7.4", "text": "y (whether voluntary or involuntary) which is not dismissed within ninety (90) calendar days; or (d) makes an assignment for the benefit of creditors.\n\n7.4 Effect of Termination. Except as set forth in Section 7.3 above, upon termination or expiration of this Agreement: (a) the licenses granted to Distributor will immediately terminate; and (b) all fees due to IMNTV will be paid to IMNTV pursuant to Section 6.3 of this Agreement. In the event that Distributor terminates this Agreement pursuant to either Section 7.2 or 7.3 above, Distributor will notify Subscribers that the Programming is no longer available. Sections 5, 6.3, 6.6, 7.2, 7.4, 8, and 9 of this MTS will survive the expiration or termination of the Agreement for any reason.\n\n8. WARRANTIES AND INDEMNIFICATION", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::7e522bde89ae", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::c19bfc208183"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::c19bfc208183", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "8.1", "section_title": "Provider Warranty and Indemnification", "clause_type": "Warranty and Indemnification", "path": "8 ➞ 8.1", "text": ".3, 6.6, 7.2, 7.4, 8, and 9 of this MTS will survive the expiration or termination of the Agreement for any reason.\n\n8. WARRANTIES AND INDEMNIFICATION\n\n8.1 Provider Warranty and Indemnification. IMNTV represents and warrants to Distributor that: (i) IMNTV is an entity duly organized and validly existing under the laws of its state of organization; (ii) IMNTV has the power and authority to enter into this Agreement and to perform fully its obligations under this Agreement; (iii) IMNTV is under no contractual or other legal obligation which could reasonably be expected to interfere in any way with its prompt and complete performance under this Agreement; and (iv) the person executing this Agreement on behalf of IMNTV has been duly authorized to do so and such execution is binding upon IMNTV.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::42c61c23acc5", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::9bf32857a937"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::9bf32857a937", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "8.1", "section_title": "Provider Warranty and Indemnification", "clause_type": "Warranty and Indemnification", "path": "8 ➞ 8.1", "text": "Agreement; and (iv) the person executing this Agreement on behalf of IMNTV has been duly authorized to do so and such execution is binding upon IMNTV.\n\nIMNTV will defend, indemnify, and hold Distributor harmless from and against any and all liabilities, claims, losses, costs, damages and expenses (including reasonable attorneys' fees and court costs) (collectively, \"Claims\") relating to or arising out of: (a) IMNTV's breach of this Agreement; (b) the Content of the Programming (e.g., if such Claim alleges copyright or trademark infringement or infringement of any other proprietary right) as furnished by IMNTV under this Agreement (excluding any Claim to the extent based on any alteration of or insertion in any IMNTV content by Distributor that is not specifically authorized by IMNTV in writing), IMNTV Marks or IMNTV Site; (c) any IMNTV online subscription service, the Programming with the Mobile Subscription Products, or IMNTV's acts or omissions with\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005", "numbers_present": null, "definition_terms": ["Claims"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::c19bfc208183", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::e5104fbf6756"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::e5104fbf6756", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "8.1", "section_title": "Provider Warranty and Indemnification", "clause_type": "Indemnification", "path": "8 ⟶ 8.1", "text": "e, the Programming with the Mobile Subscription Products, or IMNTV's acts or omissions with\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nrespect thereto (including the marketing of the foregoing by IMNTV and excluding any Claim to the extent based on any alteration of or insertion in any Programming by Distributor); (d) violation by IMNTV of any contractual obligation, including payments or royalties, that IMNTV has to any third party; (e) a claim that the Programming as provided by IMNTV does not comply with any federal, state and local laws and regulations that are applicable to Distributor's transmission or use of Programming as permitted this Agreement; or (f) IMNTV not having obtained all necessary consents, licenses, permissions and releases necessary to grant Distributor the rights IMNTV grants to Distributor hereunder.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::9bf32857a937", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::12d2b7d7d262"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::12d2b7d7d262", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "8.2", "section_title": "Distributor Warranty and Indemnification", "clause_type": "Warranty and Indemnification", "path": "8 ➞ 8.2", "text": "g obtained all necessary consents, licenses, permissions and releases necessary to grant Distributor the rights IMNTV grants to Distributor hereunder.\n\n8.2 Distributor Warranty and Indemnification. Distributor represents and warrants to IMNTV that: (i) Distributor is an entity duly organized and validly existing under the laws of its country of organization; (ii) Distributor has the power and authority to enter into this Agreement and to perform fully its obligations under this Agreement; (iii) Distributor is under no contractual or other legal obligation which could reasonably be expected to interfere in any way with its prompt and complete performance under this Agreement; and (iv) the person executing this Agreement on behalf of Distributor has been duly authorized to do so and such execution is binding upon Distributor. Distributor will defend, indemnify, and hold IMNTV harmless from and against any and all Claims relating to or arising out of: (a) the marketing by Distributor of the Programming (excluding Claims to the extent based on Programming or other content provided by or approved by IMNTV), or any Subscription Product which includes any Programming, (b) any Claim by any Subscriber concerning Distributor's operation and maintenance of the Subscription Products (except for content Claims described in Section 9.1, Claims concerning the transmission of Subscriber Information to IMNTV, or the use of Subscriber Information by IMNTV or by any third party to whom IMNTV has disclosed such information); (c) Distributor's alternation of, or insertion of material (including commercial advertisements) in, any Programming, except as explicitly authorized in each case in writing by IMNTV; and (d) any infringement of the Subscription Products on the rights of others (excluding any Claim to the extend based on any Programming).", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::e5104fbf6756", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::2b2adcbf993c"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::2b2adcbf993c", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "8.3", "section_title": "Conditions of Indemnification", "clause_type": "Indemnification", "path": "8 ➞ 8.3", "text": "by IMNTV; and (d) any infringement of the Subscription Products on the rights of others (excluding any Claim to the extend based on any Programming).\n\n8.3 Conditions of Indemnification. A party's obligation to indemnify the other party is expressly conditioned on the indemnified party: (a) giving written notice of the claim promptly to the indemnifying party; (b) giving the indemnifying party control of the defense and settlement of the claim utilizing, if necessary, legal counsel to be selected by the indemnifying party upon reasonable approval of the other party; (c) providing to the indemnifying party all available information and assistance (at the indemnifying party's expense); and (d) not compromising or settling such claim, without the other party's prior written consent which may not be unreasonably withheld.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::12d2b7d7d262", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::d079530d1cf8"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::d079530d1cf8", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "8.3(d) – 8.5; 9", "section_title": "Disclaimer of Warranties; Limitation of Liability; General", "clause_type": "Disclaimer of warranties; Limitation of liability; General provisions", "path": "8 ➞ 8.3(d) ➞ 8.4; 8 ➞ 8.5; 9", "text": "y's expense); and (d) not compromising or settling such claim, without the other party's prior written consent which may not be unreasonably withheld.\n\n8.4 Disclaimer of Warranties. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NEITHER PARTY MAKES ANY WARRANTIES OR REPRESENTATIONS RELATING TO THE SUBSCRIPTION PRODUCTS, OR THE LIKELIHOOD OF SUCCESS OF THE PROGRAMMING, THE MOBILE NTENT PRODUCT, OR ANY BUNDLE. TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IMNTV FURTHER DISCLAIMS ALL WARRANTIES IN THE SUBSCRIPTION PRODUCTS, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NONINFRINGEMENT.\n\n8.5 Limitation of Liability. NO PARTY WILL BE LIABLE TO THE OTHER PARTY IN TORT, CONTRACT OR UNDER ANY OTHER LEGAL THEORY FOR ANY CONSEQUENTIAL, INDIRECT, INCIDENTAL, PUNITIVE OR SPECIAL LOSS OR DAMAGES ARISING OUT OF THIS AGREEMENT, EVEN IF APPRISED OF THE LIKELIHOOD OF SUCH DAMAGES OCCURRING. IN NO EVENT WILL IMNTV'S LIABILITY TO DISTRIBUTOR UNDER THIS AGREEMENT EXCEED THE AMOUNT ACTUALLY DUE TO IMNTV HEREIN.\n\n9. GENERAL", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::2b2adcbf993c", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::c89ee943b0d1"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::c89ee943b0d1", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "9.1", "section_title": "Notices and Contact Information", "clause_type": "Notice", "path": "9 ➞ 9.1", "text": "DAMAGES OCCURRING. IN NO EVENT WILL IMNTV'S LIABILITY TO DISTRIBUTOR UNDER THIS AGREEMENT EXCEED THE AMOUNT ACTUALLY DUE TO IMNTV HEREIN.\n\n9. GENERAL\n\n9.1 Notices and Contact Information. All notices and demands under this Agreement will be in writing and will be delivered by personal service, express courier, or United States mail, to the following addresses:   If to IMNTV: Independent Music Network 20 Old Stagecoach Road Redding, CT 06896 USA Attention: General Counsel     If to Provider:         To the Notice Contact as set forth in Section A of the Agreement.\n\nEither party may change the addresses set forth above by written notice to the other party. Notice will be effective on receipt. Any notice or report delivered in accordance with this Section will be deemed given on the date actually\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::d079530d1cf8", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::5172a123efa5"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::5172a123efa5", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "9.2", "section_title": "Non-Assignment", "clause_type": "Assignment", "path": "9 ➞ 9.2", "text": "report delivered in accordance with this Section will be deemed given on the date actually\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\ndelivered; provided that any notice or report deemed given or due on a Saturday, Sunday or legal holiday will be deemed given or due on the next business day. If any notice or report is delivered to any party in a manner which does not comply with this Section 9.1, such notice or report will be deemed delivered on the date, if any, such notice or report is actually received by the other party.   9.2 Non-Assignment. This Agreement is binding upon each party's assigns, transferees and successors; provided that no party may assign or otherwise transfer, by operation of law or otherwise, this Agreement in whole or in part, without the other party's prior written consent. Notwithstanding the prior sentence, either party may assign this Agreement in its entirety without the other party's consent to any of the following: (i) the assignor's successor in a consolidation or merger, (ii) the assignor's successor in an acquisition of all or substantially all of the assets, equity or beneficial interests of the assignor, (iii) an entity under common control with, controlled by or in control of the assignor, or (iv) a lender, as an assignment of collateral to secure credit extended to the assignor. The assignor will give the other party written notice within thirty (30) days of any assignment described in the immediately preceding sentence.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::c89ee943b0d1", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::f68957335f30"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::f68957335f30", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "9.3", "section_title": "Confidentiality", "clause_type": "Confidentiality", "path": "9 ➞ 9.3", "text": "gnor. The assignor will give the other party written notice within thirty (30) days of any assignment described in the immediately preceding sentence.\n\n9.3 Confidentiality. The parties acknowledge that Confidential Information is valuable and unique and that disclosure in breach of this confidentiality provision will result in irreparable injury to its owner. From the Effective Date and for a period of two (2) years from the date of termination or expiration of this Agreement, neither party will use, disclose, or permit any person to obtain any Confidential Information of the other party. If either party receives a request from any third party for the Confidential Information of the other party, or if such party is directed to disclose any portion of any Confidential Information of the other party by operation of law or in connection with a judicial or governmental proceeding or arbitration, it will immediately notify the other party and will assist the other party in seeking a suitable protective order or assurance of confidential treatment to preserve the confidentiality of any such Confidential Information. If either party breaches or threatens to breach the terms of this confidentiality provision, the non-breaching party will be entitled to an injunction prohibiting any such breach. Any such relief will be in addition to and not in lieu of any appropriate relief in the way of money damages.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::5172a123efa5", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a017b2412054"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::a017b2412054", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "9.4", "section_title": "Press Releases and Public Statements", "clause_type": "Publicity", "path": "9 ➞ 9.4", "text": "injunction prohibiting any such breach. Any such relief will be in addition to and not in lieu of any appropriate relief in the way of money damages.\n\n9.4 Press Releases and Public Statements. Neither party will issue any press releases or make public statements relating to this Agreement or the relationship between the parties without the other party's review of and written consent to such press release or public statement.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::f68957335f30", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::7e3cdc032010"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::7e3cdc032010", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "9.5", "section_title": "Force Majeure", "clause_type": "Force Majeure", "path": "9 ➞ 9.5", "text": "s Agreement or the relationship between the parties without the other party's review of and written consent to such press release or public statement.\n\n9.5 Force Majeure. No party shall be deemed in default hereunder for any cessation, interruption or delay in the performance of its obligations due to causes beyond its reasonable control, including but not limited to: earthquake, flood, or other natural disaster, act of God, labor controversy, civil disturbance, war (whether or not officially declared) or the inability to obtain sufficient supplies, transportation, or other essential commodity or service required in the conduct of its business, or any change in or the adoption of any law, regulation, judgment or decree (each a \"Force Majeure Event\"). Each party shall have the right to terminate this Agreement immediately upon written notice if any Force Majeure Event of another party continues for more than ten (10) days.", "numbers_present": null, "definition_terms": ["Force Majeure Event"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a017b2412054", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::0a0b41cece25"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::0a0b41cece25", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "9.6", "section_title": "Miscellaneous", "clause_type": "Miscellaneous/Boilerplate", "path": "9 ➞ 9.6", "text": "e right to terminate this Agreement immediately upon written notice if any Force Majeure Event of another party continues for more than ten (10) days.\n\n9.6 Miscellaneous. This Agreement and Exhibits A, B, and C constitute the final agreement between the parties with regard to the subject matter herein, and supersedes and cancels all prior negotiations, understandings, correspondence and agreements, oral and written, express or implied, between the parties with regard to the subject matter herein. No waiver, amendment or modification of any provision of this Agreement will be effective unless it is in a document that expressly refers to this Agreement and is signed by both parties. Failure or delay by either party in exercising any rights or remedy under this Agreement will not operate as a waiver of any such right or remedy. The parties are independent contractors. Neither party will be deemed to be an employee, agent, partner or legal representative of the other for any purpose and neither will have any right, power or authority to create any obligation or responsibility on behalf of the other. This Agreement will be governed by the laws of the State of Florida without regard to conflicts of law provisions.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::7e3cdc032010", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::d51553126aad"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::d51553126aad", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "EXHIBIT B 1-2.2", "section_title": "TECHNICAL REQUIREMENTS; LIVE/STREAMING PROGRAMMING (AS APPLICABLE)", "clause_type": "Technical requirements / specifications", "path": "EXHIBIT B ➞ 1. TECHNICAL REQUIREMENTS; EXHIBIT B ➞ 2. LIVE/STREAMING PROGRAMMING ➞ 2.1 Preparing Content; EXHIBIT B ➞ 2. LIVE/STREAMING PROGRAMMING ➞ 2.2 Feed Delivery", "text": "ponsibility on behalf of the other. This Agreement will be governed by the laws of the State of Florida without regard to conflicts of law provisions.\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nEXHIBIT B       1. TECHNICAL REQUIREMENTS. IMNTV will comply with the following technical requirements, as applicable:\n\nOn Demand. Provider will provide all on-demand media files encoded in the Format appropriate for each stream type (e.g., audio, video, animation and other media file types as they become supported and as IMNTV may then elect to provide) to the Distributor via the File Transfer Protocol (FTP).\n\n2. LIVE/STREAMING PROGRAMMING (AS APPLICABLE)\n\n2.1 Preparing Content. IMNTV will provide Distributor with the URL for each live or simulated live stream remotely encoded by IMNTV using the conventions established by both parties.\n\n2.2 Feed Delivery. At IMNTV's election, IMNTV will deliver live feeds to the Distributor via methods other than FTP over the Internet, including delivery of physical media.", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::0a0b41cece25", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a506ff93a32a"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::a506ff93a32a", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "2.2(a)-(b); 1.1(a)-(b)", "section_title": "Feed Delivery; Programming Presentation", "clause_type": "Technical requirements (live/streaming feed delivery and programming presentation)", "path": "EXHIBIT B ➞ 2 ➞ 2.2 ➞ 2.2(a)-(b); EXHIBIT C ➞ 1 ➞ 1.1 ➞ 1.1(a)-(b)", "text": "IMNTV's election, IMNTV will deliver live feeds to the Distributor via methods other than FTP over the Internet, including delivery of physical media.\n\n(a) General. IMNTV shall take the appropriate measures to ensure that all live or simulated live feeds will be delivered continuously to the Distributor 24 hours/day, 7 days/week, except for scheduled maintenance. If any feed is provided to Distributor using transmission methods that are proprietary or uncommon, Provider agrees to provide -at no cost -- the receiver equipment to Distributor and to allow adequate time for setup and testing of equipment prior to delivery of live content.\n\n(b) Encoding. IMNTV will encode feeds to be delivered to Distributor.\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nEXHIBIT C\n\nProgramming Technical Specifications\n\n1. REPRESENTATION OF PROGRAMMING\n\n1.1 Programming Presentation. The following are requirements for all Programming:\n\n(a) Each individual item of Programming will be identified with a Programming identification code (\"Programming ID\")\n\n(b) Clicking on any Programming will instigate an \"Optimized\" presentation as follows:", "numbers_present": null, "definition_terms": ["Programming ID"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::d51553126aad", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::cdf3fb5f72f8"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::cdf3fb5f72f8", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "2.1", "section_title": "POLICIES FOR ADVERTISING AND PROMOTION WITHIN SOFTWARE", "clause_type": "Advertising/Promotion Policy", "path": "2 ➞ 2.1", "text": "fied with a Programming identification code (\"Programming ID\")\n\n(b) Clicking on any Programming will instigate an \"Optimized\" presentation as follows:\n\n(i)  When a Subscriber selects the Programming, the default start-up audio/video sequence for the presentation will start playing in the playback window of the Mobile Platform Software (\"Playback Window\").\n\n2. POLICIES FOR ADVERTISING AND PROMOTION WITHIN SOFTWARE\n\n2.1 The Programming will have a IMNTV Identification (\"IMNTV ID\"), which is similar to on-air network id, which is played each time the Programming is launched. Distributor may utilize the IMNTV ID in the Distributor's Portal for promotional purposes.\n\n(a) The IMNTV ID will be no longer than two (2) to five (5) seconds in length, and may be audio and Real Flash visual media clip.\n\n(b) All IMNTV Ids will be hosted and served by Distributor.\n\n(c) If Programming is currently playing, the IMNTV Id cannot interrupt the stream\n\n(d) If any advertisement other than a streaming advertisement is scheduled, the IMNTV ID must precede it.\n\n3. PROGRAMMING DESIGN GUIDELINES\n\n3.1 The initial opening of IMNTV ID should be authored to the following standards:", "numbers_present": null, "definition_terms": ["Programming ID", "Playback Window", "IMNTV ID"], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::a506ff93a32a", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::aca18e5d46c0"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::aca18e5d46c0", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "3", "section_title": "PROGRAMMING DESIGN GUIDELINES", "clause_type": "Design Guidelines", "path": "EXHIBIT C ➞ 3 ➞ 3.1 and 3.2", "text": "d, the IMNTV ID must precede it.\n\n3. PROGRAMMING DESIGN GUIDELINES\n\n3.1 The initial opening of IMNTV ID should be authored to the following standards:\n\n(a) For a 120 W x 96H video space (without scroll bars) subject to review with Distributor to determine suitability for Distributor's territory.\n\n3.2 Design Restrictions. The following requirements serve to ensure a consistent Subscriber experience across all Programming.\n\n(a) Distributor will provide IMNTV with page size and load time goals for the Programming.\n\n(b) Bullet points describing the Programming\n\n(c) Descriptions of the Programming that correspond with each bullet point and elaborate more on the bullet point\n\n(d) Link to the Provider's Privacy Policy\n\n(e) Link to the Provider's Terms of Use\n\n(f) Information for Customer Service and/or Technical Support to use while servicing Subscribers\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nEXHIBIT D\n\nDistribution of the Provider's Content through China Unicom Tianjin Branch", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::cdf3fb5f72f8", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::854d2d14e07d"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::854d2d14e07d", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "EXHIBIT D", "section_title": "Distribution of the Provider's Content through China Unicom Tianjin Branch", "clause_type": "Exhibit — Service Offering / Terms of Service / Pricing", "path": "EXHIBIT D ➞ 1 ➞ 1.a, 1.b ➞ 2 ➞ 2.a, 2.b ➞ 3 ➞ 3.a", "text": "bers\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005\n\nEXHIBIT D\n\nDistribution of the Provider's Content through China Unicom Tianjin Branch\n\n1. Service Offering     a. MobileVision is an authorized and fully licensed Service Provider (SP) partner who provides the programming and supports the underlyingtechnical operation of the streaming service for China Unicom Tianjin.     b. MobileVision will be making available the music video content from IMNTV on its WAP Portal pages and in links contained in its WAPpush messages through China Unicom Tianjin's networks.   2. Terms of Service     a. The China Unicom Tianjin streaming media service is offered as a pilot commercial program without charge for the period of two to threemonths. IMNTV agrees to participate in this pilot program by providing the content to China Unicom Tianjin via MobileVision without charge during this period.     b. Starting on October 1, 2005, China Unicom Tianjin intends to charge for the streaming service. The revenue sharing and payment termsbetween IMNTV and MobileVision takes effect starting on the same date of commercial service.   3. Pricing of Service     a. TBD subject to Carrier's pricing policy and IMNTV acceptance of terms", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::aca18e5d46c0", "next_id": "fdd28096-b746-4b5c-ba64-42efd884c608::14135ce67375"}
{"id": "fdd28096-b746-4b5c-ba64-42efd884c608::14135ce67375", "doc_id": "fdd28096-b746-4b5c-ba64-42efd884c608", "section_number": "3.a", "section_title": "Pricing of Service", "clause_type": "Pricing", "path": "EXHIBIT D ➞ 3 ➞ 3.a", "text": "starting on the same date of commercial service.   3. Pricing of Service     a. TBD subject to Carrier's pricing policy and IMNTV acceptance of terms\n\nSource: GLOBAL TECHNOLOGIES GROUP, INC., 10KSB, 9/28/2005", "numbers_present": null, "definition_terms": [], "metadata": {"doc_type": "Content License", "party_role": "licensor, licensee", "jurisdiction": "CN", "governing_law": "US-FL", "industry": "media"}, "prev_id": "fdd28096-b746-4b5c-ba64-42efd884c608::854d2d14e07d", "next_id": null}
